

24675

SEARCH REQUEST FORM

Requestor's
Name:

Date: 9/12/02

Serial
Number:

Art Unit: 302

GAMZEL / 1644

Phone: 302 3997

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

SEQ + SEQ INTERFERENCE
SEARCH

SEQ ID NO: 26

8

30 - 512 - 39 - 43

MP2 - 9/12 -

173 ✓

174 ✓

175 ✓

176 ✓

177 ✓

178 ✓

179 ✓

2nd quest

IN Thank

STAFF USE ONLY

Date completed: 9/13/02

Searcher: user

Terminal time: 25

Elapsed time:

CPU time: 10

Total time:

Number of Searches:

Number of Databases:

Search Site

 STIC CM-I Pre-S

Type of Search

 N.A. Sequence A.A. Sequence Structure Bibliographic

Vendors

 IG

MP2

 STN

C&I

 Dialog APS Geninfo SDC DARC/Questel Other

GenCore version 4.5
Copyright (c) 1993 - 2000 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2000, 01:18:33 ; Search time 2504.47 Seconds
(without alignments)
9990.683 Million cell updates/sec

Title: US-08-819-669E-8
Perfect score: 5674
Sequence: 1 CCGGGCACACTGGCATC.....TAATGATCTTGGTGGATCC 5674

Scoring table: IDENTITY NUC Gapop 10.0 , Gape~~1.0~~ 1.0

Searched: 5247842 seqs, 2204914090 residues

Total number of hits satisfying chosen Parameters: 10495684

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : ESTI:
1: em_est1:
2: em_est2:
3: em_est3:
4: em_est4:
5: em_est5:
6: em_est6:
7: em_est7:
8: em_est8:
9: em_est9:
10: em_est10:
11: em_est11:
12: em_est12:
13: em_est13:
14: em_est14:
15: em_est15:
16: em_est16:
17: em_est17:
18: em_est18:
19: em_est19:
20: gb_est1:
21: gb_est2:
22: gb_est3:
23: gb_est4:
24: gb_est5:
25: gb_est6:
26: gb_est7:
27: gb_est8:
28: gb_est9:
29: gb_est10:
30: gb_est11:
31: gb_est12:
32: gb_est13:
33: gb_est14:
34: gb_est15:
35: gb_est16:
36: gb_est17:
37: gb_est18:
38: gb_est19:
39: gb_est20:
40: gb_est21:
41: gb_est22:
42: gb_est23:
43: gb_est24:
44: gb_est25:
45: gb_est26:
46: gb_est27:
47: gb_est28:
48: gb_est29:
49: em_est20:
50: em_est21:
51: em_est22:
52: em_est30:
53: gb_est31:
54: gb_est32:
55: em_est23:
56: em_est24:
57: em_est25:
58: em_est26:
59: gb_est33:
60: gb_est34:
61: gb_est35:
62: gb_est36:
63: gb_est37:
64: gb_est38:
65: em_est22:
66: em_est28:
67: em_est29:
68: em_est30:
69: gb_est39:
70: gb.est40:
71: gb.est41:
72: gb.est42:
73: gb.est43:
74: gb.est44:
75: em.est31:
76: em.est32:
77: em.est33:
78: em.est34:
79: gb.est5:
80: gb.est6:
81: gb.est7:
82: em.est35:
83: em.est36:
84: em.est37:
85: gb.est8:
86: gb.est9:
87: gb.est10:
88: gb.est51:
89: gb.est52:
90: gb.est53:
91: gb.est54:
92: gb.est55:
93: gb.gss1:
94: gb.gss2:
95: gb.gss3:
96: gb.gss4:
97: em.gss5:
98: em.gss2:
99: em.gss3:
100: em.gss4:
101: gb.gss5:
102: gb.gss6:
103: em.gss5:
104: em.gss6:
105: gb.gss10:
111: gb.gss11:
112: em.gss9:
113: em.gss10:
114: em.gss11:
115: em.gss12:
116: gb.gss12:

117: qb_gss13;*
 118: qb_gss14;*
 119: qb_gss15;*
 120: qb_gss16;*
 121: qb_gss17;*
 122: qb_gss18;*
 123: qb_gss19;*
 124: em_gss13;*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Match Length | DB ID | Description |
|------------|-------|--------------|-------|-------------|
| C 1 | 427.4 | 7.5 | 869 | AI798898 |
| C 2 | 413 | 7.3 | 414 | AW103876 |
| C 3 | 392.6 | 6.9 | 728 | AI805537 |
| C 4 | 375.4 | 6.6 | 670 | AW183186 |
| C 5 | 349.6 | 6.2 | 533 | AW183186 |
| C 6 | 328.2 | 5.8 | 578 | AI044464 |
| C 7 | 328.1 | 5.8 | 599 | AI044465 |
| C 8 | 286 | 5.0 | 644 | AW673548 |
| C 9 | 285 | 5.0 | 504 | AI045429 |
| C 10 | 275.2 | 4.9 | 493 | AI863022 |
| C 11 | 272.6 | 4.8 | 511 | AW145614 |
| C 12 | 270.6 | 4.8 | 481 | AA195045 |
| C 13 | 270.6 | 4.8 | 495 | AW194089 |
| C 14 | 260.2 | 4.6 | 521 | AW50219 |
| C 15 | 257.2 | 4.5 | 559 | AI224339 |
| C 16 | 251.2 | 4.4 | 451 | AI805352 |
| C 17 | 247.6 | 4.4 | 430 | AW28104 |
| C 18 | 246.4 | 4.3 | 415 | AI200443 |
| C 19 | 243.4 | 4.3 | 519 | AW245872 |
| C 20 | 225.4 | 4.0 | 534 | AI247017 |
| C 21 | 222.8 | 3.9 | 394 | AA857809 |
| C 22 | 220.2 | 3.9 | 457 | AN731700 |
| C 23 | 218.6 | 3.9 | 566 | AI194145 |
| C 24 | 215.4 | 3.8 | 780 | AI793447 |
| C 25 | 212.4 | 3.7 | 386 | AN73455 |
| C 26 | 212.2 | 3.7 | 638 | AI248864 |
| C 27 | 206.8 | 3.6 | 514 | AW664428 |
| C 28 | 205.2 | 3.6 | 399 | AW193638 |
| C 29 | 201 | 3.5 | 488 | AI830281 |
| C 30 | 193.8 | 3.4 | 378 | AW103946 |
| C 31 | 193.2 | 3.4 | 467 | AI142010 |
| C 32 | 188.8 | 3.4 | 459 | AA17338 |
| C 33 | 188.4 | 3.3 | 597 | AK249285 |
| C 34 | 181.2 | 3.2 | 338 | R06041 |
| C 35 | 181.6 | 3.2 | 630 | AI954607 |
| C 36 | 178.6 | 3.1 | 256 | T29724 |
| C 37 | 176.4 | 3.1 | 457 | AZ070711 |
| C 38 | 175 | 3.1 | 387 | R062 |
| C 39 | 166 | 2.9 | 466 | AA104513 |
| C 40 | 164 | 2.9 | 293 | T29745 |
| C 41 | 163.2 | 2.9 | 345 | AI8756056 |
| C 42 | 159 | 2.8 | 324 | AA905816 |
| C 43 | 157.2 | 2.8 | 467 | AI032153 |
| C 44 | 155.4 | 2.7 | 441 | R23773 |
| C 45 | 150.6 | 2.7 | 523 | AQ838824 |

ALIGNMENTS

| | | | |
|----|------|--|------|
| QY | 4723 | TATGCTATGAGTCAGTGTCACTGAGTCCAGTCCTGCTGAGCAGT | 4782 |
| Db | 630 | CATACTAAGATGGTAAGACCCATTCACCCCTGCTGAAGGGCT | 571 |
| QY | 4783 | TTGAG | 4842 |
| Db | 570 | TTGAG | 514 |

RESULT AI798898/C EST CDNA clone

LOCUS AI798898

DEFINITION IMAGE:2348732 3, similar to SW:MAG_2_HUMAN P43316

18-DEC-1999

EST

CDNA

clone

| Site_2: Smal; A mini-library was made by cloning products derived from ORESTES PCR (U.S. Letters Patent application No. 196,716 - Ludwig Institute for Cancer Research) profiles into the pUC 18 vector. Reverse transcription of tissue mRNA and cDNA amplification were performed under low stringency conditions." | |
|---|---|
| b | 481 CTCAGTAGGTCTGTTAACATGGGCCATCTTCACTCCTGTTGAGAAATAATGTCAGTGT 4 22 |
| b | 4940 CTCAGTAGGTCTGTTAACATGGGCCATCTTCACTCCTGTTGAGAAATAATGTCAGTGT 4 999 |
| b | 421 CTAGTAGGTCTGTTAACATGGGCCATCTTCACTCCTGTTGAGAAATAATGTCAGTGT 3 62 |
| b | 5000 ATGTTCAATGTTTATTGGATGGTGAACACTCAGATCCAGTTATGTTAAGGAAAGTCAGTGT 5 059 |
| b | 361 ATGTTGAATGTTACCTTAAATGGTGAATTAACCTCAGATCCAGTTATGTTAAGGAAAGTCAGTGT 3 03 |
| b | 5060 ATGACAGGACACATTCCTGTTTATTGGATGGTGAACACTCAGATCCAGTTATGTTAAGGAAAGTCAGTGT 5 119 |
| b | 302 ATGTTAGTAACTATGGCTTAAATAGTTAGGTTAAGGTTAAGGCTTGTGTTAT 2 43 |
| b | 5120 TCGATTGGAAATCCATTCTATTGGTAATGGTGAATGGG --ATAATAACAGCAGTGGAAATAA 5 176 |
| b | 242 TCACTGGAAATTCATTCTATTGGTGAATGGCATAATAACAGCAGTGGAGATA 1 83 |
| b | 5177 GTACTTAAATGCAAAATGCACTAAAGAACTAAAGAAATAAAGAAATAA 5 236 |
| b | 182 GTATTAGTGTG --AATTCACCGTCAATTGGTAATGGCATGTTGGATGATGAT --AAATA 1 38 |
| b | 5237 AGAGATAGCAATCTGCCTATACCTCAGCTTATCTGTTAAATT-TTAAAGATATA 5 295 |
| b | 137 AARGATACCTAACTCCCGCTTATGCCCTAGTCATTCTGTTAAATTAAATAATAATA 7 8 |
| b | 5296 TGCATACCTGGATTCCPGGCTCTTGAGAAATGTANGAGAAATAATCTGAATAAG 5 355 |
| b | 77 GCATACCTGGATTCCPGGCTCTTGAGAAATGTANGAGAAATAATCTGAATAAT 2 21 |
| b | 5356 ATTCTTCCTGTTCA 5 370 |
| b | 20 ATTCTTCCTGTTAA 6 |
| RESULT 5 | |
| | AW83186 533 bp mRNA EST 04-FEB-2000 |
| | LOCUS PM3 HT0344-151299-004-h01 Homo sapiens cDNA, mRNA sequence. |
| | DEFINITION Homo sapiens cDNA, mRNA sequence. |
| | ACCESSION AW83186 |
| | VERSION 1 |
| | KEYWORDS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. |
| | ORGANISM Human |
| | COMMENT Unpublished (1999) |
| | CONTACT Simpson A.J.G. |
| | Laboratory of Cancer Genetics |
| | Ludwig Institute for Cancer Research |
| | Rua Prof. Antonio Prudente 109, 4 andar, 01509-010, São Paulo-SP, Brazil |
| | Tel: +55-11-2704922 |
| | Fax: +55-11-2707001 |
| | Email: asimpson@ludwig.org.br |
| | This sequence was derived from the FAPESP/LICR Human Cancer Genome Project. This entry can be seen in the following URL (http://www.ludwig.org.br/scripts/gethm12.P1?t1=PM3&t2=HT0344-151299-004-h01&t3=1999-12-15&t4=1) |
| | REFERENCE Seq. primer: puc 18 forward |
| | AUTHORS High quality sequence start: 21 |
| | JOURNAL High quality sequence stop: 533. |
| | FEATURES Location/Qualifiers |
| | source 1..533 |
| | /organism="Homo sapiens" |
| | /clonetyp="HT0344" |
| | /dev_stage="Adult" |
| | /locus="Homo sapiens, Vector: puc18, site 1, Smal" |
| | COMMENT Contact: Ansorge W |
| | MIPS An Klopferspitze 18a D-82152 Martinsried, Germany |
| | This is the 5' sequence of the clone insert |
| | Clone from S. Niemann, Molecular Genome Analysis, German Cancer |

6

| source | ATTRIBUTES | COUNT |
|---|--|-------------------------|
| <p>Research Center (DKFZ); Email s.wiemann@dkfz-heidelberg.de; sequenced by EMBL (European Molecular Biology Laboratories, Heidelberg/Germany) within the cDNA sequencing consortium of the German Genome Project. s1 sequence also available.</p> <p>This clone (DKFZp4_34H022) is available at the RZPD in Berlin-Buch/ Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.</p> | <p>Please contact the RZPD: Ressourcenzentrum, Heubnerweg 6, 14059 Berlin-Charlottenburg, GERMANY; Email: clone@rzpd.de.</p> <p>Location/Qualifiers</p> <p>1..578</p> <p>/organism="Homo sapiens" /db_xref="Taxon:19606" /clone=DKFZp4_34H022" /clone.lib="434 (synonym: htes3)" /tissue_type="testis" /dev_stage="adult" /lab.host="DH10B" /note="Vector: psp01; Site_1: NotI; Site_2: SalI"</p> | 130 a 136 c 196 g 116 t |
| | | |

| | | | |
|-----------|---|-----|---------|
| VERSION | Al044465.1 | GI: | 5432683 |
| KEYWORDS | | | |
| SOURCE | EST, | | |
| ORGANISM | human. | | |
| REFERENCE | Homo sapiens | | |
| AUTHORS | Mammalyota; Eutheraia; Pri- 1 (bases 1 to 599) | | |
| TITLE | Anзорге, W., Benes, V., K- | | |
| JOURNAL | Wiemann, S. | | |
| COMMENT | Unpublished (1999) Contact: Anзорге, W MPIBS | | |
| | Am Klopferspitze 18a D-8 This is the 3' sequence Clone from S. Wiemann, Research Center (DKFZ), sequenced by EMBL (Euro- pean Molecular Biology Labora- tory, Heidelberg, Germany). German Genome Project. | | |

| Query Match | Score | Length | EST |
|--|---|--------|-----|
| best local similarity 78.0% matches 453; Conservative 0; | Score 331; DB 47; Pred. No. 5.4e-72; Mismatches 115; Indels 13; Gaps 4; | 578; | |
| 2531 GTTGGGGCCCTAGGGAGATGGGTCCTGGGTAAAGGGGATGTACTCATGTC | | 2590 | |
| 1 GGTGGGAACTCAGGAGATAAGTGTGGTAAASAGGACTGTGTGCATT -A 58 | | | |
| 2591 GGAATGGGGTTGAAAGAACCCAGAACCAAGAACCGACGGCTGGAGATAAGTGTGAGCACAGCA | | 2650 | |
| 59 GGGGTGGGGTTGAAAGGGCACTCCCTGGAGATAAGTGTGAGCACAGCA | | 118 | |
| 2651 AGGCATATGGATCCAACCCAGAACCAALAGGGTCAACCTGAGCACCTAC----- | | 2704 | |
| 119 AGCCCATATACTGTICACCTAGAACCAAAGGGTCAGCCCTGGAGAACAGCACGTGGGG 178 | | | |
| 2705 --CCAGGATGGGCTCTTCACTCCCTGTTCAAGATCTCTGGGAGGTGAGCACCTC | | 2761 | |
| 179 GTACAGATGGC--CCCTCTACCTCTGGGACTCTGTTCAAGATCTCGGGACCTTGATGACCT 237 | | | |
| 2762 ATTCTACAGGGTACCTAGGTCAACTGAAAGGACCCCCATCTGGCTCTAAAGAACAGAGGG 2821 | | | |
| 238 GTTTCAGAAGSTGACTCAAGTCAACACAGGGCCCCATCTGTCGACAGATTCAGTGG 297 | | | |
| 2822 TCCAGGATCTCCATGCTGGTGGGAGAACATGAGGGAGGGTACCTGGTACCCAGG 2881 | | | |
| 298 TCTAGATCTGCCAGGATCAGTGTGAGGCTGAGGTAGATTGAGGTGACCCCTG 357 | | | |
| 2882 ACCAGACACTGA-GGGAGACTGCAAGAAATCACCCCTGCCCTGCMTCACCCAGAG 2940 | | | |
| 358 GCORGATGAGACAGGGGCCCATAGAATCTGCCCCTGGGTTTACTTCAGAG 417 | | | |
| 2941 AGCGGGGGCTGGCGCTCTGGCGTCCTGGGTATCTGGGATCATGTGATGTCAGGG 3000 | | | |
| 418 ACCCTGGCAGGGCTGAGGTGAGCTCCATATCTGGGATCTGTGTCAGGGTCAAGG 477 | | | |
| 3001 AGGGGGGGCTGGCTGAGAAAGCTGCGCTCAGGTCAAGTGAAGGGGAGCCTGCC 3060 | | | |
| 478 AAGGGGGGCGCTGGCTGAGGGCTGGACTCAAGTCAAGGGGAGCTCAGCC 3101 | | | |
| 538 CTGCCAGAAGTGGACCTGAGCCAGAACAGGGCTCAGCC 578 | | | |

| | | | |
|-----------|---|-----|---------|
| VERSION | AL044465.1 | GI: | 5432683 |
| KEYWORDS | | | |
| SOURCE | EST. | | |
| ORGANISM | Homo sapiens | | |
| REFERENCE | Mammalia: Eutheria; Primates; Catarrhini; Hominidae; Homo. 1 (bases 1 to 5997) | | |
| AUTHORS | Anzalone, N., Benes, J., Krieger, S., Mewes, H.W., Gassenhuber, J. and Wiemann, S. | | |
| TITLE | EST (Ansorge, Benes, et al.) | | |
| JOURNAL | Unpublished (1999) | | |
| COMMENT | Contact: Ansorge W MIPS | | |
| | Am Klopferspitz 18a D-82152 Martinsried Germany | | |
| | This is the 3'-sequence of the clone Insert | | |
| | Clone from S. Wiemann, Molecular Genome Analysis, German Cancer Research Center (DKFZ); Email: s.wiemann@dkfz-heidelberg.de; | | |
| | sequenced by EMBL (European Molecular Biology Laboratories, Heidelberg Germany) within the cDNA sequencing consortium of the German Genome Project. | | |

Tissue Procurement: DCTD/DTP cDNA Library Preparation: Ling Hong/Rubin Laboratory cDNA Library Arrayed by: The I.M.A.G.E. Consortium (ILNN) DNA Sequencing by: Berkeley MGC sequencing project Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LNNU at: www.bio.llnl.gov/bmhp/image/image.html Base Calling / Quality Scores: PAREd from University of Washington Genome Center. Vector TRIMMING: cross.match from University of Washington Genome Center PHRAP suite. Poly-T Identification: PatchPatch_P1 from Berkeley Drosophila Genome Project, University of Washington Genome Center: <http://www.genome.washington.edu/polyadenylation/>: Based upon the presence of a XhoI site followed by a run of 14 or more T residues polyadenylated.

Plate: LNCM10 **row:** N **column:** 3 **High quality sequence stop:** 427.

Location/Qualifiers

- 1. .511

/lab_host="PhiX10B (phage-resistant)"
 /note="organ: lung; Vector: pORTB;" Site_1: XhoI; Site_2:
 EcoRI; cDNA made by oligo-dT priming. Directionally
 cloned into EcoRI/XhoI sites using the following 5'
 adaptor: GGCACGAG(G). Size selected >500bp for average
 insert size 1.8kb. Library constructed by Ling Hong in
 the laboratory of Gerald M. Rubin (University of
 California, Berkeley) using ZAP-cDNA synthesis kit
 (Stratagene) and Superscript II RT (Life Technologies)."

| | | | |
|------------|--------------|---------------------------------------|----------------|
| QY | 5331 | TAGGAAATTATTCGATAAAGATT | 5359 |
| | | | |
| Db | 39 | CAACCGAAATTATTCGATTAATT | 11 |
| RESULT | 1.2 | | |
| LOCUS | AA995045/c | AA995045 | 481 bp |
| DEFINITION | out3e0.s1 | NCI_CGAP_Br2 | mRNA |
| | | | mRNA sequence. |
| ACCESSION | AA995045 | | |
| VERSION | AA995045.1 | | |
| KEYWORDS | EST. | | |
| SOURCE | human. | | |
| ORGANISM | Homo sapiens | | |
| REFERENCE | | Mammalia; Chordata; Crustacea; | |
| AUTHORS | | Metazoa; Eutheria; Primates; Ca- | |
| TITLE | | 1 (bases 1 to 481) | |
| JOURNAL | | NCI-CGAP http://www.ncbi.nlm.nih- | |
| COMMENT | | Tumor Gene Index | |
| | | Unpublished (1997) | |
| | | On May 18, 1998 this sequence was | |
| | | Contact: Robert Strausberg, Ph.D. | |
| | | Tel: (301) 496-1550 | |
| | | Email: Robert_Strausberg@nih.gov | |
| | | cDNA Library Preparation: Christopher | |
| | | Emmett-Buck, M.D., Ph.D. | |
| | | DNA Sequencing by: Greg L. | |
| | | cDNA Library Preparation: M. Be- | |
| | | Clone distribution: NCI-CGAP cl- | |
| | | found through the T.M.A.G.E. Con- | |
| | | www-bio.llnl.gov/bbr/image/Image | |
| | | Insert Length: 1718 Std Error: | |

| FEATURES | Source | High quality sequence stop: 446. |
|---|---|----------------------------------|
| Location/Qualifiers | | |
| 1..481 | | |
| /organism="Homo sapiens" | | |
| /db_xref="taxon:9606" | | |
| /clone="IMAGE:1631446" | | |
| /clone_id="NCI_CGAP_BR_2" | | |
| /sex="female; pooled" | | |
| /tissue-type="breast" | | |
| /note="Vector: PT7R3D-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from pooled breast tumor tissue, and was then primed with Not I - Oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pRT3 vector. This library is the normalized version of NCI_CGAP_BR1. Library was constructed by Bento Soares and M. Fatima Bonaldo." | | |
| base count | 165 a | 91 c |
| origin | 71 g | 154 t |
| Query Match | 4.9% | Score 272.6; DB 69; Length 511; |
| Best Local Similarity | 81.7% | Pred. No. 2.2e-57; |
| Matches 416; Conservative | 0; Mismatches 74; Indels 19; Gaps 8; | |
| b | 4862 CAGGGCCGCCAGCTCCATGCGCTTCCTGCCTGACATGAGGCCATTCTCACTC-- 491.9 | |
| b | 511 CGGGCCGATCCCTTAATGCCAACCTGCTCTGACTGCTCTCACTT 452 | |
| y | 4920 TGAAGAGCCGGCAGTGTCTCGTTCTATTGGGTCAGCTGGAGAT 4979 | |
| b | 451 TGAAGCCGGCAGCTTGGGTTTGGTGGAGAT 392 | |
| y | 4980 TATCTTGTCTCTTTGGATTGTCAAAGTTTTAAGGGATGGTGAATGAA 5039 | |
| b | 391 TATCTTGTCTCTGTGGATTGTCAAATG TTCCCTTTAACGGATGGTGAATGAG 333 | |
| y | 5040 CTICAGCATCCAAGTTATGAAATGACGAGTCACAC-- AGTCTGTGTATATAGTTAA 5097 | |
| b | 332 CGTAGCATCCAGTTATGAAATGACGAGTCACATGCTGTATATGTTAG 273 | |
| y | 5098 GGCTAAAGASTCCTGTTTCACTGATGGGAAATCCATTCTATTGGAAATTGGG-- 5155 | |
| b | 272 GAGPAAGAGCTCTGTTTCACTCAATGGAAATCCATTCTGGAAATTGTGAC 213 | |
| y | ,5156 ATTAACAGCAGTGAATAGTA -- CTTAGAAATGTCGA-AAAATGAGCACTAAATA 5210 | |
| b | 212 ATTAATATGACAGCTGTTAAAGTATTGCTTAAATGCGGAAATTACAATA 153 | |
| y | 5211 GATGAGATAAAAGRACTAAAGATAATGCAAACTTCIGCTTAACTCTGACTCT 5270 | |
| b | 152 CATGAGAT--AACTCAAGAAATCAAAGATAGTGAATTGCTTGTACCTCAATA 97 | |
| y | 5271 ATTCTGTTAAATTTAAAGATAATGCAATGGATTCTCTGGCTTCTTGGAAATG 5330 | |
| b | 96 ATTGTGTTAAAGATTAAACAAATGCAACCAGATTCTCTGACTCTTGGAAATG 40 | |
| Query Match | 4.8% | Score 270.6; DB 33; Length 481; |
| Best Local Similarity | 84.6% | Pred. No. 6.8e-57; |
| Matches 402; Conservatve | 0; Mismatches 54; | Gaps 19; |
| Qy | 4902 GAGGCCATTCTCACTC-TGAAAGAGGGCTCAGTTCTCAGTAGGTGTTCTGTT 4959 | |
| Db | 481 GAGGCCATTCTCACTCTGAGGAGCTCACATTCTAGPAGTGCGTTCTGTT 422 | |
| Qy | 4960 CTATTGGTGACTTGGAGATTATCTTGTTCTCAGTTCTGAAATTGTTCAATGTTTTT 5019 | |
| Db | 421 CTGTTGGATGACTTATGAAATTCTGTTCTGTTGGGTGTTGTTCAATG-TTCCTT 363 | |
| Qy | 5020 TTAAGGGATGGTTGAACTTCACATCCAAGTTATGAAATGACGAGTCAC--A 5079 | |


| | | | | |
|---|--|---|------|--|
| Db | 362 | TTAACGGGATGGTGAATGAGNCAGCATCAGGTATTGATGACAGTACACATA | 303 | Query Match Score 4.9%; Best Local Similarity 81.9%; Matches 417; Conservative 0; Mismatches 64; Indels 28; Gaps 0 |
| Qy | 5078 | GTCCTGTTATACTGTTAAGGGTAAAGCTCTGTTTATTGAGATTGGAAATCCAT | 5137 | Qy 4871 GTCCACAGCTTCCTCGCTCGTGACATGAGGCCATTCTCACTC---TGAAGAG 4926 |
| Db | 302 | GTGCTGTTATACTGTTAAGGGTAAAGCTCTGTTTATTGAGATTGGAAATCCAT | 243 | Db 494 GTGCACAGCTCCCTGGCTCGTGACATGAGGCCATTCTCACTGTTGAGAA 435 |
| Qy | 5138 | TGATTTGTAATTGGG-ATATACACCGCTGGATAAGTA---CTAGAATGTC | 5191 | Qy 4927 AGGGTAGTGTCTCAGTAGTGGTCTATGGTACTGGAGATTATCTT 4986 |
| Db | 242 | TCCATTGTTGTAATTGGTACATATAATGGCTTAAATGTC | 183 | Db 434 AATAGCAGTGTCTTGTAGTGGTTCTATTTGATGACTGGAGATTATCTC 375 |
| Qy | 5192 | A-AAAATGAGCATAAATAGATGAGATAAGAACTAAAGAAATTAGAGATGTCATT | 5250 | Qy 4987 TGTCTCTTGGATTGTCAAATGTTTTAAGGGATGTTGATGAACTTCAGC 5046 |
| Db | 182 | AGGAATTAGCAATACATACATGAGT---AACTAAGAAATCAAGATAGTGTATT | 127 | Db 374 TGTCTCTTAACTATGTTAAAGGATATATGCACTCTGGATT 5310 |
| Qy | 5251 | CCTGCCTTATACCTCAGTCTATTCTGTAATAATTAAAGGATATATGCACTCTGGATT | 5310 | Qy 5047 ATCCAGTT ATGATGAAAGCACTACACAGTCTGGTATAGTTAAGGTAGA 5100 |
| Db | 126 | CITGCCCTGTACCTCAATCTATCTGTAATACTGTTAAACAGGATT | 70 | Db 315 ATCCAGTTAATGATGATGAACTCTGTTAAATAGTTAGGTTAGA 256 |
| Qy | 5311 | CCTGGCTCTTCAGATTGAGAAATTAATCTGAAATAAGAATTCTCCT | 5365 | Qy 5106 GTCTCTGTTTATCAGATTGGAAATCCATTCTTGTGATATTGGGG---ATAATAA 5162 |
| Db | 69 | CCCTGACTCTTCAGATTGCAAGTCARGCAGATAATCTGAAATAATTCCTCCT | 15 | Db 255 GTCTGTGTTTATCAGATTGGAAATCCGGTCTATTTGTGATTGGACATAATA 196 |
| RESULT | 13 | | | |
| LOCUS | AW194089 | 495 bp mRNA | EST | 29-NOV-1999 |
| DEFINITION | xm12a03.x1 NCI_CGAP_Ut4 | Homo sapiens cDNA clone IMAGE:2683948 | 3 , | mRNA sequence. |
| VERSION | AW194089.1 | GI:6472822 | | |
| KEYWORDS | EST. | | | |
| SOURCE | human. | | | |
| ORGANISM | Human | | | |
| Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; | | | | |
| Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo. | | | | |
| 1 (bases 1 to 495) | | | | |
| 1 (bases 1 to 495) | | | | |
| NCI-CGAP http://www.ncbi.nlm.nih.gov/ncicgap. | | | | |
| National Cancer Institute, Cancer Genome Anatomy Project (CGAP), | | | | |
| Tumor Gene Index | | | | |
| Upublished (1997) | | | | |
| JOURNAL | On Oct 30, 1998 this sequence version replaced gi:3817926. | | | |
| COMMENT | Contact: Robert Strausberg, Ph.D. | | | |
| | Tel: (301) 496-1550 | | | |
| | Email: Robert.Strausberg@nih.gov | | | |
| | Tissue Procurement: Christopher Moskaluk, M.D., Ph.D., Michael R. | | | |
| | Emmett-Buck, M.D., Ph.D. | | | |
| | CDNA Library Preparation: Life Technologies, Inc. | | | |
| | DNA Sequencing by: Washington University Genome Sequencing Center | | | |
| | Clone distribution: NCI-OGAP Clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: www-bio.llnl.gov/bbrp/image/image.html | | | |
| Possible reversed clone: polyT not found | | | | |
| Seq Primer: -40UP from Gibco | | | | |
| High Quality sequence stop: 408 . | | | | |
| Location/Qualifiers | | | | |
| 1..495 | /organism="Homo sapiens" | | | |
| | /db_xref="taxon:9606" | | | |
| | /clone="IMAGE:2683948" | | | |
| | /tissue_type="serous papillary carcinoma, high grade, 2 | | | |
| | /pooled_tumors" | | | |
| | /lab_host="DH10B" | | | |
| | /note="Organ: uterus; Vector: pCMV-SPORT6; Site_1: Sali; Site_2: NotI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.48 kb. Life Technologies catalog #: 11542-016" | | | |
| FEATURES | Source | | | |
| BASE COUNT | 186 a | 95 c | 68 g | 146 t |
| ORIGIN | | | | |

| FEATURES | Source | SEQUENCE COUNT ORIGIN |
|--|---------------------|--------------------------|
| | | |
| presence of a XbaI site followed by a run of 14 or more T residues at the beginning of the sequence, this cDNA insert was Polyadenylated. | | |
| Plate: LICM9 | row: J column: 10 | |
| High quality sequence stop: 453. | Location/Qualifiers | |
| 1..521 | | |
| /organism="Homo sapiens" | | |
| /db_xref="taxon:9606" | | |
| /clone="IMAGE:28222505" | | |
| /clone_id="NIH_MGC_7" | | |
| /tissue_type="small cell carcinoma" | | |
| /cellline="MGC33" | | |
| /lab_host="DH10B (phage-resistant)" | | |
| /note="Organ: lung Vector: pOTB"; Site_1: XbaI; Site_2: | | |
| EcoRI; cDNA made by oligo-dT priming. Directionally cloned into EcoRI/XbaI sites using the following 5 adaptor: GGCACCA(G). Size-selected >500bp for average insert size 1.8kb. Library constructed by Ling Hong in the laboratory of Gerald M. Rubin (University of California, Berkeley) using ZAP-cDNA synthesis kit (Stratagene) and Superscript II RT (Life Technologies)." | | |
| 184 a | 100 c | 87 g |
| | | 150 t |

| | | | |
|-------------------------|---------------------------|----------------|---------|
| VERSION | All222439.1 | GI: | 3804642 |
| EST. | | | |
| SOURCE | human. | | |
| ORGANISM | Homo sapiens | | |
| REFERENCE | 1 (bases 1 to 459) | | |
| AUTHORS | NCI-CGAP | http://www.nci | |
| TITLE | National Cancer Institute | | |
| JOURNAL | Tumor Gene Index | | |
| COMMENT | Unpublished (1997) | | |
| CONTACT | Robert Straus | | |
| TEL | (301) 496-1550 | | |
| EMAIL | Robert_Straube | | |
| This clone is available | | | |
| IMAGE Consortium | Info | | |
| Insert Length: | 770 | S | |
| Seq Primer: | -40UP from | | |
| High quality sequence | | | |
| LOCATION/QUAL | | | |
| 1. | 459 | | |
| FEATURES | /organism="Homo | | |
| source | /db_xref="tax | | |
| | /clone="IMAGE | | |

Qy 5338 AATTAATCTGATAAAGAAATTCTTCCCTGTCA 5370
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 47 AATTAATCTGATAAAGAAATTCTTCCCTGTCA 15

Search completed: September 13, 2000, 02:38:16
Job time: 4783 sec



Release 3.1A John F. Collins, Biocomputing Research Unit.
Copyright (C) 1993-1998 University of Edinburgh, U.K.

Distribution rights by Oxford Molecular Ltd
MPSrch_PP protein - protein database search, using Smith-Waterman algorithm

Run on: Wed Sep 13 07:14:42 2000: MasPar time 3.43 Seconds

40.218 Million cell updates/sec
Tabular output not generated.

Title: >US-08-819-669E-26
Description: (1-9) from US08819669E.pep

Perfect Score: 61

Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150

Gap 15

Searched:

Post-processing: Minimum Match 0%
Listing first 45 summaries

a-is issued

1:15A_COMB 2:5B_COMB 3:6_COMB 4:PCT_COMB 5:backfiles1

Statistics: Mean 14.653; Variance 34.108; scale 0.430

Pred. No. is the number of results Predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Query | Match | Length | DB | ID | Description | Pred. No. |
|------------|----------|-------|--------|------------|-----------------------------------|-------------|-----------|
| 1 | 61 100.0 | 9 | 2 | US-09-036- | Sequence 1, Application 1.24e-01 | | |
| 2 | 61 100.0 | 9 | 2 | US-08-986- | Sequence 1, Application 1.24e-01 | | |
| 3 | 61 100.0 | 9 | 1 | US-07-938- | Sequence 1, Application 1.24e-01 | | |
| 4 | 61 100.0 | 9 | 1 | US-08-443- | Sequence 12, Application 1.24e-01 | | |
| 5 | 61 100.0 | 9 | 1 | US-08-787- | Sequence 49, Application 1.24e-01 | | |
| 6 | 61 100.0 | 9 | 1 | US-08-073- | Sequence 12, Application 1.24e-01 | | |
| 7 | 61 100.0 | 9 | 3 | US-08-159- | Sequence 99, Application 1.24e-01 | | |
| 8 | 61 100.0 | 9 | 3 | US-08-354- | Sequence 12, Application 1.24e-01 | | |
| 9 | 61 100.0 | 9 | 2 | US-08-902- | Sequence 21, Application 1.24e-01 | | |
| 10 | 61 100.0 | 9 | 2 | US-08-142- | Sequence 26, Application 1.24e-01 | | |
| 11 | 61 100.0 | 9 | 4 | PCT-US95-0 | Sequence 2, Application 1.24e-01 | | |
| 12 | 61 100.0 | 9 | 4 | PCT-US95-0 | Sequence 1, Application 1.24e-01 | | |
| 13 | 61 100.0 | 9 | 1 | US-08-299- | Sequence 26, Application 1.24e-01 | | |
| 14 | 61 100.0 | 9 | 2 | US-08-498- | Sequence 4, Application 1.24e-01 | | |
| 15 | 61 100.0 | 9 | 3 | US-08-967- | Sequence 26, Application 1.24e-01 | | |
| 16 | 61 100.0 | 9 | 1 | US-08-186- | Sequence 25, Application 1.24e-01 | | |
| 17 | 61 100.0 | 10 | 3 | US-08-602- | Sequence 25, Application 1.24e-01 | | |
| 18 | 61 100.0 | 10 | 1 | US-08-796- | Sequence 5, Application 1.24e-01 | | |
| 19 | 61 100.0 | 10 | 2 | US-08-498- | Sequence 4, Application 1.24e-01 | | |
| 20 | 61 100.0 | 12 | 2 | US-08-560- | Sequence 4, Application 1.24e-01 | | |
| 21 | 61 100.0 | 12 | 1 | US-08-190- | Sequence 24, Application 1.24e-01 | | |
| 22 | 61 100.0 | 309 | 1 | US-08-465- | Sequence 10, Application 1.24e-01 | | |
| 23 | 61 100.0 | 309 | 2 | US-08-993- | Sequence 6, Application 1.24e-01 | | |

ALIGNMENTS

RESULT 1
ID US-09-036-582-1
XX STANDARD;
AC PRT;
XXXXX 9 AA.

Sequence 1, Application US/09036582A
CC Patent No. 565381
CC GENERAL INFORMATION:
CC APPLICANT: van der Bruggen, Pierre
CC TITLE OF INVENTION: DELIVERY OF PROTEINS INTO EUKARYOTIC CELLS
CC TITLE OF INVENTION: WITH RECOMBINANT YERSINIA
FILE REFERENCE: 11154
CURRENT APPLICATION NUMBER: US/09/036, 582A.
CURRENT FILING DATE: 1998-03-06
NUMBER OF SEQ ID NOS: 39
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 1
CC LENGTH: 9
CC TYPE: PRT
CC ORGANISM: Human MAGE 1 peptide
SEQUENCE 9 AA: 976 MW: 576 CN:

Query Match 100.0%; Score 61; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0; /
Db 1 EADPTGHSY 9
QQ 1 EADPTGHSY 9
XX STANDARD;
AC PRT;
XXXXX 9 AA.

RESULT 2
ID US-08-986-234-1
XX STANDARD;
AC PRT;
XXXXX 9 AA.

Sequence 1, Application US/08986234
CC Patent No. 5981706

GENERAL INFORMATION:
 CC APPLICANT: Wallen, et al.
 CC TITLE OF INVENTION: Methods for Synthesizing Heat Shock Protein Complexes
 CC FILE REFERENCE: UNME-0008-1
 CC CURRENT APPLICATION NUMBER: US/08/9886,234
 CC CURRENT FILING DATE: 1997-12-05
 CC NUMBER OF SEQ ID NOS: 114
 CC SOFTWARE: PatentIn Ver. 2.0
 SEQ ID NO: 1
 LENGTH: 9
 CC TYPE: PRT
 CC ORGANISM: human
 SEQUENCE: 9 AA; 976 MW; 576 CN;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 4
 ID US-08-443-341-12 STANDARD; PRT; 9 AA.
 XX
 AC xxxxxxxx

Query Match Score 61; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 3
 ID US-07-938-334C-1 STANDARD; PRT; 9 AA.
 XX
 AC xxxxxxxx

Sequence 1, Application US/07938334C
 Sequence 1, Application US/07938334C
 GENERAL INFORMATION:
 PATENT NO. 5415940
 TITLE OF INVENTION: ISOLATED NONAPEPTIDES DERIVED FROM
 NUMBER OF SEQUENCES: 22
 CORRESPONDENCE ADDRESS:
 CC APPLICANT: Boon, Thierry; van der Bruggen, Pierre;
 CC De Plaein, Etienne; Lurquin, Christophe; Traversari, Catia
 CC TITLE OF INVENTION: ISOLATED NONAPEPTIDES DERIVED FROM
 NUMBER OF SEQUENCES: 22
 CC CORRESPONDENCE ADDRESS:
 CC STREET: 805 Third Avenue
 CC CITY: New York City
 CC STATE: New York
 CC COUNTRY: USA
 CC ZIP: 10022
 COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
 CC COMPUTER: IBM PS/2
 CC OPERATING SYSTEM: PC-DOS
 CC SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/07/938,334C
 CC FILING DATE: 31-AUG-1992
 CC CLASSIFICATION: 435
 CC PRIORITY APPLICATION DATA:
 CC APPLICATION NUMBER: 08/073,103
 CC FILING DATE: 7-JUNE-1993
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/938,334
 CC FILING DATE: 17-MAY-1995
 CC CLASSIFICATION: 435
 CC PRIORITY APPLICATION DATA:
 CC APPLICATION NUMBER: 08/037,230
 CC FILING DATE: 26-MARCH-1993
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Hanson, No. 540594 Oman D.
 CC REGISTRATION NUMBER: 30,946
 CC REFERENCE/DOCKET NUMBER: IUD 5293,5
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (212) 688-9200
 CC TELEFAX: (212) 838-3884
 CC INFORMATION FOR SEQ ID NO: 1:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 9 amino acid residues
 CC TYPE: amino acid
 CC STRANDEDNESS: single
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: protein
 CC NAME/KEY: MAGE-1 derived nonapeptide
 SEQUENCE: 9 AA; 976 MW; 576 CN;

Query Match Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01; Indels 0; Gaps 0; AC xxxxxx

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0; AC xxxxxx

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 5 ID US-08-787-547-49 STANDARD; PRT: 9 AA.

XX DT DE XX AC XXXXXX

Sequence 49, Application US/08787547

GENERAL INFORMATION:
PATENT NO. 5783567
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
NUMBER OF SEQUENCES: 107

COMPUTER READABLE FORM:
ADDRESS: Fish & Richardson, P.C.
STREET: 225 Franklin Street
CITY: Boston
STATE: MA
COUNTRY: US
ZIP: 02110-2804
NUMBER OF SEQUENCES: 107

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: Windows 95
SOFTWARE: FASTSEQ for Windows Version 2.0

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/787-547
FILING DATE: 22-JAN-1997
CLASSIFICATION: 514
PRIORITY APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Fraser, Janis K.
REGISTRATION NUMBER: 34,819
REFERENCE/DOCKET NUMBER: 08191/003001
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-542-5070
TELEFAX: 617-542-8906
TELEX: 200154
SEQUENCE NUMBER: 49;

SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
TOPOLOGY: linear
MOLECULE TYPE: peptide
SEQUENCE 9 AA: 976 MW: 576 CN:

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01; Indels 0; Gaps 0; AC xxxxxx

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 6 ID US-08-73-103A-12 STANDARD; PRT: 9 AA.

XX DT DE XX AC XXXXXX

Sequence 12, Application US/08073103A
Sequence 12, Application US/08073103A
GENERAL INFORMATION:
PATENT NO. 5462871
APPLICANT: Boon-Falleur, Thierry
APPLICANT: van der Bruggen, Pierre
APPLICANT: De Plaein, Etienne
APPLICANT: Lurquin, Christophe
APPLICANT: Traversari, Catic
APPLICANT: Gaugler, Beatrice
APPLICANT: Van den Eynde, Benoit
TITLE OF INVENTION: ISOLATED MONOPEPTIDES DERIVED FROM MAGE-3 GENE AND PRESENTED BY HLA-A1 AND USES THEREOF
NUMBER OF SEQUENCES: 22
CORRESPONDENCE ADDRESS:
ADDRESSEE: Felfe & Lynch
STREET: 805 Third Avenue
CITY: New York City
STATE: New York
COUNTRY: USA
ZIP: 10022
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
COMPUTER: IBM PS/2
OPERATING SYSTEM: PC-DOS
SOFTWARE: Wordperfect
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/073,103A
FILING DATE: 7-JUNE-1993
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/938 334
FILING DATE: 31 AUG-1992
ATTORNEY/AGENT INFORMATION:
NAME: Hasson, No. 5462871man D.
REGISTRATION NUMBER: 30,946
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 688-9200
TELEFAX: (212) 838-3884
SEQUENCE CHARACTERISTICS:
LENGTH: 9 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
SEQUENCE 9 AA: 976 MW: 576 CN:

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.24e-01; Indels 0; Gaps 0; AC xxxxxx

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 7 ID US-08-159-339A-99 STANDARD; PRT: 9 AA.

XX DT DE XX AC XXXXXX

Sequence 99, Application US/08159339A
Sequence 99, Application US/08159339A

Patent No. 6037135
 GENERAL INFORMATION:
 APPLICANT: Kubo, Ralph T.
 APPLICANT: Sette, Alessandro
 APPLICANT: Celis, Esteban
 TITLE OF INVENTION: HLA Binding peptides and their
 TITLE OF INVENTION: Uses
 NUMBER OF SEQUENCES: 1254
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Townsend and Townsend and Crew LLP
 STREET: Two Embarcadero Center, Eighth Floor
 CITY: San Francisco
 STATE: CA
 ZIP: 94111-3834

COMPUTER READABLE FORM:
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: DOS
 SOFTWARE: FastSQL for Windows Version 2.0
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/159, 339A
 FILING DATE: 29-NOV-1993
 CLASSIFICATION: 424
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/926, 666
 FILING DATE: 07-AUG-1992
 APPLICATION NUMBER: US 08/027, 746
 FILING DATE: 05-MAR-1993
 APPLICATION NUMBER: US 08/103, 395
 FILING DATE: 06-AUG-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: Weber, Ellen Lauver
 REGISTRATION NUMBER: 32,762
 REFERENCE/DOCKET NUMBER: 018623-005030US
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 570-0200
 TELEFAX: (415) 576-0300
 TELEX:
 INFORMATION FOR SEQ ID NO: 99:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: Peptide
 SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

TELEFAX: (415) 576-0300

TELEX:

INFORMATION FOR SEQ ID NO: 99:

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Peptide

SEQUENCE 9 AA; MW: 576 CN;

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 570-0200

OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/902,516
 CC FILING DATE: 29-JUL-1997
 CC CLASSIFICATION: 424
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Campbell, Cathryn A.
 CC REGISTRATION NUMBER: 31,815
 CC REFERENCE/DOCKET NUMBER: P-TM 2442
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (619)535-9001
 CC TELEFAX: (619)535-8949
 CC INFORMATION FOR SEQ ID NO: 21:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 9 amino acids
 CC TYPE: amino acid
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: Peptide
 CC SEQUENCE 9 AA; 976 MW; 576 CN;
 Query Match 100.0%; Score 61; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPFGHSY 9
 Qy 1 EADPFGHSY 9

RESULT 10
 ID US-08-142-368A-26 STANDARD; PRT; 9 AA.
 XX XXXXXXXX
 AC XXXXX
 XX DT
 XX DE Sequence 26, Application US/08142368A
 XX CC Sequence 26, Application US/08142368A
 CC Patent No. 5923729
 CC GENERAL INFORMATION:
 CC APPLICANT: Boon-Falleur, Thierry; Van der Bruggen, Thierry;
 CC De Plaein, Etienne; Van den Eynde, Beno t.; Van Pel, Aline; De Plaein, Etienne;
 CC APPLICANT: Lurquin, Christophe; Chomez, Patrick; Traversari, Catia
 CC TITLE OF INVENTION: Tumor Rejection Antigen Precursors, Tumor
 CC NUMBER OF SEQUENCES: 26
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Felfe & Lynch
 CC STREET: 805 Third Avenue
 CC CITY: New York City
 CC STATE: New York
 CC ZIP: 10036
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
 CC COMPUTER: IBM
 CC OPERATING SYSTEM: PC-DOS
 CC SOFTWARE: Wordperfect
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/142,368A
 CC FILING DATE: 02-MAY-1994
 CC CLASSIFICATION: 435
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: PCT/US92/04354
 CC FILING DATE: 22-MAY-1992
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/807,043
 CC FILING DATE: 12-DECEMBER-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/764,364
 CC FILING DATE: 23-SEPTEMBER-1991
 CC PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/728,838
 CC APPLICATION NUMBER: 9-JULY-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/705,702
 CC FILING DATE: 23-MAY-1991
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Hanson, No. 592579man D.
 CC REGISTRATION NUMBER: 30,946
 CC REFERENCE/DOCKET NUMBER: LUD 5253.4-US
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (212) 658-9200
 CC TELEFAX: (212) 838-3884
 CC INFORMATION FOR SEQ ID NO: 26:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 9 amino acids
 CC TYPE: amino acids
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: protein
 CC SEQUENCE 9 AA; 976 MW; 576 CN;
 Query Match 100.0%; Score 61; DB 2; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Db 1 EADPFGHSY 9
 Qy 1 EADPFGHSY 9

RESULT 11
 ID PCT-US95-04975-2 STANDARD; PRT; 9 AA.
 XX XXXXXXXX
 AC XXXXX
 XX DT
 XX DE Sequence 2, Application PC/TUS9504975
 XX CC Sequence 2, Application PC/TUS9504975
 CC GENERAL INFORMATION:
 CC APPLICANT: Nikolic-Zugic, Janko
 CC APPLICANT: Dyall, Rubenda
 CC TITLE OF INVENTION: INDUCTION OF CYTOTOXIC T LYMPHOCYTES (CTL) USING
 CC NUMBER OF SEQUENCES: 19
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Cooper & Dunham LLP
 CC STREET: 1185 Avenue of the Americas
 CC CITY: New York
 CC STATE: New York
 CC COUNTRY: USA
 CC ZIP: 10036
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: PatentIn Release #1.24
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: PCT/US95/04975
 CC FILING DATE:
 CC CLASSIFICATION:
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 08/233,496
 CC FILING DATE: April 22, 1994
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: White Esq., John P.
 CC REGISTRATION NUMBER: 28,678
 CC REFERENCE/DOCKET NUMBER: 45059/JPW/MSC/AMB
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: 212-278-0400
 CC TELEFAX: 212-391-0525
 CC INFORMATION FOR SEQ ID NO: 2:
 CC SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids
 TYPE: amino acids
 TOPOLOGY: Linear
 MOLECULE TYPE: Peptide
 HYPOTHETICAL: N
 ANTI-SENSE: N
 SEQUENCE - 9 AA; 976 MW; 576 CN;

Query Match Score 61; DB 4; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 13 ID US-08-299-849B-26 STANDARD: PRT: 9 AA.
 XX XX DE Sequence 26, Application US/08299849B
 XX CC Sequence 26, Application US/08299849B
 CC Patent No. 5612201
 GENERAL INFORMATION:
 CC APPLICANT: De Plaein, Etienne; Boon-Falleur, Thierry;
 Charles; Leth, Bernard; Szikora, Jean-Pierre;
 De Smet, Charles;
 CC APPLICANT: Chomez, Patrick
 CC TITLE OF INVENTION: Isolated Nucleic Acid Molecules Useful In Determining Expression Of A Tumor Antigen Precursor
 CC NUMBER OF SEQUENCES: 48
 CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Felfe & Lynch
 STREET: 805 Third Avenue
 CITY: New York City
 STATE: New York
 ZIP: 10022
 COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
 COMPUTER: IBM
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/299,849B
 FILING DATE: 1-SEPTEMBER-1994
 CLASSIFICATION: A35
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 08/037,230
 CC FILING DATE: 26-MARCH-1993
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: PCT/US92/04354
 FILING DATE: 22-MAY-1992
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/807,043
 CC FILING DATE: 12-DECEMBER-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/764,364
 FILING DATE: 23-SEPTEMBER-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/728,838
 CC FILING DATE: 9-JULY-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/705,702
 FILING DATE: 23-MAY-1991
 CC ATTORNEY/AGENT INFORMATION:
 NAME: Hanson, No. 5612201man D.
 REGISTRATION NUMBER: 30,946
 REFERENCE/DOCKET NUMBER: LOD 5355
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (206) 467-5600
 TELEFAX: (415) 543-5043
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 STRANDEDNESS: unknown
 TOPOLOGY: linear
 MOLECULE TYPE: Peptide
 SEQUENCE 9 AA; 976 MW; 576 CN;
 Query Match 100.0%; Score 61; DB 4; Length 9;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

 |||||||

Qy 1 EADPTGHSY 9

RESULT 14 ID US-08-498-461-4 STANDARD; PRT; 9 AA.

XX

AC

XXXXXX

DE Sequence 4, Application US/08498461

XX

CC Sequence 4, Application US/08498461

CC PRIORITY NUMBER: 582/073

CC GENERAL INFORMATION:

CC APPLICANT: Luescher, Immanuel; Anjiere, Fabienne;

CC APPLICANT: Layer, Andre; Romero, Pedro; Cerottini, Jean-Charles

CC TITLE OF INVENTION: Photoreactive Peptide Derivatives

CC NUMBER OF SEQUENCES: 16

CC CORRESPONDENCE ADDRESS:

CC ADDRESSEE: Feife & Lynch

CC STREET: 805 Third Avenue

CC CITY: New York City

CC STATE: New York

CC ZIP: 10022

CC COMPUTER READABLE FORM:

CC MEDIUM TYPE: Diskette, 3.5 inch, 1.44 kb storage

CC COMPUTER: IBM

CC OPERATING SYSTEM: PC-DOS

CC SOFTWARE: Wordperfect

CC CURRENT APPLICATION DATA:

CC APPLICATION NUMBER: US/08/967,727

CC FILING DATE:

CC CLASSIFICATION: 435

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 08/037,230

CC FILING DATE: 26-MARCH-1993

CC APPLICATION NUMBER: PCT/US92/04354

CC FILING DATE: 22-MAY-1992

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/807,043

CC FILING DATE: 12-DECEMBER-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/764,365

CC FILING DATE: 23-SEPTEMBER-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/728,838

CC FILING DATE: 9-JULY-1991

CC PRIOR APPLICATION DATA:

CC APPLICATION NUMBER: 07/705,702

CC FILING DATE: 23-MAY-1991

CC ATTORNEY/AGENT INFORMATION:

CC NAME: Hanson, No. 6025474man D.

CC REGISTRATION NUMBER: 30,946

CC REFERENCE/DOCKET NUMBER: LUD 5353

CC TELECOMMUNICATION INFORMATION:

CC TELEPHONE: (212) 688-9200

CC TELEFAX: (212) 838-3884

CC INFORMATION FOR SEQ ID NO: 4:

CC SEQUENCE CHARACTERISTICS:

CC LENGTH: 9 amino acids

CC TYPE: amino acids

CC TOPOLOGY: linear

CC MOLECULE TYPE: protein

CC SEQUENCE 9 AA; 976 MW; 576 CN;

Sequence 26, Application US/08967727

PATENT NO. 6025474

GENERAL INFORMATION:

APPLICANT: Gaugler, B atrice; Van den Eynde, Beno t;

APPLICANT: van der Bruggen, Pierre; Bonn-Faileur, Thierry

TITLE OF INVENTION: Isolated Nucleic Acid Molecules Coding For

TITLE OF INVENTION: Tumor Rejection Antigen Precursor Mage-3 And Uses There

NUMBER OF SEQUENCES: 30

CORRESPONDENCE ADDRESS:

ADDRESSEE: Feife & Lynch

STREET: 805 Third Avenue

CITY: New York City

STATE: New York

ZIP: 10022

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage

COMPUTER: IBM

OPERATING SYSTEM: PC-DOS

SOFTWARE: Wordperfect

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/967,727

FILING DATE:

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/037,230

FILING DATE: 26-MARCH-1993

APPLICATION NUMBER: PCT/US92/04354

FILING DATE: 22-MAY-1992

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/807,043

FILING DATE: 12-DECEMBER-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/764,365

FILING DATE: 23-SEPTEMBER-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/728,838

FILING DATE: 9-JULY-1991

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 07/705,702

FILING DATE: 23-MAY-1991

PRIOR APPLICATION DATA:

NAME: Hanson, No. 6025474man D.

REGISTRATION NUMBER: 30,946

REFERENCE/DOCKET NUMBER: LUD 5353

TELECOMMUNICATION INFORMATION:

TELEPHONE: (212) 688-9200

TELEFAX: (212) 838-3884

SEQUENCE CHARACTERISTICS:

LENGTH: 9 amino acids

TYPE: amino acids

TOPOLOGY: linear

MOLECULE TYPE: protein

SEQUENCE 9 AA; 976 MW; 576 CN;

Query Match 100.0%; Score 61; DB 3; Length 9;

Best Local Similarity 100.0%; Pred. No. 1.24e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

 |||||||

Qy 1 EADPTGHSY 9

RESULT 15 ID US-08-567-727-26 STANDARD; PRT; 9 AA.

XX

AC

XX

DT

XX

DE Sequence 26, Application US/08967727

DE XX

Query Match 100.0%; Score 61; DB 3; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

 |||||||

Qy 1 EADPTGHSY 9

RESULT 16 ID US-08-186-265-1 STANDARD; PRT; 9 AA.

XX

AC

XX

DT

XX

DE Sequence 1, Application US/08186266

DE XX

Sequence 1, Application US/08186266
 Patent No. 566907
 GENERAL INFORMATION:
 APPLICANT: KUBO, Ralph T.
 APPLICANT: SETE, Howard M.
 APPLICANT: SETE, Alessandro
 APPLICANT: CELIS, Esteban
 TITLE OF INVENTION: INDUCTION OF ANTI-TUMOR CYTOTOXIC T LYMPHOCYTES IN HUMANS USING SYNTHETIC PEPTIDE EPITOPE
 NUMBER OF SEQUENCES: 20
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Townsend and Townsend Khourie and Crew
 STREET: Stewart Street Tower, One Market Plaza
 CITY: San Francisco
 STATE: California
 COUNTRY: US
 ZIP: 94105-1493
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/186,266
 FILING DATE: 25-JAN-1994
 CLASSIFICATION: 424
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/159,339
 FILING DATE: 29-NOV-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/103,396
 FILING DATE: 06-AUG-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/027,746
 FILING DATE: 05-MAR-1993
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 07/926,666
 FILING DATE: 07-AUG-1992
 ATTORNEY/AGENT INFORMATION:
 NAME: Bastian, Kevin L.
 REGISTRATION NUMBER: 34,774
 PRACTICE/DOCKET NUMBER: 14137-50-4
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (415) 543-9600
 TELEFAX: (415) 543-5043
 INFORMATION FOR SEQ ID NO: 1:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 9 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: Peptide
 SEQUENCE 9 AA: 976 MW: 576 CN:
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0
 RESULT 17
 ID US-08-602-506A-25 STANDARD; PRT; 10 AA.
 Db 1 EADPTGHSY 9
 XX |||||
 AC 1 EADPTGHSY 9
 XX XXXXX
 Sequence 25, Application US/08602506A
 XX DT
 DE DT
 XX DE
 CC CC

Patent No. 6060257
 GENERAL INFORMATION:
 CC APPLICANT: Herman, Jean; Coulie, Pierre;
 CC APPLICANT: Boon-Falleur, Thierry; van der Bruggen, Pierre;
 CC APPLICANT: Luescher, Immanuel.
 CC TITLE OF INVENTION: Tumor Rejection Antigens Presented By HLA-
 CC NUMBER OF SEQUENCES: 30
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Feijfe & Lynch
 CC STREET: 805 Third Avenue
 CC CITY: New York City
 CC STATE: New York
 CC ZIP: 10022
 COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
 CC COMPUTER: IBM
 CC OPERATING SYSTEM: PC-DOS
 CC SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/602-506A
 CC FILING DATE: 20-FEBRUARY-1996
 CC CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 08/531,864
 CC FILING DATE: 21-SEPTEMBER-1995
 PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 08/373,636
 CC FILING DATE: 17-JANUARY-1995
 PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 08/253,503
 CC FILING DATE: 3-JUNE-1994
 ATTORNEY/AGENT INFORMATION:
 CC NAME: Hanson, No. 6060257man D.
 CC REGISTRATION NUMBER: 30,446
 CC REFERENCE/DOCKET NUMBER: LUD 5436
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (212) 688-9200
 CC TELEFAX: (212) 838-3884
 CC INFORMATION FOR SEQ ID NO: 25:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 10 amino acids
 CC TYPE: amino acid
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: protein
 FEATURE:
 CC NAME/KEY: MAGE-1/HLA-B44
 CC SEQUENCE: 10 AA; 1104 MW; 684 CN;
 SQ Query Match 100.0%; Score 61; DB 3; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.2e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 DE Sequence 25, Application US/08796883
 XX RESULT 18
 DE ID US-08-796-883-25 STANDARD; PRT; 10 AA.
 XX AC XXXXXX
 DT
 XX
 DE Sequence 25, Application US/08796883
 CC Sequence 25, Application US/08796883
 CC PRT; 10 AA.
 CC PATENT NO. 5744353
 GENERAL INFORMATION:
 CC APPLICANT: Herman, Jean; Coulie, Pierre;
 CC APPLICANT: Boon-Falleur, Thierry; van der Bruggen, Pierre;
 CC APPLICANT: Luescher, Immanuel.

TITLE OF INVENTION: TUMOR Rejection Antigens Presented By
 CC TITLE OF INVENTION: HLA-B44 Molecules, And Uses Thereof
 CC NUMBER OF SEQUENCES: 30
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESS SEE: Felipe & Lynch
 STREET: 805 Third Avenue
 CITY: New York City
 STATE: New York
 ZIP: 10022
 COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
 COMPUTER: IBM
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/796, 883
 FILING DATE: 06-FEB-1997
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/602, 506
 FILING DATE: 20-FEBRUARY-1996
 APPLICATION NUMBER: 08/531, 864
 FILING DATE: 21-SEPTEMBER-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: 08/373, 636
 FILING DATE: 17-JANUARY-1995
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: LUD 5436
 FILING DATE: 3-JUNE-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Hanson, No. 5744353man D.
 REGISTRATION NUMBER: 30, 946
 REFERENCE/DOCKET NUMBER: LUD 5436
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 688-9200
 TELEFAX: (212) 838-3884
 INFORMATION FOR SEQ ID NO: 25:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 10 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 FEATURE:
 NAME/KEY: MAGE-1/HLA-B44
 SEQUENCE 10 AA: 1104 NW; 684 CN;
 SQ Query Match Similarity 100.0%; Score 61; DB 1; Length 10;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0;
 Db 2 EADPTGHSY 10
 1 EADPTGHSY 9
 RESULT 19
 ID US-08-498-461-5 STANDARD PRT; 10 AA.
 XX
 AC XXXXX
 DT XX
 DE Sequence 5, Application US/08498461
 XX Sequence 5, Application US/08498461
 CC GENERAL INFORMATION:
 CC Patent No. 5821073
 CC APPLICANT: Luescher, Emmanuel; Anjuve, Fabiene;
 CC APPLICANT: Layer, Andreas; Ronero, Pedro; Cerottini, Jean
 CC TITLE OF INVENTION: Photoreactive Peptide Derivatives
 CC NUMBER OF SEQUENCES: 16
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Felipe & Lynch

STREET: 805 Third Avenue
 CITY: New York City
 STATE: New York
 ZIP: 10022
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 3.5 inch, 1.44 kb storage
 COMPUTER: IBM
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/498,461
 FILING DATE: 5-JULY-1995
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Hanson, No. 5827-073man D.
 REGISTRATION NUMBER: 30,946
 RECOMMENDATION NUMBER: LUD 5403
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 688-0200
 TELEFAX: (212) 838-3884
 INFORMATION FOR SEQ ID NO: 5:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 10 amino acids
 TYPE: amino acid
 TOPOLOGY: linear
 OTHER INFORMATION:
 OTHER INFORMATION: The xaa is iodinated 2',
 OTHER INFORMATION: 3'-4-azidosalicyloyl]-diaminoglycyl-
 SEQUENCE 10 AA; 1086 MW; 695 CN;
 Score 61; DB 2; Length 10
 Best Local Similarity 100 %; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0
 Db 2 EADPFGHSY 10
 ||||||| 9
 Qy 1 EADPFGHSY 9
 RESULT 20 Application US/08560024
 ID US-08-560-024-4 STANDARD PRT; 12 AA.
 XX XXXXXXXX
 AC
 DT
 AX
 DE Sequence 4 , Application US/08560024
 XX Sequence 4 , Application US/08560024
 CC Patent No. 583448
 GENERAL INFORMATION:
 CC APPLICANT: Chen, Yao-Tseng; Stockert, Elisabeth;
 CC APPLICANT: Chen, Yachi; Garin-Chesa, Pilar; Retig,
 CC APPLICANT: van der Bruggen, Pierre; Boon-Faillieur,
 CC APPLICANT: Old, Lloyd J.
 TITLE OF INVENTION: MONOCLONAL ANTIBODIES WHICH BIND
 TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSORS
 NUMBER OF SEQUENCES: 4
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Felice & Lynch
 STREET: 805 Third Avenue
 CITY: New York City
 STATE: New York
 ZIP: 10022
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage
 COMPUTER: IBM
 OPERATING SYSTEM: PC-DOS
 SOFTWARE: Wordperfect
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/560,024
 FILING DATE:

CLASSIFICATION: 514
 PRIORITY APPLICATION NUMBER: US/08/190,411
 FILING DATE: 01-FEBRUARY-1994
 APPLICATION NUMBER: 037,230
 FILING DATE: 26-MARCH-1993
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: PCT/US92/04354
 FILING DATE: 22-MAY-1992
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 07/807,043
 FILING DATE: 12-DECEMBER-1991
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 07/764,364
 FILING DATE: 23-SEPTEMBER-1991
 PRIORITY APPLICATION DATA:
 APPLICATION NUMBER: 07/705,702
 FILING DATE: 23-MAY-1991
 ATTORNEY/AGENT INFORMATION:
 NAME: Hansson, NC, 581348man D.
 REGISTRATION NUMBER: 30,946
 REFERENCE/DOCKET NUMBER: LUD 5354
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 688-9200
 TELEFAX: (212) 838-3884
 INFORMATION FOR SEQ ID NO: 4:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 12 amino acid residues
 TYPE: amino acid
 TOPOLOGY: linear
 MOLECULE TYPE: Protein
 SEQUENCE 12 AA: 1318 MW; 944 CN;
 Query Match Similarity 100.0%; Score 61; DB 2; Length 12;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 0; Mismatches 0; Gaps 0;
 Indels 0;

Db 4 EADPFGHSY 12
 |||||
 1 EADPFGHSY 9

RESULT 21
 ID US-08-411A-4 STANDARD: PRT; 12 AA.
 XX XXXXXX
 AC
 DT
 XX
 DE Sequence 4, Application US/08190411A
 CC Sequence 4, Application US/08190411A
 CC Patent No. 5541104
 CC GENERAL INFORMATION:
 CC APPLICANT: van der Bruggen, Pierre; Boon-Falleur, Thierry;
 CC APPLICANT: Chen, Yao-Tseng; Stockert, Elisabeth; Wolfgang J.;
 CC APPLICANT: Chen, Yachi; Garin-Chesa, Pilar; Rettig,
 CC APPLICANT: Old, Lloyd J.
 CC TITLE OF INVENTION: MONOCLONAL ANTIBODIES WHICH BIND TO
 CC TITLE OF INVENTION: TUMOR REJECTION ANTIGEN PRECURSOR MAGE-1, RECOMBINANT MAGE
 CC TITLE OF INVENTION: AND MAGE-1 DERIVED IMMUNOGENIC PEPTIDES
 CC NUMBER OF SEQUENCES: 4
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Elfie S. Lynch
 CC STREET: 805 Third Avenue
 CC STATE: New York City
 CC ZIP: 10022
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 5.25 inch, 360 kb storage

CC COMPUTER: IBM
 CC OPERATING SYSTEM: PC-DOS
 CC SOFTWARE: Nordperfect
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/190,411A
 CC FILING DATE: 01-FEBRUARY-1994
 CC CLASSIFICATION: 46
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 037,230
 CC FILING DATE: 26-MARCH-1993
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: PCT/US92/04354
 CC FILING DATE: 12-DECEMBER-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/764,364
 CC FILING DATE: 23-SEPTEMBER-1991
 CC PRIOR APPLICATION DATA:
 CC APPLICATION NUMBER: 07/705,702
 CC FILING DATE: 23-MAY-1991
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Hansson, NC, 5541104man D.
 CC REGISTRATION NUMBER: 30,946
 CC REFERENCE/DOCKET NUMBER: LUD 5354
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (212) 688-9200
 CC TELEFAX: (212) 838-3884
 CC INFORMATION FOR SEQ ID NO: 4:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 12 amino acid residues
 CC TYPE: amino acid
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: Protein
 CC SEQUENCE 12 AA: 1318 MW; 944 CN;
 CC Query Match Similarity 100.0%; Score 61; DB 1; Length 12;
 CC Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 CC Matches 0; Mismatches 0; Gaps 0;
 CC Indels 0;

Db 4 EADPFGHSY 12
 |||||
 1 EADPFGHSY 9

RESULT 22
 ID US-08-465-167A-24 STANDARD: PRT; 309 AA.
 XX XXXXXX
 AC
 DT
 XX
 DE Sequence 24, Application US/08465167A
 CC Sequence 24, Application US/08465167A
 CC GENERAL INFORMATION:
 CC Paten No. 5750395
 CC APPLICANT: Fikes, John D.
 CC APPLICANT: Livingston, Brian D.
 CC APPLICANT: Sette, Alessandro D.
 CC APPLICANT: Sidney, John C.
 CC TITLE OF INVENTION: DNA ENCODING MAGE-1 C-TERMINAL
 CC NUMBER OF SEQUENCES: 51
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Townsend and Townsend and Crew LLP
 CC STREET: Two Embarcadero Center, 8th Floor
 CC CITY: San Francisco
 CC STATE: CA

CC COUNTRY: USA
 CC ZIP: 98111
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Floppy disk
 CC COMPUTER: IBM PC compatible
 CC OPERATING SYSTEM: PC-DOS/MS-DOS
 CC SOFTWARE: Patentnet Release #1.0, version #1.25
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/465,167A
 CC FILING DATE: 05 JUN 1995
 CC CLASSIFICATION: 435
 CC PRIORITY APPLICATION NUMBER: US 08/103,623
 CC APPLICATION NUMBER: US 08/465,167A
 CC FILING DATE: 06-AUG-1993
 CC ATTORNEY/AGENT INFORMATION:
 CC NAME: Parmelee, Steven W.
 CC REGISTRATION NUMBER: 31,990
 CC REFERENCE/DOCKET NUMBER: 14137-60-1
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: 206-457-9500
 CC TELEFAX: 415-576-0000
 CC INFORMATION FOR SEQ ID NO: 24:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 309 amino acids
 CC TYPE: amino acid
 CC STRANDEDNESS: single
 CC TOPOLOGY: linear
 CC MOLECULE TYPE: protein
 CC SEQUENCE 309 AA: 34342 MW: 512752 CN:
 Query Match Similarity 100.0%; Score 61; DB 1; Length 309;
 Best Local Similarity 100.0%; Pred. No. 1.24e-01;
 Matches 9; Conservative 0; Indels 0; Gaps 0;
 Db 161 EADPTGHSY 169
 Qy 1 EADPTGHSY 9

RESULT 23
 ID US-08-993-118-10 STANDARD PRT: 309 AA.
 XX XXXXXX
 AC DT
 DE Sequence 10, Application US/08993118
 CC CORRESPONDENCE ADDRESS:
 CC ADDRESSEE: Feifei & Lynch
 CC STREET: 805 Third Avenue
 CC CITY: New York City
 CC STATE: New York
 CC COUNTRY: USA
 CC ZIP: 10022
 CC COMPUTER READABLE FORM:
 CC MEDIUM TYPE: Diskette, 3.5 inch, 360 kb storage
 CC COMPUTER: IBM PS/2
 CC OPERATING SYSTEM: PC-DOS
 CC SOFTWARE: Wordperfect
 CC CURRENT APPLICATION DATA:
 CC APPLICATION NUMBER: US/08/845,528C
 CC FILING DATE: April 25, 1997
 CC REFERENCE/DOCKET NUMBER: LUD 5455
 CC TELECOMMUNICATION INFORMATION:
 CC TELEPHONE: (212) 688-9200
 CC INFORMATION FOR SEQ ID NO: 10:
 CC SEQUENCE CHARACTERISTICS:
 CC LENGTH: 309

CC
CC
CC
CC
SEQUENCE 309 AA; 34342 MN; 512752 CN;
Query Match 100.0%; Score 61; DB 3; Length 309;
Best Local Similarity 100.0%; Pred. No. 1.24e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Db 161 EADPTGHSY 169
|||||||
Qy 1 EADPTGHSY 9

Search completed: Wed Sep 13 07:14:50 2000
Job time : 8 secs.

| | | | | | | |
|----|--------|------|--------|----|----------|-------------------------------|
| 25 | 1762.6 | 31.1 | 4204 | 9 | HSU03735 | Human MAGE-Sequence 13 |
| 26 | 1678.8 | 29.6 | 2531 | 5 | I36938 | I36928 Human MAGE-Sequence 14 |
| 27 | 1678.8 | 29.6 | 2531 | 5 | I36939 | I36929 Human MAGE-Sequence 14 |
| 28 | 1567.7 | 29.6 | 3871 | 10 | HSU10691 | U10691 Human MAGE-Sequence 15 |
| 29 | 1555.6 | 27.4 | 43927 | 11 | HSU9568 | U69568 Human Xq28 |
| 30 | 1555 | 27.4 | 118440 | 50 | AC016939 | AC016939 Homo sapi |
| 31 | 1536.4 | 27.1 | 3680 | 10 | HSU10692 | U10692 Human MAGE-Sequence 16 |
| 32 | 1535.3 | 27.1 | 111560 | 50 | AC016940 | AC016940 Homo sapi |
| 33 | 1504.6 | 26.5 | 2305 | 5 | I36932 | I36932 Human MAGE-Sequence 17 |
| 34 | 1410.8 | 24.9 | 2226 | 5 | I36931 | I36931 Human MAGE-Sequence 16 |
| 35 | 1396.6 | 24.6 | 74299 | 50 | AC016941 | AC016941 Homo sapi |
| 36 | 1353.8 | 23.9 | 73360 | 11 | HSU06083 | U6083 Human contig |
| 37 | 1247.4 | 22.0 | 3839 | 10 | HSU10693 | U10693 Human MAGE-Sequence 18 |
| 38 | 1226.6 | 21.6 | 2931 | 10 | HSU10694 | U10694 Human MAGE-Sequence 18 |
| 39 | 1051. | 18.5 | 3672 | 10 | HSU10686 | U10686 Human MAGE-Sequence 19 |
| 40 | 988.8 | 17.4 | 1640 | 5 | I36926 | I36926 Human MAGE-Sequence 11 |
| 41 | 955.8 | 16.8 | 16556 | 69 | AC024727 | AC024727 Homo sapi |
| 42 | 900.2 | 15.9 | 1810 | 5 | I36935 | I36935 Human MAGE-Sequence 11 |
| 43 | 866 | 15.3 | 3510 | 10 | HSU10685 | U10685 Human MAGE-Sequence 11 |
| 44 | 863.4 | 15.2 | 165648 | 69 | AC024727 | AC024727 Homo sapi |
| 45 | 834.4 | 14.7 | 1094 | 5 | AR05273 | AR05273 Sequence |

ALIGNMENTS

| | | | |
|------------|------------------------------------|------------|---|
| RESULT | 1 | REFERENCE | |
| 06060975 | AR060975 | AUTHORS | Chen, Y., Garin-Chesa, P., Rettig, W.J. and Old, L.J. |
| DEFINITION | 5674 bp | LOCATION | Stockert, E. |
| SEQUENCE | Sequence 1 from patent US 5843448. | QUALIFIERS | Old,L.J. |
| ACCESSION | AR060975 | TITLE | Tumor rejection antigen precursor |
| VERSION | AR060975.1 | PATENT | US 5843448 A 1 01-DEC-1998; |
| KEYWORDS | GI:5988666 | SOURCE | Location/Qualifiers |
| UNKNOWN | Unknown. | 1. | 1..5674 |
| ORGANISM | Unclassified. | ORGANISM | /Organization="unknown" |
| SOURCE | 1 (bases 1 to 5674) | COUNT | 1276 a 1644 c 1569 g 1185 t |
| REFERENCE | Old,L.J. | LINE | 1276 a 1644 c 1569 g 1185 t |

| | | | |
|----|------|---|------|
| Db | 1381 | CGTTGCCCTGCTCAACCCAGGAACCCCTGATGTGAACCACGTACT | 1440 |
| Qy | 1441 | TGAACCTCAGATCTGAGGAAGCCAGGTCAATTAACTGGTCTGAG | 1500 |
| Db | 1441 | TGAACCTCAGATCTGAGGAAGCCAGGTCAATTAACTGGTCTGAG | 1500 |
| Qy | 1501 | ATCCACTGAGGAACTGGTGTAGGCTCTGGAGGAAAGGTGCTAGGGAGG | 1560 |
| Db | 1501 | ATCCACTGAGGAACTGGTGTAGGCTCTGGAGGAAAGGTGCTAGGGAGG | 1560 |
| Qy | 1561 | ACTGGAGGAAACACCCAGTAGTCACCCCCAATGATCCAGTACACCCCTGCTG | 1620 |
| Db | 1561 | ACTGGAGGAAACACCCAGTAGTCACCCCCAATGATCCAGTACACCCCTGCTG | 1620 |
| Qy | 1621 | CCAGCCTGGACCAACCCGGCAGGACAGATGTCAGCTGGCCCGTCC | 1680 |
| Db | 1621 | CCAGCCTGGACCAACCCGGCAGGACAGATGTCAGCTGGCCCGTCC | 1680 |
| Qy | 1681 | CACGCCACTAACCCACAGGCATCTTAACTAGTGTAGGCGGGCAGGTT | 1740 |
| Db | 1681 | CACGCCACTAACCCACAGGCATCTTAACTAGTGTAGGCGGGCAGGTT | 1740 |
| Qy | 1741 | GTCAGAGGAGGAGGGCAAGGATCAAGTCAGCCGGCATAGGTCAAG | 1800 |
| Db | 1741 | GTCAGAGGAGGAGGGCAAGGATCAAGTCAGCCGGCATAGGTCAAG | 1800 |
| Qy | 1801 | ACCTGGAGGAACTGAGGTTCCCAACCTGTCCTCCATCAGCCGACC | 1860 |
| Db | 1801 | ACCTGGAGGAACTGAGGTTCCCAACCTGTCCTCCATCAGCCGACC | 1860 |
| Qy | 1861 | CCACTCACATCCCATACTACCCCAACCTCATCTGTCAAGATCCCTGCTG | 1920 |
| Db | 1861 | CCACTCACATCCCATACTACCCCAACCTCATCTGTCAAGATCCCTGCTG | 1920 |
| Qy | 1921 | TCAAACCCAGGAACGCAACGGCAAGGGCAAGGGCAATCCATCCA | 1980 |
| Db | 1921 | TCAAACCCAGGAACGCAACGGCAAGGGCAAGGGCAATCCATCCA | 1980 |
| Qy | 1981 | GGCTGTAGTGGAAAGGGCTGAACTGGCTCAAGGGAGGGCCCTAC | 2040 |
| Db | 1981 | GGCTGTAGTGGAAAGGGCTGAACTGGCTCAAGGGAGGGCCCTAC | 2040 |
| Qy | 2041 | TGGAGATAGGGAGGCTTAAGGACCCCTAGACCGCACCTGCTAG | 2100 |
| Db | 2041 | TGGAGATAGGGAGGCTTAAGGACCCCTAGACCGCACCTGCTAG | 2100 |
| Qy | 2101 | ACTGGGGTCACACTCTGCCCTCAAGAATCAGACATGGGACTCATGGG | 2160 |
| Db | 2101 | ACTGGGGTCACACTCTGCCCTCAAGAATCAGACATGGGACTCATGGG | 2160 |
| Qy | 2161 | GTGGGACCCAGGCTGCAAGGCTTAAGGACCCCTAGACGGGACCTT | 2220 |
| Db | 2161 | GTGGGACCCAGGCTGCAAGGCTTAAGGACCCCTAGACGGGACCTT | 2220 |
| Qy | 2221 | GGAACTCAGATCAGGAGGAGGTCTACGGGGAGGAGGAGGACTCATG | 2280 |
| Db | 2221 | GGAACTCAGATCAGGAGGAGGTCTACGGGGAGGAGGAGGACTCATG | 2280 |
| Qy | 2281 | GCCCCATATTCCTGCACTCTGAGGTGAGGAGGAGGACTCATGGGGC | 2340 |
| Db | 2281 | GCCCCATATTCCTGCACTCTGAGGTGAGGAGGAGGAGGACTCATGGGGC | 2340 |
| Qy | 2341 | TCAAGTCAACAGAGGAGGAGGTCTACGGGATCCATATGGCCAAAGATG | 2400 |
| Db | 2341 | TCAAGTCAACAGAGGAGGAGGTCTACGGGATCCATATGGCCAAAGATG | 2400 |
| Qy | 2401 | AGGATGGGATATCCTGGAGGAGGAGGAGGAGGAGGAGGACTCCAC | 2460 |
| Db | 2401 | AGGATGGGATATCCTGGAGGAGGAGGAGGAGGAGGAGGACTCCAC | 2460 |
| Qy | 2461 | TTAGTAGTCCTAGGGGACCAAGGACACATAGGGATGGCGTAGTCACTGTACCA | 2520 |
| Db | 2461 | TTAGTAGTCCTAGGGGACCAAGGACACATAGGGATGGCGTAGTCACTGTACCA | 2520 |

| | | |
|-----------------------|---|------------|
| VERSION | I24013.1 | GI:1603883 |
| KEYWORDS | Unknown | |
| ORGANISM | Unknown | |
| REFERENCE | Unclassified. | |
| AUTHORS | Chen,Y., Stockert,E., Chen,Y., Garin-Chesa,P., Rettig,W.J., van der Brugge,P., Boon-Falleur,T. and Old,L.J. | |
| TITLE | Monoclonal antibodies which bind to tumor rejection antigen precursor image-1 | |
| JOURNAL | Patent: US 5541104-A 1 30-JUL-1996; | |
| FEATURES | Location/Qualifiers | |
| source | 1..5674 /organism="unknown" | |
| BASE COUNT | 1276 a 1644 c 1569 g 1185 t | |
| ORIGIN | | |
| Query Match | 100.0% Score 5674; DB 5; Length 5674; | |
| Best Local Similarity | 100.0%; Pred. No. 0; | |
| Matches | 5674; Conservative 0; Mismatches 0; Indels 0; Gaps 0; | |
| Qy | 1 CCGGGGACCCACTGGCATTCCTACCCCCAATCCTCCTAACGCCACC 60 | |
| Db | 1 CCGGGGACCCACTGGATTCCTACCCCCAATCCTCCTAACGCCACC 60 | |
| Qy | 61 ATCCAAACATCTTCAAGCTAACCCCCAACGCCAACGGCAATCGGTTCACCCCTG 120 | |
| Db | 61 ATCCAAACATCTTCAAGCTAACCCCCAACGCCAACGGCAATCGGTTCACCCCTG 120 | |
| Qy | 121 CTCTAACACGGAAACCCAAAGTGGCCACTGACTTGACATTAGTG 180 | |
| Db | 121 CTCTAACACGGAAACCCAAAGTGGCCACTGACTTGACATTAGTG 180 | |
| Qy | 181 TTAGAGAAAGGAGGGTTTCGGCTGAAGGGGGCTTGATCGGGAGGAACGG 240 | |
| Db | 181 TTAGAGAAAGGAGGGTTTCGGCTGAAGGGGGCTTGATCGGGAGGAACGG 240 | |
| Qy | 241 CCCAGCTCTGTAAGGGCAAGTGTGACATGCTGAGGACACTTACCCC 300 | |
| Db | 241 CCCAGCTCTGTAAGGGCAAGTGTGACATGCTGAGGACACTTACCCC 300 | |
| Qy | 301 AGATAGAGGACCCAAATAATCCTCTATGCGACTCTGAGCATGTTGGGACATC 360 | |
| Db | 301 AGATAGAGGACCCAAATAATCCTCTATGCGACTCTGAGCATGTTGGGACATC 360 | |
| Qy | 361 TCAAGGTGGCACCCCCAGGCCCTTGCGCTTAACCATGGGACTCAAGTCAG 420 | |
| Db | 361 TCAAGGTGGCACCCCCAGGCCCTTGCGCTTAACCATGGGACTCAAGTCAG 420 | |
| Qy | 421 CTCCGTGTTGATCAGGGAGGGCTGTTAGGGAGGGCACGGTCCAGGCTCGCCAGCAT 480 | |
| Db | 421 CTCCGTGTTGATCAGGGAGGGCTGTTAGGGAGGGCACGGTCCAGGCTCGCCAGCAT 480 | |
| Qy | 481 CATGCTCAGGATTCTCAAGGAGGGCTGACCCACCCCTCTCATTCAGCTGACCCAAAC 540 | |
| Db | 481 CATGCTCAGGATTCTCAAGGAGGGCTGACCCACCCCTCTCATTCAGCTGACCCAAAC 540 | |
| Qy | 541 CCCCACTCCAACTGCTCACTCCGACCAACCCCTCTCATTCAGCTGACCCAAAC 600 | |
| Db | 541 CCCCACTCCAACTGCTCACTCCGACCAACCCCTCTCATTCAGCTGACCCAAAC 600 | |
| Qy | 601 CCCCAACTCCCCACCCATCCCTACCCCTGATGCCATTCGCCCCAGCTTCCACCC 660 | |
| Db | 601 CCCCAACTCCCCACCCATCCCTACCCCTGATGCCATTCGCCCCAGCTTCCACCC 660 | |
| Qy | 661 CACCCCACTCCCCACCCCAAGCCCAACTCCACCCCTGATGCCATTCGCCCCAGCTTCCACCC 720 | |
| Db | 661 CACCCCACTCCCCACCCCAAGCCCAACTCCACCCCTGATGCCATTCGCCCCAGCTTCCACCC 720 | |
| Qy | 721 CCAGGAAACATCCTGGGTGCGGGGAGGTGAGGGTCCAGGGCAAGAGA 780 | |
| Db | 721 CCAGGAAACATCCTGGGTGCGGGGAGGTGAGGGTCCAGGGCAAGAGA 780 | |

| | | | |
|----|-------|--|-------|
| Db | 4 021 | CACTGTGGTCAAAGATCTCCAGAGTCAGCGCTTCCACTAC | 4 080 |
| Qy | 4 081 | CATCAACTTCACTGACAGGGCAACCCAGTGGGTTCAGCGCTGAAAGGGGG | 4 140 |
| Db | 4 081 | CATCAACTTCACTGACAGGGCAACCCAGTGGGTTCAGCGCTGAAAGGGGG | 4 140 |
| Qy | 4 141 | GCCAGGCACCTCTGATCCTGGAGTCTCCCTGTTCCAGGATTAATCAAGAGGTGC | 4 200 |
| Db | 4 141 | GCCAGGCACCTCTGATCCTGGAGTCTCCCTGTTCCAGGATTAATCAAGAGGTGC | 4 200 |
| Qy | 4 201 | TGATTGGTGGTTTCGGCTCTGGTCAAATATCGAGCCAGCACAAAGGCCA | 4 260 |
| Db | 4 201 | TGATTGGTGGTTTCGGCTCTGGTCAAATATCGAGCCAGCACAAAGGCCA | 4 260 |
| Qy | 4 261 | AATGCTGGAGAGTGTCACTCAAAAATACAAAGCACTGTTCTCGCAAAAGC | 4 320 |
| Db | 4 261 | AATGCTGGAGAGTGTCACTCAAAAATACAAAGCACTGTTCTCGCAAAAGC | 4 320 |
| Qy | 4 321 | CTCTGAGTCCTTGCAGCTCTGGCATTTGGTGAAGGAGCCACCGCCA | 4 380 |
| Db | 4 321 | CTCTGAGTCCTTGCAGCTCTGGCATTTGGTGAAGGAGCCACCGCCA | 4 380 |
| Qy | 4 381 | CTCCPATGTCCTGACCTGCCAGGCTCTCTCTATGAGCCTGCGTGTATAATCA | 4 440 |
| Db | 4 381 | CTCCPATGTCCTGACCTGCCAGGCTCTCTCTATGAGCCTGCGTGTATAATCA | 4 440 |
| Qy | 4 441 | GATCATGCCAAAGAGGGCTTCCCTGATAATGTCCTGGCATGATGGCAATGGGG | 4 500 |
| Db | 4 441 | GATCATGCCAAAGAGGGCTTCCCTGATAATGTCCTGGCATGATGGCAATGGGG | 4 500 |
| Qy | 4 501 | CCATGCTCCGAGGGAAATCTGGAGGCTCTGGCTAGTGATGGTATGGGAG | 4 560 |
| Db | 4 501 | CCATGCTCCGAGGGAAATCTGGAGGCTCTGGCTAGTGATGGTATGGGAG | 4 560 |
| Qy | 4 561 | GGAGCACAGTCCTATGGGAGGCCAGGAAGCTGCTCACCAAGATTTGGCAGAAA | 4 620 |
| Db | 4 561 | GGAGCACAGTCCTATGGGAGGCCAGGAAGCTGCTCACCAAGATTTGGCAGAAA | 4 620 |
| Qy | 4 621 | GTACCTGGTAGTCAGCAGGGCAGACTGATCCCGAACGCTPATGAGTTCTGGGGT | 4 680 |
| Db | 4 621 | GTACCTGGTAGTCAGCAGGGCAGACTGATCCCGAACGCTPATGAGTTCTGGGGT | 4 680 |
| Qy | 4 681 | CCAAAGGCCCTGCCTGAAACACGATGATGGTAAGTCTGAGTGTACAGTCAGT | 4 740 |
| Db | 4 681 | CCAAAGGCCCTGCCTGAAACACGATGATGGTAAGTCTGAGTGTACAGTCAGT | 4 740 |
| Qy | 4 741 | GCAAGAGTTGCTCTTCTCCATCCCCTCGTGAAGCAGCTTGAGAGGGAAAGAG | 4 800 |
| Db | 4 741 | GCAAGAGTTGCTCTTCTCCATCCCCTCGTGAAGCAGCTTGAGAGGGAAAGAG | 4 800 |
| Qy | 4 801 | GGAGCTGACATGAGTGGAGCCAGGGCAAGTGGGAGGGACTGGSCACCTT | 4 860 |
| Db | 4 801 | GGAGCTGACATGAGTGGAGCCAGGGCAAGTGGGAGGGACTGGSCACCTT | 4 860 |
| Qy | 4 861 | CCAGGCCCCGCTCCAGGCTCCAGGCTCCAGGCTCCAGGCTCCAGGCTCCAGG | 4 920 |
| Db | 4 861 | CCAGGCCCCGCTCCAGGCTCCAGGCTCCAGGCTCCAGGCTCCAGGCTCCAGG | 4 920 |
| Qy | 4 921 | GAAGAGGGCTCACTGTCTCAGTAGAGTGTCTGATGGGAGCTGGAGATT | 4 980 |
| Db | 4 921 | GAAGAGGGCTCACTGTCTCAGTAGAGTGTCTGATGGGAGCTGGAGATT | 4 980 |
| Qy | 4 981 | TATCTTGTCTCTGGATTGTCATAAGTGTCTTAAAGGATGGTGAATGAC | 5 040 |
| Db | 4 981 | TATCTTGTCTCTGGATTGTCATAAGTGTCTTAAAGGATGGTGAATGAC | 5 040 |
| Qy | 5 041 | TTCAGATCCAAAGTTATGAAATGACAGCTCACAGTCTGTTATAGTTAAAGG | 5 100 |
| Db | 5 041 | TTCAGATCCAAAGTTATGAAATGACAGCTCACAGTCTGTTATAGTTAAAGG | 5 100 |
| Qy | 5 101 | TAAGACTCTGTGTTTATCAGATGGGAAATCCATCTATTTGTGATTTGGGAT | 5 160 |
| Db | 5 101 | TAAGACTCTGTGTTTATCAGATGGGAAATCCATCTATTTGTGATTTGGGAT | 5 160 |

| | | |
|----|------|---|
| Db | 2281 | GCCCATATTCCTGCATPTGAGGTGAGGAACAGGTGAGGGC 2340 |
| Qy | 2341 | TCAAGTCAAGAAGGGAGGTTCCAGGATCCATATGGCCAAGATGTCCTTCATG 2400 |
| Db | 2341 | TCAAGTCAAGAAGGGAGGTTCCAGGATCCATATGGCCAAGATGTCCTTCATG 2400 |
| Qy | 2401 | AGGACTGGGATAATCCCGCTCAAAGGAACTCCACAGTCTGTCGCCCTT 2460 |
| Db | 2401 | AGGACTGGGATAATCCCGCTCAAAGGAACTCCACAGTCTGTCGCCCTT 2460 |
| Qy | 2461 | TTAGTAGCTCTAGGGGACAGATCAGGGTGGGGTATCTACTTGACCA 2520 |
| Db | 2461 | TAGTAGCTCTAGGGGACAGATCAGGGTGGGGTATCTACTTGACCA 2520 |
| Qy | 2521 | CAGCAGGAAGTTGGGGCCCTCAGGGAGATGGGTCTGGGTAAGGGGGATGCT 2580 |
| Db | 2521 | CAGCAGGAAGTTGGGGCCCTCAGGGAGATGGGTCTGGGTAAGGGGGATGCT 2580 |
| Qy | 2581 | ACTATGTCAGGGATTGGGGCTGGAGGAACTGGGAGGATAAAGATGAGT 2640 |
| Db | 2581 | ACTATGTCAGGGATTGGGGCTGGAGGAACTGGGAGGATAAAGATGAGT 2640 |
| Qy | 2641 | GAGCACAGAGGTTATGGATCTGAAGCTAACCCAGGTCACCCCTGGACACC 2700 |
| Db | 2641 | GAGCACAGAGGTTATGGATCTGAAGCTAACCCAGGTCACCCCTGGACACC 2700 |
| Qy | 2701 | TCACOAGGAGTGGCTTCACTCTGTTCACTCTGTTCACTCTGGGAGGTGGACCT 2760 |
| Db | 2701 | TCACOAGGAGTGGCTTCACTCTGTTCACTCTGGGAGGTGGACCT 2760 |
| Qy | 2761 | CATTCTAGGGGTOACTCTGGTCACTGGGACCTGGCTTAAGAACAGGG 2820 |
| Db | 2761 | CATTCTAGGGGTOACTCTGGGACCTGGCTTAAGAACAGGG 2820 |
| Qy | 2821 | GTCAGGAGGATGCGATGGCTGGGAGACTGGTCACTGGGACCTGGGACCTGG 2880 |
| Db | 2821 | GTCAGGAGGATGCGATGGCTGGGAGACTGGTCACTGGGACCTGGGACCTGG 2880 |
| Qy | 2881 | GACCGAAACCTGGGAGCTGCAGAAATCAGGGAAACATGGGAGGACTGGGACCTGG 2940 |
| Db | 2881 | GACCGAAACCTGGGAGCTGCAGAAATCAGGGAAACATGGGAGGACTGGGACCTGG 2940 |
| Qy | 2941 | AGCAGGGCTGGGCTGGCTGGGAGCTGGCTGGGAGCTGGCTGGGAGCTGG 3000 |
| Db | 2941 | AGCAGGGCTGGGCTGGCTGGGAGCTGGCTGGGAGCTGGCTGGGAGCTGG 3000 |
| Qy | 3001 | ACGGGAGGCCCCCTGGCTGAGGAAGGCTGGCTCACTAGCAGGGAGGCTGG 3060 |
| Db | 3001 | ACGGGAGGCCCCCTGGCTGAGGAAGGCTGGCTCACTAGCAGGGAGGCTGG 3060 |
| Qy | 3061 | CTGCCAGGAGCTCAAGGTGAGGACCAAGGGCGGACTCCACCAAGACATTAATCCAAAT 3120 |
| Db | 3061 | CTGCCAGGAGCTCAAGGTGAGGACCAAGGGCGGACTCCACCAAGACATTAATCCAAAT 3120 |
| Qy | 3121 | GAATTTGATATCCTTGCCTTCATCCCTATCACTGGTGAACCTCTGATGGGATCTCG 3180 |
| Db | 3121 | GAATTTGATATCCTTGCCTTCATCCCTATCACTGGTGAACCTCTGATGGGATCTCG 3180 |
| Qy | 3181 | GTCCCCCTCTGTCCTTCATCCCTATCACTGGTGAACCTCTGATGGGATCTCG 3240 |
| Db | 3181 | GTCCCCCTCTGTCCTTCATCCCTATCACTGGTGAACCTCTGATGGGATCTCG 3240 |
| Qy | 3241 | ACCGAAAGGGCAGGATCAGGCCCTGGGAAATAAGGGCTGGCTGGTGAAGA 3300 |
| Db | 3241 | ACCGAAAGGGCAGGATCAGGCCCTGGGAAATAAGGGCTGGTGAAGA 3300 |
| Qy | 3301 | CAGAGGGGTTCATCCACTGATGAGGTGGGATGTCACAGAGTCAGGCCACCCCTCTG 3360 |
| Db | 3301 | CAGAGGGGTTCATCCACTGATGAGGTGGGATGTCACAGAGTCAGGCCACCCCTCTG 3360 |
| Qy | 3361 | GTAGGACTGGAAGCAGGGCTGAGGCCCTGGGATGTCACAGAGTCAGGCCACCCCTCTG 3420 |
| Db | 3361 | GTAGGACTGGAAGCAGGGCTGAGGCCCTGGGATGTCACAGAGTCAGGCCACCCCTCTG 3420 |

| | | | | | |
|----|------|--|----|-------|---|
| Qy | 4501 | CCATGCTCCTGAGGAGGAATCTGGAGGAGGTGAGTGTGAGGGGTATGATGGAG 4 560 | Db | 5581 | GTGGAGTGTAATGCCCTGAGCTGGCATTTGGAAACCTGGCTCTTC 5640 |
| Db | 4501 | CCATGCTCCTGAGGAGGAATCTGGAGGAGGTGAGTGTGAGGGGTATGATGGAG 4 560 | Qy | 5641 | GGGGAGCTGATTTGGATCTCTGGGATTC 5674 |
| Qy | 4561 | GGAGCACACTGCTATGGGAGCCAGGCTACCCAGATTGGTAGGAAA 4 620 | Db | 5641 | GGGGAGCTGATTTGGATTC 5674 |
| Db | 4561 | GGAGCACACTGCTATGGGAGCCAGGCTACCCAGATTGGTAGGAAA 4 620 | Qy | 4621 | GTAAGCTGGAGTACGGCAGGTGGCGAACAGTGTGATCCCACGGTAGTGTGGGT 4 680 |
| Db | 4621 | GTAAGCTGGAGTACGGCAGGTGGCGAACAGTGTGATCCCACGGTAGTGTGGGT 4 680 | Db | 82670 | 275159 bp DNA Homo sapiens chromosome Xq28 pSHMG17 Pseudogene, complete sequence; and melanoma antigen family A1 (MAGEA1) and zinc finger protein 275 (ZNF275) genes, complete cds. U82670 U82672 |
| Qy | 4681 | CAAGGGGCCTCGCTGAGAACAGCTATGTAAGTCTTGTAGTATGTGAGTCAGT 4 740 | Qy | 4681 | CAAGGGGCCTCGCTGAGAACAGCTATGTAAGTCTTGTAGTATGTGAGTCAGT 4 740 |
| Db | 4681 | CAAGGGGCCTCGCTGAGAACAGCTATGTAAGTCTTGTAGTATGTGAGTCAGT 4 740 | Qy | 4741 | CGAGAGTCGCTTTCTCCATCCCTGGGACTGGCCAGTGGAGGAGAG 4 800 |
| Db | 4741 | CGAGAGTCGCTTTCTCCATCCCTGGGACTGGCCAGTGGAGGAGAG 4 800 | Db | 4801 | GGAGTCGAGATGAGTGGCAGCAAGGGCAGTGGAGGGACTGGCCAGTGGCACCT 4 860 |
| Qy | 4801 | GGAGTCGAGATGAGTGGCAGCAAGGGCAGTGGAGGGACTGGCCAGTGGCACCT 4 860 | Db | 4801 | GGAGTCGAGATGAGTGGCAGCAAGGGCAGTGGAGGGACTGGCCAGTGGCACCT 4 860 |
| Db | 4801 | GGAGTCGAGATGAGTGGCAGCAAGGGCAGTGGAGGGACTGGCCAGTGGCACCT 4 860 | Qy | 4861 | CAAGGGCCGGTCCAGGAGCTTCCCTTGCTGTGACATGGGCCCATTTCACTCT 4 920 |
| Db | 4861 | CAAGGGCCGGTCCAGGAGCTTCCCTTGCTGTGACATGGGCCCATTTCACTCT 4 920 | Db | 4861 | CAAGGGCCGGTCCAGGAGCTTCCCTTGCTGTGACATGGGCCCATTTCACTCT 4 920 |
| Qy | 4921 | GAAGAGCCGGTCAAGTGTCTCAGTAGGGTCACTGGTGACTGGAGAC 4 980 | Qy | 4921 | GAAGAGCCGGTCAAGTGTCTCAGTAGGGTCACTGGTGACTGGAGAC 4 980 |
| Db | 4921 | GAAGAGCCGGTCAAGTGTCTCAGTAGGGTCACTGGTGACTGGAGAC 4 980 | Db | 4981 | TATCTTGTCTCTTGGAAATTGTCAAATGTTTAAAGGGATGTTGAATGAAAC 5040 |
| Qy | 4981 | TATCTTGTCTCTTGGAAATTGTCAAATGTTTAAAGGGATGTTGAATGAAAC 5040 | Db | 4981 | TATCTTGTCTCTTGGAAATTGTCAAATGTTTAAAGGGATGTTGAATGAAAC 5040 |
| Db | 4981 | TATCTTGTCTCTTGGAAATTGTCAAATGTTTAAAGGGATGTTGAATGAAAC 5040 | Qy | 5041 | TTCAGCATCAAGTTATGAAATGACAGGTACACAGTTCTGTATACTTTAAAGG 5100 |
| Db | 5041 | TTCAGCATCAAGTTATGAAATGACAGGTACACAGTTCTGTATACTTTAAAGG 5100 | Db | 5041 | TTCAGCATCAAGTTATGAAATGACAGGTACACAGTTCTGTATACTTTAAAGG 5100 |
| Qy | 5041 | TTCAGCATCAAGTTATGAAATGACAGGTACACAGTTCTGTATACTTTAAAGG 5100 | Db | 5101 | TAAGACTCTGTTTATTCAGTTGGAAATTCATCTTATTTGGGATTAAT 5160 |
| Db | 5101 | TAAGACTCTGTTTATTCAGTTGGAAATTCATCTTATTTGGGATTAAT 5160 | Qy | 5161 | AACAGCAGTGGAAATAGTACTTAAATGAAATAGCCTAAATAGTGTGAGATAA 5220 |
| Qy | 5161 | AACAGCAGTGGAAATAGTACTTAAATGAAATAGCCTAAATAGTGTGAGATAA 5220 | Db | 5161 | AACAGCAGTGGAAATAGTACTTAAATGAAATAGCCTAAATAGTGTGAGATAA 5220 |
| Db | 5221 | AGAACTAAAGAAATTAAGCATAGTAACTTCCCTTATCTGCTTAAATAGGAGATAAT 5280 | Qy | 5221 | AGAACTAAAGAAATTAAGCATAGTAACTTCCCTTATCTGCTTAAATAGGAGATAAT 5280 |
| Db | 5221 | AGAACTAAAGAAATTAAGCATAGTAACTTCCCTTATCTGCTTAAATAGGAGATAAT 5280 | Db | 5281 | ATTTTAAGATATATGCACTACCTGGATTCTGGCTCTTGAGAAATGAGAAAT 5340 |
| Qy | 5281 | ATTTTAAGATATATGCACTACCTGGATTCTGGCTCTTGAGAAATGAGAAAT 5340 | Db | 5281 | ATTTTAAGATATATGCACTACCTGGATTCTGGCTCTTGAGAAATGAGAAAT 5340 |
| Db | 5341 | TAATCTGAAATTAAGAAATCTCCCTGTCACTGGCTCTTCTCATGACTGAGCA 5400 | Qy | 5341 | TAATCTGAAATTAAGAAATCTCCCTGTCACTGGCTCTTCTCATGACTGAGCA 5400 |
| Db | 5341 | TAATCTGAAATTAAGAAATCTCCCTGTCACTGGCTCTTCTCATGACTGAGCA 5400 | Db | 5401 | TCTGCTTGGAAAGCCCTGGGTAGTGGAGATGCTAAGCTGGCTCTTC 5460 |
| Qy | 5401 | TCTGCTTGGAAAGCCCTGGGTAGTGGAGATGCTAAGCTGGCTCTTC 5460 | Db | 5401 | TCTGCTTGGAAAGCCCTGGGTAGTGGAGATGCTAAGCTGGCTCTTC 5460 |
| Db | 5461 | CCACCCATAGGTCTTGAATGCTTCTGGAGCTGCACTCACTCATTAATGAGGTGCAAGATGC 5520 | Qy | 5461 | CCACCCATAGGTCTTGAATGCTTCTGGAGCTGCACTCACTCATTAATGAGGTGCAAGATGC 5520 |
| Db | 5461 | CCACCCATAGGTCTTGAATGCTTCTGGAGCTGCACTCACTCATTAATGAGGTGCAAGATGC 5520 | Db | 5521 | CTCTAAAGATTAAGGAAATCTGGAAATGAGGGTCACTCTGGCTTGGGAGGTG 5580 |
| Qy | 5521 | CTCTAAAGATTAAGGAAATCTGGAAATGAGGGTCACTCTGGCTTGGGAGGTG 5580 | Db | 5521 | CTCTAAAGATTAAGGAAATCTGGAAATGAGGGTCACTCTGGCTTGGGAGGTG 5580 |
| Qy | 5581 | GTGGAGTGTCAAATGCCCTGACCTGGAAACTGCACTGGCTTGGGAAACTGCACTGGCTTCTCT 5640 | Qy | 5581 | GTGGAGTGTCAAATGCCCTGACCTGGAAACTGCACTGGCTTGGGAAACTGCACTGGCTTCTCT 5640 |

```

repeat_region /rpt_family="LTR8"
  complement(3818..5353)
repeat_region /rpt_family="MSTA-internal"
repeat_region /rpt_family="MSTA"
repeat_region 5946..6175
repeat_region /rpt_family="HERVR"
repeat_region 6553..721
repeat_region /rpt_family="HUERS-P3"
repeat_region complement(7422..7887)
repeat_region /rpt_family="LTR19A"
repeat_region 7588..7902
repeat_region /rpt_family="HUERS-P3"
repeat_region complement(8146..8460)
repeat_region 8603..9022
repeat_region /rpt_family="AluJb"
repeat_region 9443..9437
repeat_region /rpt_family="MSTA"
repeat_region complement(9872..1036)
repeat_region /rpt_family="MER41A"
repeat_region 1037..1038
repeat_region /rpt_family="L2"
repeat_region complement(10383..11111)
repeat_region /rpt_family="MER1-internal"
repeat_region complement(11112..11400)
repeat_region /rpt_family="AluSg1"
repeat_region complement(11401..11700)
repeat_region /rpt_family="MER1-internal"
repeat_region complement(11700..11089)
repeat_region /rpt_family="MER4-internal"
repeat_region complement(13073..13190)
repeat_region /rpt_family="MER7-internal"
repeat_region complement(13787..13807)
repeat_region /rpt_family="MER57-internal"
repeat_region complement(13903..14255)
repeat_region /rpt_family="MER57-internal"
repeat_region 14274..15228
repeat_region /rpt_family="LIPAS5"
repeat_region 15217..18398
repeat_region /rpt_family="LIPAS5"
repeat_region 18442..18975
repeat_region /rpt_family="LIPAS5"
repeat_region 19013..19652
repeat_region /rpt_family="LTR49"
repeat_region 19335..52906
repeat_region /organism="Homo sapiens"
repeat_region /db_xref="ntaxon:9606"
repeat_region /clone="LK0813"
repeat_region 19653..20413
repeat_region /rpt_family="L1M3"
repeat_region 21078..21748
repeat_region /rpt_family="MER31-internal"
repeat_region 21752..21886
repeat_region /rpt_family="AluYa5/8"
repeat_region 21819..22268
repeat_region /rpt_family="MER31-internal"
repeat_region 22269..22477
repeat_region /rpt_family="AluJc"
repeat_region 22240..22618
repeat_region /rpt_family="MER31-internal"
repeat_region 22256..22957
repeat_region /rpt_family="MER31-internal"
repeat_region 22268..23269
repeat_region /rpt_family="AluJc"
repeat_region 23285..23685
repeat_region /rpt_family="L1M4"
repeat_region complement(24864..25145)
repeat_region /rpt_family="AluJb"
repeat_region 25444..25454
repeat_region /rpt_family="(GAA)n"
repeat_region complement(23765..25894)
repeat_region /rpt_family="MLT1H"

misc_feature 25769..26426
  /note="DSS52; acc. no. GDB:187392"
repeat_region 25918..26172
repeat_region /rpt_family="AluY"
repeat_region complement(26173..26252)
repeat_region /rpt_family="polypurine"
repeat_region 26252..26359
repeat_region /rpt_family="(TA)n"
repeat_region complement(26798..26907)
repeat_region /rpt_family="NIR"
repeat_region 31846..32441
repeat_region /note="CPG Island: 64.8 %GC, o/e=0.93, #CPGs=62"
repeat_region complement(32209..32167)
repeat_region /rpt_family="AluJc"
repeat_region complement(33163..33210)
repeat_region /rpt_family="AluJc"
repeat_region 34175..34216
repeat_region /rpt_family="MSTD"
repeat_region 34754..34823
repeat_region /rpt_family="MSTD"
repeat_region 35068..35384
repeat_region /rpt_family="MSTD"
repeat_region 35436..37928
repeat_region /rpt_family="HERVL"
repeat_region complement(38008..38402)
repeat_region /rpt_family="AluY"
repeat_region 38510..38962
repeat_region /rpt_family="LTR16B"
repeat_region 39463..39779
repeat_region /rpt_family="AluSx"
repeat_region complement(40031..40384)
repeat_region /rpt_family="L2"
repeat_region complement(40610..40802)
repeat_region /rpt_family="LIME1"
repeat_region complement(40759..40937)
repeat_region /rpt_family="LIM4"
repeat_region complement(41210..41395)
repeat_region /rpt_family="LIME"
repeat_region 41398..41663
repeat_region /rpt_family="L2"
repeat_region complement(41928..41993)
repeat_region /rpt_family="MLTFB"
repeat_region 41994..42022
repeat_region /rpt_family="(GA)n"
repeat_region complement(42033..42381)
repeat_region /rpt_family="MLTFB"
source 42155..103943
repeat_region /organism="Homo sapiens"
repeat_region /db_xref="taxon:9606"
repeat_region /clone="RPI-T11:K1776"
repeat_region /rpt_family="MLTFB"
repeat_region complement(42824..43114)
repeat_region 43685..44167
repeat_region /rpt_family="MLTFD"
repeat_region 44916..45363
repeat_region /rpt_family="MER41B"
repeat_region 47017..47143
repeat_region /rpt_family="MER85"
repeat_region complement(47288..47344)
repeat_region /rpt_family="L2"
repeat_region 47349..47645
repeat_region /rpt_family="AluJb"
repeat_region 48693..49693
repeat_region /rpt_family="THE1C-internal"

Query Match 98.18; Score 5566.2; DB 50; Length 275159;
Best Local Similarity 99.6%; Pred. No. 0; Mismatches 5654; Conservative 0; Indels 7; Gaps 7;
Matches 1 CCGGGGCCACCTGCGATCCCTCCCTACTACCCCCAACTCCCTCCCTAACGCCACCC 60
Qy ||||| 127368 CCGGGGCCACCTGCGATCCCTCCCTACTACCCCCAACTCCCTCCCTAACGCCACCC 127309

```

| | | | |
|-----|--------|--|--------|
| Qy | 61 | ATCCAAACATCTTCAAGCTCACCCCCAGGCCAACGGAGAAATCGGTTCCACCCCTG | 120 |
| Ddb | 127308 | ATCCAAACATCTTCAAGCTCACCCCCAGGCCAACGGAGAAATCGGTTCCACCCCTG | 122249 |
| Qy | 121 | CTCTCAACCCACGGAAACCCAGGTGCCACTGACTGAGCATTAATGTT | 180 |
| Ddb | 127248 | CTCTCAACCCACGGAAACCCAGGTGCCACTGACTGAGCATTAATGTT | 121789 |
| Qy | 181 | TTAGAGAAGACCGAGGTTTCGGTCTGAGGGGGGGTTGAGATCGTGGAGGAAGGGG | 240 |
| Ddb | 127188 | TTAGAGAAGACCGAGGTTTCGGTCTGAGGGGGGGTTGAGATCGTGGAGGAAGGGG | 127129 |
| Qy | 241 | CCCA - GCTCTGTAAGGGCAGGTGACATCTGAGGGGAGACTGGGACCACTTACCC | 299 |
| Ddb | 127128 | CCCAAGGGCTCTGTAAGGGCAGGTGACATCTGAGGGGAGACTGGGACCACTTACCC | 127069 |
| Qy | 300 | CAGATAAGGCCCAAATAATCCCTCATGCCAGTCCTGGACCATCTGGTGTGACTT | 359 |
| Ddb | 127068 | CAGATAAGGCCCAAATAATCCCTCATGCCAGTCCTGGACCATCTGGTGTGACTT | 127009 |
| Qy | 360 | CTCAGGGTGGCACCCAGGCCCTTGCGCTTAACACMTGGGACTGGTAATCAGA | 419 |
| Ddb | 127008 | CTCAGGGTGGCACCCAGGCCCTTGCGCTTAACACMTGGGACTGGTAATCAGA | 126949 |
| Qy | 420 | GTCCTGGTGTGATCAGGAAGGCTGCTTAGAGAAGGGCTCAAGGCTGGAGACA | 479 |
| Ddb | 126948 | AACTCGTTGTGATCAGGAAGGCTGCTTAGAGAAGGGCTCAAGGCTGGAGACA | 126889 |
| Qy | 480 | TATGTCAGGATTCTAAGGGGGCTGAGGGTCCCTAAGGCCCAACTCGTGCACCAA | 539 |
| Ddb | 126888 | TATGTCAGGATTCTAAGGGGGCTGAGGGTCCCTAAGGCCCAACTCGTGCACCAA | 126829 |
| Qy | 540 | CCGCCACTCCATGTCACTCCGGTACCCCAACCCCTCTCATGTCATGCCAACCCC | 599 |
| Ddb | 126828 | CCGCCACTCCATGTCACTCCGGTACCCCAACCCCTCTCATGTCATGCCAACCCC | 126769 |
| Qy | 600 | ACCCCAATCCCCACCCATGCCCTAACCTGATGCCATGCCGACGGATTGCC | 659 |
| Ddb | 126768 | ACCCCAATCCCCACCCATGCCCTAACCTGATGCCATGCCGACGGATTGCC | 126709 |
| Qy | 660 | TGACCCCCACCCACCCCAACCCCACTCCACCCOCACCCAGGGAGGATCGTTCCC | 719 |
| Ddb | 126708 | TGACCCCCACCCACCCCAACCCCACTCCACCCOCACCCAGGGAGGATCGTTCCC | 126649 |
| Qy | 720 | GCGAGGAACATCGGTGCGGATGTCGGAATGTTGGGGAG | 779 |
| Ddb | 126648 | GCGAGGAACATCGGTGCGGATGTCGGAATGTTGGGGAG | 126589 |
| Qy | 780 | AGAAGCAGGGTTCCATCTGAGGGAGGGTAGATGTTGGGGAG | 839 |
| Ddb | 126588 | AGAAGCAGGGTTCCATCTGAGGGAGGGTAGATGTTGGGGAG | 126529 |
| Qy | 840 | GCTCTGTGAGGAGGCCAGGTGAGGGTGTGAGGGACTGAGGACCCCACTCAAAT | 899 |
| Ddb | 126528 | GCTCTGTGAGGAGGCCAGGTGAGGGTGTGAGGGACTGAGGACCCCACTCAAAT | 126469 |
| Qy | 900 | AGAGAGCCCCAATATTCCAGGCCCTTCCTGCCAGGGAAACTGCCAG | 959 |
| Ddb | 126468 | AGAGAGCCCCAATATTCCAGGCCCTTCCTGCCAGGGAAACTGCCAG | 126409 |
| Qy | 960 | ACCTCTAGCTGGCTGCCCTGCCAGGCCCTTCCTCCAAAAGCCTTGAGAGCACCAAGGT | 1019 |
| Ddb | 126408 | ACCTCTAGCTGGCTGCCCTGCCAGGCCCTTCCTCCAAAAGCCTTGAGAGCACCAAGGT | 126349 |
| Qy | 1020 | CTTCCTCCAAAGTCTGAAATCAAGAGTTGACCGGGAGACTGTTAGAGG | 1079 |
| Ddb | 126348 | CTTCCTCCAAAGTCTGAAATCAAGAGTTGACCGGGAGACTGTTAGAGG | 126289 |
| Qy | 1080 | GGCAGGGCACAGGCCCTTCAGCCAGAACCTAGACCCAGGGAGGGTGGGCC | 1139 |
| Ddb | 126288 | GGCAGGGCACAGGCCCTTCAGCCAGAACCTAGACCCAGGGAGGGTGGGCC | 126229 |
| Qy | 2217 | CTTGTAAATCGAATCAAGATCAAGTGTGGACCTCGGCCAGCTAGGGGACA | 2276 |

| | | | | | | | |
|-----------|--|--|--------|------|---|---|--------|
| Db 125149 | CCTGGAAATCCAGATCAGTGGACCTCGGCCCTGAGAGTCAGGGCACGCCACA | 125090 | Qy | 3357 | CCTGGTACCACTGAGAACCCAGGGTCAAGGCTGAGCTGCGCTGAGGCCCGGTGAT | 3416 | |
| Qy | 2277 | TATGGCCCATATTCTGATCTTGAGGTGACAGGACAGTGAGCTGCGCTGAGAAGTGG | 2336 | Db | 124010 | CCTGGTACCACTGAGAACCCAGGGTCAAGGCTGAGCTGCGCTGAGGCCCGGTGAT | 123951 |
| Db | 125089 | TATGGCCCATATTCTGATCTTGAGGTGACAGGACAGTGAGCTGCGCTGAGAAGTGG | 125030 | Qy | 3417 | TCCCTCTCTGGCTCCAGGACTCCAGAACCCAGGACTGGCTTGAGACAGTATCCCA | 3476 |
| Qy | 2337 | GGCCCTAGGTAAACAGGGAGGTCCAGGATCCAGGATCCATAGGCCAAAGATGCCCCCT | 2396 | Db | 123950 | TCCCTCTCTGGCTCCAGAACCCAGGACTGGCTTGAGACAGTATCCCA | 123891 |
| Db | 125029 | GGCCCTAGGTAAACAGGGAGGTCCAGGATCCATAGGCCAAAGATGCCCCCT | 124970 | Qy | 3447 | GGTACAGAGCAGAGGATGCAAGGGTGCAGAGCTGGCTTGAGCTGAGTATCCCA | 3536 |
| Qy | 2397 | CATGGACTGGGATAATCCGGTCAAGAGGGACTCCAGAACACTCGCTGTC | 2456 | Db | 123890 | GGTACAGAGCAGAGGATGCAAGGGTGCAGAGCTGGCTTGAGCTGAGTATCCCA | 123831 |
| Db | 124969 | CATGGACTGGGATAATCCGGTCAAGAGGGACTCCAGAACACTCGCTGTC | 124910 | Qy | 3537 | CCAAGGGCCCAACTGCAAGACAGATAGGACTCCAGAGTCTGGCTCACCTCC | 3596 |
| Qy | 2457 | CCTTTAGTACTCTAGGGGACCAAGATGGATGGGTATTTCAATTCACTGT | 2516 | Db | 123830 | CCAAGGGCCCACTGGCACAGACAGATAGGACTCCAGAGTCTGGCTCACCTCC | 123771 |
| Db | 124909 | CCTTTAGTACTCTAGGGGACCAAGATGGATGGGTATTTCAATTCACTGT | 124850 | Qy | 3597 | ACGTCTAGTCCTGAGATGCACTGACCTCTGGCTGTACCTGAGTACCTCTCACT | 3656 |
| Qy | 2517 | ACACAGGAGGAAGTGGGGCTTCTGGTAAGAAGGGGAT | 2576 | Db | 123770 | ACGTCTAGTCCTGAGATGCACTGACCTCTGGGGCTGTACCTGAGTACCTCTCACT | 123711 |
| Db | 124849 | ACACAGGAGGAAGTGGGGATATCCGGTCAAGAGGGACTCCACAGTC | 124790 | Qy | 3657 | TCCCTCTCAGGTTTCAAGGGACAGGAGGATCCCTGGAGGAC | 3716 |
| Qy | 2577 | GTCTACTCATGTCAGGAAATGGGGTGTGGCAAGGAATAAGAT | 2636 | Db | 123710 | TCCNCCTCTCAGGTTTCAAGGGACAGGAGGATCCCTGGAGGAC | 123651 |
| Db | 124789 | GTCTACTCATGTCAGGAAATGGGGTGTGGCAAGGAATAAGAT | 124730 | Qy | 3717 | AGAGGACCAAGGAGGAGGAGATGTAGTAGGSCCTTGTAGTGA | 3776 |
| Qy | 2637 | GTGTGAGACACAAGGCTATGGATAATCCACAGGGTCAAGCCTGSA | 2696 | Db | 123650 | AGAGGACCAAGGAGGAGATGTAGTAGGSCCTTGTAGTGA | 123591 |
| Db | 124729 | GTGTGAGACACAAGGCTATGGATAATCCACCCAGACACAAGGTC | 124670 | Qy | 3777 | TCTAGCCTGGGGCTCTACACACTCCCTCCTCCAGGCTCTGCTGCTATGGCC | 3836 |
| Qy | 2697 | CACTTACCCAGATGTGGCTCTTTCACTCCCTGGGAGGTGAG | 2756 | Db | 123590 | TCTAGCCTGGGGCTCTACACCTCCCTCCTCCAGGCTCTGCTGCTATGGCC | 123531 |
| Db | 124669 | CACTTACCCAGGATGTGGCTCTTTCACTCCAGTCAGTCAGTGGAG | 124611 | Qy | 3837 | AGCCTCTGCCACACTCTGGCTCTGCTGCCCTGAGGAGTCATCATGCTCTGAGA | 3896 |
| Qy | 2757 | ACCTCATTCAGAGGGTGAATCTGTCAGTGGACCCCATCTGTC | 2815 | Db | 123530 | AGCCTCTGCCACACTCTGGCTCTGCTGCCCTGAGGAGTCATCATGCTCTGAGA | 123471 |
| Db | 124610 | ACCTCATTCAGAGGGTGAATCTGTCAGTGGACCCCATCTGTC | 124551 | Qy | 3897 | GGAGTCTGACTGCAAGCTGAGGAAGCCCTGGAGGCCAACAGGCCCCTGG | 3956 |
| Qy | 2817 | CGAGGACCAACTCTGGGAGACTCTGCACTGAGTGGGGTACCC | 2876 | Db | 123470 | GGAGTCTGACTGCAAGCTGAGGAAGCCCTGGAGGCCAACGCCCCTGG | 123411 |
| Db | 124550 | ACGGTCCCAAGATCTGCCATGTCATGGTGGGGTAGGGTACCC | 124491 | Qy | 3957 | TGTCGCACTCTGGCTCAAGAGATCTCCAGAGTCTGGCTGGAGG | 4016 |
| Qy | 2877 | CGAGGACCAACTCTGGGAGACTCTGCACTGAGTGGGGTACCC | 2936 | Db | 123410 | TGTCGCACTCTGGCTCAAGAGTCTGGCTGGAGGG | 123351 |
| Db | 124490 | CGAGGACCAACTCTGGGAGACTCTGCACTGAGTGGGGTACCC | 124431 | Qy | 4017 | TGCCCACTCTGGCTCAAGAGATCTCCAGAGTCTGGCTGGCTTCCCA | 4076 |
| Qy | 2937 | AGAGCATGGCTGGCCCTCTCCGTTATCTGGGATCATGTC | 2996 | Db | 123350 | TGCCCACTCTGGCTCAAGAGTCTGGCTGGCTTCCAGGAGG | 123291 |
| Db | 124430 | AGAGCATGGCTGGCCCTCTCCGTTATCTGGGATCATGTC | 124371 | Qy | 4077 | CTACCATCAACTTACTGAGACAGGGAAACCCAGTGGCTGAGGG | 4136 |
| Qy | 2997 | AGGACGGAGGCGCTGGCTCCATGTCAGTGGCTAGTGGAGGTCCA | 3056 | Db | 123290 | CTACCATCAACTTACTGAGACAGGGAAACCCAGTGGCTGAGGG | 123231 |
| Db | 124370 | AGGACGGAGGCGCTGGCTCCATGTCAGTGGAGGTCCA | 124311 | Qy | 4137 | AGGGCCAGCACCTCTGATCTGGCTGAGGAGTATCACTAAGAGG | 4196 |
| Qy | 3057 | GCCCMGCAAGGAGTAAGGTGAGGACCAAGGGACCTAACATTIC | 3116 | Db | 123230 | AGGGCCAGCACCTCTGATCTGGCTGAGGAGTATCACTAAGAGG | 123171 |
| Db | 124310 | GCCCMGCAAGGAGTAAGGTGAGGACCAAGGGACCTAACATTIC | 124251 | Qy | 4197 | TGGCTGATTCGCTGGTGTGCTGAGGAGTATCACTAAGAGG | 4256 |
| Qy | 3117 | CAATGAAATTGATATCTCTGCTGCCCTCCCAAGGACCTAGCTGGCAGAT | 3176 | Db | 123170 | TGGCTGATTCGCTGGTGTGCTGAGGAGTATCACTAAGAGG | 123111 |
| Db | 124250 | CAATGAAATTGATATCTCTGCTGCCCTCCCAAGGACCTAGCTGGCAGAT | 124191 | Qy | 4257 | CAGAAATGTTGGAGAGTGTCAAAATTACAGCTGTTCTCGCCA | 4316 |
| Qy | 3177 | GTTTGCCCTGCTGCTTCCATTCATGAGTGTAACTCTGATTTGGATTIC | 3216 | Db | 123110 | CAGAAATGTTGGAGATGTCATCAAAATTACAGCTGTTCTCGCCA | 123051 |
| Db | 124190 | GTTTGCCCTGCTGCTTCCATTCATGAGTGTAACTCTGATTTGGATTIC | 124131 | Qy | 4317 | AAGCTCTGAGTCCTGAGTGTGCTGAGGAGTCAAGCCCCACG | 4376 |
| Qy | 3237 | TCAGCAGGAAAAGGGCAGGATCCAGGCCCTGGCTGAGGAAATAA | 3296 | Db | 123050 | AAGCTCTGAGTCCTGAGTGTGCTGAGGAGTCAAGCCCCACG | 122991 |
| Db | 124130 | TCAGCAGGAAAAGGGCAGGATCCAGGCCCTGGCTGAGGAAATAA | 124071 | Qy | 4377 | GCCACTCTGATGTCCTGCTGAGGAGTCAAGGAGTCAAGGAGTCA | 4436 |
| Qy | 3297 | AGACAGGGGGTCACTGCACTGAGTGGGATGCAAGTCCAGGCCACCC | 3336 | Db | 122990 | GCCACTCTGATGTCCTGCTGAGGAGTCAAGGAGTCAAGGAGTCA | 122931 |
| Db | 124070 | AGAACAGAGGGGGTCACTGCACTGAGTGGGATGCAAGTCCAGGCCACCC | 124011 | | | | |

| | | | | |
|----|------|--|------|--|
| QY | 1 | CCGGGGGACCATGGATCCCCTACCCCCAATCCGCCCTTAAGCCACCC | 60 | |
| Db | 9070 | CCGGGGCACCATGGATCCCCTACCCCCAATCCGCCCTTAAGCCACCC | 9011 | |
| QY | 61 | ATCCAACATCTTCACCTCACTTCACTTCACTTCACTTCACTTCACTT | 120 | |
| Db | 9010 | ATCCAACATCTTCACCTCACTTCACTTCACTTCACTTCACTTCACTT | 8951 | |
| QY | 121 | CCTCAACCAGGAAGCCCAAGGTGGCAGATGTGACGCCACTGTACTTG | 180 | |
| Db | 8950 | CCTCAACCAGGAAGCCCAAGGTGGCAGATGTGACGCCACTGTACTTG | 8891 | |
| QY | 181 | TAGAGAAAGGAGGGTTTCGGTCAGGGGGCTTGAGATCGTGGCCAG | 240 | |
| Db | 8890 | TAGAGAAAGGAGGGTTTCGGTCAGGGGGCTTGAGATCGTGGCCAG | 8831 | |
| QY | 241 | CCCA-GCTCTGAAAGGGCAAGGTGACATGGAGGACTGGTGTGACTT | 299 | |
| Db | 8830 | CCAGGCTCTGAAAGGGCAAGGTGACATGGAGGACTGGTGTGACTT | 8771 | |
| QY | 300 | CAGATAGGACCCAAAATAATCCCTCATGCAGCCTGACCATCTGGTGTGACTT | 359 | |
| Db | 8770 | CAGATAGGACCCAAAATAATCCCTCATGCAGCCTGACCATCTGGTGTGACTT | 8711 | |
| QY | 360 | CTCAGCTGGACCCAGCCCTGGTAAACCACTGGGACTGAACTCAGA | 419 | |
| Db | 8710 | CTCAGCTGGACCCAGCCCTGGTAAACCACTGGGACTGAACTCAGA | 8651 | |
| QY | 420 | GTCCTGGTGTGATAGGAAAGGCTGCTTAGAGGAACTGGCTGAGGAGA | 479 | |
| Db | 8650 | AGTCCTGGTGTGATAGGAAAGGCTGCTTAGAGGAACTGGCTGAGGAGA | 8591 | |
| QY | 480 | TCTAGCTCAGGATTCTCAGGGGGCTGAGGCTGGCTCCTAACGCCAA | 539 | |
| Db | 8590 | TCTAGCTCAGGATTCTCAGGGGGCTGAGGCTGGCTCCTAACGCCAA | 8531 | |
| QY | 540 | CCCCACCTCCATATGCTCACTCCGTCATCTCAACCCCC | 599 | |
| Db | 8530 | CCCCACCTCCATATGCTCACTCCGTCATCTCAACCCCC | 8471 | |
| QY | 600 | ACCCACATCCCCACCCCCATCTCAACCTGATGCCCATATCTCAACCCCC | 659 | |
| Db | 8470 | ACCCACATCCCCACCCCCATCTCAACCTGATGCCCATATCTCAACCCCC | 8411 | |
| QY | 660 | TCAACCCACCCCCACCCCCACCTCCACCCACAGGGGATCGTTCC | 719 | |
| Db | 8410 | TCAACCCACCCCCACCCCCACCTCCACCCACAGGGGATCGTTCC | 8351 | |
| QY | 720 | CCAGGAAACATTCGGGATGTGGGGAGATGTGGGGAGAG | 779 | |
| Db | 8350 | CCAGGAAACATTCGGGATGTGGGGAGATGTGGGGAGAG | 8291 | |
| QY | 780 | AGAGCGAGGTTTCACATCTGAGGGAGGGCTAGAGTCCGCCAG | 839 | |
| Db | 8290 | AGAGCGAGGTTTCACATCTGAGGGAGGGCTAGAGTCCGCCAG | 8231 | |
| QY | 840 | GCCTCTGAGGGCAAGGTGAGGCTGAGGGACTGAGGACCCGCACTC | 899 | |
| Db | 8230 | GCCTCTGAGGGCAAGGTGAGGCTGAGGGACTGAGGACCCGCACTC | 8171 | |
| QY | 900 | AGAGGCCAAATAATTCCAGGGCCCTGGCCACCCGGGAAG | 959 | |
| Db | 8170 | AGAGGCCAAATAATTCCAGGGCCCTGGCCACCCGGGAAG | 8111 | |
| QY | 960 | AGTCTCAGCCGGCTGCCCTGCCCCAGACCCCTGAGAGACCCAGGTT | 1019 | |
| Db | 8110 | AGTCTCAGCCGGCTGCCCTGCCCCAGACCCCTGAGAGACCCAGGTT | 8051 | |
| QY | 1020 | CTTCCTCCAAAGTCTGAAATAGAGTTGCTGAGGGCAGSACTGTAGAG | 1079 | |
| Db | 8050 | CTTCCTCCAAAGTCTGAAATAGAGTTGCTGAGGGCAGSACTGTAGAG | 7991 | |
| QY | 1080 | GGAGGGACAGGCTCTGCCAACGCTGAGGAGGAGGAGGAGGAGGAG | 1139 | |
| Db | 7990 | GGCAGGGCCAGGGATCTGCCCTTCCACAGGGAGGGCTGTGGSCC | 7931 | |
| QY | 1140 | CCCAAGACTGACTCCTGACCTTCCACCTGGCATTCCTCCACCC | 1199 | |
| Db | 7930 | CCCAAGACTGACTCCTGACCTTCCACCTGGCATTCCTCCACCC | 7871 | |
| QY | 1200 | CCCCATCTCTAGCTACCTCACCCTACTCCACTCTACTCCACTGTG | 1259 | |
| Db | 7870 | CCCCATCTCTAGCTACCTCACCCTACTCCACTCTACTCCACTGTG | 7811 | |
| QY | 1260 | CCCCCTGGCCAGCACGCCCAACCCCTGTCACCCCTACGTG | 1319 | |
| Db | 7810 | CCCCCTGGCCAGCACGCCCAACCCCTCTGCCACCTACTGCCCA | 7751 | |
| QY | 1320 | CCCCACCCATCTCTCATCTCTCATGTGCCCTCCACTGCCATCTG | 1379 | |
| Db | 7750 | CCCCACCCATCTCTCATGTGCCCTCCACTGCCATCTGCA | 7691 | |
| QY | 1380 | CGGTGTTGCCCTGCTCACAACCGGGAAGCCCTGGTAGGCCGATG | 1439 | |
| Db | 7690 | CGGTGTTGCCCTGCTCACAACCGGGAAGCCCTGGTAGGCCGATG | 7631 | |
| QY | 1440 | TTGAACTCTACAGATCTGGAGAGGCCAGGTCTATTAAAGGTTCTG | 1499 | |
| Db | 7630 | TTGAACTCTACAGATCTGGAGAGGCCAGGTCTATTAAAGGTTCTG | 7571 | |
| QY | 1500 | GATCCACTGAGGGAGGTGGTTTGGCTCTGTGAGGAGCAAGGTG | 1559 | |
| Db | 7570 | GATCCACTGAGGGAGGTGGTTTGGCTCTGTGAGGAGCAAGGTG | 7511 | |
| QY | 1560 | GACTGAGGGCACACCCAGTAGATGGCCCAAATATGATCAGPACCA | 1619 | |
| Db | 7510 | GACTGAGGGCACACCCAGTAGATGGCCCAAATATGATCAGPACCA | 7451 | |
| QY | 1620 | GCCAGCCCTGGACCCGCCAGGACAGATGGTGTGAGGAGCACCC | 1679 | |
| Db | 7450 | GCCAGCCCTGGACCCGCCAGGACAGATGGTGTGAGGAGCACCC | 7391 | |
| QY | 1680 | CCACTGCCCACCTTAACCCACAGGAATCTGTAGTCACTCTATG | 1739 | |
| Db | 7390 | CCACTGCCCACCTTAACCCACAGGAATCTGTAGTCACTCTATG | 7331 | |
| QY | 1740 | TGGTAGGAGA-GCCAGGGCCAGGCATTAAGGTCATCAGGTC | 1797 | |
| Db | 7330 | TGGTAGGAGGAGGGAGGCCAGGCATTAAGGTCATCAGGTC | 7271 | |
| QY | 1798 | AGGACCTGGAGGGAACTGGGTTCCACCTGCTACCC | 1857 | |
| Db | 7270 | AGGACCTGGAGGGAACTGGGTTCCACCTGCTACCC | 7211 | |
| QY | 1858 | ACCCACTCATCCACCTCCACCTACCCCTACCCCAACCTCATCT | 1917 | |
| Db | 7150 | ACCCACTCATCCACCTCCACCTACCCCTACCCCAACCTCATCT | 7091 | |
| QY | 1918 | CTGTCAACCCAGGAACTGCTGAGGAACTGCTGAGCTTC | 1977 | |
| Db | 7090 | CTGTCAACCCAGGAACTGCTGAGGAACTGCTGAGCTTC | 7032 | |
| QY | 2038 | TACTGGAGATGAGGGGCTCAGAGGCCAACCTAGAACCC | 2097 | |
| Db | 7031 | TACTGGAGATGAGGGGCTCAGAGGCCAACCTAGAACCC | 6972 | |
| QY | 2098 | GAGACTGAGGCTGCACTCTGGCTCAGAAACGATGGGAC | 2156 | |
| Db | 6971 | GAGACTGAGGCTGCACTCTGGCTCAGAAACGATGGGAC | 6912 | |
| QY | 2157 | GGGCTGGACCCAGGCTGCAAGGCTTACGGGAGGAGGAGGAGG | 2216 | |

| | | | | | |
|----|------|--|----|------|--|
| Db | 6911 | AGGGTGGACCCAGGCTGCAAGGTTAACGGAGGAAGGAGGACTCAGGGAA 6852 | Qy | 3297 | AGAACAGGGGTCACTGCATGAGACTGGGATGTCACAGTGTGAGAATGGCCACCT 3356 |
| Qy | 2217 | CTTGGAAATCCAGATCAGTGTGACCCCTGAGGTCACGCGTGGCACA 2276 | Db | 5775 | AGAACAGGGGTCACTGCATGAGACTGGGATGTCACAGTGTGAGAATGGCCACCT 5716 |
| Db | 6851 | CCTTGGAAATCCAGATCAGTGTGACCCCTGAGGTCACGCGTGGCACA 6792 | Qy | 3357 | CTGGPAGCACTGAGACCGGCTGACCCCTGAGGTCACAGTGTGAGAATGGCCACCT 3416 |
| Qy | 2217 | TATGGCCCATATTCCGATTTGGGTGAGAATGGCTGAGAATGGCTGAGTGG 2336 | Db | 5715 | CTGGPAGCACTGAGACCGGCTGACCCCTGAGGTCACAGTGTGAGAATGGCCACCT 5656 |
| Db | 6791 | TATGGCCCATATTCCGATTTGGGTGAGAATGGCTGAGAATGGCTGAGTGG 6732 | Qy | 3417 | TCCTCTTCTGGAGCAGGCTGAGGAAACGGCAGTGACCCCTGGTCAAGTACCTCA 3476 |
| Qy | 2337 | GCCTCTAGGTCAACAGGGAGGAGTCAGGATCCAGATGCCAAAGATGCCCCCT 2396 | Db | 5655 | TCCTCTTCTGGAGCAGGCTGAGGAAACGGCAGTGACCCCTGGTCAAGTACCTCA 5596 |
| Db | 6731 | GCCTCTAGGTCAACAGGGAGGAGTCAGGATCCAGATGCCAAAGATGCCCCCT 6672 | Qy | 3477 | GTCACAGGGAGGATGACAGGGTGTGCCAGCATGAGATGTTGCCCTGAATGACA 3536 |
| Qy | 2397 | CATGAGGACTGGGATAATCCGGCTCAGAAAAGGGACATGCCACACAGTGTGCT 2456 | Db | 5595 | GTCACAGGGAGGATGACAGGGTGTGCCAGCATGAGATGTTGCCCTGAATGACA 5536 |
| Db | 6671 | CATGAGGACTGGGATAATCCGGCTCAGAAAAGGGACATGCCACACAGTGTGCT 6612 | Qy | 3537 | CCAAGGGCCACCTGGCACAGGACACATAGAACCTACAGAGTCAGGCTCACCTCCCT 3596 |
| Qy | 2457 | CTTTTACTGGCTTAAGGGGACCAAGATCACGGATGCCGATGTCCTCACTCT 2516 | Db | 5535 | CCAAGGGCCACCTGGCACAGGACACATAGAACCTACAGAGTCAGGCTCACCTCCCT 5416 |
| Db | 6611 | CTTTTACTGGCTTAAGGGGACCAAGATCACGGATGCCGATGTCCTCACTCT 6552 | Qy | 3597 | ACTGTCAGTCCTGTGAAATGCCCTGACCCCTGACCCCTGAGTACCCCTCTACT 3656 |
| Qy | 2517 | ACCAAGGGAAAGTGGGGCCCTCAGGGAGATGGCTTGGGTAAAGGGGAT 2576 | Db | 5475 | ACTGTCAGTCCTGTGAAATGCCCTGACCCCTGACCCCTGAGTACCCCTCTACT 5416 |
| Db | 6551 | ACCAAGGGAAAGTGGGGCCCTCAGGGAGATGGCTTGGGTAAAGGGAT 6495 | Qy | 3657 | TCCTCTTCTGGAGGATGGGGACAGGCCACCCAGGGAGGATGGGGCTGGGCCAC 3716 |
| Qy | 2577 | GRCATACATGCGGAAATGGGGTGAAGCAGGGCTGGCAGGAATAAGAT 2636 | Db | 5415 | TCCTCTTCTGGAGGATGGGGACAGGCCACCCAGGGAGGAGGATGGGGCTGGGCCAC 5356 |
| Db | 6494 | GRCATACATGCGGAAATGGGGTGAAGCAGGGCTGGCAGGAATAAGAT 6435 | Qy | 3717 | AGAGGGCACAAGGGAAAGATCTGTAAGTGGCTTGTGAGTCAAGGTTCTAGT 3776 |
| Qy | 2637 | GAGTGAGACAGAAAGCTATGGAAATCCACACCCAGAACCAAAGGGTGA 2696 | Db | 5355 | AGAGGGCACAAGGGAAAGATCTGTAAGTGGCTTGTGAGTCAAGGTTCTAGT 5296 |
| Db | 6434 | GAGTGAGACAGAAAGCTATGGAAATCCACACCCAGAACCAAAGGGTGA 6375 | Qy | 3777 | TCTCACTTGGGCCCTTCACACTCCCTCTCCAGGGCTGGGCTTCATGCC 3836 |
| Qy | 2697 | CACCTCAACCAGGATGTGGCTCTTTCACCTCTGGTCCAGATGGCCAGGTGAGC 2756 | Db | 5295 | TCTCACTTGGGCCCTTCACACTCCCTCTCCAGGGCTGGGCTTCATGCC 5236 |
| Db | 6374 | CACCTCAACCAGGATGTGGCTCTTTCACCTCTGGTCCAGATGGCCAGGTGAGC 6316 | Qy | 3837 | AGCTCTGCCAACACTCTGCTGGCCCTTGAACAGGAGTCACTGCTTGAGCAGA 3896 |
| Qy | 2757 | ACCTCATCTCAGGGGTGACTCGGGTCACTGGGACCCATCTGGCTAAAGACAG 2816 | Db | 5235 | AGCTCTGCCAACACTCTGCTGGCCCTTGAACAGGAGTCACTGCTTGAGCAGA 5176 |
| Db | 6315 | ACCTCATCTCAGGGGTGACTCGGGTCACTGGGACCCATCTGGCTAAAGACAG 6256 | Qy | 3897 | GGAGTGTGCACTGCCAGGCTGGGACCCCTGAACAGGAGGCTGGCTGGCTGG 3956 |
| Qy | 2817 | AGGGTGGCCAGGATCTCCATCGGTCAGGGAGACATGGGGAGGACTGGGTAC 2876 | Db | 5175 | GGAGTGTGCACTGCCAGGCTGGGACCCCTGAACAGGAGGCTGGCTGGCTGG 5116 |
| Db | 6255 | AGGGTGGCCAGGATCTCCATCGGTCAGGGAGACATGGGGAGGACTGGGTAC 6196 | Qy | 3957 | TGTGTTGTGAGGCTGGCTCCCTCTCCCTCTGGGACCCCTGGGAGGAGG 4016 |
| Qy | 2877 | CCAGGACCAAGACCTGGGGAGACTCCACAGAAATCAGGCTCTGGCTGTCACCC 2936 | Db | 5115 | TGTGTTGTGAGGCTGGCTCCCTCTCCCTCTGGGCTGGCTGGCTGGGAGG 5056 |
| Db | 6195 | CCAGGACCAAGACCTGGGGAGACTCCACAGAAATCAGGCTCTGGCTGTCACCC 6136 | Qy | 4017 | TGCCCTACTGCTGGGCAACAGATCTCCCGGAGAAGTCCTGGGCTCTGGCTGG 4076 |
| Qy | 2937 | AGAGGATGGCTGGCGCTGGCCAGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 2996 | Db | 5055 | TGCCCTACTGCTGGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 4996 |
| Db | 6135 | AGAGGATGGCTGGCGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 6076 | Qy | 4077 | CTACCATCAACTTCACCTGACAGGGAAACCCAGGAGGTTCTCAAGCGCTGTAAGAGG 4136 |
| Qy | 2997 | AGGACGGGGAGGCGCTGGTCTGGTCTGGTCTGGTCTGGCTGGCTGGCTGGCTGG 3056 | Db | 4995 | CTACCATCAACTTCACCTGACAGGGAAACCCAGGAGGTTCTCAAGCGCTGTAAGAGG 4936 |
| Db | 6075 | AGGACGGGGAGGCGCTGGTCTGGTCTGGTCTGGTCTGGCTGGCTGGCTGG 6016 | Qy | 4197 | TGGCTGATTTGGTGTGGTTCTGCTCTCAAATAATGAGGCCAGGTCAAAAGG 4256 |
| Qy | 3057 | CCGCCCTGCAAGGAGTCAGGTGAGGACCAAGGGGACCTACCCAGGACACATTAA 3116 | Db | 4875 | TGGCTGATTTGGTGTGGTTCTGCTCTCAAATAATGAGGCCAGGTCAAAAGG 4816 |
| Db | 6015 | CCGCCCTGCAAGGAGTCAGGTGAGGACCAAGGGGACCTACCCAGGACACATTAA 5956 | Qy | 4257 | CAGAAATGCTGAGACTGTCATCAAATAATGAGGCCAGGTCAAAAGG 4316 |
| Qy | 3117 | CAATGAATTTCAGGAGTCAGGTGAGGACCAAGGGGACCTACCCAGGACACATTAA 3176 | Db | 4815 | CAGAAATGCTGAGACTGTCATCAAATAATGAGGCCAGGTCAAAAGG 4756 |
| Db | 5955 | CAATGAATTTCAGGAGTCAGGTGAGGACCAAGGGGACCTACCCAGGACACATTAA 5896 | Qy | 4317 | AAAGCCCTCTGGACTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 4376 |
| Qy | 3177 | GTTTGTCCCCTGCTGCTCTCATTCCTATCATGGATGTAACCTCTGATTGATTTC 3236 | Db | 4755 | AAAGCCCTCTGGACTCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 4696 |
| Db | 5895 | GTTTGTCCCCTGCTGCTCTCATTCCTATCATGGATGTAACCTCTGATTGATTTC 5836 | Qy | 3237 | TCAGACCAAAAGGGCAATCCAGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 3296 |
| Qy | 5835 | TCAGACCAAAAGGGCAATCCAGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG 5776 | Db | | |


```

repeat_region    4837 . 5414
  /rpt_family="LIMC5"
  /evidence="not_experimental
  complement(21306 . 21496)
  /rpt_family="MIRB"
  /evidence="not_experimental
  complement(21670 . 21839)
repeat_region    5566 . 6545
  /rpt_family="LIM4"
  /evidence="not_experimental
  complement(6905 . 6963)
repeat_region    7611 . 7697
  /rpt_family="MIR"
  /evidence="not_experimental
  note="L11 with 85% homology to L12"
  /rpt_type="inverted"
  /evidence="not_experimental
  7844 . 7981
  /note="Thomology = 66.10%, score = 48, counts = 28"
  /rpt_type="tandem
  /rpt_unit="cccac
  /evidence="not_experimental
  7814 . 8708
  /note="GC score = 44.00 (895bp)"
  /note="Region: GC content"
  /evidence="not_experimental
  8294 . 8511
  /note="CPG Island score = 0.74, GC = 66.50%, CGs = 17"
  /note="Region: CPG island"
  /evidence="not_experimental
  9054 . 8831
  /note="L12 with 85% homology to L11"
  /rpt_type="inverted
  /evidence="not_experimental
  9050 . 11121
  /gene="MAGE10"
  /note="1. 2072 of gblu106851HSU10685 Human
  MAGE-10 antigen (MAGE10) gene, complete cds. 6/95 P = 0.0
  S = 9975,
  9936 . 10064
  /note="GC score = 5.60 (129bp)"
  /note="Region: GC content"
  /evidence="not_experimental
  10412 . 10533
  /note="GC score = 8.80 (122bp)"
  /note="Region: GC content"
  /evidence="not_experimental
  11391 . 49375
  /note="Region: Cosmid 3h5"
repeat_region    12154 . 12482
  /rpt_family="LIM5"
  /evidence="not_experimental
  complement(12670 . 12980)
  /rpt_family="AlusX"
  /evidence="not_experimental
  complement(11281 . 14525)
  /rpt_family="MIP"
  /evidence="not_experimental
  complement(16047 . 17011)
  /rpt_family="LTR5"
  /evidence="not_experimental
  17635 . 17747
  /rpt_family="LIME1"
  /evidence="not_experimental
  17800 . 17815
  /rpt_family="LIM4"
  /evidence="not_experimental
  17843 . 17817
  /rpt_family="LIM4"
  /evidence="not_experimental
  20010 . 20829
  /rpt_family="LIMC/D"
  /evidence="not_experimental
  complement(20859 . 21195)
  /rpt_family="MLT2E"
  /evidence="not_experimental
  21198 . 21305
repeat_region    22796 . 23134
  /rpt_family="LIM4"
  /evidence="not_experimental
  23127 . 23300
  /rpt_family="LIMD3"
  /evidence="not_experimental
  23271 . 23837
  /rpt_family="LIMC5"
  /evidence="not_experimental
  24267 . 250
  /rpt_family="LIM4"
  /evidence="not_experimental
  26071 . 26817
  /note="Region: GC content"
  /evidence="not_experimental
  26655 . 26726
  /rpt_type="tandem
  /rpt_unit="atacc
  /evidence="not_experimental
  27233 . 27358
  /note="homology = 65.90%, score = 34, counts = 21"
  /rpt_type="tandem
  /rpt_unit="ccccca
  /evidence="not_experimental
  27403 . 27510
  /note="CPG island score = 1.29, GC = 61.10%, CGs = 9"
  /note="Region: CPG island"
  /evidence="not_experimental
  27829 . 27906
  /note="homology = 79.20%, score = 36, counts = 12"
  /rpt_type="tandem
  /rpt_unit="atccc
  /evidence="not_experimental
  28990 . 29073
  /note="homology = 69.00%, score = 26, counts = 14"
  /rpt_type="tandem
  /rpt_unit="ccccaa
  /evidence="not_experimental
  30461 . 30520
  /note="GC score = 5.00 (160bp)"
  /note="Region: GC content"
  /evidence="not_experimental
  30896 . 30958
  /note="homology = 82.50%, score = 20, counts = 3"
  /rpt_type="tandem
  /rpt_unit="aggcttagggatcaccagg
  /evidence="not_experimental
  31110 . 31778
  /gene="undefined MAGE"
  /note="1. 185 of gpb1D2077 HUMMAGEC_1 Homo
  sapiens Human mRNA for MAGE-41 protein, complete_P =
  6 . 0e-15
  S = 592 . 193 . 283 of gpb1D2076 HUMMAGEB_1 Homo
  sapiens Human mRNA for MAGE-6 protein, complete_cds; P =
  1.5e-80
  S = 3556
  31172 . 31331
  /note="GC score = 13.00 (160bp)"
repeat_region    32219 . 32814
  /rpt_family="LIMC/D"
  /evidence="not_experimental
  32271 . 32814
  /rpt_family="LIMC/D"
  /evidence="not_experimental
  32296 . 32814
  /rpt_family="LIMC/D"
  /evidence="not_experimental
  32317 . 32814
  /rpt_family="LIMD3"
  /evidence="not_experimental
  32327 . 32837
  /rpt_family="LIMC5"
  /evidence="not_experimental
  32427 . 3250
  /rpt_family="LIM4"
  /evidence="not_experimental
  326071 . 326817
  /note="Region: GC content"
  /evidence="not_experimental
  326655 . 326726
  /rpt_type="tandem
  /rpt_unit="atacc
  /evidence="not_experimental
  327233 . 327358
  /note="homology = 65.90%, score = 34, counts = 21"
  /rpt_type="tandem
  /rpt_unit="ccccca
  /evidence="not_experimental
  327403 . 327510
  /note="CPG island score = 1.29, GC = 61.10%, CGs = 9"
  /note="Region: CPG island"
  /evidence="not_experimental
  327829 . 327906
  /note="homology = 79.20%, score = 36, counts = 12"
  /rpt_type="tandem
  /rpt_unit="atccc
  /evidence="not_experimental
  328990 . 329073
  /note="homology = 69.00%, score = 26, counts = 14"
  /rpt_type="tandem
  /rpt_unit="ccccaa
  /evidence="not_experimental
  330461 . 330520
  /note="GC score = 5.00 (160bp)"
  /note="Region: GC content"
  /evidence="not_experimental
  330896 . 330958
  /note="homology = 82.50%, score = 20, counts = 3"
  /rpt_type="tandem
  /rpt_unit="aggcttagggatcaccagg
  /evidence="not_experimental
  331110 . 331778
  /gene="undefined MAGE"
  /note="1. 185 of gpb1D2077 HUMMAGEC_1 Homo
  sapiens Human mRNA for MAGE-41 protein, complete_P =
  6 . 0e-15
  S = 592 . 193 . 283 of gpb1D2076 HUMMAGEB_1 Homo
  sapiens Human mRNA for MAGE-6 protein, complete_cds; P =
  1.5e-80
  S = 3556
  331172 . 331331
  /note="GC score = 13.00 (160bp)"

```


| | | | | | | | | |
|----|-------|--|----|------|--|----|-------|--|
| Db | 29225 | AAGCCCTGTGGGAGTAAGGGGGCTCAGGAACCCAGGTCCTAGATGGGGTCC 29284 | Qy | 2083 | ACCGCACCCCTGTCTGAGCTGAG - GCTGCCACTTCTGGCTCAAGATCAGAACATG 2140 | Db | 29285 | ACTCAACCCCTGTCTGAGCTGAGCTGAGCTCCTTCATCTGGCATAGGGATG 29344 |
| Db | 29405 | GGGAGGACTCAGTGGATGGGGCTGAGGCTTACCGGGAGAAGAGGA 2200 | Qy | 2141 | GGGAGGACTCAGTGGATGGGGCTGAGGCTTACCGGGAGAAGAGGA 2200 | Db | 29345 | GAGGACTCAGTGGGGCTGAGGCTTACCGGGAGAAGAGGA 29404 |
| Db | 29405 | GGGAGGACTCAGTGGATGGGGCTGAGGCTTACCGGGAGAAGAGGA 2260 | Qy | 2201 | GGGAGGACTCAGTGGATGGGGCTGAGGCTTACCGGGAGAAGAGGA 2260 | Db | 29405 | GGGAGGACTCAGTGGATGGGGCTGAGGCTTACCGGGAGAAGAGGA 29464 |
| Db | 29525 | GGCAGCGGCCCCATATGCCATATTCCGCATATTGGGGCAT - - - AGGAGAG 2316 | Qy | 2261 | GGCAGCGGCCCCATATGCCATATTCCGCATATTGGGGCAT - - - AGGAGAG 2316 | Db | 29465 | GTGGCACAGGGCCACCTGTAGCCCATGTCGACCTCTGGTGCACAAAGGGAG 29524 |
| Db | 29525 | GGCAGCGGCCCCATATGCCATATTGGGGCAT - - - AGGAGAG 29584 | Qy | 2317 | GGCAGCGGCCCCATATGCCATATTGGGGCAT - - - AGGAGAG 29584 | Db | 29585 | GCCCCAAGATGTGCCCTCATAGGGACTGGGGATATCCGGCTCAGAAAGAGGGAC 2436 |
| Db | 29644 | TCCACACAGCTGCTGCCCTTCTAGGGGACAGACAGGGATGGGG 2496 | Qy | 2437 | TCCACACAGCTGCTGCCCTTCTAGGGGACAGACAGGGATGGGG 2496 | Db | 29703 | CCCCAGACAGCTGCTGCCCTCATGGGACAGGGATGGGG 29703 |
| Db | 29704 | TATGTCCTTCTACTTGACCCAGGGGAGTTGGGGCTTAGGGAGATGGG 2556 | Qy | 2497 | TATGTCCTTCTACTTGACCCAGGGGAGTTGGGGCTTAGGGAGATGGG 2556 | Db | 29763 | TCTGGGGTAAGGGGGATGTCTACTTGACGGGATTTGGGGTGGAGACAG 2616 |
| Db | 29764 | TCTGCACTGAAAGGGGGATGTCTACTTGACGGGATTTGGGGTGGAG 29823 | Qy | 2617 | TCTGCACTGAAAGGGGGATGTCTACTTGACGGGATTTGGGGTGGAG 29823 | Db | 29824 | GCCCCATACGGGACAGGGGATGTCTACTTGACGGGATTTGGGGTGGAG 29879 |
| Db | 29880 | CCAAAGGGGTCTACCTGACCCATGTCGGGTGACGGGTAGC-TCCATCICAT 29938 | Qy | 2728 | TCCCTGTTCCAGATCTGGGCAAGTGGGGCTCATTCAGAGGGTACTCAGGTCAAC 2787 | Db | 29939 | TCCCTGTTCCAGATCTGGGCAAGTGGGGCTCATTCAGAGGGTACTCAGGTCAAC 29998 |
| Db | 29999 | GTAGGACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 2847 | Qy | 2788 | GTAGGACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 2847 | Db | 30058 | GAGGAACACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 30058 |
| Db | 30059 | GAGGAACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 30118 | Qy | 2848 | GAGGAACACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 30118 | Db | 30119 | GAGGAACATGGGGCAAGTGGGGCTGAGGACTTCTGGGATGCTGGGT 30178 |
| Db | 30119 | GAAATCTGCCCTGCCCCTGTTGACTCCAGGCTGAGGACTTCTGGGATGCTGGGT 30178 | Qy | 2908 | GAAATCTGCCCTGCCCCTGTTGACTCCAGGCTGAGGACTTCTGGGATGCTGGGT 2908 | Db | 30179 | GAAATCTGCCCTGCCCCTGTTGACTCCAGGCTGAGGACTTCTGGGATGCTGGGT 30237 |
| Db | 30179 | GAAATCTGCCCTGCCCCTGTTGACTCCAGGCTGAGGACTTCTGGGATGCTGGGT 30237 | Qy | 3026 | CITGGCTCAGTCACTGAGTGGAGGCTGAGGACTTCTGGGATGCTGGGT 3026 | Db | 30298 | AGGGGCCACCTGAGTGGAGGCTGAGGACTTCTGGGATGCTGGGT 30357 |
| Db | 30298 | AGGGGCCACCTGAGTGGAGGCTGAGGACTTCTGGGATGCTGGGT 30357 | Qy | 3028 | CITGACTCAGTCACTGAGTGGAGGCTGAGGACTTCTGGGATGCTGGGT 30297 | Db | 31315 | GCCGTAAGAGGGGGCCAAGGACCTCTGATCTGGCTCCAGGAGCT 31374 |
| Db | 31315 | GCCGTAAGAGGGGGCCAAGGACCTCTGATCTGGCTCCAGGAGCT 31374 | Qy | 4125 | GCCGTAAGAGGGGGCCAAGGACCTCTGATCTGGCTCCAGGAGCT 4125 | Db | 31375 | ACCAAGAAGAGGGGGCCAAGGACCTCTGATCTGGCTCCAGGAGCT 31434 |

| | | | |
|---|---|--|-------------|
| QY | 4185 | TCACTAAGGAGGGCGCTGATTTGGTTCTGCGCTTCTGAGTCAGTGCTGAAATGAGCCAGGGC | 4244 |
| Db | 31435 | TCACTAAGGAGGGCGCTGATTTGGTTCTGCGCTTCTGAGTCAGTGCTGAAATGAGCCAGGGC | 31494 |
| QY | 4245 | CAGICACAAAGGCGAAATCTGAGATGTCATCAAATTAACACACTTTCCTG | 4304 |
| Db | 31495 | CGGTACACAAAGGCGAAATCTGAGACCGTCAATCAAATTAACACACTTTCCTG | 31554 |
| QY | 4305 | AGATCTTCGCAAGGCGCTGAGTCAGTGCTGAGTCAGTGCTGAAAGAAG | 4364 |
| Db | 31555 | AGATCTTCGCAAGGCGCTGAGTCAGTGCTGAGTCAGTGCTGAAAGAAG | 31614 |
| QY | 4365 | CAGACCCACCGGCCACTGCTGCGCTGAGTCAGTGCTGAAAGAAG | 4424 |
| Db | 31615 | CAGACCCACCGGCCACTGCTGCGCTGAGTCAGTGCTGAAAGAAG | 31672 |
| QY | 4425 | TGCTGGGTGATAATCAGATCAATGCCAACAGCGCTCTGATAATTGTCCTGCTGATGA | 4484 |
| Db | 31673 | TGCTGGGTGATAATCAGATCAATGCCAACAGCGCTCTGATAATTGTCCTGCTGATGA | 31730 |
| QY | 4485 | TTGCAATGGGGGGCATGCTCTGAGGGAAATCTGGGAGGCTGTAGTGATGG | 4544 |
| Db | 31731 | TTGCAATGGGGGGCATGCTCTGAGGGAAATCTGGGAGGCTGTAGTGATGA | 31790 |
| QY | 4545 | AGGCTATGATGTCGGGAGGACACACTGCTATGGGAGGCCACACAAAG | 4604 |
| Db | 31791 | AGGCTATGATGTCGGGAGGACACACTGCTATGGGAGGCCACACAAAG | 31850 |
| RESULT | | | |
| QY | 4605 | ATTGGTGGAGGAAAGTACTGGAGTA-CGGAGGTGCCAGACTGATCCGGAGCT | 4663 |
| Db | 31851 | ATTGGTGGAGGAAAGTACTGGAGGTGCCAGACTGATCCGGAGCT | 31910 |
| QY | 4664 | ATGAGTCCCTGGGGCTCAAGGGCCCTGCTGAAACAGCTATGTGAAAGGCTCTTGT | 4723 |
| Db | 31911 | ATGAGTCACTGGGTCAAGGGCACCTGCTGAGGAGCAGCT | 31960 |
| QY | 4724 | ATGTGATCAGGTAGTGGAAAGAACTGGCTTCCCTGGTAAAGCAGCTT | 4783 |
| Db | 31961 | ACGGGTCAGGGCAATGAAAGCTTCATTCCTGGTAAAGCAGCTT | 32020 |
| QY | 4784 | TGAGAGGGAGGAGGGAGGCTGACCATGAGTGGAGGGGA | 4843 |
| Db | 32021 | TGAGAGGGAGGAGGGAGGAGGGAGGCTGAGCTGAGGATGAGCTGAGG | 32080 |
| QY | 4844 | CTGGCCAGTGCACTTCCAGGGCCGCTCAGAGCTTCCCTGCC-TGCTGTGACATG | 4902 |
| Db | 32081 | CTGGCCAGTGCACTTCCAGGGTCCGTCAAGTGTGACATG | 32140 |
| QY | 4903 | AGGCCATTTCACTC - TGAAGAGGGCTGAGTCAGTGTCTGTC | 4960 |
| Db | 32141 | AGGCCATTTCACTCAGTGTCTGTCAGTGTCTGTC | 32200 |
| QY | 4961 | TATGGGTGACTGGAGATTATCTTGTCTTGGAAATGTTCTT | 5020 |
| Db | 32201 | TATGGGTGACTGGAGATTGTGCTTGGAAATGTTCTT | 32259 |
| QY | 5021 | TAAGGGATGGTGAATGAACTTCAGCATCOAGTTTACATGAGCAGTCAC - AG | 5078 |
| Db | 32260 | TAATGGGTGATGAACTTCAGCATCOAATTGATGAGCTGCTACATAG | 32319 |
| QY | 5079 | TTCTGGTGTATAAGGTAAAGGTTGCTGTTTATCAGATGGAAATCCATT | 5138 |
| Db | 32320 | TGCTGGTTTATAGTGTAGGTAAGACTGTTGTTTATCAGATGGAAATCCATT | 32379 |
| QY | 5139 | CTATTTGGAAATGGG - ATAAAACAGGAGTGGAAATGACTTA-GAAATGTA | 5195 |
| Db | 32380 | CCATTTGGAAATGGACATAGTACAGTGGAAATGATCATTAGTAATGTGA | 32439 |
| QY | 5196 | ATGACGAGTAAATGATGAGAAAGACTTAAGGAGATGTCATTCTGC | 5255 |
| Db | 32440 | ATGACGAGTAAATGATGCA-----TAAAGAAATTAAAGATATTCTGC | 32491 |
| RESULT | | | |
| HS10687 | 7 | HS10687 11495 bp DNA | PRI |
| LOCUS | | Human MAGE-4a antigen (MAGE4a) gene, complete cds. | |
| DEFINITION | | | |
| VERSION | U10687 | 11495 bp | 23-JUN-1995 |
| VERSION | U10687.1 | GI:533514 | |
| KEYWORDS | | | |
| ORGANISM | Homo sapiens | | |
| EUTHERIA; METAZOA; CHORIOPA; CRANIATA; VERTEBRATA; MAMMALIA; | | | |
| PRIMATES; CATARRHINI; HOMINIDAE; HOMO. | | | |
| REFERENCE | 1 (bases 1 to 11495) | | |
| AUTHORS | De Paeen,E., Traversari,C., Gaforio,J.J., Szikora,J.P., Lurquin,C. | | |
| DE Smet,C., Brusseur,F., van der Bruggen,P., Lethe,B., De Backer,O., Cavenee,W. and Boon,T. | | | |
| Brasseur,R., Chomez,P. | | | |
| STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY | | | |
| TITLE | JOURNAL | | |
| JOURNAL | Immunogenetics | 40 (5), 360-369 (1994) | |
| MEDLINE | | | |
| REFERENCE | 2 (bases 1 to 11495) | | |
| AUTHORS | De Paeen,E. | | |
| TITLE | Direct Submission | | |
| JOURNAL | Submitted (14-JUN-1994) Etienne De Paeen, Ludwig Institute for Cancer Research, 74 Avenue Hippocrate, Brussels, 1200, Belgium | | |
| FEATURES | Location/Qualifiers | | |
| SOURCE | 1. .11495 | | |
| /organism="Homo sapiens" | | | |
| /isolate="Patient MZ2" | | | |
| /db_xref="Taxon 9606" | | | |
| /chromosome="X" | | | |
| /sex="female" | | | |
| /cell_type="lymphocyte" | | | |
| /tissue_type="blood" | | | |
| /dev_stage="adult" | | | |
| exon | 450..510 | | |
| | /note="exon 1-1" | | |
| | 836..937 | | |
| | /note="exon 1-2" | | |
| | 1418..1556 | | |
| | /note="exon 1-3" | | |
| | 2108..2246 | | |
| | /note="exon 1-4" | | |
| | 2836..2928 | | |
| | /note="exon 1-5" | | |
| exon | 3508..3607 | | |
| | /note="exon 1-6" | | |
| | 5256..5313 | | |

JOURNAL Submitted (19-DEC-1996) Genome Analysis, Institut for Molecular
Biotchnology, Beuttenbergrstrasse 11, Jena 07745, Germany

FEATURES Location/Qualifiers

source 1..15898 /organism="Homo sapiens"
/db_xref="Taxon:9606"
/chromosome="X"
/map=Xq28:
1..39138 /note="Region: cosmid IF064"
1..106 /rpt_family="LIPall"
/evidence="not_experimental"
213..282 /rpt_family="LIMB3"
/evidence="not_experimental"
complement(1180..1244)
/note="GRAIL, score = 43.000%, comment = marginal"
exon /evidence="not_experimental"
complement(1683..1767)
/note="MZF, score = 60%"
/evidence="not_experimental"
complement(2062..2120)
/note="FEXHB, score = 11.76%"
repeat_region /evidence="not_experimental"
complement(2637..2710)
/rpt_family="LIME2"
/evidence="not_experimental"
complement(2859..3038)
/rpt_family="LIME3A"
/evidence="not_experimental"
complement(2911..2918)
/note="MZF, score = 79.7%"
/evidence="not_experimental"
4230..4311 /note="GRAIL, score = 52.000%, comment = good shadow"
/evidence="not_experimental"
complement(4639..4866)
/rpt_family="LIMA2"
/evidence="not_experimental"
complement(4893..5233)
/rpt_family="LIMA2"
/evidence="not_experimental"
complement(4974..5117)
/note="GRAIL, score = 61.000%, comment = good"
repeat_region /evidence="not_experimental"
complement(5206..5561)
/rpt_family="LIMA2"
/evidence="not_experimental"
complement(5562..5602)
/rpt_family="LIMA9"
/evidence="not_experimental"
complement(5619..5655)
/rpt_family="LIMA5"
/evidence="not_experimental"
complement(6084..6254)
/rpt_family="MLTID"
/evidence="not_experimental"
complement(6362..6322)
/rpt_family="MLTID"
/evidence="not_experimental"
complement(6384..6519)
/rpt_family="MLTID"
/evidence="not_experimental"
6664..6771 /note="homology = 89.80%, score = 82, counts = 27"
/rpt_type=tandem
/rpt_unit=tctt
/evidence="not_experimental"
exon 6807..6884 /note="FEXHB, score = 10.83%"
/evidence="not_experimental"
repeat_region 7337..7454 /evidence="not_experimental"

/rpt_family="L1"
/evidence="not_experimental"
7483..733 /note="FEXHB, score = 12.95%"
repeat_region 7950..8010 /rpt_family="MSTA"
/evidence="not_experimental"
8147..8338 /rpt_family="MSTA"
/evidence="not_experimental"
8245..8286 /rpt_family="MSTA"
/evidence="not_experimental"
8287..8361 /rpt_family="MSTC1"
/evidence="not_experimental"
8878..8921 /note="homology = 97.70%, score = 20, counts = 2"
repeat_region /rpt_type=tandem
/rpt_unit=gatttaatgtcaaggcgcta
/evidence="not_experimental"
complement(9471..9526)
/note="MZF, score = 85.6%"
/evidence="not_experimental"
complement(9474..9529)
/note="FEXHB, score = 12.02%"
/evidence="not_experimental"
9618..9660 /rpt_family="MER3"
/evidence="not_experimental"
10066..10099 /note="GRAIL, score = 61.000%, comment = good"
/evidence="not_experimental"
11110..11190 /note="GRAIL, score = 76.000%, comment = excellent"
/evidence="not_experimental"
11257..11275 /note="FEXHB, score = 19.61%"
/evidence="not_experimental"
11360..11419 /note="homology = 91.70%, score = 20, counts = 2"
/rpt_type=tandem
/rpt_unit=aggccaaatagctagaactttatcatcaggc
/evidence="not_experimental"
11613..11637 /note="Xbound exon prediction, score = 68% (0%)"
/evidence="not_experimental"
complement(12650..12662)
/note="FEXHB, score = 13.07%"
/evidence="not_experimental"
13530..13600 /rpt_family="MLT2B2"
/evidence="not_experimental"
13607..13760 /rpt_family="MLT2B2"
/evidence="not_experimental"
13820..13947 /note="GRAIL, score = 88.000%, comment = excellent"
/evidence="not_experimental"
13924..13977 /rpt_family="MLT2D"
/evidence="not_experimental"
13978..14043 /note="homology = 75.80%, score = 23, counts = 6"
/rpt_type=tandem
/rpt_unit=tcttcctcttt
/evidence="not_experimental"
14054..14087 /note="homology = 94.10%, score = 28, counts = 17"
/rpt_type=tandem
/rpt_unit=tg
/evidence="not_experimental"

| | | | |
|----|-------|---|-------|
| Db | 58825 | GAGGAGGCCAACCCAAAGATAGA -GGAACCCAATAATCCAGCGCAGCTCTGCNGGCCA | 58883 |
| Qy | 1624 | GCCGTGGCACCGGCCAGAGAGATTCAGCTGGACACCCCCGTCGTCAC | 1683 |
| Db | 58884 | GTCCTGGCACACCGG - -GGAAAGACTCTCA - -GGCTGGCATCCAGCTCCAC | 58936 |
| Qy | 1684 | TGCCACTTAACCCACAGGCACTGTAGTACATAGCTATGGACCCGGCAGGGTTGT | 1743 |
| Db | 58937 | TGCACTTAAGCTACAGGGACTCTAGTCAAGAGTTGTGTGCCA - - - - | 58985 |
| Qy | 1744 | CAGGAGGCAGGGCAAGGATCAAGTCAGCATCGCCGGCATTAGGGTCAAGGAC | 1803 |
| Db | 58986 | - - - - -AGCAAGGCCAGC - | 59025 |
| Qy | 1804 | CTGGAGGGAACTGAGGGTTCCACCCACACTGTCCTCATCACCACCCCA | 1863 |
| Db | 59026 | TTCAGGAACTGAGGGCTAACCCACCTGGCTCATCACCACCCCA | 59075 |
| Qy | 1864 | CTACATTCGCCATACCTACCCCTACCCCAACCTCACTGTCAATCCTGCTCA | 1923 |
| Db | 59076 | TGCCAGGCCATCCCAACTCGTTTGCAAGATTCATTTC - - - - TCCCTGCACTCA | 59131 |
| Qy | 1924 | ACCCAGGAAAGCCACGGGAAATGGGGAGGACTGGATCTGAATCCTCAGGG | 1983 |
| Db | 59132 | ACCCGGAAAGACCTGGAAAT - - - CAGGZACTCGATCTGAATCCTACATCGAGG | 59188 |
| Qy | 1984 | TCTGTAGGGAAAGGG - - - - - - GCTGAACAGGGCTCAAGGGAGGAG - - - | 2032 |
| Db | 59189 | CTGAAGGGGAAAGGGTGTATCATGAGGCTCAAGGTACAGAGGAGAAC | 59248 |
| Qy | 2033 | - -GCCCTACTGGAGATGAGGGAGGCTCAAGGGACCCCTAGGACACCG - - - | 2086 |
| Db | 59249 | CTGCCCNCTGGAGATGAGGAAGGGCTCAAGGACCCAGAACCTAAGGGGCC | 59308 |
| Qy | 2087 | - -CACCCCTCTGAGCTG - - - QCTGCCACTCTGGCTCAAGATCGAAAGATG | 2140 |
| Db | 59309 | CACCCACCCGCTGAGATGAGGCTCTCTTCTAGCTCAGAAATCCAGGATG | 59368 |
| Qy | 2141 | GGACTCTGATTCATGGGGGG - -CCCAAGGCTGAAGGCTAACGGGAGG | 2198 |
| Db | 59369 | GCAACTCGGTCAAGGGGGGGTCAAGGGCTCAAGGCTTCAGGATCAAGGAGAC | 59428 |
| Qy | 2199 | CAGGGAGGACTCAGGGGACATATGGCCATATTCCTGAGCTGGACCTGGCT | 2258 |
| Db | 59429 | GAGGGAGGATTCAGGGGCTTCAGGATTCAGGAGGACTCTGGAGGTC | 59488 |
| Qy | 2259 | CAGGGAGGCTGCCAACATGGCCATATTCCTGAGCTGGACCTGGCT | 2314 |
| Db | 59489 | CTGGCAAGGTACCTGACTCTCATACTTCCTGAGCTGGACCTGGCT | 59548 |
| Qy | 2315 | AGAGCTGCTGAGAAGTGGGCTCAAGGTCACAGAGGGAGGACTCCAGGATCAT | 2374 |
| Db | 59549 | AGGCTCATGGTCAAGGGTACTCAGGCTGGGACTCCAGGATTCAC | 59608 |
| Qy | 2434 | GACTCCAGACAGTGGCTGGCCTTCTAGCTGGGAGGATCAAGGATGGTGG | 2493 |
| Db | 59669 | ATGGCCCAAGGATGGCTCCACTCTCACTGAGCTGGGATATCCGGCTCAAGAGG | 59728 |
| Qy | 2494 | CGGTATGTCATTCACCTGACGGGAACTGGGGCCCTCAAGGAGATG | 2553 |
| Db | 59609 | AGGACCCAGGATGGTGCACACTTCAGGAAATGGGATACCTGTGCTCAAGGAGAT | 59668 |
| Qy | 2554 | GGCTCTGGGTAAAGGGGGAGTGTCACTCATGAGGAACTTCAGGAGG | 2613 |
| Db | 59729 | CCCTATGTCACATTCACTGTGTCACAGGAACTGGTGGGAAGG | 59848 |
| Qy | 2614 | CAGCGCTGGCACAAATAAGATGAGTCAGAACGGCTATGGAAATCCACCCA | 2673 |
| Db | 59849 | CAGGCCCTGTCAGGGCAACAGGATGAGTCAGAACGGCTATGGAAATCCACCCA | 59925 |
| Qy | 2674 | GAACCAAAGGGTCAGGGCTCACCTGGACACCTCACCTGGAGGTGT | 2725 |
| Db | 59909 | GAACCAAAGGGTCAGGGCTCACCTGGACACCCACAGGGTGCAC | 59968 |
| Qy | 2726 | ACTCTGTTCCAGATGGGGAGGACTCTAGGGTGAATCTAGGGTACTC | 2785 |
| Db | 59969 | ATTCTGATTCCAGATCTCACTGAGGACTCTAGGGTACTCAGGGT | 60028 |
| Qy | 2786 | ACGTAAGGACCCCCTATGGCTAAAGACAGAGGGCATTGGCCATGGTGG | 2845 |
| Db | 60029 | CCACAGGACCCCCATGGGTTACACACACAGGGTCCAGGGAGACTCTG | 60088 |
| Qy | 2846 | CTGAGGAACATGAGGGGGACTGAGGGTACCCAGGGACACAGGAGACTGCA | 2905 |
| Db | 60069 | GTGAGGAATGTGGGGATTGGGGTACCAACAGGGCACGCAATGACCCA | 60148 |
| Qy | 2906 | CAGAACATGGCCCTGCTGGTCACCCAGAGAACATGGGCTGGCCCTGGCAG | 2965 |
| Db | 60149 | CAGAACATGGCCCTGCTGGTCACCCAGAGAACATGGGCTGGCAG | 60208 |
| Qy | 2966 | GRCCCTTCGTTATCTGGGATCATGTTGCTGGAGGGCTGGCTCTGAGAAGG | 3025 |
| Db | 60209 | GRCCCTTCCTTATCCGGATCACTGGTCTGGACTGGGCTGGCTGAGGG | 60268 |
| Qy | 3026 | CTRGCGCAGGGTAGGAGGCTGGGCTCCAGGGTGAAGTGGAGGACCA | 3085 |
| Db | 60269 | CTGCAACCCAGGTCAGTGGAGGAGGTTGGGGTCAAGGGTACACCA | 60328 |
| Qy | 3086 | AGGGGACCTAACCGAGACATTATCAATGATTTGATCTCTGTCGCTCC | 3145 |
| Db | 60329 | AGCAGGCTCCGGATCCAGGACATGGGCTCAATGATTGACATCTGCTGT | 60388 |
| Qy | 3146 | TC-CCCAAGGACCTAGGACCTGGACCTGGCTGGCAGATGTTTCCCTCCATCTCT | 3204 |
| Db | 60399 | TCTCGGAAAGCTTAGGAGGCTAGGAGGTTGGGAGATGTTCTAGGFCCT - -GTTCC | 60445 |
| Qy | 3205 | TATCATGGATGTCAGCTGTTGGATTCTCTGAGGATCCAGGATCCAGG | 3264 |
| Db | 60446 | TCTCAGSGATGAGGCTGCTGATCTGTTGGATGTCAGCTGAGTGGGATCAGG | 60505 |
| Qy | 3265 | CCTGGCAAGGAAATAAGGGCCCTGGGAGAAGGGGCTGATCCACTGGTGA | 3324 |
| Db | 60506 | CCTGGCCTGGAGAAATGTGGGGATGATCCTGAGTGGGGATCAGCTGAGTGGG | 60565 |
| Qy | 3325 | GACTGGGGATGTCAGAGTGGCCACCTGGGAGGAGGGGCTGATGGGACT | 3384 |
| Db | 60566 | GRTGGGGAGCTTCAGAGTGGGGACTCTGGGACTGAGGGGGGTGT | 60625 |
| Qy | 3385 | CTTGGCGGCTGACCTGGGGCTGGGGCTGGGGCTGGGGCTGGGGCTGGGG | 3444 |
| Db | 60626 | GCTTACAGTGTGACCTTAAGGGCCCTGGATTCCCTAGGGTCCAGGAACAGG | 60685 |
| Qy | 3445 | CAGTGGAGGCCTGGCTGAGAGCTTGGGAGGATGGCACAGGAGGATGG | 3504 |
| Db | 60686 | CAGTGGAGGTGGCTGAGAGCTGGGAGGATGGCACAGGAGGATGG | 60745 |
| Qy | 3505 | TGCCAGGAGTGAATGTTGGCTGAATGGCACAGGAGGACACA | 3564 |
| Db | 60746 | TGGCAGGAGTGAATGTTGGCTGAATGGCACAGGAGGACACA | 60805 |
| Qy | 3555 | TAGGACCCACAGGAGGATTCCTGGCTCACCTCCCTACTGTCAGTGGCTGAAATGGCTCT | 3624 |
| Db | 60806 | TAGGACCTCCAAAGGTGTGGCTCACCTCCCTACCCATCAATCTGGCAAGTGGCTCT | 60865 |
| Qy | 3625 | CTGGCCSCTGTAACCTGGCTGAGTGGCTGAGGAGGAGGAGG | 3683 |
| Db | 60866 | CTGGCCGCGTACCCCTGAGGAGGAGGAGGAGGAGGAGGAGG | 60925 |
| Qy | 3684 | CCAACCCAGGAGGACGATTCTGGGAGGCCACCTGGCCACAGGAGGATCTGTA | 3743 |
| Db | 60936 | CCAACCCAGGAGGATCCGGGAGGCCACCTGGCCACAGGAGGAGGAGG | 60984 |

| | | |
|---|--|---|
| AUTHORS | De Plaen,E., Arden,K., Traversari,C., Gaforio,J.J., Szikora,J.-P., De Smet,C., Brasseur,F., van der Bruggen,P., Lethe,B., Lurquin,C. | Qy 1838 GTCTGCCTATCTCACCGCCACCACTCACATCCCCATACCTTACCCCACAC 1897 |
| Brasseur,R., Chomez,P., De Becker,O., Cavenee,W., and Boon,T. | Db 927 CATCGCATC----- -CAACATCCAGGCCATCCCCAACCTGTTTGCAAGA 976 | |
| Structure, chromosomal localization, and expression of 12 genes of the MAGE family | Qy 1898 TCAVCTTGTCAGATUCCUGCTGTAACCCACGGAAAGACCGGAAGGGCAGGCAC 1957 | |
| JOURNAL Immunogenetics 40 (5), 360-369 (1994) | Db 977 TCCATTGTTT---TCCCTCGCACTGAACTGGAAATGT---CAGSCAC 1029 | |
| MEDLINE 95014257 | Qy 1958 TCGGATCTGACGTCTCCCATCCAGGTCTGATGGAAAGGG---- -GCTTGAAAG 2010 | |
| REFERENCE 2 (bases 1 to 4895) | Db 1030 TCGATCTGACATCACATCGAGGGCTAGAAGGAAACTTGGATATGAGC 1089 | |
| AUTHORS De Plaen,E. | Db 1090 AGCCATCGGGTAGAGGGAGGCCCTGCCCCTCTGGAGATGAGAAGGGCTCAGGA 1149 | |
| TITLE Direct Submission | Db 1095 GACCCAGCCCC----- -TAGGACACCGCACCCCTGTCAGACTGAG -- GCTGCCA 2113 | |
| JOURNAL Submitted (14-JUN-1994) Etienne De Plaen, Ludwig Institute for Cancer Research, 74 Avenue Hippocrate, Brussels, 1200, Belgium | Qy 2011 GGCCTCACTCGAGATGAGGGGGAGG---- -GCCCTACTCGAGATGAGGGCTCAGAG 2064 | |
| LOCATION/QUALIFIERS 1. | Db 1150 GACCCATCGGGAGCCACCCACCCCTGTCAGAAAGGGCTCAG 1209 | |
| /organism="Homo sapiens" | Qy 2114 CTCTGGCTCTCAAATCGAAACATGGGACTCAGATTGCTGGGGGGGA -CCAG 2171 | |
| /isolate="Patient M22" | Db 1210 CCTTAGCTCAGGATCAGGAACTAGGAGGAGGAGGTTCCAG 1269 | |
| /chromosome="X" | Qy 2172 GCCTGCAAGGCCTTACGGAGGAGGAGGACTCAGGGACCTTGGAAATCCAGAT 2231 | |
| /db_xref="Taxon: 9606" | Db 1270 CCCTTCAGGATCAAGGAAGGAGGAGGATTCAGGGCCCTTGCACTCCAGAT 1329 | |
| /sex="female" | Qy 2232 CAGTTGACCTGGCCCTGAGCTGGCCAGGGTACATGGCCATATTC 2291 | |
| /cell_type="lymphocyte" | Db 1330 CAGTGGAGGACTGGCCCTGGAGGTCCCTGGCAAGGAGGCCACATGGCC 1389 | |
| /tissue_type="blood" | Qy 2292 CTGCATCTTGAGGT--- -GACAGAACAGCTGGGTGAGAGTGGGGCTCAGGT 2347 | |
| /dev_stage="adult" | Db 1390 CTGCATCTGAGGTACAGGAGGCTACAGAGGAGGGCTATGGCTGAGGGT 1449 | |
| 2777 .. 2848 | Qy 2348 AACAGGGAGGAGGTCCAGGATCCATGGCCAGATGGCTGAGGGCT 2406 | |
| /number="2 | Db 1450 CGAGAGGGAGGAGGAGGATCACAGAGGAGGGCTAGGGTGGCAACTTCAGGGAA 1509 | |
| 2924 .. 4491 | Qy 2407 GGGATATCCGGCTCAGAAAGGGGACTCTGGCTGTCCTTTAGAA 2465 | |
| /number="3 | Db 1510 GGATACCTGGGTCAAAAGGGGCCAACAGCTGGCTGCCCCCTCTTA 1560 | |
| 2989 .. 3942 | Qy 2467 GCTCPAGGGGACCAGATCAGGGATGGGGTATGTTCCACTCTTCACTGTTACAGGCA 2526 | |
| /gene="MAGE4b" | Db 1570 GCTCAGGGGACCAGAGGGATGGGGTATGGCCCTATGGCCAAATTCACTTTCAGGGCA 1629 | |
| 2989 .. 3942 | Qy 2527 GGAAGTTGGGGCCCTCAAGGAGATGGGCTCTGGGTAAGGGGGGTGCTACTCT 2585 | |
| /gene="MAGE4b" | Db 1630 GGAAGTTGGGAAACCTTCAGGGAGTGGGGATGGAAAGGGCAATGTTGCTAT 1689 | |
| /codon_start=1 | Qy 2587 GTCAGGGAAATTGGGATTCAGACCCAGAACGGCTGGGAAATAAGTGAATGAGA 2641 | |
| /product="MAGE-4b antigen" | Db 1690 CTCAAGGGGTTGGGGTTGGAGAAGGGAGGCCCTGAGGACCTTCACCC 1743 | |
| /protein_id="AA68877.1" | Qy 2647 GACAAGGGTATTGGATTCAGACCCAGAACGGCTGGGAAATGGCTAAAGCACAG 2705 | |
| /db_xref="GI: 533217" | Db 1749 CAGGGCCATCAGAACCTTCACCCAGAACGGCTGGGCAACCCAC 1808 | |
| /translation="MSEEQKSQHCKPKEEGVEAQEEBALGLYQAQAPTEEQEAVSSSS | Qy 2707 AG----- -GATGGCTCTTTCACCTCTGTTCAAGATGGGGAGGGAGGC 2578 | |
| PLVPGTLEEVPAESGPPQPQGAELPITFISFCWQRQAEPEKLVKPEVIFGKAEPSLDA | Db 1809 AGGGGACAGATGTGGCTCTTCATTCGATTCAGATTCAGGGTACAC 1868 | |
| ESIPLERLSNVDELAHFILRKYAKELTHKAEMLERVKPEVIFGKAEPSLDA | Qy 2759 CTCATCTCAGAGGGTGAATCAGGTCAACCTGAGGACCCCATCTGGTCAAGACAG 2819 | |
| MIFGIDKWEDETNTVYLVCLGSDREHTYGEPKSLTQDWDYENLYLRQVEGSNPARYEFLWP | Db 1889 CTGGTCCAGGATCTGCAAGGATGAGGATGGGGTACAGGAGGATGGCTACAG 1943 | |
| RLAIWELSYKVYLEHVYRVNAVRVIAPIYSSRLREALLEEEVV" | Qy 2819 CGGTCCAGGATCTGCAAGGATGAGGACTGAGGGTACGGTAAAGCACAG 2878 | |
| polyA_signal 4472 .. 4477 | Db 1929 TGGTCCAGGATCTGCAAGGATGAGGACTGAGGGTACGGTAAAGCACAG 1988 | |
| BASE COUNT 1134 a 1235 c 1433 g 1093 t | Qy 2879 AGGACCAAGAACACTGAGGGAGACTGAGGGTACGGTAAAGCACAG 2938 | |
| ORIGIN | Db 2879 AGGACCAAGAACACTGAGGGAGACTGAGGGTACGGTAAAGCACAG 2938 | |

QY 5064 ACACCGAGTCACACAGCTGTTGTATATAAGGGTAAGAGTCCTGTGTTTATTCTAG 5123
 Db 4202 GTGGTAACTGATATTGTGTTAATAGTTCAG 4261
 QY 5124 ATGGGAAATCATTCTTGTGAATTGG --ATAATACAGCAAGTAAAGTAC 5180
 Db 4262 ATGGGAAATCCTTGTGAATTGGCAAAATACAGCAAGTAAAGTAT 4321
 QY 5181 TAGAACATGCAAAATGCAACTAAATAGTGAGATAAAGAAATAAGAG 5240
 Db 4322 TTGAAAGTGC--AATTCACCTGAAATAATGGTGTGAT-----AAATPAAAAG 4366
 QY 5241 ATAGCAATTCTGCCCTATACTCAGCTATCTGTAATAAGATATATGCT 5300
 Db 4367 ATACTTAATTCGGCCATTGCTCACATCTGTGAAATAATTTAAATATATGCT 4426
 QY 5301 ACCGGATTCTCCTGGCTCTTGAAAGATAAATCTGAATAAGATT 5360
 Db 4427 ACCGGATTCTCCTGGCTCTGGCTC--GTGATGTGAGAAATAATATTTC 4483
 QY 5361 TCCGTGTCACGGCTCTTCTCCATGGCACTGAGCATGTCGTTTGGAGGCCCT 5420
 Db 4484 TTCTGTAACTGGCTATTCTCTATGGACTGAGCATGTCGCTGTGGAGGCCA 4543
 QY 5421 GGTTAGTAGGGAGATCTAAGTAACCACTAGGGTCGTAGAG 5480
 Db 4544 GGAATAGTAGGGAGATCTAAGTAACCACTAGGGTCGTAGGGATTAAGA 4603
 Query Match Score 2429 / 6; DB 10; Length 4736
 Best Local Similarity 75.9%; Pred. No. 0;
 Matches 3736; Conservative 0; Mismatches 47;
 QY 715 TTCCGCCAGAAAATCCGGTGCCTGGATGAGCAGCTGCTGGGG 774
 Db 15 TTCAACCCGGGATCCGGGATCCCTGGTGCAGATGCTGGCACTGTTGAGTT 74
 QY 716 CAGGAAAGGGGGTTTCATTCTGAGGACGGGGTAGGTGGCCGAGCTGGT 74
 Db 75 CGGAGAAAGGGCTGCTGGGGCAGG-TGGAGATAGCTGAGGGAGCTG 133
 QY 835 CCAGGCTCTGAGGGCAAGGGTAGGGACTGGGGGGACTGGGGCCAC 894
 Db 134 CCCTGCCTGTGAGGATGAGGGTATCCACCC 193
 QY 895 CAATAGAGGGCCCAATAATTCCAG--CCCGCCCTCTGGCAGGGCCACCC 951
 Db 194 CTGGPAGTGGAGGAAATATCCAGTGCACCTCTGGTGGACCATCC 253
 QY 952 GCGGAGAGCTCTAGCMGGCGCCAGACGGCTGGCTGGAGAG 1011
 Db 254 AGGGCAGGACTCTTGTGGCTGGGACCCAGTCCCACCGGTTAACCGGG 312
 QY 1012 ACCAGGTCTCTCCCAAAGTCTGGAAATGAGGTGGTGTGACCAGGGACTGT 1071
 Db 313 -----CTCAGGAGAAGACTCTGGATGACGGCAGACTGGT 352
 Homo sapiens Eukarya; Metazoa; Chordata; Craniata; Vertebrata; Mammalia;
 DEFINITION Human MAGE-5b antigen (MAGE5b) gene, complete cds. 23-JUN-1995
 ACCESSION U10690
 VERSION GI:533520
 KEYWORDS human
 SOURCE human
 ORGANISM Homo sapiens
 Eukarya; Primates; Catarrhini; Hominidae; Homo.
 REFERENCE 1 (bases 1 to 4736)
 AUTHORS De Plaein,E., Arden,K., Traversari,C., Geforio,J.J., Szikora,J.P.,
 De Smet,C., Brasseur,F., van der Bruggen,P., Lethe,B., Lurquin,C.,
 Brasseur,R., Chomere,P., De Baecher,O., Cavenee,W. and Boon,T.
 TITLE Structure, chromosomal localization, and expression of 12 genes of
 the MAGE family
 JOURNAL Immunogenetics 40 (5), 360-369 (1994)
 MEDLINE 95012457
 REFERENCES 2 (bases 1 to 4736)
 AUTHORS De Plaein,E.
 TITLE Direct Submission
 JOURNAL Submitted (14-JUN-1994) Etienne De Plaein, Ludwig Institute for
 Cancer Research, 74 Avenue Hippocrate, Brussels, 1200, Belgium
 FEATURES Location/Qualifiers 1. 4736
 source /organism="Homo sapiens"
 QY 1312 GCCCCAAACCCACCCACTCTCATGTCCCCACTCCATGCCCTCCCCATCTG 1371

| | | | | | |
|----|------|---|-------|------------|-----|
| | | | ----- | CCCTATCCTG | 530 |
| Db | 513 | TCCCCA - | ----- | | |
| Qy | 1372 | GCAGAATCGTT - TGCCCTGTCTCACCCAGGGANGCCCTGGTAGGCCCATGTGAA | 1430 | | |
| Db | 531 | GCAGAATCGATTCTGCCCCTGATTCACCCGGGGCTAGCTGAA | 590 | | |
| Qy | 1431 | ACACTGACTTGACCTACAGATCTGAGAAGCCAGTCAATTAAATGGTCTGAGGG | 1490 | | |
| Db | 591 | GCTCTGACTTGACATGGGTCAGAGAACTGAA | 644 | | |
| Qy | 1491 | GGCTGTGAGATCCTAGGGAGTGGGGAGTGGTTAGGTGAGATGAGATG | 1550 | | |
| Db | 645 | GCGACTAGATAGAGGGAAATGGCCGGCTGTGGAGGAGCAAGTGAGCC | 704 | | |
| Qy | 1551 | CT-GAGGGAGACTGAGGGACACACCCAGGTAGATGGCCCCAAATGANTCAGTAC | 1609 | | |
| Db | 705 | CCCGAGGAGATGGAGGAGGCTTACCC - AGATAGAAACCCAAATAATCCAGTAC | 762 | | |
| Qy | 1610 | CACCCCTGTGCCAGGCCCTGGACACCCGGCCGGACAGATGNTCTCACTGGACCACCC | 1669 | | |
| Db | 763 | TACCTCTGTGCCAGGCCCTGGACAC - - CCAGGGCAGACTCTCAGCTGAACTTC | 818 | | |
| Qy | 1670 | CCGCCCGCNCCTAACCTGCTGCCACTTAAACCCAGGGAAATCTGAGTACATT - ATGTAC | 1728 | | |
| Db | 819 | C---CCCTCCCCTACTGCCACTTAAACCCAGGGAAATCTGAGTACATT - ATGTAC | 875 | | |
| Qy | 1729 | CGGGCAGGGTTGTCAGSGAGGCCAGCATGGTCCAGGATCCAGATCCGCCGGC | 1788 | | |
| Db | 876 | CAGGAAGGGCCGGTAGAGGAGG - - - - - GCGGGCCAGGCTCGTCAGC | 922 | | |
| Qy | 1789 | ATTAGGGTCAGGCCCTGGAGGAACCTGGGTTCCCAACCCACCTGTCTCTCATC | 1848 | | |
| Db | 923 | ATCAAATGGACCCCTGAGAGAAATTGGGCCACCCATAACCCATCC | 912 | | |
| Qy | 1849 | TCCACCGCACCACACTCAATTCCATCTACC --- CCPТАCCCAACCTCATCT | 1904 | | |
| Db | 983 | CTAACCCATACCCACTCTACTGCACTCCAGCCCATCCCACCTAACCCATCT | 1042 | | |
| Qy | 1905 | GTCAGAA - - - - - TCCCTGTCAACCCACGGAAAGCCAGGGAAATGGCGCAGG | 1954 | | |
| Db | 1043 | GGCAGAACTGTGTCTCTCTCGAGTAACCCACAGGGCCACAGAGACAG | 1102 | | |
| Qy | 1955 | CACRGGATCTGACGTCCCATCGGGTCTGAGGTGAGGG - - - - - GCTTGTAA | 2007 | | |
| Db | 1103 | CACACCCATTCTGACGTCACTCCAGGGCTGAGGGAAAGGCCTAGTATCATAG | 1162 | | |
| Qy | 2008 | CAGGGCCTAGGGAGCAGGG - - - GGGGCCCTACTCGAGATGGAGGCCTCAGA | 2063 | | |
| Db | 1163 | CAGGGCCTAGGGAGTCTGCTCTCAAGCCCTCTGGAGTAAGGGAGGCTCAG | 1222 | | |
| Qy | 2064 | GGACCCAGCACCTAGGA - - - - - CACCGAACCCCTGTCGAGCTGAGG - - TGCC | 2112 | | |
| Db | 1223 | GAACCCAGGCTCAGGATGGGGTCCACTCAACCCCTGTCAGACTAGGGCCNCC | 1282 | | |
| Qy | 2113 | ACHTCTGGCTCAAGAATGAGGATGGGACTCTGCACTGGGGTGGACCTCAG | 2172 | | |
| Db | 1283 | TCTTTCATCTCGGAATACAGGATGGGACTACGTCAAGGAGGGGGCCCAAC | 1342 | | |
| Qy | 2173 | CCPGCAAGGCTTACGGGAGGAAGGGAGGAGGACTCAGGGACCTCTGCAARTCAGAT | 2232 | | |
| Db | 1343 | CCPSCCAGGATCAAGGAGAAAGGGAGGACTACGTCAAGTGGCTCAGTCCAG | 1402 | | |
| Qy | 2233 | AGTTGGACCTCGGCCCTAGAGGTCAGGTCAGCTGACATGGCCCATATTTC | 2292 | | |
| Db | 1403 | AATGGGACCTTSCCCSGAGSTCCAGTGCACAGTGTACCCCATGCTTC | 1462 | | |
| Qy | 2293 | TGATCTTGTAGGTGAC - - - AGACAGACCTGTTGAGAATGGGGCTAGGTA | 2348 | | |
| Db | 1463 | TGACCTCTGGGAGCAAAAGGGAGGGCTGNGTCAAGGTACTAGGACTAGGICA | 1522 | | |
| Qy | 2349 | ACAGGGAGGAGTCCAGATCCATATGCCCAAAGATGTGCCCCATGTGAGGACTG | 2408 | | |
| Db | 1523 | GCAGAGGGAGGAGTCCAGATCTGAGATGCCCTGAGGGCTCTGCTGCCCCATGTGAGTGG | 1584 | | |
| Qy | 2409 | GGATATCCCGGGCTCAAGAAAAGGGACTCCACAGATCTGGCTGCCCTTGTAGTAGC | 2468 | | |
| Db | 1583 | GGACA - CCCTGGCTCAAGAAGGGACCCACAGTCGGCTGCCCTGATTTGTC | 1641 | | |
| Qy | 2469 | TCTAGGGGACCAATCAGGATGCCATCTGGATGGCTATGTCATCTCACTGTCACACGGAGG | 2528 | | |
| Db | 1642 | TCAGAGGGACCAATCAAGATACCCTCATGTCACAGGACAGAAAG | 1701 | | |
| Qy | 2529 | AAGTGGGGCCCTCAGGAGATGGGGTGTCACTATGT | 2588 | | |
| Db | 1702 | AAGTGAAGGGCTGAGTAAAGGGGGCTAGTGTGAGACAGA | 1761 | | |
| Qy | 2589 | CAGGAATTGGGGTGGCCAGGATAAGATGAGTGTGAGACAGA | 2643 | | |
| Db | 1762 | CAGGGGTTICAGGTTGAGAATGCCAGGCCATACGTGAGAGTAA | 1819 | | |
| Qy | 2649 | CAAGCTATGGGAATCACAACCCAGAACAAAGGGTCAAGCCCTGACACCTCA | 2703 | | |
| Db | 1820 | ---AGCCATAGAAACACTCCAGAACAAAGGGTCAACCCATGTGTC | 1875 | | |
| Qy | 2704 | ---CCAGGATGGGGCTCTTTTCACTCTGTTCCACATCTGGGAGGTGAGGACC | 2759 | | |
| Db | 1877 | GGGTGACAGGATGAGCT - CCATCTCATCTGGTGGAGAATGGGGACCTT | 1935 | | |
| Qy | 2760 | TCACTCTCAAGGGTGGACTAGGGCAACCTCTGCTAAAGAGAGC | 2813 | | |
| Db | 1936 | TTGTTCTCCGAGGATGACTAGGICAACAGGGCCCCATCTGGTGTAGACAGT | 1995 | | |
| Qy | 2820 | GGTCCCAGGATCTGCACTGGCTGGGAAACATGGGAGGACTGAGGGTACCCA | 2879 | | |
| Db | 1996 | GGTCCAGGATCTGTCAGTGTAGTTCGGTGGAGAATGGGGACCTTGGGGACCTT | 2055 | | |
| Qy | 2880 | GGACCAAGAACACTGGGAGACTGCAAGAAATCAGGCCCTGGCCCTGCTGACCCAGA | 2939 | | |
| Db | 2056 | GGGCCAGAAATCAGGCCCTGGCCCTGCTGCTGACCTTGGGGACCTTGGGGACCTT | 2115 | | |
| Qy | 2940 | GAGCATGGCTGGGCGCTCTGGCCAGGCTCTTC - GTTATCCTGGATCATCTGTC | 2997 | | |
| Db | 2116 | GAGCATGGGAGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 2175 | | |
| Qy | 2998 | GGACGGGAGGGCCGGCTGGAGGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG | 3057 | | |
| Db | 2176 | GTGATGGGGAGGTCTGTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 2234 | | |
| Qy | 3058 | GCCCTGCCAGGAGTCAAGGTGAGGACCAAGGGCCACTCAGCCAGCACATTATTC | 3117 | | |
| Db | 2235 | GCCCTGCCAGGAGTCAAGGTGAGGACCAAGGGCCACTCAGCCAGCACATTATTC | 2291 | | |
| Qy | 3118 | AATGAAATTGATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 3176 | | |
| Db | 2295 | AATGAAATTGATCTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 2351 | | |
| Qy | 3177 | GTGTTGCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCCCTCC | 3233 | | |
| Db | 2355 | GTGATGCTCTCTCATGTCCT -- - GTCCTCATGTCCTCATGTCCT | 2411 | | |
| Qy | 3237 | TCAAGACGAAAGGGCAAGGATGAGCTGAGGAGGAAATAATAGGGCCCTGCTGTG | 3295 | | |
| Db | 2412 | TCAAGACGAAAGGGCAAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGG | 2471 | | |
| Qy | 3297 | AGAACAGGGGGCTTCAGGCTGAGTGTGACAGTGGGACTCTGCTGCTGCTGCTG | 3356 | | |
| Db | 2472 | AGCACAGGGGACCTTACGCCAGAGGTGGAAACCTTCAGGTTCCAGCTTCC | 2531 | | |
| Qy | 3357 | CCTGGTACCTGAGAGGGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 3416 | | |
| Db | 2532 | CCTGTTAGCACTGGGGCTGAGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTG | 2591 | | |
| Qy | 3417 | TCCTCTCCCTGAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG | 3476 | | |
| Db | 2592 | TCCCTCTCCCTGAGGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTGAGCTG | 2651 | | |

| | | | RESULT | 11 |
|----|------|---|--------|--|
| Qy | 3477 | GGTCACAGCAGGAGATGGCACAGGGT---GTGCCAGGTGAATGTTGCCCTGTAATG | 3532 | HSU10689 |
| Db | 2652 | GGTCACAGCAGGAGATGGCACAGGGTGAATGTTGCCCTGTAATGTTGCCCTGTAATG | 2711 | HSU10689 |
| Qy | 3533 | CNCACAGGCCCCACCCCAAGGACAGAACATAGACTCACAAGTGCGCTCA-OC | 3551 | 4741 bp |
| Db | 2712 | CACACTAATGCCCTCATCCGCCCAAGAACATAGACTCACAAGTGCGCTCAACCC | 2771 | DNA |
| Qy | 3592 | TCCCTACTGTAGTCGTCGTAATGACCTCTGTCGGGGCTGTACCCGTACCCCTC | 3651 | Human MAGE-5a antigen (MAGE5a) gene, complete cds. |
| Db | 2772 | TCTCTACTGTAGTCGTCGTAATGACCTCTGTCGGGGCTGTACCCGTACCCCTC | 2831 | PRI |
| Qy | 3652 | TCACHTCCTCCTTCAGGTTTCAGGGACAGGCCAACCCAGGAC-----A | 3698 | 4741 bp |
| Db | 2832 | TCACHTTTCCTTCAGGTTTCAGGGACAGGCCAACCCAGGAC-----A | 2891 | DNA |
| Qy | 3699 | GGATTCCTGGGGCACAGGGCACAGGGCACAGGGCACAGGATACCAGAAAGTCAGA | 3757 | 23-JUN-1995 |
| Db | 2892 | GGATTCCTGGGGCACAGGGCACAGGGCACAGGGCACAGGAGTCAGA | 2951 | DEFINITION |
| Qy | 3758 | AGAGTCTCCAGGTTCAAGTCTCAAGCTCAAGCACTTCACCCCTCTCCTCCAGG | 3817 | |
| Db | 2952 | AGAGTCTCCAGGTTCAAGTCTCAAGCTCAAGCACTTCACCCCTCTCCTCCAGG | 3011 | |
| Qy | 3818 | CTGGGGCTCTCATGCCCAGCTCTGCCCACACTCTGCCCAGCTCTGCCCAGG | 3877 | |
| Db | 3012 | CTGGGGCTCTCATGCCCAGCTCTGCCCACACTCTGCCCAGCTCTGCCCAGG | 3071 | |
| Qy | 3878 | ATCATCTCTCTGAGCAGGAGGTCTGCACTGCAGCCAGCTCTCAGCTGCA | 3937 | |
| Db | 3072 | GTATGTCCTGTCAGAAGAGTAGCAGCTGCAAGCTGCAAGCTGCA | 3131 | |
| Qy | 3938 | CAAGAGGCCCTGGGCTCTGCTGTGCAAGCTGCACTGCACTGCACTGCA | 3976 | |
| Db | 3132 | GAAGAGGCCCTGGGCTCTGCACTGCACTGCACTGCACTGCACTGCA | 3191 | |
| Qy | 3977 | TCCTCTCTCTCTCTGGCTCTGGCACCTGGGCAACTCTGGTGGTCACAAC | 4036 | |
| Db | 3192 | TCCTCTCTCTCTCTGGCTCTGGCACCTGGGCACTCTGGTGGTCACAAC | 3251 | |
| Qy | 4037 | GATCCCTCCCAGAGTCCTCAGGAGCTCAGGAGCTCCCTACCATCACTTACTCA | 4096 | |
| Db | 3252 | GATCCCTCCCAGAGTCCTCAGGAGCTCAGGAGCTCCCTACCATCACTTACTCA | 3311 | |
| Qy | 4097 | CAGAGCAACCCAGCTGGGCTCCAGCCAGGCGTGAAGAGGAGGGCCACCC | 4156 | |
| Db | 3312 | TGGAGCAATTCAAAGGGTCCAGCAACCAAGAGGAGGGCCACCC | 3371 | |
| Qy | 4157 | ATCCCTGGAGCTCTGGCTCCAGCAGTAATCACTAAAGAAGGGCTGATTTGGT | 4216 | |
| Db | 3372 | GACCCAGAGGT | 3431 | |
| Qy | 4217 | CTGCTCTCTCAAATAICGAGGAGGCCAGTCAAAAGCAGAAATGCTGGAGGTG | 4276 | |
| Db | 3432 | CTGCTCTCTCAAATAAGCTGCAAGGAGCCGCTCAGGAGACGCTGCTG | 3491 | |
| Qy | 4277 | ATCAAAAATACAAGCACTGTTCTGAGATCTCGGCCAGCTGCTGCTG | 4336 | |
| Db | 3492 | ATCAAAAATACAAGCGCTCTTCCTGAGATCTCGGCCAGCTGCTGCTG | 3551 | |
| Qy | 4337 | CTGGCTTGGCATGAGTGAAGAGGAGCCACCGCCACTCCPAATGTCGTC | 4396 | |
| Db | 3552 | CTGGCTTGGCATGAGTGAAGAGGAGCCACCCACCCPAACCTTCGTC | 3611 | |
| Qy | 4397 | ACCTGCCTCTGAGTCGTCCTGAGTAAATCACTGCCCCAAAGACA | 4456 | |
| Db | 3612 | ACCTGCCTGGG---ACCTCTATGATGCTGGGGT-TATCAATCATGCCAAAGAC | 3667 | |
| Qy | 4457 | GGCTCTCTGATAATGTCCTGGCTCATGATGCAATGGAGGGCCATGTCCTGAGG | 4516 | |
| Db | 3668 | GGCTCTCTGATAATGTCCTGGCTCATGATGCAATGGAGGGCCATGTCCTGAGG | 3727 | |

| | | | | | | | |
|----|------|--|------|----|------|---|------|
| Qy | 2064 | GACCCAGCACCTAGGA-----CACCGCACCCCTGTCTGAGACTGAG--GCTGCC | 2112 | Qy | 3118 | AATGAATTTCATATCCTGCTGCCCTTCCCCA-AGGACCTAGGCACCTGGCCAGAT | 3176 |
| Db | 1223 | GAACCGAGCTCTAGGATGGGGTCACTTCAACCTGAGTGAATGGCC | 1282 | Db | 2295 | AATGCATTCTAGCATTCTCTCTCCATGAGCTTACCTGAGCTTACCTGGCCAGAT | 2344 |
| Qy | 2113 | ACTTCTGCCTCAAGAACGATGGGACTCAGATTGATGGGGTGGGACCCAGG | 2172 | Qy | 3117 | GTTTGCCCCCTCTGCTCCATCCTTATCATGGATGAACTCTTGATTGGATTIC | 3235 |
| Db | 1283 | TCTTCATCTGGAACTACAGGATGAGTCACTGAGCTTACAGGGTGGGCCAAC | 1342 | Db | 2355 | GTGAGTCCTCATGTCCT - GTTACCTCATGGATGAGCTCTTAACTCAGTTC | 2411 |
| Qy | 2173 | CCTGAAGGTTAGGGTAGGGAGGAGACTCAGGGACCTGGGATCCAGATC | 2232 | Qy | 3237 | TCAAGCAGAAAAAGGCAAGATGGGGCTGGGAGAAAATAAGGCCCTGGCAGTG | 3295 |
| Db | 1343 | CCTCCAGGATCAAGGAGGAAAGGGAGGACTCAGGTACGGTCAAGAAC | 1402 | Qy | 3297 | AGAACAGGGGTATCAGCTGGGATGTCAGAGTCAAGGTCAGCCACCC | 3355 |
| Qy | 2233 | AGTGTGACCTGGCCCMGAGAGTCCAGGGAGGGGACTCAGGGACCTGGG | 2292 | Db | 2412 | TCAGGCAAGAAAAGTGGGATCAGGGTGGGAGTGGGGAAAGTGAAGGCC | 2471 |
| Db | 1403 | ATGGGGACCTTGGCCCGGGAGGGTCAAGTGGGAGGAGCTGGG | 1462 | Db | 2472 | ACACAGGGGACCATTCACGGTCAAGGGTGGGACCTGGGACCTAACCT | 2531 |
| Qy | 2293 | TGATCTTGGGGTAC-----AGGACAGGCTGGGTGAGGAAAGTGGGCTCAGSTCA | 2348 | Qy | 3357 | CCTGGPAGCAGTGGAGGAGGAGGCTGGCTGGCTGGCTGGCTGGGGCTG | 3416 |
| Db | 1463 | TGCACTCTGGGTGAGCAAGGGAGGACTCAGGTACGGTCAAGAAC | 1522 | Db | 2532 | CTGTTAGACCTGGGGCTGGGGCTGGGGCTGGGGCTGGGGCTGGGGCTG | 2591 |
| Qy | 2349 | ACAGAGGGAGGAGTCCAGGATCCATATGGCCCATATGGGATATTCC | 2408 | Qy | 3417 | TCTCTPTCTGAGCTCAGGTCAGGTCAGGTCAGTGGCTGAGAGTATCCTCA | 3476 |
| Db | 1523 | GAAGGGGGAGGATGGGCTGAGAACAGTGTGCCCCCTCATAGGAGACTGG | 1582 | Db | 2592 | TCTCTPTCTCAGAGCTCAGGTCAGGTCAGGTCAGTGGCTGAGACCTGACCTCA | 2651 |
| Qy | 2409 | GATATCCCGGCTCAGGATCCACAGGGACTCCACAGGGCTGAGTGG | 2468 | Qy | 3477 | GGTCAAGGAGGAGGAGGATGACAGGGT-----GTGCAAGGAGTGTGCTGAA | 3532 |
| Db | 1583 | GAATA-CCTTGTCTGAGGAGCCCAGCATTCAGGAGGAGCCCAGG | 1641 | Db | 2652 | GGTCAZAGGAGGAGGAGGAGGAGGAGGAGTGGCTGAGCTTGGCTGAA | 2711 |
| Qy | 2469 | TCTAGGGGACGAGTCAAGGATGGGATGGGTATGTCATTCTCACTTGATCAGG | 2528 | Qy | 3533 | CACACAGGGACCCACCTGGCAGACAGGACATAGGACATGGCTGGCCNCA | 3591 |
| Db | 1642 | TCAAGGGGACCAATCAGGATAGCCATTGTCACCTATTTGCCCCAAG | 1701 | Db | 2712 | CAACATGGGCCCCATGGCCCAACACATGGGACTCAGGACCTGGCTCACCC | 2771 |
| Qy | 2529 | AAGTGGGGGGCTCAGGATGGGCTCTGGGATGGGTCTGGGTAAGGGGG | 2588 | Qy | 3592 | TCCCTACTGTCAGTCTGTTAGAATGTCAGCCTGACAGCTGCGGCTGTPACCTG | 3651 |
| Db | 1702 | AAGTGAAGAAGCCCTCAGGGTGTGGGCTCTGAGAAAGGGGCTGTCACCT | 1761 | Db | 2772 | TCTCTATGTCAGTCTGACAATTCAGCCTGTCAGGCTGACCTGCCCC | 2831 |
| Qy | 2589 | CAGGAATTTGGGGTTGAGGAAGCACGGCTGGGAGAAATAAGTGGAGA | 2648 | Qy | 3652 | TCACTTCCTCTCAGGTTTCAAGGTTTCAAGGTTTCAAGGTTTCAAGG | 3698 |
| Db | 1762 | CAGGGGGTTCTAGGATGGGATGGGAGGCCCCTCATCGATAGAGTAACCCACGG | 1819 | Db | 2832 | TCACTTTTCTCAGGTTTCAAGGTTTCAAGGTTTCAAGGTTTCAAGG | 2891 |
| Qy | 2649 | CAAGGCTATTGGAAATCCACACCCAGAACAAAGGGCTGGACACCTCA | 2703 | Qy | 3699 | GGATCCCTGAGGGCACAGGAGGACACAGGAGGACACAGGAGGAC----- | 3757 |
| Db | 1820 | - -AGCCATGAACACTACCCAGAACACGGGCTCATCTGGACACCCATGG | 1876 | Db | 2892 | GGATCCCTGAGGGCACAGGAGGACACAGGAGGACACAGGAGGAC----- | 2951 |
| Qy | 2704 | - -CCAGGATGTTGCTCTCTCTCACTCTGGGCTGGGCAAGTGAGGACC | 2759 | Qy | 3758 | AGAGTCICAAGGTTAGTTCACTGAGGCTCTCAACACTCCCTCTCCAGGC | 3817 |
| Db | 1877 | GGTACAGATGAGTAGC-TCCAICTCATCCTGTTAGGAGGTGAGAAC | 1935 | Db | 2952 | AGAGCTTCAGGTTAGTTCACTGAGGCTCTCAACACTCCCTCTCCAGGC | 3011 |
| Qy | 2760 | TCACTCTCAGAGGGTGAATCTGGGACCCCCATCTGGCTAAAGACAGAGC | 2819 | Qy | 3818 | CITGTGGSTCTTCATGGCCACACCTCTGGCTGCGCTGAGAGTC | 3871 |
| Db | 1936 | TGTCTCTCCAGGATGAGTCAACAGGGCCCCCATTGGNGATAAGACAGT | 1995 | Db | 3012 | CAGTGGGTTCTCATGGCCAGCTCTGGCCACACCTCTGGCTGAGGAGAGTC | 3071 |
| Qy | 2880 | GACCAAAACATAGGGAGACTCACAGAACATGGGAGGAGCTGGCCCTGTG | 2939 | Qy | 3878 | ATCATGTCCTCTGAGGAGGAGTCTGCACTGGGAGGAGCCCTGAGCCAA | 3937 |
| Db | 2056 | GGCCAGAACACAGATGAGGAGGAGCTACGGAAATGCTGGCCCTGAGA | 2879 | Qy | 3977 | TCTTCCTCTCTGCTGGCTGGGACCTGGAGGAGTCTGGCTGGCTAACCA | 4035 |
| Db | 1996 | GGTCCAGGATCTGGGAGGCTGGGCTGGGAGGCTCTGGCTGAGGGAGCT | 2055 | Db | 3192 | TCTTCCTCTGCTGGCTGGCTGGCTGGCTGAGGGAGCTGGCTAACCA | 3251 |
| Qy | 2940 | GAGATGGGGGGGGGGTGGGGCTGGCTGGGAGCTGGGAGCTGGGAGCT | 2997 | Qy | 4037 | GATCCMCCCTCAGGAGCTCAGGAGCTCAGGAGCTCAGGAGCTCAGG | 4095 |
| Db | 2116 | GAGCATGGGCAAGGCTGTCAGTGGGAGCTGGGAGCTGGGAGCTGGT | 2175 | Db | 3252 | GTCCTCTCAGGAGCTCAGGAGCTCAGGAGCTCAGGAGCTCAGGAG | 3311 |
| Qy | 2998 | GGAGGG | 3057 | Db | 3192 | TCTTCCTCTGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGGCTAACCA | 3251 |
| Db | 2176 | GGATGGGGAGGCTGGGCTGGGAGGCTGGCTGGCTGGCTGGCTGGCT | 2234 | Qy | 4097 | CAGGGCAACCGAGTGGGTCAAGGGTCAAGGGTCAAGGGTCAAGGGT | 4156 |
| Qy | 3058 | GCTCTGGCAAGGAGTCAAGGGAGCACTACCCAGACATTAATTC | 3117 | Db | 3312 | TGGAGGCAATCCATTAAAGGGTCTCCAGCAACAGGAGGAGGAGGAG | 3371 |
| Db | 2235 | GCCCTGCCAGGAGGAGCTGGGAGGAGGAGGAGGAGGAGGAGGAGGAG | 294 | Qy | 4157 | ATCCCTGGAGTCCTTGTCTCGAGCAAGGAGGAGGAGGAGGAGGAGG | 4215 |

| | | | | RESULT | 13 |
|-------------|------|--|------|--|--------------------------------------|
| Qy | 3616 | CGACCTCTGCCGGCTGTACCCCTGAGTACCCCTCACTTCCTCAGTTTCAG | 3675 | GAACCACTA C T A N T G A A A G T C C T G A G A T G T G A T C A A G G T C A G T G C A A G G T C A G T G C G C T T 4755 | |
| Dy | 361 | CCACCTCTGCCGGCTGTACCCCTGAGTACCCCTCACTTCCTCAGTTTCAG | 420 | | |
| Dy | 3676 | GGACAGGCCAACCCAGGGACAGGATTCCCTGGGACAGGCCAACAGGAGAA | 3735 | | |
| Dy | 421 | GGACAGGCCAACCCAGGGACAGGATTCCCTGGGACAGGCCAACAGGAGAA | 480 | | |
| Dy | 3736 | GATCTGAAGTAGGCCCTTGTAGAGTCTCAGGTTCACTGAGGCCCTCA | 3795 | | |
| Dy | 481 | GATCTGAAGTAGGCCCTTGTAGAGTCTCAGGTTCACTGAGGCCCTCA | 540 | | |
| Dy | 3796 | CACACTCCCTCTCCCAAGGCCTGGGTCAGCTCCAGGAACTCCT | 3855 | | |
| Dy | 541 | CACACTCCCTCTCCCAAGGCCTGGGTCAGCTCCAGGAACTCCT | 600 | | |
| Dy | 3856 | GCTGCTGCCCTGAGCAGAGTCATCACTGTCCTTGAGCAGGAGTGTGCA | 3915 | | |
| Dy | 601 | GCTGCTGCCCTGAGCAGAGTCATCACTGTCCTTGAGCAGGAGTGTGCA | 660 | | |
| Dy | 3916 | TGAGGAAGCCCTTGAAGCCCAAAGGGCTGGGCTGGCTGCTGAGGTG | 3975 | | |
| Dy | 661 | TGAGGAAGCCCTTGAAGCCCAAAGGGCTGGGCTGGCTGCTGAGGTG | 720 | | |
| Dy | 3976 | CGCTCTCCCTCTCTGCTGGCACCTGGGCCACTGCTGGGTCAC | 4035 | | |
| Dy | 721 | CGCTCTCCCTCTCTGCTGGCACCTGGGCCACTGCTGGGTCAC | 780 | | |
| Dy | 4036 | AGATCCCTCCCAGAGTCTCAAGGAGCTCAGGCTGCTGAGCTC | 4095 | | |
| Dy | 781 | AGATCCCTCCCAGAGTCTCAAGGAGCTCAGGCTGCTGAGCTC | 840 | | |
| Dy | 4096 | ACAGGGCAACCCAGTGGGTTCCAGGCGCTTAATCACTAAGCCCTTG | 4155 | | |
| Dy | 781 | ACAGGGCAACCCAGTGGGTTCCAGGCGCTTAATCACTAAGCCCTTG | 900 | | |
| Dy | 4156 | TATCCTGGAGTCTTCTGGCTGGAGCTAATCACTAAGGGAGCTGGTT | 4215 | | |
| Dy | 901 | TATCCTGGAGTCTTCTGGCTGGAGCTAATCACTAAGGGAGCTGGTT | 960 | | |
| Dy | 4216 | TCTGCTCTCAATAATCAGGCCAGGAGCCAGTACAAGGCGAAATGCTG | 4275 | | |
| Dy | 961 | TCTGCTCTCAATAATCAGGCCAGGAGCCAGTACAAGGCGAAATGCTG | 1020 | | |
| Dy | 4276 | CATCAAAAATAGAACGACTGTTCTCTGAGTCTGGCTGAGTCCTGCA | 4335 | | |
| Dy | 1021 | CATCAAAAATAGAACGACTGTTCTCTGAGTCTGGCTGAGTCCTGCA | 1080 | | |
| Dy | 4336 | GCCTGGCTTGGCATGCTGAGGAGCAAGCCCACTCTCTCTCTGT | 4395 | | |
| Dy | 1081 | GCCTGGCTTGGCATGCTGAGGAGCAAGCCCACTCTCTCTCTGT | 1140 | | |
| Dy | 4396 | CACTGCTCTGGCTGAGGAGCAAGCCCACTCTCTCTCTGT | 4455 | | |
| Dy | 1141 | CACTGCTCTGGCTGAGGAGCAAGCCCACTCTCTCTCTGT | 1200 | | |
| Dy | 4456 | AGGCTTCTGATATTGCTCTGGCTGAGGAGCAAGCTGCTGAGA | 4515 | | |
| Dy | 1201 | AGGCTTCTGATATTGCTCTGGCTGAGGAGCAAGCTGCTGAGA | 1260 | | |
| Dy | 4516 | GGAAATCAGGCCAGGAGCTACCCAGAATTTGCTGAGAAGTACGG | 4575 | | |
| Dy | 1261 | GGAAATCAGGCCAGGAGCTACCCAGAATTTGCTGAGAAGTACGG | 1320 | | |
| Dy | 4576 | TGGGAGGCCAGGAGCTACCCAGAATTTGCTGAGAAGTACGG | 4635 | | |
| Dy | 1321 | TGGGAGGCCAGGAGCTACCCAGAATTTGCTGAGAAGTACGG | 1380 | | |
| Qy | 4636 | CAGTGGCCGACAGTGGCTCCAGGCTATGAGTTCTGGGTCAGGGCCCTGCT | 4695 | | |
| Dy | 1381 | CAGTGGCCGACAGTGGCTCCAGGCTATGAGTTCTGGGTCAGGGCCCTGCT | 1440 | | |
| RESULT | 13 | | | | PAT |
| AR0073_31 | | | | | AR0073_31 2420 bp |
| LOCUS | | | | | Sequence 23 from patient US 5750395. |
| DEFINITION | | | | | |
| 04-DEC-1998 | | | | | 04-DEC-1998 |

| | | | | | |
|---|---|--|------------------------|-----------|--|
| QY | 5115 | TCTTATTAGAGATGGAAATCCATTCTTATTGTTGAAATTACAGCACTGGAAAT 5174 | intron | | /cell_line="M22-MEL-43" |
| Db | 1861 | TTTATTAGAGATGGAAATCCATTCTTATTGTTGAAATTACAGCACTGGAAAT 1920 | | 1..412 | /partial |
| QY | 5175 | AGTACTCTAGAAATGCTGAAATGCACTAAATAGATGAGATAAAGAACATAAGAAAT 5234 | | | /gene="MAGE-1" |
| Db | 1921 | AGTACTCTAGAAATGCTGAAATGCACTAAATGAGATAAAGAACATAAGAAAT 1980 | exon | number1 | 413..485 |
| QY | 5235 | TAAGAGTAGCAGAACATCTTGCTTAAACCCAGCTTATCTGAAATTAAAGATAT 5294 | | | /gene="MAGE-1" |
| Db | 1981 | TAAGAGTAGCAGAACATCTTGCTTAAACCCAGCTTATCTGAAATTAAAGATAT 2040 | intron | number2 | join(413..485, 561..2111) |
| QY | 5295 | ATGCATACCTGTGATTCTGGTCTTCAGTCACTGTTGAAATGAAATTCTGATAAA 5354 | | | /gene="MAGE-1" |
| Db | 2041 | ATGCATACCTGTGATTCTGGTCTTCAGTCACTGTTGAAATGAAATTCTGATAAA 2100 | exon | 561..2111 | /gene="MAGE-1" |
| QY | 5355 | GAATTCTTCCTTCACTGGCCTTCTCCATGCACTGCTTGTCTTTGGAA 5414 | | | /number3 |
| Db | 2101 | GAATTCTTCCTTCACTGGCCTTCTCCATGCACTGCTTGTCTTTGGAA 2160 | gene | 626..1555 | /gene="MAGE-1" |
| QY | 5415 | GACCTCGGGTAAAGTAAAGCTAAACCCACCATAGGGTC 5474 | | | /gene="MAGE-1" |
| Db | 2161 | GCCCCGGGTAGTAGTGGAGTGGAGCTAACCCATAGGGTC 2220 | | | /codon_start=1 |
| QY | 5475 | CTAGAGCTCTAGAGGCTCAGTCACGTAATCGGTTGGCAAGATGTCCTCTAAAGATGTAG 5534 | | | /product="MAGE-1" |
| Db | 2221 | CTAGAGCTCTAGAGGCTCAGTCACGTAATCGGTTGGCAAGATGTCCTCTAAAGATGTAG 2280 | | | /protein_id="GI:416115" |
| QY | 5535 | GGAAAGTGGAGCAGGGGTGAGGGTGTGGGCTCCTGGTGAAGCTGGTGAATG 5594 | | | /db_xref="MSL:QSLHCKPPEALEAQEALGGLCYCOAATSSSPLVIGLE" |
| Db | 2281 | GGAAAGTGGAGCAGGGGTGAGGGTGTGGGCTCCTGGTGAAGCTGGTGAATG 2340 | | | /EVPTAGSDPPQDPQGAAKPTINFRRQRQPSSEEGPSSEEEPSLILSPLVIGLE |
| QY | 5595 | CCCTGAGTGGCCATTGGGAAACTGGCTTGGGAGCTGGTGCATTG 2400 | | | /TKVADLGFLFGLSYDGLNDIMPKTGFLIVLYMAMEGHAPAEPEWELL |
| Db | 2341 | CCCTGAGTGGCCATTGGGCTTGGGAGCTGGTGCATTG 2420 | | | /SVNEYDREHSYGEPKLKLTDIVQEKLEYRQFDSDPARYELWGPRALEYSY |
| QY | 5655 | TAATGATCTGGTGGATC 5674 | | | /VKLEYVVKVSARVRFFPSLREALREEEGV |
| Db | 2401 | TAATGATCTGGTGGATC 2420 | | | /2005..2100 |
| | | | | | /gene="MAGE-1" |
| | | | | | /partial |
| | | | | | /number=3 |
| | | | BASE COUNT | 562 a | |
| | | | ORIGIN | 582 c | |
| | | | | 677 g | |
| | | | | 599 t | |
| RESULT | 14 | | Query Match | 42.4% | Score 2408; DB 9; Length 2420; |
| HUMMAG1A | | PRI | Best Local Similarity | 100.0% | Pred. No. 0; |
| LOCUS | | | Matches 2419; Conserv. | 0; | Mismatches 0; |
| DEFINITION | Human antigen (MAGE-1) gene, complete cds. | | Indels 1; | | Gaps 1; |
| ACCESSION | M77481..1 | | | | |
| VERSION | GI:416114 | | | | |
| KEYWORDS | | | | | |
| SOURCE | Homo sapiens (individual_isolate patient M22) melanoma | | | | |
| ORGANISM | metastasis of melanoma DNA. | | | | |
| Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; | | | | | |
| Butharia; Primates; Catarrhini; Hominidae; Homo. | | | | | |
| REFERENCE | 1 (bases 785 to 1286) | | | | |
| AUTHORS | van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plen, E., Van den Ende, B., Kruth, A. and Boon, T. | | | | |
| TITLE | A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma | | | | |
| JOURNAL | Science 254, 1543-1547 (1991) | | | | |
| MEDLINE | 9208661 | | | | |
| REFERENCE | 2 (bases 1 to 2420) | | | | |
| AUTHORS | van der Bruggen, P. | | | | |
| TITLE | Direct Submission | | | | |
| JOURNAL | Submitted (05-FEB-1992) Pierre van der Bruggen, Ludwig Institute for Cancer Research, Brussels Branch, Avenue Hippocrate, 74, UCL 7459, Brussels, B-1000, Belgium | | | | |
| COMMENT | On Nov 15, 1993 his sequence version replaced gi:187294. | | | | |
| FEATURES | Location/Qualifiers | | | | |
| SOURCE | 1..2420 | | | | |
| | /db_xref="Organism=Mono sapiens" | | | | |
| | /map="X" | | | | |
| | /sex="female" | | | | |
| | 361 CGACCTCTGTTGGCCAGCAGCAATGTTGCCCTGATGCAACAAAGGCC | | | | |
| | 3616 CGACCTCTGTTGGCCAGCAGCAATGTTGCCCTGATGCAACAAAGGCC | | | | |
| | 3661 CGACGGTGTGGCCAGCAGCAATGTTGCCCTGATGCAACAAAGGCC | | | | |
| | 3661 CGACGGTGTGGCCAGCAGCAATGTTGCCCTGATGCAACAAAGGCC | | | | |

| QY | 3.676 | GGACAGGCCCCAACCCAGGAGCACAGGATTOCTTGAGGCCAACAGGAGAACAGGAA | 3735 | Db | 1501 | TTCCTCCATCCCGTGAAGCTTGAGAGGGAAAGGGCATG | 1569 |
|----|-------|--|------|----|-------|--|------|
| Db | 4.21 | GGACAGGCCCCAACCCAGGAGCACAGGATTOCTTGAGGCCAACAGGAGAACAGGAA | 480 | QY | 4.815 | AGTGCAGCAAGGCCACTGGGGGACTGGSCCAGTCAGTGTGCAAGGGCGGTCC | 4874 |
| QY | 3.736 | GACCTGTAAGTAGGCCCTTGTAGCTCAAGGTCAAGTTCTAGTGTAGCTCTCA | 3795 | Db | 1561 | AGTGCAGCAAGGCCACTGGGGGACTGGSCCAGTCAGTGTGCAAGGGCGGTCC | 1620 |
| QY | 3.796 | CACACTCCCTCTCCCAAGGCCCTGTGGGTCTCATGCCAGTCAGGTCAAGCTCT | 3855 | Db | 1681 | GTGTCAGTCAGTAGTGTGTCGTTGCTGAGCTGGAGATTATTTGTTCTCT | 4999 |
| Db | 5.41 | CACACTCCCTCTCCCAAGGCCCTGTGGGTCTCATGCCAGTCAGTGTAGCTCT | 600 | QY | 4.995 | TTGGAAATTTCATAAATGTTTTAAGGATGTTGATGAACTTCAGTCAGTCAG | 5054 |
| QY | 3.856 | GCTCTGCTGCCTGAGTCATGCTCTGAGGAGTCAGTGTGAGCTGCAACCC | 3915 | Db | 1741 | TTTGGAAATTGTCAAAATGTTTTAAGGATGTTGATGAACTTCAGTCAGTCAG | 1800 |
| Db | 6.01 | GCTCTGCTGCCTGAGTCATGCTCTGAGGAGTCAGTGTGAGCTGCAACCC | 660 | QY | 5.055 | TTATGATGACAGCAGTCACAGCTCATATTTGTAAGGTTAAGAGTCAGTCAG | 5114 |
| QY | 3.916 | TGAGGAAGCCCTTGTGGGCCCTGGCTGGTGTGAGCTGAGCTGCAAC | 3975 | Db | 1801 | TTATGATGACAGCAGTCACAGTCAGTCAGTCAGTCAGTCAGTCAGTCAG | 1860 |
| Db | 6.61 | TGAGGAAGCCCTTGTGGGCCCTGGCTGGTGTGAGCTGAGCTGCAAC | 720 | QY | 5.115 | TTTATCAGATTGGAAACCATCTATTTGTAATGGATAAACAGCAGTCAG | 5171 |
| QY | 3.976 | CT | 4035 | Db | 1861 | TTTATCAGATTGGAAACCATCTATTTGTAATGGATAAACAGCAGTCAG | 1920 |
| Db | 7.21 | CT | 840 | QY | 5.175 | AAGTACTTACAATGTGAAATGCACTGAGTAAATGAGATAAGAACTAAAGAA | 5231 |
| QY | 4.036 | AGATCCTCCAGAGTCTCAGGCTTCAGGAGTCAGTGTGAGCTACTCTG | 4095 | Db | 1921 | AAGTACTTACAATGTGAAATGCACTGAGTAAATGAGATAAGAACTAAAGAA | 1980 |
| Db | 7.81 | AGATCCTCCAGAGTCTCAGGAGCTTCAGGAGTCAGGAGTCAGGAG | 840 | QY | 5.235 | TAAGAGATAGTCATTCTCCCTATACCTCAGTCTATCTGTAATTTAAGATA | 5291 |
| QY | 4.096 | ACAGAGGCAACCCAGTGTAGGTTCTAGCAGCCGAGCCAGACCTCTG | 4155 | Db | 1981 | TAAGAGATAGTCATTCTCCCTATACCTCAGTCTATCTGTAATTTAAGATA | 2040 |
| Db | 8.41 | ACAGAGGCAACCCAGTGTAGGTTCTAGCAGCCGAGCCAGACCTCTG | 900 | QY | 5.295 | ATGCAACCTGGATTCCTGGCTCTTGTGAAATGTAAGAAATAATCTGATAAA | 5353 |
| QY | 4.156 | TATCTGGAATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 4215 | Db | 2041 | ATGCAACCTGGATTCCTGGCTCTTGTGAAATGTAAGAAATAATCTGATAAA | 2100 |
| Db | 9.01 | TATCTGGAATCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 960 | QY | 5.355 | GAATTCCTCTGTGTCATGCTGCTCTCTCTCTCTCTCTCTCTCTCTCT | 5414 |
| QY | 4.216 | TCTGCT | 4275 | Db | 2101 | GAATTCCTCTGTGTCATGCTGCTCTCTCTCTCTCTCTCTCTCTCTCT | 2160 |
| Db | 9.61 | TCTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 1020 | QY | 5.415 | GGCCCTGGGTAGTGTGAGATGCTAAGGTCAGACTCATCCACCCATAGGGTC | 5471 |
| QY | 4.276 | CATAAAAAAATACAGCACTGTCTCTCTCTCTCTCTCTCTCTCTCT | 4335 | Db | 2161 | GGCCCTGGGTAGTGTGAGATGCTAAGGTCAGACTCATCCACCCATAGGGTC | 2220 |
| Db | 10.21 | CATCAAATATACAGCACTGTCTCTCTCTCTCTCTCTCTCTCT | 1080 | QY | 5.475 | GTAGAGTCAGGTGCACTGAGTCAGTCACTGAACTGTCCTAAAGATGTG | 5534 |
| QY | 4.336 | GCTGGCTCTGGCATTTGAGCTGGAGAACAGAACCCCCACTCTCTG | 4395 | Db | 2221 | GTAGAGTCAGGTGCACTGAGTCAGTCACTGAACTGTCCTAAAGATGTG | 2280 |
| Db | 10.81 | GCTGGCTCTGGCATTTGAGCTGGAGAACAGAACCCCCACTCTCTG | 1140 | QY | 5.535 | GGAAAAGTGAAGAGGGTGGGGCTGGGTGAGGTGTGAGTGTGAACTG | 5594 |
| QY | 4.396 | CACCTGGCTTGTGCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 4455 | Db | 2281 | GGAAAAGTGAAGAGGGTGGGGCTGGGTGAGGTGTGAACTGTCCTAAAG | 2340 |
| Db | 11.41 | CACCTGGCTTGTGCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 1200 | QY | 5.595 | CCCTGAGCTGGCAATTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG | 5654 |
| QY | 4.456 | AGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 4515 | Db | 2341 | CCCTGAGCTGGCAATTGGCTGGCTGGCTGGCTGGCTGGCTGGCTGG | 2400 |
| Db | 12.01 | AGGTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCTCT | 1260 | QY | 5.655 | TAATGATCTGGTGGTGGATCC | 5674 |
| QY | 4.516 | GGAAATCTGGAGGAGCTGAGTGTGAGGGTGTGATGAGGGG | 4575 | Db | 2401 | TAATGATCTGGTGGTGGATCC | 2420 |
| Db | 12.61 | GGAAATCTGGAGGAGCTGAGTGTGAGGGGATGAGGGG | 1320 | QY | 4.695 | TGAACCAAGGAGCTGTCATGCCAGCTGGTGTGAGGGGAGCTG | 4754 |
| QY | 4.576 | TGGGAGGCCAGGAGCTGTCATGCCAGCTGGTGTGAGGGG | 4694 | Db | 1381 | TGGGAGGCCAGGAGCTGTCATGCCAGCTGGTGTGAGGGGAGCTG | 4754 |
| Db | 13.21 | TGGGAGGCCAGGAGCTGTCATGCCAGCTGGTGTGAGGGG | 1380 | QY | 4.635 | GCAGGTGGGGAGCACTGTCAGTCAGTCAGTCAGTCAGTCAGTC | 4814 |
| QY | 4.695 | TGAACCAAGGAGCTGTCATGCCAGCTGGTGTGAGGGGAGCTG | 4754 | Db | 1441 | TGAACCAAGCTATGTCATGCCAGCTGGTGTGAGGGGAGCTG | 4754 |
| QY | 4.755 | TTCTCTCCGATCCCTGCTGTAAGCTCTGATGTCAGTCAGTC | 4754 | Db | 1441 | TGAACCAAGCTATGTCATGCCAGCTGGTGTGAGGGGAGCTG | 4754 |

| misc_feature | 25118. | 29998 | /note="assembly_fragment" | |
|--------------------|---------|--|----------------------------------|--|
| misc_feature | 30099. | .34538 | /note="assembly_fragment" | |
| misc_feature | 34539. | .39508 | /note="assembly_fragment" | |
| misc_feature | 39619. | .46103 | /note="assembly_fragment" | |
| misc_feature | 46204. | .52117 | /note="assembly_fragment" | |
| misc_feature | 522218. | .58555 | /note="assembly_fragment" | |
| misc_feature | 58656. | .65212 | /note="assembly_fragment" | |
| misc_feature | 65313. | .72795 | /note="assembly_fragment" | |
| misc_feature | 72896. | .78614 | /note="assembly_fragment" | |
| misc_feature | 78715. | .89051 | /note="assembly_fragment" | |
| misc_feature | 89152. | .100736 | /note="assembly_fragment" | |
| misc_feature | 100837. | .117851 | clone_end;sp6 vector_side:right" | |
| misc_feature | 111952. | .1135700 | vector_side:right" | |
| misc_feature | 133801. | .153915 | /note="assembly_fragment" | |
| misc_feature | 15016. | .178515 | /note="assembly_fragment" | |
| misc_feature | 34971. | a 34971 c | /note="assembly_fragment" | |
| BASE COUNT | 54258 | a 34971 c 35239 g 51342 t | | |
| ORIGIN | | | | |
| Query Match | 41.0% | Score 2328; | DB 74 | |
| Best Local Matches | 37901 | Similarity 71.9%; | Pred. No. 0; | |
| | | Conservative | Mismatches 1140 | |
| QY | 1 | CCCGGGACCACTGCGATCCTTACCCCCCTACACCCCCAACTC | | |
| Ddb | 73670 | CCATGAGAACCCCCATCCCTCCAGGGCCCACTACTCTCATC | | |
| QY | 61 | ATCCAAACACTCTCACGCTCACCCCCAGGGCAAGCCAGGGAG | | |
| Ddb | 73730 | CATTACCTACCTTACCCCCCTATCCCTACATCTGGTAG | | |
| QY | 121 | CTTCACCCAGGGAG -CCCAAGGTGCCAGATGTGACGCCA | | |
| Ddb | 73790 | CTTCACCCAGGGATCCGGCCGATGTGACGCCA | | |
| QY | 180 | GTTAGAGAAAGCCAGGTTCCTGGCTGAGGTGAGCTCTGGAG | | |
| Ddb | 73849 | GTCAGATAGGGCCCAAATATCCAGCACTCTGGCTTGGAG | | |
| QY | 240 | GCCCA -GCTCTGTAAAGGGCAAGTGACSTGCTTGGGGG | | |
| Ddb | 73909 | GTGGGACTCTCTGTAAAGGGCAAGTGAGCTTAAGGGGG | | |
| QY | 299 | CCAGATAGGGCCCAAATATCCAGCACTCTGGCTTGGAG | | |
| Ddb | 73969 | CCAGATAGGGCCCAAATATCCAGCACTCTGGCTTGGAG | | |
| QY | 350 | TGGGGACTCTCTGTGGCTGGCAACCCCCAGGCCCT----- | | |
| Ddb | 74029 | GGGGGACTCTCTGTGGCACTCCGGCACTACTCTGGCTGCG | | |
| QY | 401 | CTGGGACTC -GAAGTCAGGCTCCGTGATCAGGGAAAGGG | | |

| | | |
|----|-------|--|
| Db | 74089 | CAAGGACTCTGGATCAGACTCTGGTGACCAAGGGAGGGTAGGGTGTAGGGAGGGCAG 7414 |
| Qy | 460 | CGTCAGGGCTCTGGAGACATCATGCTCAGGATCTCAAGGGGGCTGAGGGTCCCTAAG 519 |
| Db | 74149 | TGGCAAGCTGCGAGGCATCACATGGCTCACATGGACCCCTAACTGGGCCCRAC 7420 |
| Qy | 520 | ACCC-----CATCCCCACTCCATGCTCACTCCGTTGACCCACCCC 576 |
| Db | 74209 | CCCCATCCCATTCCCATCCCCATCCCCATCCCCATCCCCATCCCCATCCCCATCCCC 7426 |
| Qy | 577 | TCTTCATGTCATCCAACCCCCACCCACCCACCCATCCCCACCCATCCCCACCTGATGC 636 |
| Db | 74269 | CCAGAACCCCTATCCGCCACCCATTCCACCCAGAACCCCTATCCGCACTCCACCCC 695 |
| Qy | 637 | CCATGGCCAGGCTTACCCCTACCCCTACCCCTACCCCTACCCCTACCCCTACCC 7432 |
| Db | 74329 | TACTCCACCATTCATCTCCATCTCCACCCCTGACCTCTCTCCATCCACCC 7438 |
| Qy | 696 | CCACCAAGGAGGAACCTGGGG-----TTCGGCAGAATCCGGGAGGCGCG 7442 |
| Db | 74389 | ACACCTGGCAAACTGGGTCTGGATCTGGTACCTGGTACCA 7444 |
| Qy | 743 | GATGTAACGCCACTGACTCTGGCATTTGGGGTCCATTCTGGAG 802 |
| Db | 74449 | GATGTTGGGACTCTGTCACATTGAGGTCCTGGAGAAGGAGGGCTCTCTGAG 7450 |
| Qy | 803 | GGACCGGTAGATGTTGGCCGAAGAACCTGACCCAGGCTCTGAGGGCAAGGTGAG 862 |
| Db | 74509 | GGGCACCT-GGGAGATCAGCTGGGGCAGCTGGGCTCTGGGCTCTGGGATGGCTGGAG 7456 |
| Qy | 863 | AGGTAGGGGACTGAGACCCGGCAACTCCAAATAAGAGGCCAAATAATTCACCC 922 |
| Db | 74568 | ATGGCTGGGGAGGACTAAGGATATCCCACCCCTGGTGTGGACCCCAAATAATCTCAGTG 7462 |
| Qy | 923 | CCGCCT---CTTGCTCGACGCCCTGGCCACCCGGGGAGACGTCCTAGCCTGGCTGCC 979 |
| Db | 74628 | CCACCTCTCTGGCTGGTAGCTGACCTCCAGGGAGACTCTGGGGCTGGCTGG 7468 |
| Qy | 980 | CCAGAACCCCTGCTCCAAAAGCCTTGAGGACACCGGTTCTCTCCCAAGGTCTGGAA 1039 |
| Db | 74688 | CCCAAGGCCCCACCTGTTAGCGGGGGAA-----CTAGGAG 7472 |
| Qy | 1040 | TCAGAGGTCTGGCTGACCCAGGAGACCTGGCTTGGAGAGGGCACAGGGCTCTGCC 1099 |
| Db | 74727 | ACAGAGGTGTTGATGACCGGGAGACTCTGGTTAGAGGGACAGCTCCAGGTCTGCC 7478 |
| Qy | 1100 | AGGCACTAACGATCAGCACCCAAAGGGGGCTGTTGGCCCCCZAGACTGACTCAATC 1159 |
| Db | 74787 | AGGAACAACGCTGAGAACCTAAAGGGAAAGCTGACCTGGCTGG 7482 |
| Qy | 1160 | CCCACTCCACCCATTGGAATCCATCCCCAACCCCACTCTCTGAGCTACAC 1219 |
| Db | 74830 | -----C-CAC 7483 |
| Qy | 1220 | CTCCACCCCATCCCTACTCTGACCTGGTACCTGGACCCACCTCCAGGCCAGGCC 1279 |
| Db | 74833 | GCACAACTCTATTCTGTCCTACCTGGCTGACCTGGCTGGGGGGCTGAGCTATCC 7488 |
| Qy | 1280 | AGCCCAACCCCTCTGCCACCTACCTGGCCACCCCTACCTGGACTCTCACTCTCTCA 1339 |
| Db | 74888 | CACCCATCTCCACCGCTPATCCCAATCCCCA-----CTGG 7492 |
| Qy | 1340 | TGTGCCCACTCTCCATCGCCTCCCATCTGGCAAGAATCCGGTT-----TGGCTCTCA 1398 |
| Db | 74927 | -----CCCTATCTGGCAAACTGGCTCCCTGAGCTGGGGCTGAGCTATGGGGTCAGA 7495 |
| Qy | 1399 | ACCAAGGGAGCCCTGGTAGGCCCATGATGGTGAATGGGGCTGAGCTGGGGCTGG 1518 |
| Db | 74966 | ACCCAGGGAGCCCTGGGGCCGATGATGGTGAATGGGGCTGAGCTGGGGCTGG 7502 |
| Qy | 1459 | GAAACCCAGGTTCTATTIAATGGTCTGAGGCTGAGCTCACTGGGGCTGG 1518 |
| Db | 75026 | GAAATCAAGG-----GGATGGTTCTGGAAAGCCGACTGAGATCAGGGCAATGG 7507 |

| | | | |
|----|-------|---|-------|
| Qy | 1519 | TITTAGGCTCTGTGAGGGAGCAAGGTGAGA-TGCTGAGGGAGACTGAGGGACACAC | 1577 |
| Db | 75080 | GCCCCGGTCTGTGAGGGAGCAAGGTGAGGGCCATGAGGATGAGGAAGGCCTAAC | 75139 |
| Qy | 1578 | CCCAAGGTAGTGGGCCCARAATGTCCTACACCCCTCTGCGAGCCGTGACCCAC | 1637 |
| Db | 75140 | CC - AGATAGAAACCCCAATAATCCAGTAACCTTGTCAGGCTTGACCACT- | 75195 |
| Qy | 1638 | GGCCAGGACAGATGTCCTACGTGACCCCGTCCACIGCAGCTAACCA | 1697 |
| Db | 75196 | -CCGGGGCAGACTCTCGCTGGACCTTTCC - CCGTCCCACCTGACACTAACCA | 75250 |
| Qy | 1698 | CAGGGCAATTGTAGCTCATAGCT - ATGTAACCGGGCAGGGTGTGAGGGCAGG | 1756 |
| Db | 75251 | CAAGGGACTCTGGAGTCAGMCCCTGGTGTGACCCGGGAGGGGTGAGGG --- | 75306 |
| Qy | 1757 | GCCCCAGGGCATCAAGGTCAGCATCGCCGGCATTAGGGTCAAGGAGGAACT | 1816 |
| Db | 75307 | ----- - CGAGGGCCAGCTGTCAATGAGCTAACATGAGGAGGAAATT | 75357 |
| Qy | 1817 | GAGGGTTCCCACCCACACTGTCTCCATCTCACCGCACCCACTCACATCCCCAT | 1876 |
| Db | 75358 | GAGGGCCCCAACCCCCAACCTCTAACCCCTATCCCCATCACCGCACCCACTCTACATGCCATT | 75417 |
| Qy | 1877 | ACCTACC --- CCCTACCCCAACCTCATCTCCATCTGCCATT | 1922 |
| Db | 75418 | CCCCAGCCCCATCCCCAACCCCTACCCCATCTGGCAGAACTCTGTTCTCCCTGCACTC | 75477 |
| Qy | 1923 | AACCCACGGAAAGCCAGGGAAATGGGGGAGGAACTCGGATCTTGACGCCATCCAGG | 1982 |
| Db | 75478 | AAACCCACAGAGGCCAGGZATGACAGAGGGCACCCATTCTGACGTCAATCCAGG | 75537 |
| Qy | 1983 | GTCITGATGGAGGGAGGG - - - - GCTGAACAGGGCTCAAGGGAGGAGG --- GA | 2031 |
| Db | 75538 | GCTGAGGGAGGGAAAGGGTAGTATGAGCAGGGCTCAAGGGCTCTGCTCTC | 75597 |
| Qy | 2032 | GGGCCCTACTGCGAGATGAGGGAGCCCTCAAGGACCCAGCACCTAGA - - - - C | 2082 |
| Db | 75598 | AAGCCCTGCTGGAGTAAGGGAGCCCTAAGGACCCAGTCCATAGGGTTCT | 75657 |
| Qy | 2083 | ACCGAACCCCTGTGAGCTGAG - - GCTGCCACTCTGCCCTCAAGATCAAACGATG | 2140 |
| Db | 75658 | ACTCCAACCTGTGAGCTGAGGCTCTGGGAGGGCTGAGGCTGAGGAGGATG | 75717 |
| Qy | 2141 | GGGACTCAGATTGCTATGGGGTGGGACCCAGGGCTGCAAGCTACGGGAGGAGGA | 2200 |
| Db | 75718 | GAGACTCACCTCAGAGGGTGGGCCAACCTGCGAGCATCAAGGGAGGAGA | 75777 |
| Qy | 2201 | GGGAGGACTCTAGGGACCATATGGAACTCCAGATCAGTGTGGCCCTGAGGGTCA | 2260 |
| Db | 75778 | GGGAGGACTCTAGGTACCTTGAGGACCATGGGAACTTGGCCTGGGAGGTCA | 75837 |
| Qy | 2261 | GGGCAAGGGCCACATAAGGCCATATTTGCCATTTGAGGTGAC - - AGGACAG | 2316 |
| Db | 75838 | GTGGCACTGTCACCTGTGACCCATTGTCACCTCTGGTACAAGGAGGAG | 75897 |
| Qy | 2317 | AGCTGTGTTGAGAGTGGGCTCAAGGGAGGAGTCCAGGTCCAT | 2376 |
| Db | 75898 | GGCCTGGTCAAGAGCTGTTGACTGAGGTGACTCGSTCAGAGGGAGGAGTCAG | 75957 |
| Qy | 2377 | GGCCCAAGATGTCGCCCTCATGAGGACTGGGATATCCGGCTCAAGAAAGGGAC | 2436 |
| Db | 75958 | GCCCCAATGTGTCGCCCTCATGAGGAGTGGGATCTTGGGAGGAGTCAG | 76016 |
| Qy | 2437 | TCCACAGACTGTGGTGGGAGGAGTGGGAGGAGTGGGAGGAGTCAG | 2496 |
| Db | 76017 | CCCAAGAGCTCACTTGTGAGGAGGAGGAGTGGGAGGAGTCAG | 76076 |
| Qy | 2497 | TATGTCCCATCTCACTTGTGAGGAGGAGGAGTGGGAGGAGTCAG | 2556 |
| Db | 76077 | CCCAAGAGCTCACTTGTGAGGAGGAGGAGTGGGAGGAGTCAG | 76136 |
| Qy | 3620 | CTCTGGCTGAGGGCTGACCTCTCACTTGTGAGGAGGAGTGGGAGGAGTCAG | 3675 |

lease 3-1A John F. Collins, Biocomputing Research Unit.
Copyright (c) 1993-1998 University of Edinburgh, U.K.
Distribution rights by Oxford Molecular Ltd.

protein - protein database search, using Smith-Waterman algorithm
run on: Tue Sep 12 13:19:06 2000; MasPar time 5.54 Seconds.

Title: >US-08-819-669E-26
Tabular output not generated.

Sequence: 1 EADPTGHSY 9 perfect Score: 61 / 61

scoring table: PAM 150 Gap 15

- Listing first 45 summaries

Database: pir64

Statistics: Mean 20.662; Variance 21.178; scale 0.976

No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| result No. | Score | Query Length | Match Length | DB ID | Description | Pred. No. |
|------------|-------|--------------|--------------|-------|--|-----------|
| 1 | 61 | 100.0 | 280 | 2 | JC2358 tumor-associated anti MAGE-8 antigen - huma | 1.51e-04 |
| 2 | 54 | 88.5 | 234 | 2 | I38667 MAGE-9 antigen - huma | 1.43e-02 |
| 3 | 54 | 88.5 | 315 | 2 | I38667 MAGE-10 antigen - huma | 1.43e-02 |
| 4 | 52 | 85.2 | 369 | 2 | I38659 MAGE-11 antigen - huma | 5.00e-02 |
| 5 | 51 | 83.6 | 129 | 2 | E72655 hypothetical protein | 9.24e-01 |
| 6 | 48 | 78.7 | 129 | 2 | E72655 hypothetical protein | 5.60e-01 |
| 7 | 48 | 78.7 | 269 | 2 | A49334 Ras homolog Rad - hum | 5.60e-01 |
| 8 | 48 | 78.7 | 925 | 1 | A39216 plasma cell membrane protein protein (III) | 1.01e+01 |
| 9 | 47 | 77.0 | 497 | 1 | S33935 MAGE 5 protein - huma | 1.79e+00 |
| 10 | 46 | 75.4 | 9 | 2 | PH1293 tumor-associated anti type I site-specific | 1.79e+00 |
| 11 | 46 | 75.4 | 314 | 2 | JC2350 S02166 hypothetical protein | 3.17e+00 |
| 12 | 45 | 73.8 | 1033 | 2 | F70763 hypothetical protein | 5.55e+00 |
| 13 | 44 | 72.1 | 98 | 2 | F70763 hypothetical protein | 5.55e+00 |
| 14 | 44 | 72.1 | 128 | 2 | T09932 nucleotide Pyrophosph | 5.55e+00 |
| 15 | 44 | 72.1 | 461 | 2 | T09932 sulfite oxidase (EC 1 | 5.55e+00 |
| 16 | 44 | 72.1 | 488 | 1 | S55874 sulfite oxidase (EC 1 | 5.55e+00 |
| 17 | 44 | 72.1 | 488 | 1 | A53101 myelin transcription | 5.55e+00 |
| 18 | 44 | 72.1 | 725 | 2 | A45033 hypothetical protein | 9.63e+00 |
| 19 | 43 | 70.5 | 197 | 2 | A70832 hypothetical protein | 9.63e+00 |
| 20 | 43 | 70.5 | 243 | 2 | S64312 tumor-associated anti | 9.63e+00 |
| 21 | 43 | 70.5 | 314 | 2 | JC2361 matrix metalloproteinase | 9.63e+00 |
| 22 | 43 | 70.5 | 347 | 2 | T38029 matrix-Xp protein - hum | 9.63e+00 |
| 23 | 43 | 70.5 | 669 | 2 | T38029 matrix metalloproteinase | 9.63e+00 |

```

24      43    70.5   745      2   T10924   3C3.15c protein - Str 9.62e+00
25      43    70.5   875      2   T12794   hypothetical yomp pro 9.63e+00
26      43    70.5   878    2,5   S44143   hypothetical protein 9.63e+00
27      42    68.9   156      2   B36505   conserved hypothetical 1.66e+01
28      42    68.9   283      2   E69626   methyltransferanoylof 1.66e+01
29      42    68.9   288      2   A56219   carbon-monoxide dehydro 1.66e+01
30      42    68.9   301      2   C71194   hypothetical protein 1.66e+01
31      42    68.9   317      2   JC2359   tumor-associated anti 1.66e+01
32      42    68.9   326      1   S44753   C13G5.2 protein - Cae 1.66e+01
33      42    68.9   348      1   DEEPBOT  dihydroorotate (EC 3. 1.66e+01
34      42    68.9   461      2   B47093   probable oxidoreducta 1.66e+01
35      42    68.9   503      2   H70509   hypothetical protein 1.66e+01
36      42    68.9   503      2   G70506   hypothetical protein 1.66e+01
37      42    68.9   508      1   ISRIS5   protein disulfide-iso 1.66e+01
38      42    68.9   555      1   RGA5WA   regulatory protein we 1.66e+01
39      42    68.9   700      2   S38928   translation elongatio 1.66e+01
40      42    68.9   747      2   B47093   cellulase (EC 3.2.1.4 1.66e+01
41      42    68.9   1052     2   T14313   zinc finger RNA bindi 1.66e+01
42      42    68.9   3396     1   A42551   genome polyrnp - 1.66e+01
43      41    67.2   366      2   A53286   cell-surface glycopro 2.82e+01
44      41    67.2   637      2   T03842   fission yeast Skb1 pr 2.82e+01
45      41    67.2   3898     1   A44217   genome polyprotein - 2.82e+01

                                ALIGNMENTS

RESULT      1          JC2358   #type complete
ENTRY       TITLE      tumor-associated antigen MAGE-1 - human
TITLE       ORGANISM #common_name man
ORGANISM   DATE      20-Feb-1995 #sequence_revision 20-Feb-1995 #text_change
DATE        04-Sep-1998

ACCESSIONS JC2358
REFERENCE JC2358
#authors Ding, M.; Beck, R.J.; Keller, C.J.; Fenton, R.G.
#journal Biochem. Biophys. Res. Commun. (1994) 203:549-555
#cross-references Cloning and analysis of MAGE-1-related genes.
#cross-references MUID:94311935
#accession JC2358
##molecule_type mRNA
##residues 1-280 #label DIN
##experimental_source melanoma cell line DM150

GENETICS
#gene MAGE
CLASSIFICATION #superfamily tumor associated protein MAGE
FEATURE SUMMARY #region HLA-A1 binding #status predicted
#length 280 #molecular-weight 30932 #checksum 4677

Query Match Score 61; DB 2; Length 280;
Best Local Similarity 100.0%; Pred. No. 1.5le-04;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
DATE      24-Sep-1999

ACCESSIONS I38667
REFERENCE De Plaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Szikora, J.P.; De Smet, C.; Brassasseur, F.; van der Bruggen, P.; Lethe, B.; Lurquin, C.; Brassasseur, R.; Chomez, P.; De Backer, O.; Cavégnin, W.; Boon, T.
#authors Immunogenetics (1994) 40:360-369
#journal #title #cross-references chromosomal localization, and expression of 12 genes of the MAGE family.

```

```

#cross-references MUID:95012457
#accession I38667
#status preliminary; translated from GB/EMBL/DBBJ
##molecule-type DNA
##residues 1-234 #label RES
##cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;
#cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;

GENETICS
#gene GDB:MAGEA8; MAGEB
##cross-references GDB:311123
#map_position Xq28-Xq28
#introns #status absent
#classification #superfamily tumor associated protein MAGE
#summary #length 234 #molecular-weight 25197 #checksum 311

Query Match 88.5%; Score 54; DB 2; Length 234;
Best Local Similarity 77.8%; Pred. No. 1.43e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTGHSY 179
Qy 1 EADPTGHSY 9

RESULT 3 I38668 #type complete
ENTRY MAGE9 antigen - human
TITLE #formal_name Homo sapiens #common_name man
ORGANISM #sequence_revision 07-Jun-1996 #text_change
DATE 07-Jun-1996 #sequence_revision 07-Jun-1996 #text_change
24-Sep-1999

ACCESSIONS I38668
REFERENCE I38659
#authors De Piaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Brugge, S.; Sikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen, P.; Lethe, B.; Lurquin, C.; Brassier, R.; Chomez, P.; De Backer, O.; Cavenee, W.; Boon, T.

#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12 genes of the MAGE family.
#cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;
#accession I38668
#status preliminary; translated from GB/EMBL/DBBJ
##molecule-type DNA
##residues 1-315 #label RES
##cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;
#cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;

GENETICS
#gene GDB:MAGEA8; MAGEB
##cross-references GDB:311123
#map_position Xp21.3-Xp1.3
#introns #status absent
#classification #superfamily tumor associated protein MAGE
#summary #length 315 #molecular-weight 30088 #checksum 24668

Query Match 88.5%; Score 54; DB 2; Length 315;
Best Local Similarity 77.8%; Pred. No. 1.43e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 167 EVDPTGHSY 179
Qy 1 EADPTGHSY 9

RESULT 4 I38659 #type complete
ENTRY MAGE10 antigen - human
TITLE #formal_name Homo sapiens #common_name man
ORGANISM #sequence_revision 07-Jun-1996 #text_change
DATE 24-Sep-1999

ACCESSIONS I38659
REFERENCE I38659
#authors De Piaen, E.; Arden, K.; Traversari, C.; Gaforio, J.J.; Brugge, S.; Sikora, J.P.; De Smet, C.; Brasseur, F.; van der Bruggen, P.; Lethe, B.; Lurquin, C.; Brassier, R.; Chomez, P.; De Backer, O.; Cavenee, W.; Boon, T.

#journal Immunogenetics (1994) 40:360-369
#title Structure, chromosomal localization, and expression of 12 genes of the MAGE family.
#cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;
#accession I38660
#status preliminary; translated from GB/EMBL/DBBJ
##molecule-type DNA
##residues 1-319 #label RES
##cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;
#cross-references EMBL:U10694; NID:g533525; PIDN:AAA68876.1;

GENETICS
#gene GDB:MAGEA11; MAGEB11
##cross-references GDB:311128
#map_position Xq18-Xq28
#introns #status absent
#classification #superfamily tumor associated protein MAGE
#summary #length 319 #molecular-weight 35536 #checksum 9402

Query Match 83.6%; Score 51; DB 2; Length 319;
Best Local Similarity 77.8%; Pred. No. 9.24e-02;
Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Db 171 EVDPTGHSY 179
Qy 1 EADPTGHSY 9

RESULT 6 E72685 #type complete
ENTRY E72685
TITLE Hypothetical protein APE0301 - Aeropyrum pernix (strain K1)
ORGANISM #formal_name Aeropyrum pernix
#sequence_revision 20-Aug-1999 #sequence_change
DATE 20-Aug-1999 #sequence_revision 20-Aug-1999 #sequence_change

```

#formal_name Homo sapiens #common_name man
 DATE 10-Sep-1999 #sequence_revision 10-Sep-1999 #text_change
 ACCESSIONS E72450
 REFERENCE #authors Kawarabayasi, Y.; Hino, Y.; Horikawa, H.; Yamazaki, S.; Baba, S.; Ankei, A.; Kosugi, H.; Takahashi, M.; Seine, M.; Fukui, S.; Nagai, Y.; Nishijima, K.; Nakazawa, H.; Hosoya, A.; Matsuda, S.; Funahashi, T.; Tanaka, T.; Kudo, Y.; Yamazaki, J.; Kusuda, N.; Oguchi, A.; Aoki, K.; Kubota, K.; Nakamura, Y.; Nomura, N.; Saito, Y.; Kikuchi, H.
 #journal DNA Res. (1999) 6:83-101
 #title Complete genome sequence of an aerobic hyper-thermophilic Crenarchaeon, Aeropyrum pernix K1.
 #cross-references MUID:9310339
 #accession E72685
 #status Preliminary
 #molecule-type DNA
 #cross-references 1-129 #label KAW
 #cross-references DBJ:AP000060; NID:95104188; PID:BA79885.1;
 #cross-references PID:di3671; PID:95104570
 #experimental_source strain K1
 GENETICS #gene APE0901
 SUMMARY #length 129 #molecular-weight 14303 #checksum 2150
 Query Match 78.7% Score 48; DB 2; Length 129;
 Best Local Similarity 85.7% Pred. No. 5.60-01;
 Matches 6; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
 Db 115 DPAGHSY 1.21
 QY 3 DPAGHSY 9
 RESULT 7 A49334 #type complete
 ENTRY Ras homolog Rad - human
 TITLE Ras associated with diabetes (Rad)
 ALTERNATE_NAMES Ras associated with diabetes (Rad)
 ORGANISM #formal_name Homo sapiens #common_name man
 DATE 07-Oct-1994 #sequence_revision 07-Oct-1994 #text_change
 28-Aug-1998
 A49334
 REFERENCE A49334
 #authors Reynt, C.; Kahn, C.R.
 #journal Science (1993) 262:1441-1444
 #title Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans.
 #cross-references MUID:94069319
 #accession A49334
 #status Preliminary
 #molecule-type mRNA
 #residues 1-269 #label REY
 #cross-references GB:124564
 KEYWORDS alternative initiators: GTP binding; P-loop
 FEATURE 59-66 #region nucleotide-binding motif A (P-loop)\n 164-167 #region GTP-binding NXKD motif
 SUMMARY #length 269 #molecular-weight 29262 #checksum 9237
 Query Match 78.7% Score 48; DB 2; Length 269;
 Best Local Similarity 55.6%; Pred. No. 5.60e-01;
 Matches 5; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 Db 80 EAFAAHTY 88
 QY 1 EADPTGHSY 9
 RESULT 8 A39216 #type complete
 ENTRY plasma cell membrane glycoprotein PC-1 - human
 TITLE phosphoprotein (EC 3.6.1.9); phosphodiesterase I
 CONTAINS (EC 3.1.4.1)
 FEATURE 1-111 #region domain transmembrane #status Predicted
 #map-position 6922-6923
 CLASSIFICATION #superfamily nucleotide Pyrophosphatase; somatomedin B homology
 KEYWORDS glycoprotein; phosphoprotein; phosphoric diester hydrolase;
 GENETICS #genes GDB:DPNP1; M6SI; NPBS
 #cross-references GDB:132615; OMIM:173355
 #map-position 6922-6923
 #domain somatomedin B homology #label SBH1\\
 #domain somatomedin B homology #label SBH2\\
 FEATURE 77-97 #domain transmembrane #status Predicted #label TMN
 104-144 #map-position 6922-6923
 145-198 #domain somatomedin B homology #label SBH1\\
 179-185,341,477,
 731-748 #binding_site carbohydrate (Asn) (covalent) #status Predicted
 256 #binding_site AMP (Thr) (covalent) #status Predicted
 #length 925 #molecular-weight 104924 #checksum 7446
 SUMMARY #length 925 #molecular-weight 104924 #checksum 7446
 Query Match 78.7% Score 48; DB 1; Length 925;
 Best Local Similarity 66.7%; Pred. NO. 5.60e-01;
 Matches 6; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
 Db 374 EPDSSGHSY 382
 QY 1 EADPTGHSY 9

CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
 CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
 CC PROGRESSION. ANTIGEN RECOGNIZED ON A MELANOMA BY AUTOLOGOUS
 CC CYTOLYTIC T LYMPHOCYTES.
 CC -!- SUBCELLULAR LOCATION: CYTOPLASMIC.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES. NEVER EXPRESSED IN KIDNEY TUMORS, LEUKEMIAS AND
 CC LYMPHOMAS.
 CC -!- SIMILARITY: THE VARIANT AT POSITION 32 LIKELY REPRESENTS A
 CC POLYMORPHISM OF THE MAG-1 GENE.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC DR EMBL; U10693; AAA68876; 1; - .
 CC DR PFAM; PF01454; MAGE; 1.
 CC KW Antigen; Multigene family; Tumor antigen.
 CC FT DOMAIN 40 43 POLY-SER.
 CC SQ SEQUENCE 234 AA; 25197 MW; 058A2EE6003A9B2 CRC64; 0;

CC Query Match Score 54; DB 1; Length 234;
 CC Best Local Similarity 77.8%; Pred. No. 4.36e-03;
 CC Matches 7; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 CC DR 171 EVDPAGHSY 179
 CC QY 1 EADPTGHSY 9

CC RESULT 3
 CC ID MAG9_HUMAN STANDARD; PRT; 315 AA.
 CC AC PA3362; Q92910;
 CC DT 01-NOV-1995 (Rel. 32, Created)
 CC DT 01-NOV-1995 (Rel. 32, Last sequence update)
 CC DT 01-NOV-1997 (Rel. 35, Last annotation update)
 CC DE MELANOMA-ASSOCIATED ANTIGEN 9 (MAGE-9 ANTIGEN).
 CC OS Homo sapiens (Human).
 CC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 CC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 CC RN [1]
 CC RP SEQUENCE FROM N.A.
 CC MEDLINE; 95012457.
 CC RA de Plaein E., Arden K., Traversari C., Gaforio J.J., Szikora J.-P.,
 CC RA de Smet C., Brassseur F., van der Bruggen P., Lethe B., Turquin C.,
 CC RA Brassseur R., Chomez P., de Backer O., Cavenee W., Boon T.;
 CC RT "Structure, chromosomal localization, and expression of 12 genes of
 CC the MAGE family,"
 CC RL Immunogenetics 40:360-369(1994).
 CC RN [2]
 CC RP SEQUENCE FROM N.A.
 CC RA Timms K.M., Bondeson M.L., Ansari-Lari M.A., Lagerstedt K.,
 CC RA Nelson D.L., Pettersson U., Gibbs R.A.;
 CC RL Submitted (Sep-1996) to the EMBL/Genbank/DBJ databases.
 CC -!- FUNCTION: NOT KNOWN, THOUGH MAY PLAY A ROLE IN EMBRYONAL
 CC DEVELOPMENT AND TUMOR TRANSFORMATION OR ASPECTS OF TUMOR
 CC PROGRESSION.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN MANY TUMORS OF SEVERAL TYPES,
 CC SUCH AS MELANOMA, HEAD AND NECK SQUAMOUS CELL CARCINOMA, LUNG
 CC CARCINOMA AND BREAST CARCINOMA, BUT NOT IN NORMAL TISSUES EXCEPT
 CC FOR TESTES AND PLACENTA.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.

CC DR EMBL; U10694; AAA68877; 1; - .
 CC DR PFAM; PF01454; MAGE; 1.
 CC KW Antigen; Multigene family; Tumor antigen.
 CC FT DOMAIN 34 37 POLY-GLU.
 CC FT DOMAIN 87 90 POLY-GLU.
 CC SQ SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64; 0;

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC DR EMBL; U10695; AAA68888; 1; - .
 CC DR PFAM; PF01454; MAGE; 1.
 CC KW Antigen; Multigene family; Tumor antigen.
 CC FT DOMAIN 34 37 POLY-GLU.
 CC FT DOMAIN 87 90 POLY-GLU.
 CC SQ SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64; 0;

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC DR EMBL; U10696; AAA68889; 1; - .
 CC DR PFAM; PF01454; MAGE; 1.
 CC KW Antigen; Multigene family; Tumor antigen.
 CC FT DOMAIN 34 37 POLY-GLU.
 CC FT DOMAIN 87 90 POLY-GLU.
 CC SQ SEQUENCE 315 AA; 35088 MW; 7FD2ED10D680D928 CRC64; 0;

Query Match 78.7%; Score 48; DB 1; Length 268;
 Best Local Similarity 55.6%; Pred. No. 2.19e-01; Gaps 0;
 Matches 5; Conservative 0; Indels 0; Gaps 0;

Db 80 EAEEAAGHTY 88

[1:::1::1]

Oy 1 EADPFGHSD 9

RESULT 7
 ID RAD_HUMAN STANDARD; PRT; 269 AA.

AC P55042;

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-NOV-1997 (Rel. 35, Last annotation update)

DE GTP-BINDING PROTEIN RAD (RAS ASSOCIATED WITH DIABETES) (RAD1).

DE RND OR RAD.

GN Homo sapiens (Human); Chordata; Craniata; Vertebrata; Euteleostomi;

OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

RN [1]

SEQUENCE FROM N.A.

PC TISSUE=SKELETAL MUSCLE;

MEDLINE; 94069319.

RA Reynt C.; Kahn C.R.;

RT "Rad: a member of the Ras family overexpressed in muscle of type II

RT diabetic humans";

RL Science 262:1441-1444 (1993).

CC -!- TISSUE SPECIFICITY: SKELETAL AND CARDIAC MUSCLE, LUNG, LESSER

AMOUNTS IN PLACENTA AND KIDNEY, DEFECTED IN ADIPOSE TISSUE.

CC -!- OVEREXPRESSED IN MUSCLE OF TYPE II DIABETIC HUMANS.

CC -!- SIMILARITY: BELONGS TO THE RAD/GEM FAMILY OF GTP-BINDING

PROTEINS.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

CC

OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 OC Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
 RN [1] SEQUENCE FROM N.A.
 RP MEDLINE; 9109202.
 RX
 RA Furukoshi I., Kato H., Horie K., Yano T., Hori Y., Kobayashi H.,
 RA Inoue T., Suzuki H., Fukui S., Tsukahara M., Kajii T.,
 RA Yamashina I.,
 RT "Molecular cloning of cDNAs for human fibroblast nucleotide
 RT phosphorylase.",
 RT P295180-187(1992).
 RL Arch. Biochem. Biophys.
 CC -!- FUNCTION: MAY HAVE A ROLE IN THE REGULATION OF N-GLYCOSYLATION.
 CC -!- CATALYTIC ACTIVITY: HYDROLYTICALLY REMOVES 5'-NUCLEOTIDES
 CC SUCCESSIVELY FROM THE 3'-HYDROXY TERMINI OF OLIGO-NUCLEOTIDES.
 CC -!- CATALYTIC ACTIVITY: A DINUCLEOTIDE + H(2)O = 2 MONONUCLEOTIDE.
 CC -!- SUBUNIT: HOMODIMER. DISULFIDE-LINKED.
 CC -!- SUBCELLULAR LOCATION: TYPE II MEMBRANE PROTEIN.
 CC -!- TISSUE SPECIFICITY: EXPRESSED IN PLASMA CELLS AND ALSO IN A NUMBER
 CC OF NON-LYMPHOID TISSUES, INCLUDING THE DISTAL CONVOLUTED TUBULE
 CC OF THE KIDNEY, CHONDROCYTES, AND EPIDIDYMIS.
 CC -!- SIMILARITY: CONTAINS 2 SOMATOMEDIN-B TYPE DOMAINS.

CC ---
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).
 CC ---
 CC DR M57736; AA63237.1;
 CC DR EMBL; M57736; AA63237.1;
 CC DR PIR; A39216; A39216.
 DR MIM: 173335;
 DR PF01663; Phosphodiester; 1.
 DR PFAM; PF01033; Semaphorin_B;
 DR PRINTS; PRO0022; SOMATOMEDINB.
 DR PROSITE; PS00524; SOMATOMEDIN_B;
 KW Glycoprotein; Transmembrane; Diphcation; Signal-anchor; Hydrolase.
 FT DOMAIN; 1 24 CITOPLASMIC (POTENTIAL).
 FT DOMAIN; 25 45 SIGNAL-ANCHOR (TYPE-II MEMBRANE PROTEIN)
 FT DOMAIN; 46 873 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN; 52 92 SOMATOMEDIN-B LIKE.
 FT DOMAIN; 93 136 SOMATOMEDIN-B LIKE.
 FT CABBOHYD 127 127 POTENTIAL.
 FT CABBOHYD 233 233 POTENTIAL.
 FT CABBOHYD 289 289 POTENTIAL.
 FT CABBOHYD 425 425 POTENTIAL.
 FT CABBOHYD 533 533 POTENTIAL.
 FT CABBOHYD 591 591 POTENTIAL.
 FT CABBOHYD 648 648 POTENTIAL.
 FT CABBOHYD 679 679 POTENTIAL.
 SQ SEQUENCE 873 AA; 93929 MW; 872808C20B048070 CRC64;

Query Match 78.7%; Score 48; DB 1; Length 269;
 Best Local Similarity 55.6%; Pred. No. 2.19e-01; Gaps 0;
 Matches 5; Conservative 0; Indels 0; Gaps 0;

Db 80 EAEEAAGHTY 88

[1:::1::1]

Oy 1 EADPFGHSD 9

RESULT 8
 ID PCL_HUMAN STANDARD; PRT; 873 AA.

AC P22413;

DT 01-AUG-1991 (Rel. 19, Created)

DT 15-FEB-2000 (Rel. 39, Last sequence update)

DE PLASMA CELL MEMBRANE GLYCOPROTEIN PC-1 [INCLUDES: ALKALINE

DE PHOSPHODIESTERASE I (EC 3.1.4.1); NUCLEOTIDE PYROPHOSPHATASE

(EC 3.6.1.9) (NPASE)].

GN PDNP1 OR PC1 OR NPPS.

OS Homo sapiens (Human).

OS

OC

Query Match 78.7%; Score 48; DB 1; Length 873;
 Best Local Similarity 66.7%; Pred. No. 2.19e-01;
 Matches 3; Mismatches 0; Indels 0; Gaps 0;

Db 322 EPDSGGHSY 330

1:::1::1

Qy 1 EADPTGHSY 9

CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (see <http://www.isb-sib.ch/announce/>
 CC or send an email to license@isb-sib.ch).

CC DR EMBL; U93163; AAC23619_1; .
 DR EMBL; AC005185; AAD10637_1; .
 DR MIM; 300153; .

DR PFAM; PF04454; MAGE_1.
 KW Antigen; Multigene family.

SEQUENCE 346 AA; 38923 MW; 804F260BD50F036A CRC64;
 SQ

Query Match 75.4%; Score 46; DB 1; Length 346;
 Best Local Similarity 66.7%; Pred. No. 7.58e-01; Indels 0; Gaps 0;

Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 168 EVNPHTSY 176
 QY 1 ADPFGHST 9

RESULT 12
 ID VP57_BDV STANDARD; PRT; 503 AA.
 AC P52638; .

DT 01-OCT-1996 (Rel. 34, Created)

DT 01-OCT-1996 (Rel. 34, Last sequence update)

DT 01-NOV-1997 (Rel. 35, Last annotation update)

CC -1- SUBCELLULAR LOCATION: INTEGRAL MEMBRANE PROTEIN (POTENTIAL).

CC This SWISS-PROT entry is copyright. It is produced through a collaboration

CC between the Swiss Institute of Bioinformatics and the EMBL outstation -

CC the European Bioinformatics Institute. There are no restrictions on its

CC use by non-profit institutions as long as its content is in no way

CC modified and this statement is not removed. Usage by and for commercial

CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>

CC or send an email to license@isb-sib.ch).

CC DR EMBL; U04608; AAA20227_1; .

KN GLYCOPROTEIN; Transmembrane.

FT TRANSEM 5 25 POTENTIAL.

FT TRANSEM 274 294 POTENTIAL.

FT TRANSEM 468 488 POTENTIAL.

FT CARBOHD 63 63 POTENTIAL.

FT CARBOHD 109 109 POTENTIAL.

FT CARBOHD 139 139 POTENTIAL.

FT CARBOHD 192 192 POTENTIAL.

FT CARBOHD 196 196 POTENTIAL.

FT CARBOHD 202 202 POTENTIAL.

FT CARBOHD 221 221 POTENTIAL.

FT CARBOHD 230 230 POTENTIAL.

FT CARBOHD 235 235 POTENTIAL.

FT CARBOHD 321 321 POTENTIAL.

FT CARBOHD 328 328 POTENTIAL.

FT CARBOHD 388 388 POTENTIAL.

FT CARBOHD 438 438 POTENTIAL.


SEQUENCE 503 AA; 56652 MW; 081B5347DF91A08 CRC64;

SQ Query Match 73.8%; Score 45; DB 1; Length 503;
 Best Local Similarity 55.6%; Pred. No. 1.39e-00; Indels 0; Gaps 0;

Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

| | |
|----|---|
| CC | Db 416 ETDPINHAY 424 |
| CC | QY 1 ADPFGHST 9 |
| CC | RESULT 13 |
| CC | ID TIRI_ECOLI STANDARD; PRT; 1033 AA. |
| CC | AC P10486; . |
| CC | DT 01-JUL-1989 (Rel. 11, Created) |
| CC | DT 01-JUL-1989 (Rel. 11, Last sequence update) |
| CC | DT 15-DEC-1998 (Rel. 37, Last annotation update) |
| CC | GN HSR OR HSR. |
| CC | OS Escherichia coli. |
| CC | OS Plasmid IncFIV R124/3. |
| CC | OC Bacteria; Proteobacteria; gamma subdivision; Enterobacteriaceae; |
| CC | OC Escherichia. |
| CC | RN [1] |
| CC | RP SEQUENCE FROM N.A. |
| CC | RX MEDLINE; 89178628. |
| CC | RA Price C.; Lingner J.; Bickle J.; Firman T.A.; Glover S.W.; Ecor124/3 |
| CC | RT "basis for changes in DNA recognition by the EcoR124 and EcoR124/3 |
| CC | RT TYPE I DNA restriction and modification enzymes."; |
| CC | RL J. Mol. Biol. 205:115-125(1989). |
| CC | -1- FUNCTION: THE ECOR124/3 I ENZYME RECOGNIZES 5'GAA(N)RTCG. |
| CC | -1- SUBUNIT: SUPUNIT R IS REQUIRED FOR BOTH NUCLEASE AND ATPASE |
| CC | CC ACTIVITIES: BUT NOT FOR MODIFICATION. |
| CC | -1- SUBUNIT: THE TYPE I RESTRICTION & MODIFICATION SYSTEM IS COMPOSED |
| CC | CC OF THREE POLYPEPTIDES R, M AND S. |
| CC | -1- MISCELLANEOUS: TYPE I RESTRICTION AND MODIFICATION ENZYMES ARE |
| CC | CC COMPLEX, MULTIFUNCTIONAL SYSTEMS WHICH REQUIRE ATP, S-ADENOSYL |
| CC | CC METIONINE AND MG (+) AS CO-FACTORS AND, IN ADDITION TO THEIR |
| CC | CC ENDONUCLEOLYTIC AND METHYLASE ACTIVITIES, ARE POTENT DNA-DEPENDENT |
| CC | CC ATPIASES. |
| CC | -1- SIMILARITY: WITH APASES. |
| CC | CC This SWISS-PROT entry is copyright. It is produced through a collaboration |
| CC | CC between the Swiss Institute of Bioinformatics and the EMBL outstation - |
| CC | CC the European Bioinformatics Institute. There are no restrictions on its |
| CC | CC use by non-profit institutions as long as its content is in no way |
| CC | CC modified and this statement is not removed. Usage by and for commercial |
| CC | CC entities requires a license agreement (See http://www.isb-sib.ch/announce/ |
| CC | CC or send an email to license@isb-sib.ch). |
| CC | CC EMBL; X13145; CAA21543_1; . |
| CC | DR PIR; S02168; S02168. |
| CC | DR RELEASE: RB0089; ECOR124II. |
| CC | KW Plasmid; Restriction System; Hydrolase; DNA-binding; ATP-binding. |
| CC | SQ SEQUENCE 1033 AA; 119656 MW; B55F3991356C1506 CRC64; |
| CC | Query Match 73.8%; Score 45; DB 1; Length 1033; |
| CC | Best Local Similarity 75.0%; Pred. No. 1.39e+00; Indels 0; Gaps 0; |
| CC | Matches 6; Conservative 1; Mismatches 1; Indels 0; Gaps 0; |
| CC | Db 23 AEPTGDSY 30 |
| CC | QY 2 ADPFGHST 9 |
| CC | RESULT 14 |
| CC | ID YD22_MYCTU STANDARD; PRT; . |
| CC | AC Q10635; . |
| CC | DT 01-OCT-1996 (Rel. 34, Created) |
| CC | DT 01-OCT-1996 (Rel. 34, Last sequence update) |
| CC | DT 15-FEB-2000 (Rel. 39, Last annotation update) |
| CC | DE HYPOTHETICAL 11.3 KDA PROTEIN RV1322. |
| CC | GN RV1322 OR MTGY130_07. |
| CC | OS Mycobacterium tuberculosis. |
| CC | OC Actinomycetales; Firmicutes; Actinobacteria; Actinomycetidae; |
| CC | OC Bacteria; Firmicutes; Corynebacteriaceae; Mycobacteriaceae; Mycobacter |
| CC | RN [1] |
| CC | RP SEQUENCE FROM N.A. |
| CC | RC STRAIN=H37RV; |

| | | |
|-----------------------|--|-----------|
| RX | LINK | 98295987. |
| RA | Cole S.T., Broesch R., Parkhill J., Garnier T., Churcher C., Harris D., Gordon S.V., Eiglemeier K., Gas S., Barry C.E., III, Tekaiwa F., Badcock K., Basham D., Brown D., Chillingworth T., Connor P., Davies R., Devlin K., Feltwell T., Gentles S., Hamlin N., Holroyd S., Hornsby T., Jagels K., Krogh A., McLean J., Moule S., Murphy L., Oliver S., Osborne J., Quail M.A., Rajandream M.A., Rogers J., Rutter S., Seeger K., Skelton S., Squares S., Squires R., Sulston J.B., Taylor K., Whitehead S., Barrell B.G., | |
| RA | "Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence." Nature 393:537-544 (1998). | |
| RT | TUBERCULIST; Rv1322; -. | |
| RT | KW Hypothetical protein. | |
| CC | This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation of the European Bioinformatics Institute. There are no restrictions on use by non-profit institutions as long as its content is in no modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announcements.html or send an email to license@isb-sib.ch). | |
| CC | EMBL; 273905; CA980086.1; -. | |
| DR | DR TUBERCULIST; Rv1322; -. | |
| DR | DR TUBERCULIST; Rv1322; -. | |
| SQ | SEQUENCE 98 AA; 1134 MN; 72DF33AG8405AE4B CRC64; | |
| Query Match | Score 44; DB 1; Length 98; | |
| Best Local Similarity | 66.7%; Pred. No. 2.5±0.00; | |
| Matches | 6; Conservative 0; Mismatches 3; Indels 0; Gaps 0 | |
| Db | 24 EAGPDGEY 32 | |
| Qy | 1 EADPTGHSY 9 | |
| RESULT 15 | STANDARD; PRT; 488 AA. | |
| ID | SD00_HUMAN | |
| AC | P51687; | |
| DT | 01-OCT-1996 (Rel. 34, Created) | |
| DT | 01-OCT-1996 (Rel. 34, Last sequence update) | |
| DT | 15-JUL-1998 (Rel. 36, Last annotation update) | |
| DE | SULFITE OXIDASE PRECURSOR (EC 1.8.3.1). | |
| GN | SOX | |
| OS | Homo sapiens (Human). | |
| OC | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; | |
| OC | Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo. | |
| RN | [1] | |
| RP | SEQUENCE FROM N.A. | |
| TC | TISSUE-LIVER; | |
| RX | LINK | |
| RA | Garrett R.M., Bellissimo D.B., Rajagopalan K.V.; | |
| RT | "Molecular cloning of human liver sulfite oxidase." ; | |
| RL | Biochim. Biophys. Acta 1262:147-149 (1995). | |
| RN | [2] | |
| RA | VARIANTS GIN-160; ASP-208; TYR-370 AND ASP-473. | |
| RX | LINK | |
| RA | Kisker C., Schindelin H., Pacheco A., Wehbi W.A., Garrett R.M., Rajagopalan K.V.; | |
| RA | "Human sulfite oxidase R160Q: identification of the mutation in a sulfite oxidase-deficient patient and expression and characterization of the mutant enzyme." ; | |
| RT | Proc. Natl. Acad. Sci. U.S.A. 95:6394-6398 (1998). | |
| RL | -1 - CATALYTIC ACTIVITY: SULFITE + O(2) + H(2)O = SULFATE + H(2)O (2). | |
| CC | -1 - COFACTOR: MOLYBDENUM (POLYDOPOTERIN) AND ONE PROTHOME GROUP. | |
| CC | -1 - PATHWAY: TERMINAL REACTION IN THE OXIDATIVE DEGRADATION OF SULFUR | |



Release 3.1A John F. Collins, Biocomputing Research Unit.

Copyright (c) 1993-1998 University of Edinburgh, U.K.
 Distribution rights by Oxford Molecular Ltd

MPsrch_pp Protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:18:37 2000; MasPar time 8.87 Seconds

Tabular output not generated.
 70.368 Million cell updates/sec

Title: >US-08-819-669E-26

Description: (1-e) from US08819669E.pep

Perfect Score: 61

Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
 Gap 15

Searched: 225578 seqs, 69334122 residues

Post-processing: Minimum Match 0%
 Missing first 45 summaries

Database: sptremb12

sptremb12
 1:sp-archaea 2:sp-bacteria 3:sp-mammal 4:sp-fungi 5:sp-human
 5:sp-invertibrate 6:sp-mammal 7:sp-mhc 8:sp-organelle
 9:sp-phage 10:sp-plant 11:sp-rodent 12:sp-unclassified
 13:sp-vertebrate 14:sp-virus

Statistics:

Mean 20.592; Variance 19.613; scale 1.050

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query | Match | Length | DB ID | Description | Pred. No. |
|------------|-------|-------|-------|--------|--------|-------------------------|-----------|
| 1 | 49 | B0.3 | 347 | 4 | 000601 | DAM10=DSS-AHC CRITICAL | 2.04e-01 |
| 2 | 49 | B0.3 | 807 | 4 | 075862 | MAGE-B1 | 2.04e-01 |
| 3 | 48 | 78.7 | 129 | 1 | Q9YDL2 | 129AA LONG HYPOTHETICA | 3.86e-01 |
| 4 | 48 | 78.7 | 308 | 11 | 088667 | RAS-LIKE GTP-BINDING P | 3.86e-01 |
| 5 | 48 | 78.7 | 308 | 4 | Q92788 | RAD GTPASE | 3.86e-01 |
| 6 | 47 | 77.0 | 3942 | 11 | 088737 | BASSOON | 7.24e-01 |
| 7 | 46 | 75.4 | 1187 | 2 | Q59278 | ENDOXYLASE (EC 3.2.1.1) | 1.35e+00 |
| 8 | 45 | 73.8 | 131 | 2 | 088701 | HYPOTHETICAL 14.2 KD P | 2.48e+00 |
| 9 | 45 | 73.8 | 330 | 11 | Q66763 | MELANOMA ANTIGEN, RELA | 2.48e+00 |
| 10 | 45 | 73.8 | 330 | 11 | 060761 | MELANOMA ANTIGEN, RELAT | 2.48e+00 |
| 11 | 45 | 73.8 | 353 | 14 | Q88626 | ORFIV | 2.48e+00 |
| 12 | 45 | 73.8 | 503 | 14 | Q9YNA0 | GLYCOPROTEIN GP94 | 2.48e+00 |
| 13 | 45 | 73.8 | 503 | 14 | 010403 | P57 (FRAGMENT) | 2.48e+00 |
| 14 | 45 | 73.8 | 503 | 14 | 010399 | P57 (FRAGMENT) | 2.48e+00 |
| 15 | 45 | 73.8 | 503 | 14 | 010394 | P57 (FRAGMENT) | 2.48e+00 |
| 16 | 45 | 73.8 | 503 | 14 | 085459 | GLYCOPROTEIN | 2.48e+00 |
| 17 | 45 | 73.8 | 503 | 14 | 010400 | P57 (FRAGMENT) | 2.48e+00 |
| 18 | 45 | 73.8 | 503 | 14 | Q8857 | GLYCOPROTEIN | 2.48e+00 |
| 19 | 45 | 73.8 | 503 | 14 | Q10397 | P57 (FRAGMENT) | 2.48e+00 |
| 20 | 45 | 73.8 | 1032 | 11 | Q61989 | INTEGRIN ALPHA-4 SUBUN | 2.48e+00 |

ALIGNMENTS

| RESULT | 1 | PRELIMINARY; | PRF; | 347 AA. |
|--------|---|---------------------------------------|------|---------|
| ID | 000601 | | | |
| AC | 000601; 1 | | | |
| DT | 01-JUL-1997 | (TREMBLrel. 04, Created) | | |
| DT | 01-JUL-1997 | (TREMBLrel. 04, Last sequence update) | | |
| DE | DAM10=DSS-AHC CRITICAL INTERVAL MAGE SUPERFAMILY PROTEIN. | | | |
| GN | DAM10. | | | |
| OS | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Homo sapiens (Human). | | | |
| OC | Eutheria; Primates; Catarrhini; Hominidae; Homo. | | | |
| RN | [1..] | | | |
| RP | SEQUENCE FROM N.A. | | | |
| RC | TISSUE=TESTIS; | | | |
| RX | MEDLINE; 96081328. | | | |
| RA | DABOVIC B., ZANARIA E., BARDONI B., LISA A., BORDIGNON C., CAMERNO G; | | | |
| RA | MAPESSI C., TRAVERSARI C.; | | | |
| RT | "A family of rapidly evolving genes from the sex reversal critical region in Xp11.2." | | | |
| RT | RT | | | |
| RL | Genome 6:571-580(1995). | | | |
| DR | EMBL; S80936; AAC97145; 1; -. | | | |
| DR | PFAM; PRO1454; MABE; 1. | | | |
| SQ | SEQUENCE 347 AA; 39049 MW; AE96D5BB CRC32; | | | |

| Query | Match | Length | DB | Score | DB 4; | Score | DB 4; |
|------------|------------|----------------|----|-------|-------|-------|-------|
| Query | Match | Length | DB | Score | DB 4; | Score | DB 4; |
| Best Local | Similarity | 55.6% | | | | | |
| Matches | 5; | Conservative | | | | | |
| 3; | Mismatches | 1; | | | | | |
| Indels | 0; | Gaps | | | | | |
| Db | 167 | EDNPSGRHRY 175 | | | | | |
| QY | 1 | EADPTGHSY 9 | | | | | |

| RESULT | 2 | PRELIMINARY; | PRF; | 347 AA. |
|--------|---|--------------|------|---------|
| ID | 075862; | | | |
| AC | 075862; | | | |
| DT | 01-NOV-1998 (TREMBLrel. 08, Created) | | | |
| DT | 01-NOV-1998 (TREMBLrel. 08, Last sequence update) | | | |
| DE | DAM10. | | | |
| GN | MAGE-B1. | | | |
| OS | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; Homo sapiens (Human). | | | |
| OC | Eutheria; Primates; Catarrhini; Hominidae; Homo. | | | |

| | | |
|--|---|------------------------------|
| RN [1] | SEQUENCE FROM N.A. | RA FINLIN B.S., ANDRES D.A.; |
| RP MUZNY D., ARENSON A.D., ADAMS C., BRUNDAGE E., BUNAC S., CARVELLI K., CHACKO J., CHEN J., DI W., DING Y., DURBIN S., FORCUM J., GANESWAN R., GARCIA C., GOODMAN M., GORRELL J.H., HAYWOOD M., HERNANDEZ J.J., JACKSON L., JIN S., KAMPAL R., KARFATHY S., KOVAR C., LEAL B., LI Y., LICHATARGE O., LIU W., LOGAN O., LU J., LY T., MARTINEZ C., OSWALD G., PEREZ L., RASHID N.D., ROWLAND K., SAVAGE L., SCHERRER S.E., SHEN H., SIMON M., STOVALL K., TIDDS K.M., TODD J., VO Q., WILLIAMSON A., WORLEY K.C., YU W., CHINAULT C., NELSON D., GIBBS R.A.; | RT "Cloning of the mouse Rad gene."; | |
| RT Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. | RL Submitted (AUG-1998) to the EMBL/GenBank/DDBJ databases. | |
| RA AF084466; AAC33133.1; | DR HSSP; P10114; 2RAP. | |
| RA AF084466; AAC33133.1; | DR PEM; PF00071; ras; 1. | |
| RA SEQUENCE 308 AA; | DR SEQUENCE 308 AA; | |
| Db 167 EDNPQSHY 175 | Query Match 78.7%; Score 48; DB 11; Length 308; | |
| OY 1 EADPTGHSY 9 | Best Local Similarity 55.6%; Pred. No. 3.86e-01; Matches 5; Conservative 4; Indels 0; Gaps 0; | |
| Db 119 EAEEAGHTY 127 | Query Match 78.7%; Score 48; DB 11; Length 308; | |
| OY 1 EADPTGHSY 9 | Best Local Similarity 55.6%; Pred. No. 3.86e-01; Matches 5; Conservative 4; Indels 0; Gaps 0; | |
| RESULT 5 | RESULT 5 | |
| ID Q9YD12 PRELIMINARY; PRT; 308 AA. | ID Q97788 PRELIMINARY; PRT; 308 AA. | |
| AC Q9YD12; | AC Q97788; | |
| DR 01-NOV-1999 (TREMBLrel. 12, Created) | DR 01-FEB-1997 (TREMBLrel. 02, Last sequence update) | |
| DR 01-NOV-1999 (TREMBLrel. 12, Last annotation update) | DR 01-NOV-1997 (TREMBLrel. 02, Last annotation update) | |
| DR 129AA LONG HYPOTHETICAL PROTEIN. | DR 129AA LONG HYPOTHETICAL PROTEIN. | |
| GN APE0911. | GN APE0911. | |
| OS Aeropelix pernix. | OS Aeropelix pernix. | |
| OC Archaea; Crenarchaeota; Aeropyrum. | OC Archaea; Crenarchaeota; Aeropyrum. | |
| RN [1] | RN [1] | |
| RP SEQUENCE FROM N.A. | RP SEQUENCE FROM N.A. | |
| RC STRAIN=K1. | RC STRAIN=K1. | |
| RX MEDLINE; 99310339. | RX MEDLINE; 94060319. | |
| RA KAWABAYASI Y., HINO Y., HORIKAWA H., YAMAZAKI S., HAIKAWA Y., JIN-NO K., TAKAHASHI M., SEKINE M., BABA S., ANKAI A., KOGUCHI H., HOSOYAMA A., FUKUI S., NAGAI Y., NISHIJIMA K., NAKAZAWA H., MASUDA S., KUSHIDA N., OGUCHI A., TANAKA T., KUDOH Y., NOMURA N., SAKO Y., KIKUCHI H.; | RA REYNET C., KAHN R.C.; | |
| RA YAMAZAKI J., KUSHIDA N., OGUCHI A., AOKI K., KUROTA K., NAKAMURA Y., RT "Complete genome sequence of an aerobic hyper-thermophilic | RT "Rad: a member of the Ras family overexpressed in muscle of type II diabetic humans."; | |
| RT crenarchaeon, Aeropyrum pernix K1."; | RT Science 262:1441-1444 (1993). | |
| RT DNA Res. 6:83-101(1999). | RT DNA Res. 6:83-101(1999). | |
| RT EMBL; AP000060; BAA19985.1; | RT EMBL; AP000060; BAA19985.1; | |
| DR SEQUENCE 129 AA; | DR SEQUENCE 129 AA; | |
| DR 14303 MW; | DR 14303 MW; | |
| SQ A25B2774 CRC32; | SQ A25B2774 CRC32; | |
| Db 119 EAEEAGHTY 127 | Query Match 78.7%; Score 48; DB 4; Length 308; | |
| OY 1 EADPTGHSY 9 | Best Local Similarity 55.6%; Pred. No. 3.86e-01; Matches 5; Conservative 4; Indels 0; Gaps 0; | |
| RESULT 6 | RESULT 6 | |
| ID 088667 PRELIMINARY; PRT; 3942 AA. | ID 088667 PRELIMINARY; PRT; 3942 AA. | |
| AC 088667; | AC 088667; | |
| DR 01-NOV-1998 (TREMBLrel. 08, Created) | DR 01-NOV-1998 (TREMBLrel. 08, Last sequence update) | |
| DR 01-NOV-1998 (TREMBLrel. 08, Last sequence update) | DR 01-NOV-1998 (TREMBLrel. 08, Last sequence update) | |
| DR 01-NOV-1999 (TREMBLrel. 12, Last annotation update) | DR 01-NOV-1998 (TREMBLrel. 08, Last annotation update) | |
| DR RAS-LIKE GTP-BINDING PROTEIN RAD. | DR RAS-LIKE GTP-BINDING PROTEIN RAD. | |
| OS Mus musculus (Mouse). | OS Mus musculus (Mouse). | |
| Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; | Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Mammalia; | |
| Eutheria; Rodentia; Sciurognathi; Murinae; Mus. | Eutheria; Rodentia; Sciurognathi; Murinae; Mus. | |
| GN BASSCON. | GN BASSCON. | |
| RN [1] | RN [1] | |
| RP SEQUENCE FROM N.A. | RP SEQUENCE FROM N.A. | |
| RC STRAIN=129 SWJ; | RC STRAIN=129 SWJ; | |
| RX MEDLINE; 98345363. | RX MEDLINE; 98345363. | |
| RA DICK S., SAMMARTI-VILLA L., LANGNAESE K., RICHTER K., KINDLER S., SOYKE A., WEX H., SMALLA K.H., KAMPF U., FRANZER J.T., STUMM M., GARNER C.C., GUNDELTINGER E.D., | RA DICK S., SAMMARTI-VILLA L., LANGNAESE K., RICHTER K., KINDLER S., SOYKE A., WEX H., SMALLA K.H., KAMPF U., FRANZER J.T., STUMM M., GARNER C.C., GUNDELTINGER E.D., | |

| | |
|---|---|
| RT | "Bassoon, a novel zinc-finger CAG/glutamine-repeat protein selectively localized at the active zone of presynaptic nerve terminals."; |
| RL | J. Cell Biol. 142:499-509(1998). |
| EMBL; Y17034; | CAA76598.1; |
| DR | JOINED. |
| EMBL; Y17035; | CAA76598.1; |
| DR | JOINED. |
| EMBL; Y17036; | CAA76598.1; |
| DR | JOINED. |
| EMBL; Y17037; | CAA76598.1; |
| DR | JOINED. |
| EMBL; Y17038; | CAA76598.1; |
| DR | JOINED. |
| SQ | SEQUENCE 3942 AA; 41B739 MW; 9D6C5BC6 CRC32; |
| Query Match | Score 47; DB 11; Length 3942; Best Local Similarity 55.6%; Pred. No. 7.24e-01; Gaps 0; |
| Matches 5; | Mismatches 0; Indels 0; |
| Qy 1 EADPFGHSY 9 | |
| RESULT 7 | PRELIMINARY; PRT: 1187 AA. |
| ID Q59278 | |
| AC Q59278; | |
| DT 01-NOV-1996 (TREMBLrel. 01, Created) | |
| DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update) | |
| DT 01-NOV-1995 (TREMBLrel. 12, Last annotation update) | |
| DE ENDOXylanase (EC 3.2.1.8) (ENDO-1,4-BETA-XYLANASE) | |
| DE (1,4-BETA-D-XYLAN XYLANOHYDROLASE). | |
| GN XNC. | |
| OS Cellulomonas fimi. | |
| OC Bacteria; Firmicutes; Actinobacteria; Actinobacteridae; Actinomycetales; Micrococcales; Cellulomonadaceae; Cellulomonas. | |
| RN [1] | |
| RP SEQUENCE OF 1-352 FROM N.A. | |
| RX MEDLINE: 9524531. | |
| RA CLARKE J.H., DAVIDSON K., GILBERT H.J., FONTES C.M., HAZLEWOOD G.P.; | |
| RT A modular xylanase from mesophilic Cellulomonas fimi contains the same cellulose-binding and thermostabilizing domains as xylanases from thermophilic bacteria. ^a | |
| RT FEMS Microbiol. Lett. 139:27-35(1996). | |
| RL [2] | |
| RP SEQUENCE FROM N.A. | |
| RA CLARKE J.H.; | |
| RL Submitted (AUG-1995) to the EMBL/GenBank/DDBJ databases. | |
| CC -1- CATALYTIC ACTIVITY: ENDOHYDROLYSIS OF 1,4-BETA-D-XYLOSIDIC LINKAGES IN XYLANS. | |
| EMBL; 250866; CAA90745.1; -. | |
| DR HSSP; P14758; ICLX | |
| DR PFAM; PF00331; Glyco_hydro_10; 1. | |
| DR PRINTS; PRO0134; GLYHYDRASE10 | |
| DR PFAM; PF0122; Polyac_desact; 1. | |
| DR Xylan degradation; Hydrolase; Glycosidase. | |
| KW Sequence | |
| SQ SEQUENCE 1187 AA; 125378 MW; 92B3994 CRC32; | |
| Query Match | Score 46; DB 2; Length 1187; |
| Best Local Similarity 75.0%; Pred. No. 1.35e+00; Gaps 0; | |
| Matches 6; | Mismatches 0; Indels 0; |
| Qy 2 ADPFGHSY 9 | |
| RESULT 8 | PRELIMINARY; PRT: 131 AA. |
| ID Q85701 | |
| AC Q85701; | |
| DT 01-NOV-1998 (TREMBLrel. 08, Created) | |
| DT 01-NOV-1998 (TREMBLrel. 08, Last sequence update) | |
| DT 01-NOV-1998 (TREMBLrel. 08, Last annotation update) | |
| DE HYPOTHETICAL 14.2 KD PROTEIN. | |
| OS Streptomyces lividans. | |
| OC Bacteria; Firmicutes; Actinobacteria; Actinomycetaceae; Streptomyces. | |
| OC Actinomycetales; Streptomyces; Streptomyctaceae; Streptomyces. | |
| RN [1] | |

CC TYPES BUT NOT IN NORMAL TISSUES EXCEPT TESTIS.
 CC -!- SIMILARITY: BELONGS TO THE MAGE FAMILY.
 DR EMBL; U16031; AAA86096.1; ALT-INIT.
 DR EMBL; U19032; AAA85097.1; -.

DR MGD; MGI:105117; Mageb2.
 DR PFAM; PPF01454; MageF; 1.

KW Antigen; Tumor antigen
 SEQUENCE 330 AA;

35936 MW; 36D760C5 CRC32;

Query Match 73.8%; Score 45; DB 11; Length 330;

Best Local Similarity 66.7%; Pred. No. 2.48e+00; Indels 0; Gaps 0;
 Matches 6; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Db 161 ETDPGHSY 169

Qy . 1 EADPTGHSY 9

RESULT 11 PRELIMINARY; PRT; 353 AA.

ID Q88626; PRELIMINARY; PRT; 353 AA.

AC Q88626; PRELIMINARY; PRT; 353 AA.

DR 01-NOV-1996 (TREMBLrel. 01, Created)

DT 01-NOV-1996 (TREMBLrel. 01, Last sequence update)

DT 01-NOV-1998 (TREMBLrel. 08, Last annotation update)

DE ORFIV.

OS Borna disease virus (BDV).

CC ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RX MEDLINE; 94149825.

RA CUBITI B., OLDSTONE C., LA TORRE J.;

RT "Sequence and genome organization of Borna disease virus.";

RL J. Virol. 68:1382-1396 (1994).

DR EMBL; L2077; AA:2066.1; -.

SQ SEQUENCE 353 AA; 39939 MW; 555715F0 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 353;

Best Local Similarity 55.6%; Pred. No. 2.48e+00; Indels 0; Gaps 0;
 Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Db 266 ETDPINHAY 274

Qy . 1 EADPTGHSY 9

RESULT 12 PRELIMINARY; PRT; 503 AA.

ID Q9WN00; PRELIMINARY; PRT; 503 AA.

AC Q9WN00; PRELIMINARY; PRT; 503 AA.

DR 01-NOV-1999 (TREMBLrel. 12, Created)

DT 01-NOV-1999 (TREMBLrel. 12, Last sequence update)

DT 01-NOV-1999 (TREMBLrel. 12, Last annotation update)

DE GLYCOPROTEIN GP94.

OS Borna disease virus (BDV).

CC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=RN98;

RX MEDLINE; 99329142.

RA PLANZ O., RENTZSCHE C., BATRA A., BATRA A., WINIKLER T., BIETTNER M.,

RA RZIHA H.-J., STITZ L.,

RT "Pathogenesis of Borna disease virus: granulocyte fractions of psychiatric patients harbor infectious virus in the absence of antiviral antibodies."

RT J. Virol. 73:6551-6556 (1999).

DR EMBL; AF158633; AAP45291.1; -.

SQ 503 AA; 56588 MW; EC993A56 CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;

Best Local Similarity 55.8%; Pred. No. 2.48e+00; Indels 2; Mismatches 2; Indels 0; Gaps 0;

Db 416 ETDPINHAY 424

Qy . 1 EADPTGHSY 9

RESULT 15 PRELIMINARY; PRT; 503 AA.

ID Q10394; PRELIMINARY; PRT; 503 AA.

AC Q10394; PRELIMINARY; PRT; 503 AA.

DR 01-JUL-1997 (TREMBLrel. 04, Created)

DT 01-JUL-1997 (TREMBLrel. 04, Last sequence update)

DT 01-AUG-1998 (TREMBLrel. 07, Last annotation update)

DE P57 (FRAGMENT).

OS Borna disease virus (BDV).

CC Viruses; ssRNA negative-strand viruses; Mononegavirales.

RN [1]

RP SEQUENCE FROM N.A.

RC STRAIN=436;

RA ZIMMERMANN W., KOKORSCH J., LUNDGREN A.L., LUDWIG H.;

RT Submitted (MAR-1997) to the EMBL/GenBank/DBJ databases.

DR EMBL; U94866; AAC53715.1; -.

SQ NON_TER 503 MW; 56578 MW; B543AFCA CRC32;

Query Match 73.8%; Score 45; DB 14; Length 503;
Best Local Similarity 55.6%; Pred. No. 2, 48e+00;
Matches 5; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Db 416 FNDPINHAY 424
Qy 1 EADPTGHSY 9

Search completed: Tue Sep 12 13:18:50 2000
Job time : 13 secs.

autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;
osteosarcoma; leukemia; carcinoma.
Homo sapiens.
W0991/329-A1.
PD 25-MAR-1999; 018601.
PR 12-SEP-1997; US-928615.
PA (LUDWIG) LUDWIG INST CANCER RES.
PA (UYTR) UNIV VRIJE BRUSSEL.
PI Boon-Falleur T, Chaux P, Corthals J, Heirman C,
Luiten R, Stroobant V, Thielemans K, Van Der Bruggen P;
PT Isolated peptides that bind to human leucocyte antigen class II
molecules
PS Disclosure; Page 27; 88PP; English.
CC The present sequence represents an exemplary tumour associated peptide
CC antigen. The specification describes a MAGE-3 tumour associated peptide
CC antigen. Peptides (Y01721-25) that bind human leucocyte antigen (HLA) Class II
CC molecules can be derived from the MAGE-3 protein. These peptides and
CC autologous CD4+ cells that bind to a complex of MAGE-3 peptide
CC and HLA Class II, are used to treat MAGE-3 related diseases,
CC particularly cancers (e.g. melanoma, osteosarcoma, leukemia and
CC various forms of carcinoma). The peptides are also used to produce
CC specific antibodies. Detection of the peptides, e.g. in binding
CC assays, particularly with antibodies, is used for diagnosis of such
CC diseases.
SQ Sequence 9 AA;

Query Match 3 standard; Peptide; 9 AA.
ID Y10633;
AC Y10633;
DT 12-MAY-1999 (first entry)
DE Peptide antigen SEQ ID N:563.
KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.
OS Homo sapiens.
PN W09902183-A2.
PD 21-JAN-1998; 014289.
PR 10-DEC-1997; US-988320.
PR 10-JUL-1997; CA-2020815.
PA (CTLI) CTL IMMUNOTHERAPIES CORP.
PI Kuendig TM, Simard JJL;
DR WPI: 99-120514/10.
PT Inducing a cytotoxic T lymphocyte response - by maintaining a level
PT of antigen in the lymphatic system of a mammal so as to provide a
PT sustained CTL response, used to treat, e.g. AIDS
PS Disclosure; Page 52; 199PP; English.

CC The present invention describes a method of inducing and/or sustaining
CC an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The
CC method comprises: (a) delivering an antigen to the mammal at a level to
CC induce an immunological CTL response in the mammal's lymphatic system to maintain
CC the level of the antigen in the mammal's lymphatic system to maintain
CC the immunologic CTL response. The method can be used for the delivery of
CC e.g. a differentiation antigen, a tumour-specific multilneage antigen,
CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor
CC gene antigen, or a viral antigen. They can be used for the treatment of
CC disease such as cancer, e.g. malignant melanoma or infectious disease,
CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery
CC to the lymphatic system provides for potent CTL stimulation that takes
CC place in the milieu of the lymphoid organ, and it sustains stimulation
CC that is necessary to keep CTL active, cytotoxic and recirculating

CC through the body. Y100071 to Y10639 represent examples of peptide
CC antigens given in the present invention.
Sequence 9 AA;

Query Match 4 standard; Peptide; 9 AA.
ID Y06683;
AC Y06683;
DT 12-MAY-1999 (first entry)
DE Tumour antigen booster peptide MAGE-1 HLA-A1.
KW Tumour antigen; booster Peptide; immune response modulation; allergy;
KW immune response enhancer; tumour cell; autoimmune disease;
KW leukocyte antigen-presenting molecule; autoimmune disease;
KW allograft rejection.
OS Homo sapiens.
PN W09858956-A2.

RESULT 4
ID Y06683;
AC Y06683;
DT 12-MAY-1999 (first entry)
DE Tumour antigen booster peptide MAGE-1 HLA-A1.
KW Tumour antigen; booster Peptide; immune response modulation; allergy;
KW immune response enhancer; tumour cell; autoimmune disease;
KW leukocyte antigen-presenting molecule; autoimmune disease;
KW allograft rejection.
OS Homo sapiens.
PN W09858956-A2.
PR 23-JUN-1998; US-880579.
PD 30-DEC-1998.
PP 19-JUN-1998; US-12894.
PA (LUDWIG) LUDWIG INST CANCER RES.
PI Boon-Falleur T, Uyttenhoeve C, Warrier G;
DR WPI: 99-105612/09.
PT Immunization methods using viruses expressing antigen for priming
PT and booster immunizations - useful for modulating immune responses
PT against antigen, e.g. enhancing immune response against tumour cells
PT expressing tumour rejection antigens
PS Claim 3; Page 9; 33PP; English.
CC This sequence represents a tumour antigen booster peptide that can be
CC used in the method of the invention. The method is for modulating an
CC immune response in a mammal against an antigen, and comprises:
CC (A) inducing an immune response by: (i) administering a virus containing
CC a nucleic acid molecule encoding the antigen of its precursor to generate
CC an immune response; and (ii) administering at least one booster dose
CC comprising a peptide including the antigen, in an adjuvant, in a combined
CC amount effective to enhance the initial immune response; or
CC (B) reducing an immune response as defined for (A) but using a
CC non-adjuvant with the peptide which includes the antigen, in an amount
CC effective to reduce the initial immune response. Method (A) is used to
CC enhance the immune response against tumour cells expressing tumour
CC rejection antigens, and against pathogens in subjects having human
CC leukocyte antigen-presenting molecules. Method (B) is used to reduce the
CC immune response in allergy, autoimmune disease, and allograft rejection.
CC Method (A) provides an immunisation method which, unlike prior art, is
CC not limited by the host immune response against viral vectors.
SQ Sequence 9 AA;

Query Match 5 standard; Peptide; 9 AA.
ID Y10424;
AC Y10424;
DT 12-MAY-1999 (first entry)
DE HLA Class I motif peptide SEQ ID NO:354.
KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.
OS Synthetic.
PT Y10424;
PR 1 EADPTGHSY 9
PS 1 EADPTGHSY 9

RESULT 5
ID Y10424;
AC Y10424;
DT 12-MAY-1999 (first entry)
DE HLA Class I motif peptide SEQ ID NO:354.
KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
KW immunisation; tumour; infectious disease; immunotherapy; cancer;
KW malignant melanoma; viral disease; hepatitis; AIDS.
OS Synthetic.
Homo sapiens.

PN WO9902183-A2.
 PD 21-JAN-1999; U14289.
 PF 10-DEC-1998; US 988320.
 PR 10-JUL-1997; US 988320.
 PR 10-JUL-1997; CA-209815.
 (CTLI-) CTL IMMUNOTHERAPIES CORP.
 PI Kuendig TM, Simard JUJ;
 WPI; 99-120514/10.
 DR
 PT Inducing a cytotoxic T lymphocyte response - by maintaining a level of antigen in the lymphatic system of a mammal so as to provide a sustained CTL response, used to treat, e.g. AIDS.
 PS Disclosure; Page 39; 199pp; English.
 CC The present invention describes a method of inducing and/or sustaining an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The method comprises: (a) delivering an antigen to the mammal at a level to induce an immunological CTL response in the mammal; and (b) maintaining the level of the antigen in the mammal's lymphatic system to maintain the immunologic CTL response. The method can be used for the delivery of e.g. a differentiation antigen, a tumour-specific multilneage antigen, an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene antigen, or a viral antigen. They can be used for the treatment of disease such as cancer, e.g. malignant melanoma or infectious disease, e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery to the lymphatic system provides for potent CTL stimulation that takes place in the milieu of the lymphoid organ, and it sustains stimulation that is necessary to keep CTL active, cytotoxic and recirculating through the body. Y10071 to Y10639 represent examples of Peptide sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Gaps 0;
 SQ

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 6
 ID R50281 standard; Peptide; 9 AA.
 AC Y10623- standard; Peptide; 9 AA.
 DT 12-MAY-1999 (first entry)
 DE Peptide antigen SEQ ID NO:53.
 KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;
 KW immunisation; tumour; infectious disease; immunotherapy; cancer;
 KW malignant melanoma; viral disease; hepatitis; AIDS.
 OS Synthetic.
 OS Homo sapiens.
 PN WO9902183-A2.
 PD 21-JAN-1999.
 PR 10-DEC-1997; U14289.
 PR 10-DEC-1997; CA 209815.
 PA (CTLI-) CTL IMMUNOTHERAPIES CORP.
 PI Kuendig TM, Simard JUJ;
 WPI; 99-120514/10.
 DR
 PT Inducing a cytotoxic T lymphocyte response - by maintaining a level of antigen in the lymphatic system of a mammal so as to provide a sustained CTL response, used to treat, e.g. AIDS.
 PS Disclosure; Page 51; 199pp; English.
 CC The present invention describes a method of inducing and/or sustaining an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The method comprises: (a) delivering an antigen to the mammal; and (b) maintaining the level of the antigen in the mammal's lymphatic system to maintain the immunologic CTL response. The method can be used for the delivery of e.g. a differentiation antigen, a tumour-specific multilneage antigen, an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor gene antigen, or a viral antigen. They can be used for the treatment of disease such as cancer, e.g. malignant melanoma or infectious disease, e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery to the lymphatic system provides for potent CTL stimulation that takes

CC place in the milieu of the lymphoid organ, and it sustains stimulation that is necessary to keep CTL active, cytotoxic and recirculating through the body. Y10071 to Y10639 represent examples of peptide sequence 9 AA; in the present invention.

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Gaps 0;
 SQ

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 7
 ID W54622 standard; peptide; 9 AA.
 AC W54622;
 DT 23-SEP-1998 (first entry)
 DE Peptide from Mage-1 161-169.
 KW Mannose; antigen-presenting cell; mannosylated peptide; T cell; vaccine; treatment.
 OS Synthetic.
 PN W9813378-A1.
 PD 02-APR-1998.
 PR 25-SEP-1996; EP-202701.
 PA (URL-) RIJKSUNIV LEIDEN.
 DR W98-230631/20.
 PT Increasing uptake and presentation of antigen(s) - by adding mannose residues(s) to antigen for increasing T cell response, useful in, e.g. vaccines against viral infection(s)
 PS Disclosure; Page 28; 47PP; English.
 CC The peptides W5459-W54809 are examples of peptides to which at least 1 (preferably 2) mannose can be attached to increase their uptake as antigens by antigen-presenting cells. Uptake of agonist mannosylated peptides will increase the T cell response, whereas uptake of antagonist peptides blocks the T cell response. Blocking binding of immunogenic autoantigens can be used in treatment of type I diabetes, rheumatoid arthritis, graft rejection etc., also to induce T-cell non-responsiveness. Vaccines containing mannosylated antigen are used to prevent or treat infections by, e.g. bacteria, viruses, fungi, helminths and parasites.
 CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Gaps 0;
 SQ

Db 1 EADPTGHSY 9
 QY 1 EADPTGHSY 9

RESULT 8
 ID R50281 standard; Protein; 9 AA.
 AC R50281;
 DT 26-SEP-1994 (first entry)
 DE MAGE-1 nonapeptide.
 KW histocompatibility; cancer; melanoma; breast; cancer; HLA; therapy; vaccine.
 OS Synthetic.
 PN WO45304-A.
 PR 30-AUG-1994.
 PR 31-AUG-1992; US-938334.
 PR 26-MAR-1993; US-0373103.
 PR 07-JUN-1993; US-073103.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Boon-faillieu T, De Plaen E, Lurquin C, Traversari C,
 Van Derbruggen P;

Page 4

RESULT 12
ID W77125; standard; peptide; 9 AA.
AC W77125;
DT 16-NOV-1998 (first entry)
DE gp75/TRP-1 synthetic peptide epitope 1.
KW Tyrosinase; tyrosinase cytotoxic lymphocyte response;
cytotoxic T lymphocyte; cysteine-depleted; melanoma;
Synthetic.
OS W0983810-A2.
PN 06-AUG-1998.
PD 29-JAN-1998; 001592.
PR 30-JAN-1997; US-037781.
(CVRL) ONT VIRGINIA PATENT FOUND.
PI Engelhard VH, Hunt DF, Kittlesen D, Slingluff CL;
WPI; 98-437389/37.
PT Disease specific immunogen - comprises disease specific cytotoxic T lymphocyte epitope used to elicit melanoma specific CTL response
PS Disclosure: Page 27; 93pp; English.
CC The peptide epitope W7719-W77138 were created for human tumour-specific cytotoxic T lymphocyte. These peptides are are cysteine-depleted mutants of a native disease-specific CTL epitope. The cysteine-depleted CTL epitopes elicit a stronger or more specific CTL response in a disease-specific than the native epitope. The epitopes can be used in a disease-specific immunogen to protect a mammal against disease in particular melanomas.
CC The Peptides may also be used to screen a sample for the presence of an antigen with the same epitope, or with a different cross-reactive epitope.
CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 14
ID W00897; standard; Peptide; 9 AA.
AC W00897;
DT 23-MAY-1997 (first entry)
DE Human melanoma MAGE1 tumour associated antigen p161-169.
KW Adeno-associated virus; vector; liposome; transfection;
dendritic cell; melanoma; MAGE1; adoptive immunotherapy;
KW tumour associated antigen.
OS Homo sapiens.
PN WO970303-A1.
PD 06-FEB-1997.
PR 19-JUL-1996; U12012.
PR 21-JUL-1995; US-001312.
PR 01-NOV-1995; US-007184.
PR 01-DEC-1995; US-566286.
PA (RHON) RHONE POULEN RORER PHARM INC.
PI Lebkowski JS, Phillip R;
DR WPI; 97-142208/13
PT Adeno-associated virus:liposome complexes for transfecting dendritic cells - for inducing immune response, useful for treating e.g. neoplasia or infections
PT Example 5; Page 58; 134pp; English.
PS Tumour associated antigens (W3660-61, W00878-903) can be loaded into dendritic cells and used to induce antitumour immunity.
CC Alternatively, the dendritic cells are transfected with adeno-associated virus plasmid DNA (which includes DNA encoding the tumour associated antigen) complexed with cationic liposomes. The antigen loaded or transfected dendritic cells can be used to generate tumour antigen-specific cytotoxic T lymphocytes for use in adoptive immunotherapy in a patient having the corresponding tumour. A suitable antigen comprises amino acids 161-169 (W00897) of human melanoma MAGE1.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 15
ID W75736; standard; Peptide; 9 AA.
AC W75736;
DT 19-NOV-1998 (first entry)
DE Peptidase-resistant peptide 4.
KW Tumour antigen MZ2-E; T-cell; immunotherapy; cytolytic T-cell; CML;
human leucocyte antigen; MHC; lysis; vaccine.
KW Synthetic.
Key Location/Qualifiers
Misc_difference 2
Misc_difference 8
FT /note= "D-form residue"
FT /note= "D-form residue"
PN W09833511-A1.
PD 06-AUG-1998.
PR 19-NOV-1997; U21296.
(CNRS) CNRS NAT RECH SCI.
PA (LUDWIG INST CANCER RES.) LUDWIG INST CANCER RES.
PI Ayyoub M, Gairin JE, Matargull H, Monsarrat B, Van Den Eynde B;
DR WPI; 98-431166/37.
PT Peptidase-resistant peptide(s) that bind to HLA molecules and related antibodies - particularly for treatment of cancer by inducing proliferation of cytotoxic T cells
PT Claim 20; Page 20; 32pp; English.
PS Sequences W75733-W7736 are peptidase-resistant peptides which are analogues of the tumour antigen MZ2-E. This antigen is a potential target for T-cell based immunotherapy and can also be used to stimulate the antigen-specific CTL, however its use as a therapeutic agent is limited due to its degradation by peptidase. The MZ2-E antigen peptide analogues were modified at both peptidase sensitive portions, and were all shown to exhibit a longer half-life relative to peptidase degradation as well as the ability to bind a human leucocyte antigen (HLA). The
CC Key Location/Qualifiers
FT Modified_site 2
FT /note= "N-Methyl-Alanine"

| | | | | | | | | | | | | | | |
|-----------------------|---|---|--------------------------|--|---------|----|--------------|----|------------|----|--------|----|------|----|
| FT | Modified-site | 8 | /note= "N-Methyl-Serine" | | Matches | 9; | Conservative | 0; | Mismatches | 0; | Indels | 0; | Gaps | 0; |
| FT | W0933511-A1. | | | | Db | 1 | EADPTGHSY 9 | | | | | | | |
| PN | 06-AUG-1998. | | | | | | | | | | | | | |
| PD | 06-NOV-1997; U21296. | | | | QY | 1 | EADPTGHSY 9 | | | | | | | |
| PR | 05-FEB-1997; US-79733. | | | | | | | | | | | | | |
| PA | (CNRS) CENT NAT RECH SCI. | | | | | | | | | | | | | |
| PA | (LUDW.) LUDWIG INST CANCER RES. | | | | | | | | | | | | | |
| PI | Ayyoub M, Gairin JE, Nazarquiel H, Monsarrat B, Van Den Eynde B; | | | | | | | | | | | | | |
| DR | WPI: 98-43716/37. | | | | | | | | | | | | | |
| PT | Peptidase-resistant peptide(s) that bind to HLA molecules and | | | | | | | | | | | | | |
| PT | related antibodies - particularly for treatment of cancer by | | | | | | | | | | | | | |
| PT | inducing proliferation of cytotoxic T cells | | | | | | | | | | | | | |
| PS | Claim 20; Page 20; 32pp; English. | | | | | | | | | | | | | |
| PS | Sequences W75733-W75736 are Peptidase-resistant peptides which are | | | | | | | | | | | | | |
| CC | analogues of the tumour antigen M22-E. This antigen is a potential | | | | | | | | | | | | | |
| CC | target for T-cell based immunotherapy, and can also be used to stimulate | | | | | | | | | | | | | |
| CC | the antigen-specific CTL, however its use as a therapeutic agent is | | | | | | | | | | | | | |
| CC | limited due to its degradation by peptidase. The M22-E antigen peptide | | | | | | | | | | | | | |
| CC | analogue were modified at both peptidase sensitive portions, and were | | | | | | | | | | | | | |
| CC | all known to exhibit a longer half-life relative to peptidase degradation | | | | | | | | | | | | | |
| CC | as well as the ability to bind a human leucocyte antigen (HLA). | | | | | | | | | | | | | |
| CC | specific peptides W75733 and W75735 were established to have a comparable | | | | | | | | | | | | | |
| CC | affinity for the MHC as the tumour antigen, and W75735 was found to be | | | | | | | | | | | | | |
| CC | the ideal peptide analog to use due to it also being able to sensitise | | | | | | | | | | | | | |
| CC | the target cells to lysis by effector molecules at similar concentrations | | | | | | | | | | | | | |
| CC | to those of the antigen M22-E. These peptide analogues can be used in | | | | | | | | | | | | | |
| CC | vaccines to induce an immune response for treating conditions in which | | | | | | | | | | | | | |
| CC | abnormal HLA-peptide complexes are present on the surface of cells. | | | | | | | | | | | | | |
| Sequence | 9 AA; | | | | | | | | | | | | | |
| Query Match | Score 61; DB 1; Length 9; | | | | | | | | | | | | | |
| Best Local Similarity | 100.0%; Pred. No. 2.32e-01; | | | | | | | | | | | | | |
| Matches | 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0; | | | | | | | | | | | | | |
| Db | 1 EADPTGHSY 9 | | | | | | | | | | | | | |
| QY | 1 EADPTGHSY 9 | | | | | | | | | | | | | |
| RESULT | 16 | | | | | | | | | | | | | |
| ID | R8288 standard; Peptide; 9 AA. | | | | | | | | | | | | | |
| AC | R82888 | | | | | | | | | | | | | |
| DT | 26-FEB-1996 (first entry) | | | | | | | | | | | | | |
| DE | P815 antigen; P1A antigen; | | | | | | | | | | | | | |
| KW | Synthetic. | | | | | | | | | | | | | |
| OS | W0932387-A1. | | | | | | | | | | | | | |
| PN | 08-SEP-1995. | | | | | | | | | | | | | |
| PF | 23-FEB-1995; U02203. | | | | | | | | | | | | | |
| PR | 01-MAR-1994; US-204727. | | | | | | | | | | | | | |
| PR | 10-MAR-1994; US-205172. | | | | | | | | | | | | | |
| PR | 01-SEP-1994; US-239849. | | | | | | | | | | | | | |
| PR | 30-NOV-1994; US-346774. | | | | | | | | | | | | | |
| PA | (LUDW.) LUDWIG INST CANCER RES. | | | | | | | | | | | | | |
| PA | Boon-Falleur T, Brasseur F, Chomez P, De Plaen E, | | | | | | | | | | | | | |
| PI | De Smet C, Gaugler B, Lethe B, Marchand M, Patard J; | | | | | | | | | | | | | |
| PI | Szikora J, Van Den Eynde B, Van DeBruggen P, Weynants P; | | | | | | | | | | | | | |
| PI | WPI: 95-20865/41. | | | | | | | | | | | | | |
| PT | Determination of cancerous condition(s) - using a nucleic acid as a primer to determine expression of a MAGE tumour rejection antigen | | | | | | | | | | | | | |
| PT | precursor. | | | | | | | | | | | | | |
| PS | Example 13; Page 22; 121pp; English. | | | | | | | | | | | | | |
| CC | Using the sequence of the P115A antigen precursor gene P1A (R01176), an antigenic peptide (R82908) which was A+B+ (i.e. | | | | | | | | | | | | | |
| CC | characteristic of cells which express both A and B antigens) was produced. The peptide lysed PC-RTR cells in the presence of | | | | | | | | | | | | | |
| CC | cytolytic T lymphocyte cell lines, and may be useful as a vaccine component. | | | | | | | | | | | | | |
| SQ | Sequence 9 AA; | | | | | | | | | | | | | |
| Query Match | Score 61; DB 1; Length 9; | | | | | | | | | | | | | |
| Best Local Similarity | 100.0%; Pred. No. 2.32e-01; | | | | | | | | | | | | | |
| CC | OS | | | | | | | | | | | | | |

RESULT 17
ID R90692 standard; peptide; 9 AA.
AC R90692; R90695.
DT 31-JUL-1996 (first entry)
DE Human leukocyte antigen (HLA-A1) presented peptide MZ2-E.
KW Human leukocyte antigen; HLA-A1; MAGE-1 derived;
KW blood mononuclear cell; BMC; CD8-beta+ cell; cytolytic T cell;
KW CTL cell; treatment; tumour cell; diagnosis; assay;
KW presented peptide.
OS Synthetic.
PN W0955500-A1.
PD 28-DIC-1995.
PP 14-JUN-1995; U07559.
PR 17-JUN-1994; US-261541.
PA (LUDW.) LUDWIG INST CANCER RES.
PI Boon-Falleur T, Coulie P, Van Der Bruggen P;
DR WPI: 96-05851/06.
PT Product of specific cytolytic T cell sub-populations - by contacting blood mononuclear cells with specific peptide(s) and a population of CD8-beta(+) cells
PT Claim 5; Page 19; 25pp; English.
PS The present peptide is the human leukocyte antigen (HLA-A1), MAGE-1 derived presented peptide, MZ2-E. By contacting a sample of blood mononuclear cells (BMC) with the peptide (which binds directly to HLA-A1 mol's. on the surface of the BMC) and CD8-beta cells (which stimulate peptide/HLA-A1 complex specific cytolytic T (CTL) cell subpopulation can be obtd. The CTL cells obt'd can be administered to a patient to treat tumour cell related conditions, and can be used in diagnostic methods, e.g. in assays for the peptide/HLA-A1 complex.
SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OS Synthetic.
PN W0956779 standard; peptide; 9 AA.
AC W0956779; W095678.
DT 31-JUL-1998 (first entry)
DE MAGE-1 antigenic partial peptide sequence (residues 161-169).
KW MAGE; replication defective; adenovirus; tumour; antigen; cancer;
KW immunotherapy; tumour rejection antigen precursor; TRAP; CTL;
KW synthetic.
OS Synthetic.
PN W095638-A2.
PD 16-APR-1998.
PP 06-OCT-1997; U17948.
PR 06-OCT-1996; US-027891.
PA (LUDW.) LUDWIG INST CANCER RES.
PI Cerrutiini J, Jongeneel CV, Reed DS, Rimoldi D,
PI Romero P;
DR WPI: 98-240824/21.
PT New replication-defective adenoviruses - comprise insert encoding immunotherapy antigen precursor(s), useful for, e.g. cancer Examples; Page 42; 56pp; English.
PS CC This is a partial sequence of the MAGE-1 antigenic peptide used in the method of the invention. The specification provides a new nucleic acid molecule comprising a replication-defective adenovirus genome containing CC

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;

an insert encoding a tumour rejection antigen Precursor (TRAP). The replicating-defective adenovirus genome is useful as a vector for introducing a TRAP molecule into mammalian (especially human) cells. The recombinant adenovirus is preferably targeted to tumour cells, e.g. by binding a ligand to the virus coat. The TRA peptides which are generated from the expressed TRAP are presented by human leukocyte antigen (HLA) molecules and as a result cytolytic T lymphocyte (CTL) production is increased (claimed). The CTL's then kill the TRAP-expressing tumour cells. Also, cells transfected by the recombinant adenovirus can be used for assessing the processing of TRAPs, including post-translational modifications. The adenovirus (genome) can be administered by injection, topical application or intracavitory in 106-1010 pfu doses. The range of TRA peptides produced by replication-defective adenovirus means that patients with a range of HLA phenotypes can be treated. Also, host cell immune response to TRA's is enhanced, e.g. by induction of tumour-specific cytolytic T lymphocytes.

Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 19
 ID R7554 standard; Peptide; 9 AA.
 AC R7554;
 DT 06-MAR-1996 (first entry)
 DE Melanoma antigen (MAGE-1) epitope.
 KW melanoma antigen; vaccine; immune response; immunogenic peptide; cytotoxic T lymphocyte response; CTL; melanoma; breast cancer; antibody; Homo sapiens.
 OS W09519783 A1.
 PD 27-JUL-1995.
 PF 25-JAN-1995; U010000.
 PR 25-JAN-1994; US-185266.
 PA (CYTE-) CYTEL CORP.
 PI Cells E, Grey HM, Kubo RT, Sette A;
 WP; 95-269270/35.

PT Immunogenic peptide(s) that induce immune response to cancer cells - that express a MAGE-3 protein peptide epitope used in vaccines or adoptive immunotherapy to induce cytotoxic T lymphocytes

PS Example: Page 33; 44PP; English.

CC R7554 is derived from MAGE-1 protein. It was used to show the specificity of CTL response to MAGE-3. Peptides shown in R75942-53. CC R7542 is derived from the sequence of the melanoma antigen (MAGE-3) protein and can be used to elicit a primary cytotoxic T lymphocyte response against cells expressing MAGE-3. Synthetic Peptides R75945-53 can be used therapeutically to elicit CTL responses to melanoma, breast, colon, prostate, or other cells which express proteins with this epitope. CC The peptides have specific HLA-A1 binding capacity.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 21
 ID W78838 standard; peptide; 9 AA.
 AC W78838;
 DT 17-NOV-1998 (first entry)
 DE MAGE-1 Protein fragment 161-169.
 KW Microparticle; delivery; polymeric matrix; autoantigen; tumour antigen; class II associated peptide; Pathogen; gene therapy; genetic disease; infection; downregulation; immune response.
 OS Homo sapiens.
 PS New Preparations of microparticiles - comprising a synthetic polymer matrix and nucleic acid comprising an expression vector for use in gene therapy

PN W09831398 A1.

PD 23-JUL-1998.
 PF 22-JAN-1998; U01499
 PR 06-JAN-1998; US-003253.
 DT 22-APR-1997 (first entry)

PA (PANG-) PANGAEA PHARM INC.
 PI Curley JM, Hedley ML, Langer RS, Lunsford LB;
 DR WPI; 98-421556/36.

PT New Preparations of microparticiles - comprising a synthetic polymer matrix and nucleic acid comprising an expression vector for use in gene therapy

PS Disclosure; Page 10; 101PP; English.

CC A microparticle preparation (MP) has been developed, consisting of microparticles having a diameter of less than 100 μm. The MP comprises:
 CC (a) a polymeric matrix (PM) consisting of one or more synthetic polymers
 CC (a) a polymeric matrix (PM) consisting of one or more synthetic polymers
 CC having a solubility in water of less than 1 mg/l; and (b) an expression
 CC vector selected from RNA molecules (at least 50% of which are closed
 CC circles) or circular Plasmid DNA (at least 50% of which are supercoiled).
 CC Also described is a MP of at most 20 microns in diameter, comprising: (a)

RESULT 20
 ID R99343 standard; Protein; 9 AA.
 AC R99343;
 DT 22-APR-1997 (first entry)

DE MAGE-1 nonapeptide,
 HLA binding Peptide,
 tumour rejection antigen Precursor; TRA; MAGE-1; tumour; cancer; cell;
 antibody; melanoma; universal effector cell; vaccine; breast cancer; CTL;

RW therapy.
 OS Homo sapiens.
 PN WO9626214 A1.
 PD 29-AUG-1996; U01489.
 PR 23-FEB-1995; US-393273.
 PA (LUDW) LUDWIG INST CANCER RES.
 PI Boon-Palleur T, De Plaen E, Gaugler B, Lurquin C;
 Romero P, Traversari C, Van Den Eynde B, Van Der Bruggen P;
 DR WPI; 96-402317/40.
 DR N-PSDB; T35408.
 PT New nona:peptide(s) that bind to HLA molecule(s) and induce lysis by specific cytolytic T cells, for diagnosis and treatment of tumours and to expand T cells in vitro.
 PS Example 4; Fig 4; 41PP; English.
 CC R99343-R93350 represent MAGE nonapeptides, based on the tumour rejection antigen region of the full length MAGE sequences. These peptides were used to design the nonapeptides of the invention (see R99337-R9342), which bind to a HLA molecule on a cell, and provoke lysis by cytolytic T cells (CTLs) specific for a complex of the HLA molecule and nonapeptide. The nonapeptides can be used diagnostically to identify tumours expressing a particular HLA molecule, or to identify cancer cells. The peptides can also be used therapeutically, to induce a CTL response to tumours (where the peptides are optionally coupled to tumour-specific antibodies), or to induce a response by CTLs that are otherwise inactive. The peptide sequences may also be used to expand specific CTLs in vitro for later return to the patient, such as for treating melanoma. Tumour cells can be identified by using DNA encoding the nonapeptides as probes. Non-human cells transformed with the HLA-A1 gene and a DNA sequence encoding one of the peptides, can be used to generate CTLs, or to detect the presence of CTLs in human samples. The non-human transformed cells, when polytransfected, are universal effector cells, and can be used in vaccines, or for treating melanoma or breast cancer.

SQ Sequence 9 AA;
 Query Match 100.0%; Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01; Indels 0; Gaps 0;
 Matches 9; Conservative 0; Mismatches 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 21
 ID W78838 standard; peptide; 9 AA.
 AC W78838;
 DT 17-NOV-1998 (first entry)
 DE MAGE-1 Protein fragment 161-169.
 KW Microparticle; delivery; polymeric matrix; autoantigen; tumour antigen; class II associated peptide; Pathogen; gene therapy; genetic disease; infection; downregulation; immune response.
 OS Homo sapiens.
 PS New Preparations of microparticiles - comprising a synthetic polymer matrix and nucleic acid comprising an expression vector for use in gene therapy

PN W09831398 A1.

PD 23-JUL-1998.
 PF 22-JAN-1998; U01499
 PR 06-JAN-1998; US-003253.
 DT 22-JAN-1997; US-787847.

PA (PANG-) PANGAEA PHARM INC.
 PI Curley JM, Hedley ML, Langer RS, Lunsford LB;

a PM; and (b) a NAM comprising an expression control sequence operatively linked to a coding sequence, where the coding sequence encodes an expression product selected from: (1) a polypeptide at least 7 amino acids in length, having a sequence identical to the sequence of: (i) a fragment of a naturally-occurring mammalian protein; or (ii) a fragment of a naturally occurring protein from an infectious agent which infects a mammal; (2) a peptide having a length and sequence which permits it to bind to an MHC class I or II molecule; and (3) the polypeptide or the peptide linked to trafficking sequence, W69763 to W6975, and W78793 to W78897 are peptide fragments for use in the present invention. The MPS are highly effective vehicles for the delivery of polynucleotides into phagocytic cells. They can be used for gene therapy, e.g. for treating genetic diseases, infections or tumours or for downregulating an immune response.

Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | |
Qy 1 EADPTGHSY 9

RESULT 22

ID R65112 standard; peptide: 9 AA.
AC R65112;
DT 06-OCT-1995 (first entry)
DE MAGE 1 immunogenic peptide 161-169;
KW DE MAGE 1 immunogenic peptide 161-169;
KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
KW fungal infections; tuberculosis; hepatitis.
OS Homo sapiens.
PN WO9504811-A.
PD 16-FEB-1995.
PR 01-AUG-1994; US-5672.
PR 06-AUG-1993; US-103401.

(CYTE-) CYTEL CORP.

PI Celis E, Kubo R, Serra H, Tsai V, Wentworth P;
DR WPI: 95-090895/12.
PT In vitro activation of cytotoxic T cells for selected killing of target cells - for treating e.g. cancer, AIDS, hepatitis etc. by incubating them with antigen presenting cells loaded with appropriate immunogenic peptide
PS Example 3: Page 35; 53PP; English.
CC R65109-R65115 are immunogenic peptides, they are used in a new method for the in vitro activation of cytotoxic T cells (Ctc). This is achieved by incubating the CTCs with antigen presenting cells loaded with an appropriate immunogenic peptide (e.g. one of the above peptides). By selecting the peptides used the following diseases and infections can be treated: cancer, AIDS, hepatitis, other viral and bacterial infections, malaria and tuberculosis. Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | |
Qy 1 EADPTGHSY 9

RESULT 23

ID R63675 standard; Protein; 9 AA.
AC R63675;
DT 22-JUN-1995 (first entry)
DE Synthetic peptide derived from exon 3.1 of MAGE 1.
KW Melanoma antigen-1; MAGE-1; cytolytic T cells; antigen E; exon 3.1.
OS Synthetic.
PN WO9423031-A.

PD 13-OCT-1994.
PF 17-MAR-1994; US-02877.

PR 26-MAR-1993; US-03230.
PA (LUDWIG) LUDWIG INST CANCER RES.

PI Boon-faïeur T, Gaugier B, Van DER BRUGGEN P;
DR WPI: 94-33197/41.
PT New tumour resection antigen precursor MAGE3 - useful in treatment and diagnosis of cancer.

PS Example 34; Page 36; 105PP; English.
CC R6375 is a synthetic peptide derived from exon 3.1 of melanoma antigen-1 (MAGE-1), it was used to transfer antigen E cytolytic T lymphocyte sensitivity to normally non-sensitive cells.

SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | |
Qy 1 EADPTGHSY 9

RESULT 24

ID R78324 standard; peptide: 9 AA.
AC R78324;
DT 26-OCT-1996 (first entry)
DE MAGE-1 cytotoxic T lymphocyte epitope.
KW DE MAGE-1; cytotoxic T cell; epitope; helper T; lymphocyte; cell; viruses; parasites; tumours; antigens; disease prevention; KW treatment; Homo sapiens.
OS PN WO922317-A1.
PD 24-AUG-1995.
PR 16-FEB-1995; US-137484.
PA (CITE-) CYTEL CORP.
PI Cells E, Chestnut RW, Grey H, Sette AD, Vitiello MA;
DR WPI: 95-102545/39.

PT Compsn. inducing cytotoxic T lymphocyte response to pref. viral, bacterial, parasitic or tumour antigens - useful in the treatment and prevention of diseases associated with the antigen e.g. PT hepatitis B
PS Disclosure; Page 17; 109PP; English.
CC A compsn. which induces a cytotoxic T lymphocyte (CTL) response to an antigen (Ag) in a mammal comprising a CTL Ag response inducing CC peptide (1.e. R7884-R7853) and a lipid conjugated helper T cell CC inducing Peptide. The compsn. induces a CTL response to bacterial, CC viral or tumour Ags, and is therefore useful in the treatment and CC prevention of diseases associated with the Ag.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
| | | | | | |
Qy 1 EADPTGHSY 9

RESULT 25

ID R65135 standard; peptide: 9 AA.
AC R65135;
DT 09-OCT-1995 (first entry)
DE MAGE 1 immunogenic peptide A01.
KW MAGE 1; immunogenic peptide A01; cytotoxic T cells; in vitro activation; cancer; AIDS; bacterial infections; malaria;
OS PN WO944811-A.
PD 16-FEB-1994; US-08672.
PP 01-AUG-1994; US-08672.

| RESULT | 26 | R49224 standard; Protein: 9 AA. |
|-----------------------|--|---|
| ID | R49224 | AC R49224 standard; Protein: 9 AA. |
| AC | | |
| DT | 31-AUG-1994 | (first entry) |
| HLA-A1 | MAGE 1 antigen peptide fragment | 958-01. |
| ImmunoGenic: | HIA-A3 2; | HIA-A1: HIA-A1: binding motif: MHC molecule |
| KW | immune response; viral infection; cancer; prostate cancer; lymphoma; hepatitis; AIDS; antibody; diagnosis; melanoma antigen. | |
| KW | Synthetic. | |
| OS | | |
| PN | WO943205-A. | |
| PD | 17-FEB-1994. | |
| PR | 06-AUG-1993; U07421. | |
| PR | 07-AUG-1992; US-926666. | |
| PR | 05-MAR-1993; US-927746. | |
| PA | (CYTE-) CYTEL CORP. | |
| PI | Grey HM, Kubo RT, Sette A; | |
| DR | WPI: 94-065403/08. | |
| PT | Peptide which specifically binds selected MHC allele - used to induce an immune response for treatment or prevention of viral infection or cancer, or for diagnosis. | |
| PT | Baxmple 16; Page 116; 150PP; English. | |
| PS | The sequences given in R17304-33 and R19201-44 are immunogenic peptides which have a HLA-A3.2, HLA-A1 or a HLA-A11 binding motif. | |
| CC | These Peptides may be used in the composition of the invention. | |
| CC | These Peptides are capable of binding selected MHC molecules and inducing an immune response. They can be used to treat and/or prevent viral infection and cancer, eg. prostate cancer, lymphoma, hepatitis or AIDS. They can also be used to produce antibodies for use as diagnostic or therapeutic agents. The peptides can also be used as diagnostic or therapeutic agents. | |
| CC | Sequence 9 AA: | |
| SQ | | |
| Query Match | 100.0% | Score 61; DB 1; Length 9; |
| Best Local Similarity | 100.0% | Pred. No. 2.32e-01; |
| Matches | 9; | Mismatches 0; |
| Conservative | | Indels 0; Gaps |
| Db | 1 EADPFGHSY 9 | |
| Qy | 1 EADPFGHSY 9 | |

| | | | | |
|--------|---|---------------------------|--|--|
| SQ | Sequence | 10 AA; | Score 61; DB 1; Length 10; | CC R70969. These peptides are useful for defining epitopes that |
| | Query Match | 100.0%; | Pred. No. 2.32e-01; | CC engender a HLA-restricted cytotoxic lymphocyte activity against |
| | Best Local Similarity | 100.0%; | MAGE-1 antigens. Compns. containing these peptides can be | |
| | Matches | 9; | administered, as a vaccine to patients susceptible to MAGE | |
| | | | associated tumours, e.g. melanomas. | |
| Db | 2 | EADPTGHSY 10 | 0; Mismatches 0; Indels 0; Gaps 0; | SQ sequence 309 AA; |
| Qy | 1 | EADPTGHSY 9 | 0; Mismatches 0; Indels 0; Gaps 0; | |
| RESULT | 29 | | | |
| ID | R80520; | standard; Protein; 12 AA. | | |
| AC | R80520; | | | |
| DT | 28-FEB-1996 | (first entry) | | |
| DE | Immunoactive peptide of tumour rejection antigen (MAGE-1). | | | |
| KW | Tumour rejection antigen; MAGE-1; monoclonal antibody; Mab; diagnosis; immunoassay; cancer; immunogen; antisera. | | | |
| KW | Homo sapiens. | | | |
| OS | W0920974-A1. | | | |
| PN | 05-JAN-1995; US0095; | | | |
| PD | 01-FEB-1994; US19041. | | | |
| PR | 05-JAN-1995; US19041. | | | |
| PA | (LUDWIG INST CANCER RES. | | | |
| PA | (SLOK) SLOAN KETTERING INST CANCER RES. CENT. | | | |
| PA | (SLOK) MEMORIAL SLOAN-KETTERING CANCER CENT. | | | |
| PI | Boon-failler T, Chen Y, Garin-chesa P, Old LJ, Retting WJ; | | | |
| PI | Stockert E, Van der Bruggen P; | | | |
| DR | WPI: 95-233606/37. | | | |
| PT | New monoclonal antibody binding specifically to MAGE-1 - useful for diagnosis and monitoring of cancer, also new hybridomas, recombinant MAGE-1 and immunoactive Peptide(s) | | | |
| PT | Claim 12; Page 20; 33PP; English. | | | |
| PS | A monoclonal antibody directed against the tumour rejection antigen (MAGE-1) can be used to detect MAGE-1 in samples by standard immunoassay methods for diagnosis and monitoring of cancer etc. The monoclonal antibody is designated MA454 and is produced by the hybridoma deposited as ATCC HB11540. The monoclonal antibody is specific for MAGE-1, having no reactivity for MAGE-2 or MAGE-3. Peptide fragments of MAGE-1 (See R80618-20) may be useful as immunogens for production of the monoclonal antibody and antisera. | | | |
| CC | Sequence 12 AA; | | | |
| CC | Query Match | 100.0%; | Score 61; DB 1; Length 12; | Score 61; DB 1; Length 309; |
| CC | Best Local Similarity | 100.0%; | Pred. No. 2.32e-01; | Pred. No. 2.32e-01; |
| CC | Matches | 9; | Mismatches 0; Indels 0; Gaps 0; | Mismatches 0; Indels 0; Gaps 0; |
| CC | SQ | | | |
| Db | 4 | EADPTGHSY 12 | | |
| Qy | 1 | EADPTGHSY 9 | | |
| RESULT | 30 | | | |
| ID | R70909 standard; Protein; 309 AA. | | | |
| AC | R70909; | | | |
| DT | 09-OCT-1995 | (first entry) | | |
| DE | Human melanoma antigen MAGE-1. | | | |
| KW | Human melanoma antigen; MAGE-1; vaccines; MAGE associated tumours; HLA-restricted cytotoxic T-lymphocyte activity. | | | |
| OS | Homo sapiens. | | | |
| PN | W0950542-A. | | | |
| PD | 16-FEB-1995. | | | |
| PR | 02-AUG-1994; US08721. | | | |
| PR | 06-AUG-1993; US103623. | | | |
| PA | (CYTE) CYTEL CORP. | | | |
| PI | Pikes JD, Livingston BD, Sette AD, Sidney JC; | | | |
| DR | N-PSDB; Q85435. | | | |
| PI | Human melanoma antigen, MAGE-1, peptide(s) - useful for stimulating immune response against melanoma | | | |
| PS | Example 1; Fig 1; 59PP; English. | | | |
| CC | Q85435 encodes R70909 human melanoma antigen MAGE-1, it was used to produce the C-terminal MAGE-1 peptides described in R70915 to | | | |

Search completed: Wed Sep 13 07:14:24 2000
Job time : 7 secs.

Release 3.1A John F. Collins, Biocomputing Research Unit.
 Copyright (c) 1993-1998 University of Edinburgh, U.K.

Distribution rights by Oxford Molecular Ltd

Mpsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:23:01 2000: MasPar time 5.52 Seconds
 76.943 Million cell updates/sec

Tabular output not generated.

Title: >US-08-819-669E-26
 Description: (1-9) from US08819669E.pep
 Perfect Score: 61

Sequence: 1 EADPTGHSY 9

Scoring table: PAM 150
 Gap 15

Searched: 142080 seqs, 47172406 residues

Post-processing: Minimum Match 0.8
 Listing first 1000 summaries
 Maximum DB seq length 9

Database: Pir64

1:pir1 2:pir2 3:pir3 4:pir4
 Mean 20.662; Variance 21.178; scale 0.976

Statistics:
 Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.


SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description | Pred. No. |
|------------|-------|-------------|--------|----------|-----------------------|-----------|
| 1 | 46 | 75.4 | 9 | 2 PH1299 | MAGE 5 protein - huma | 1.79e+00 |

Note: Post processor removed 999 summaries from list due to search parameters chosen.

ALIGNMENTS

| | | | |
|-----------------|---|---|----------------|
| RESULT | 1 | PH1299 | #type fragment |
| ENTRY | | MAGE 5 protein - human (fragment) | |
| TITLE | | MAGE 5I protein | |
| ALTERNATE NAMES | | #formal name Homo sapiens #common_name man | |
| ORGANISM | | 30-Sep-1993 #sequence_revision 30-Sep-1993 #text_change | |
| DATE | | 03-Aug-1998 | |
| ACCESSIONS | | PH1299; PH1300 | |
| REFERENCE | | Traversari, C.; van der Bruggen, P.; Luescher, I.F.; Lurquin, C.; Chomez, P.; Van Pele, A.; De Blaen, E.; Amar-Costelet, A.; Boon, T. | |
| #authors | | J. Exp. Med. (1992) 176:1453-1457 | |
| #journal | | A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor | |
| #title | | | |



***** Release 3.1A John F. Collins, Biocomputing Research Unit.
***** Copyright (C) 1993-1998 University of Edinburgh, U.K.
***** Distribution rights by Oxford Molecular Ltd

Mpsrch_pp protein - protein database search, using Smith-Waterman algorithm

Run on: Tue Sep 12 13:20:57 2000; MasPar time 3.60 Seconds

Tabular output not generated.

Title: >US-08-819-669E-26

Description: (1-9) from US0819669E.pep

Perfect Score: 61

Sequence: 1 EADPQHSHY 9

Scoring table: PAM 150
Gap 15

Searched: 85661 seqs, 30989116 residues

Post-processing: Minimum Match 08
Listing first 1000 summaries
Maximum DB seq length 9

Database: swiss-prot38
1:swissprot

Statistics: Mean 21.172; Variance 19.906; scale 1.064

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Query | Match Length | DB ID | Description | Pred. NO. |
|------------|-------|--------------|-------|-------------|-----------|
|------------|-------|--------------|-------|-------------|-----------|

No matches found.

Search completed: Tue Sep 12 13:21:37 2000

Job time : 40 secs.

| Result No. | Query | Match Length | DB ID | Description | Pred. NO. |
|------------|-------|--------------|-------|-------------|-----------|
|------------|-------|--------------|-------|-------------|-----------|

Release 3.1A John F. Collins, Biocomputing Research Unit.

Copyright (c) 1993-1998 University of Edinburgh, U.K.

Distribution rights by Oxford Molecular Ltd.

MPSrch_PP protein - protein database search, using Smith-Waterman algorithm

Description: >US-08-819-669E-26
(1-9) from US08819669E.pep

Perfect Score: 61

Sequence: 1 EADPTGHSY 9

Tabular output not generated.

Title: >US-08-819-669E-26

Run on: Wed Sep 13 06:32:58 2000; MasPar time 3.59 Seconds

59.387 Million cell updates/sec

Scoring table: PAM 150

Gap 15

Searched: 188963 seqs, 23686106 residues

Post-processing: Minimum Match 0%
Listing first 1000 summaries
Maximum DB seq length 9

Database: a-geneseq36

1:geneseq36

Statistics: Mean 15.425; Variance 35.537; scale 0.434

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description | Pred. No. |
|------------|-------|-------------|--------|----------|--|-----------|
| 1 | 61 | 100.0 | 9 | 1 W98945 | HLA-A1 binding peptide | 2.32e-01 |
| 2 | 61 | 100.0 | 9 | 1 Y01727 | Exemplary antigenic peptide | 2.32e-01 |
| 3 | 61 | 100.0 | 9 | 1 Y10633 | Peptide antigen SEQ ID | 2.32e-01 |
| 4 | 61 | 100.0 | 9 | 1 Y00685 | Tumour antigen booster | 2.32e-01 |
| 5 | 61 | 100.0 | 9 | 1 Y10424 | HLA Class I motif Pept | 2.32e-01 |
| 6 | 61 | 100.0 | 9 | 1 Y10623 | Peptide antigen SEQ ID | 2.32e-01 |
| 7 | 61 | 100.0 | 9 | 1 W54622 | Peptide from Mage-1 16 | 2.32e-01 |
| 8 | 61 | 100.0 | 9 | 1 R50281 | MAGE-1 nonapeptide. | 2.32e-01 |
| 9 | 61 | 100.0 | 9 | 1 R83932 | MHC class I restricted Antigen E peptide | 2.32e-01 |
| 10 | 61 | 100.0 | 9 | 1 R29769 | Human MAGE-1 Peptide b | 2.32e-01 |
| 11 | 61 | 100.0 | 9 | 1 W68371 | gp75/TRP-1 synthetic p | 2.32e-01 |
| 12 | 61 | 100.0 | 9 | 1 W77125 | Peptides-resistant peptide | 2.32e-01 |
| 13 | 61 | 100.0 | 9 | 1 W75734 | Human melanoma MAGE1 t | 2.32e-01 |
| 14 | 61 | 100.0 | 9 | 1 W00897 | Peptides-resistant peptide | 2.32e-01 |
| 15 | 61 | 100.0 | 9 | 1 W75736 | PB15 antigenic peptide | 2.32e-01 |
| 16 | 61 | 100.0 | 9 | 1 R82988 | Human leukocyte antigen | 2.32e-01 |
| 17 | 61 | 100.0 | 9 | 1 R90692 | MAGE-1 antigen part1 | 2.32e-01 |
| 18 | 61 | 100.0 | 9 | 1 W56729 | Melanoma antigen (MAGE | 2.32e-01 |
| 19 | 61 | 100.0 | 9 | 1 R75954 | MAGE-1 nonapeptide | 2.32e-01 |
| 20 | 61 | 100.0 | 9 | 1 R99343 | MAGE-1 protein fragment | 2.32e-01 |
| 21 | 61 | 100.0 | 9 | 1 W8838 | MAGE-1 immunogenic pep | 2.32e-01 |
| 22 | 61 | 100.0 | 9 | 1 R65112 | The Present invention describes peptides which bind to an HLA-A2 | 2.32e-01 |

Note: Post-processor removed 932 summaries from list due to search parameters chosen.

ALIGNMENTS

| | | |
|--------|------------------------------------|--|
| RESULT | 1 | Standard; peptide; 9 AA. |
| ID | W88945, | (first entry) |
| AC | W88945; | HLA-A1 binding peptide derived from MAGE-1. |
| DT | 08-MAY-1999 | HLA Class I motif Pept |
| DE | W88945 | MAGE-3 nonapeptide. |
| DE | R49122 | Peptide antigen SEQ ID |
| DE | W75942 | MAGE-41 nonapeptide. |
| DE | Y10603 | Peptide antigen SEQ ID |
| DE | R50281 | MAGE-41 nonapeptide. |
| DE | W88945 | MAGE-4 nonapeptide. |
| DT | 23-JUN-1997 | Peptide antigen SEQ ID |
| DR | 99-105609/09 | MAGE-4 nonapeptide. |
| PT | WIFI | Identify HLA-A2 positive cells and provoke T cells |
| PT | Example 7, Page 18, 45pp; English. | The Present invention describes peptides which bind to an HLA-A2 |
| PS | CC | |

CC molecule and have Val at the carboxy terminus, and either: (a) Ala, Tyr or Phe at the amino terminus, and Ala at position 2 (P1); or (b) Glu at the amino terminus, and Ala, Leu, or Met at positions 2 and 3, with the provision that Ala is not at both positions (P2). The peptides of the present invention are used to identify HLA-A2 positive cells, provoke T cells, and determine the presence of particular T cells including cytolytic T cells (CTLs). They provide a better target than the prior art CTL-stimulating peptide. The present sequence represents a peptide used in an example from the present invention.

Sequence 9 AA:
 Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT

ID Y01727 standard; Peptide; 9 AA.

AC 04-127;

DT 25-JUN-1999 (first entry)

DE Exemplary antigenic peptide derived from MAGE-1.

KW MAGE-3; tumour associated gene; human leucocyte antigen Class II;

KW autologous CD4+ cell; MAGE-3 related disease; cancer; melanoma;

KW osteosarcoma; leukemia; carcinoma.

OS Homo sapiens.

PN WO914346-A1.

PD 25-MAR-1999.

PE 04-SEP-1998; U188601.

PR 12-SEP-1997; US-948615.

PA (LUDWIG) LUDWIG INST CANCER RES.

CC (UYVR-) UNIV VRIJE BRUSSEL.

PI Boon-Falleur T, Chaux P, Corthals J, Heirman C,

PI Luitjen R, Stroobant V, Thielemans K, Van Der Bruggen P;

DR WPI: 99-244031/20.

PT Isolated peptides that bind to human leucocyte antigen class II

PT molecules

PS Disclosure: Page 27; 88pp; English.

CC The present sequence represents an exemplary tumour associated peptide

CC antigen. The specification describes a MAGE-3 tumour associated gene.

CC Peptides (Y01721-35) that bind human leucocyte antigen (HLA) Class II

CC molecules can be derived from the MAGE-3 protein. These peptides and

CC analogous CD4+ cells that bind to a complex of MAGE-3 peptide

CC and HLA Class II, are used to treat MAGE-3 related diseases,

CC particularly cancers (e.g. melanoma, osteosarcoma, leukemia and

CC various forms of carcinoma). The peptides are also used to produce

CC specific antibodies. Detection of the peptides, e.g. in binding

CC assays, particularly with antibodies, is used for diagnosis of such

CC diseases.

CC Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT

ID Y10633 standard; Peptide; 9 AA.

AC Y10633;

DT 12-MAY-1999 (first entry)

DE Peptide antigen SEQ ID NO:563.

KW Cytotoxic T-lymphocyte response; CTL; antigen; lymphatic system;

KW immunisation; tumour; infectious disease; immunotherapy; cancer;

KW malignant melanoma; viral disease; hepatitis; AIDS.

OS Synthetic.

OS Homo sapiens.

WO9902183-A2.

PN 21-JAN-1999.

PD 10-TUL-1998; U14289.

PF 10-DEC-1997; US-988320.

PR 10-TUL-1997; CA-299815.

PA (CTLI-) CTL IMMUNOTHERAPIES CORP

PA Kuendig TM, Simard JJL;

DR WPI: 99-12054/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level

PT of antigen in the lymphatic system of a mammal so as to provide a

PT sustained CTL response, used to treat, e.g. AIDS

PS Disclosure: Page 52; 199pp; English.

The present invention describes a method of inducing and/or sustai

an immunological cytotoxic T lymphocyte (CTL) response in a mammal.

CC The method comprises: (a) delivering an antigen to the mammal at a level

CC to induce an immunological CTL response in the mammal; and (b) maintaining

CC the level of the antigen in the mammal's lymphatic system to maintain

CC the immunologic CTL response. The method can be used for the delivery of

CC e.g. a differentiation antigen, a tumour-specific multilineage antigen,

CC an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor

CC gene antigen, or a viral antigen. They can be used for the treatment

CC of disease such as cancer, e.g. malignant melanoma or infectious disease

CC e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery

CC to the lymphatic system provides for potent CTL stimulation that take

CC place in the milieu of the lymphoid organ, and it sustains stimulati

CC that is necessary to keep CTL active, cytotoxic and recirculating

CC through the body. Y10071 to Y10639 represent examples of peptide

CC antigens given in the present invention.

SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01;

Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT

ID Y00685 standard; peptide; 9 AA.

AC Y00685;

DT 12-MAY-1999 (first entry)

DE Tumour antigen booster Peptide MAGE-1 HLA-A1.

KW tumour antigen; booster peptide; immune response modulation; allergy;

KW immune response enhancer; tumour cell; tumour rejection antigen;

KW leukocyte antigen-presenting molecule; autoimmune disease;

KW allograft rejection.

OS Homo sapiens.

PN WO9856956-A2.

PD 30-DEC-1998.

PR 19-JUN-1997; U12894.

PA (LUDWIG) LUDWIG INST CANCER RES.

PI Bon-Rallent T, Uttenhove C, Warnier G;

DR WPI: 99-105612/09.

PT Immunization methods using viruses expressing antigen for priming

PT and booster immunizations - useful for modulating immune responses

PT against antigen, e.g. enhancing immune response against tumour cells

PT expressing tumour rejection antigens.

PS Claim 3; Page 9; 33pp; English.

CC This sequence represents a tumour antigen booster Peptide that can be

CC used in the method of the invention. The method is for modulating an

CC immune response in a mammal against an antigen, and comprises:

CC (A) inducing an immune response by: (i) administering a virus containing

CC a nucleic acid molecule encoding the antigen or its precursor to generate

CC an immune response; and (ii) administering at least one booster dose

CC comprising peptide including the antigen, in an adjuvant, in a combined

CC amount effective to enhance the initial immune response; or

CC (B) reducing an immune response as defined for (A) but using an amount

CC non-adjuvant with the peptide which includes the antigen, in an amount

CC effective to reduce the initial immune response. Method (A) is used to

CC enhance the immune response against tumour cells expressing tumour

rejection antigens, and against pathogens in subjects having human CC leucocyte antigen presenting molecules. Method (B) is used to reduce the CC immune response in allergy, autoimmune disease, and allograft rejection. CC Method (A) provides an immunisation method which, unlike prior art, is CC not limited by the host immune response against viral vectors.

Sequence 9 AA;

Query Match 100.0% Score 61; DB 1; Length 9;

Best Local Similarity 100.0% Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EADPTGHSY 9

RESULT 5
ID Y10424 standard Peptide: 9 AA.

AC Y10424; 12-MAY-1999 (first entry)

DE HLA Class I motif peptide SEQ ID NO:354.

CC Cytoxic T-lymphocyte response; CTL; antigen; lymphatic system;

KW immunisation; tumour; infectious disease; immunotherapy; cancer;

KW malignant melanoma; viral disease; hepatitis; AIDS.

OS Synthetic.

OS Homo sapiens.

PN WO9902183-A2.

PI Kuendig TM, Simard JJJ;

PR WPI; 99-120514/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level

of antigen in the lymphatic system of a mammal so as to provide a

PT sustained CTL response, used to treat, e.g. AIDS

PS Disclosure: Page 39; 199pp; English.

CC The present invention describes a method of inducing and/or sustaining

an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The

method comprises: (a) delivering an antigen to the mammal at a level to

induce an immunological CTL response in the mammal; and (b) maintaining

the level of the antigen in the mammal's lymphatic system to maintain

the immunologic CTL response. The method can be used for the delivery

e.g. a differentiation antigen,

an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor

gene antigen, or a viral antigen. They can be used for the treatment

of disease such as cancer, e.g. malignant melanoma or infectious disease

e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery

to the lymphatic system provides for potent CTL stimulation that takes

place in the milieu of the lymphoid organ, and it sustains stimulation

that is necessary to keep CTL active, cytotoxic and recirculating

through the body. Y10071 to Y10639 represent examples of Peptide

Sequence 9 AA;

Query Match 100.0% Score 61; DB 1; Length 9;

Best Local Similarity 100.0% Pred. No. 2.32e-01;

Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 EADPTGHSY 9

RESULT 6
ID Y10623 standard Peptide: 9 AA.

AC Y10623; 12-MAY-1999 (first entry)

DE Peptide antigen SEQ ID NO:553.

CC Cytoxic T-lymphocyte response; CTL; antigen; lymphatic system;

KW immunisation; tumour; infectious disease; immunotherapy; cancer;

KW malignant melanoma; viral disease; hepatitis; AIDS.

OS Synthetic.

OS Homo sapiens.

PN WO9902183-A2.

PI Kuendig TM, Simard JJJ;

PR WPI; 99-120514/10.

PT Inducing a cytotoxic T lymphocyte response - by maintaining a level

of antigen in the lymphatic system of a mammal so as to provide a

PT sustained CTL response, used to treat, e.g. AIDS

PS Disclosure: Page 51; 199pp; English.

CC The present invention describes a method of inducing and/or sustaining

an immunological cytotoxic T lymphocyte (CTL) response in a mammal. The

method comprises: (a) delivering an antigen to the mammal at a level to

induce an immunological CTL response in the mammal; and (b) maintaining

the level of the antigen in the mammal's lymphatic system to maintain

the immunologic CTL response. The method can be used for the delivery

e.g. a differentiation antigen,

an embryonic antigen, an oncogene antigen, a mutated tumour-suppressor

gene antigen, or a viral antigen. They can be used for the treatment

of disease such as cancer, e.g. malignant melanoma or infectious disease

e.g. viral disease such as hepatitis or AIDS. Sustained antigen delivery

to the lymphatic system provides for potent CTL stimulation that takes

place in the milieu of the lymphoid organ, and it sustains stimulation

that is necessary to keep CTL active, cytotoxic and recirculating

through the body. Y10071 to Y10639 represent examples of Peptide

Sequence 9 AA;

Query Match 100.0% Score 61; DB 1; Length 9;

Best Local Similarity 100.0%; Pred. No. 2.32e-01; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
AC |||||||
QY 1 EADPTGHSY 9

RESULT 8
JD R50281; standard; Protein; 9 AA.
AC R50281;
DT 26-SEP-1994 (first entry)
DE MAGE-1 nonapeptide.
KW nonapeptide; cancer; melanoma; breast cancer; HLA;
KW histocompatibility; human leucocyte antigen; probe; treatment;
KW therapy; vaccine.
OS Synthetic.

PN W940304.A.
PD 17-MAR-1994.
PF 30-AUG-1993; U08157.
PR 31-AUG-1992; US-93834.
PR 26-MAR-1993; US-037230.
PA (LUDWIG) LUDWIG INST CANCER RES.
PI Bon-Dalleur T, De Plaein E, Lurquin C, Traversari C;
Van Derbruggen P;
DR WPI: 94-108844/1-2.
DR N-PSDD: Q44751.
PT New nonapeptide derived from tumour rejection antigen precursor
- presented by HLA-A1 cancer cells, for use in diagnosis or
therapy of esp. melanoma and breast cancer.
PS Disclosure; Page 19; 33pp; English.
CC An isolated nonapeptide having the amino acid sequence Glu-Val-Asp-
Pro-Ile-Gly-His-Leu-Tyr is derived from the tumour rejection antigen
precursor encoded by the MAGE-3 gene and present by HLA-A1. The
nonapeptide can be used in a vaccine to treat a cancerous condition
involving HLA-A1 subtype cancerous cells. The nucleic acid encoding
the nonapeptide can be used as a probe to identify tumour cells.
CC This sequence is homologous to the peptide described and is encoded
by the MAGE-1 gene.
SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01; Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
AC |||||||
QY 1 EADPTGHSY 9

RESULT 9
ID R83932 standard; peptide; 9 AA.
AC R83932;
DT 05-JUN-1996 (first entry)
DE MHC class I restricted antigenic Peptide #2.
KW MHC class I; antigen; MAGE; melanoma; breast cancer; bladder cancer;
KW Tittermax; Cytotoxic T-lymphocyte; tumour; Pathogenic disease; bacteria;
KW parasite; human; animal.
OS Synthetic.

PN W0952958-A1.
PD 02-NOV-1995.
PF 21-APR-1995; U01975.
PR 22-APR-1994; US-233496.
PA (SLOK) SLOAN KETTERING INST CANCER RES.
PI Dyall R, Nikolic-Zugic J;
DR WPI: 95-38848/49.
PT Cytotoxic T-cell induction by MHC class I-restricted peptide in
pathogenic diseases
PT Adjacent - useful for treating tumours and bacterial or parasitic
pathogenic diseases
PS Claim 11; Page 38; 50PP; English.
CC The sequences given in R83931-49 are MHC class I restricted 8-12
amino acid antigenic peptides. This peptide is derived from MAGE

and is present in melanoma, breast and bladder cancer. These peptides may be administered to a subject in combination. These peptides may be used in the treatment of a tumour or a pathogenic disease, esp. diseases of bacterial or parasitic origin, in humans and animals, e.g. monkeys, dogs, cows, horses, etc.

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
QY 1 EADPTGHSY 9

RESULT 10
ID R27769 standard; peptide; 9 AA.
AC R27769;
DT 22-APR-1993 (first entry)
DE Antigen E peptide.
KW Antigen; tumorigenic cell; A+ B+; T-cell; response; syngeneic;
KW animal; mouse; tumour rejection antigen precursor; TRAP; PLA;
OS Homo sapiens.
PN WO20336-A.
PD 26-NOV-1992.
PF 22-MAY-1992; U04354.
PR 23-MAY-1991; US-764364.
PR 09-JUL-1991; US-728838.
PR 23-SEP-1991; US-764364.
PR 12-DEC-1991; US-807043.
PA (LUDWIG) LUDWIG INST CANCER RES.
PI Boon T, Chomez P, De Plaein E, Lurquin C, Traversari C;
PI Van Den Bynden B, Van Der Bruggen P, Van Pel A;
DR WPI: 92-415160/50.
PT Nucleic acid mol. encoding a human tumour rejection antigen
precursor - useful as an immunostimulant in a vaccine for
treating and preventing cancers; also useful in diagnosis
PS Disclosure; Page 9; 142pp; English.
CC This sequence represents the sequence of the antigen E. Antigens such
as this one cause a T-cell response to be elicited which transplanted
CC into a syngeneic animal, usually a mouse. This antigen is derived from
CC the cell line MEL3.1. See also Q32351.
SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
AC |||||||
QY 1 EADPTGHSY 9

RESULT 11
ID W68371 standard; peptide; 9 AA.
AC W68371;
DT 14-OCT-1998 (first entry)
DE Human MAGE-1 Peptide binds HLA-A1.
KW Antigen; major histocompatibility complex; MHC; lymphocyte; detection
KW immobilization; cytotoxic T-cell; tumour; leukaemia; lymphoma;
OS Synthetic.
OS Homo sapiens.
PN W0944657-A2.
PD 27-NOV-1997.
PF 21-MAY-1997; F00892.
PR 21-MAY-1996; US-051925.
PA (INRM) INSEM INST NAT SANTE & RECH MEDICALE.
PA (INSP) INST PASTEUR.
PI Abastado J, Kourilsky P, Langlade-Demoyen P, Lone Y;
DR WPI: 96-018653/02.

PT Detection, purification and elimination of antigen-specific lymphocytes - for producing cytotoxic T cells for immuno-therapy of cancers and viral infection
 PT Disclosure; Page 30; 22pp; French.
 PS Peptides W68301-W68384 are examples of antigens (Ag) which can be loaded onto recombinantly produced major histocompatibility complex (MHC) molecules in a method of detecting antigen-specific lymphocytes. The MHC-antigen complex is then immobilised on a solid support and a sample containing cells recognising the MHC-Ag complex may be isolated. This peptide is derived from the human MAGE-1 protein and binds the human leukaocyte antigen A1 (HLA A1). A similar method is used to isolate, purify or eliminate Ag-specific T-cells or to produce Ag-specific cytotoxic T-cells (CTL). The method is also used to detect and quantify tumour-specific T-cells and to generate CRC for specific killing of tumour cells (solid tumours, leukaemia or lymphoma) by injection into a human or animal, but also for treating viral infections.

SQ Sequence 9 AA;

| | | | |
|------------------------------|---------------------|---------------|-----------|
| Query Match | Score 61; | DB 1; | Length 9; |
| Best Local Similarity 100.0% | Pred. No. 2.32e-01; | Indels 0; | Gaps 0; |
| Matches 9; | Conservative 0; | Mismatches 0; | Gaps 0; |

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 12
 ID W7125 standard peptide; 9 AA.
 AC W77125;
 DT 16-NOV-1998 (first entry)
 DE 9P75/FRP-1 synthetic peptide 1.

PA (UYVI-)UNIV VIRGINIA PATENT FOUND.
 PI Engelhardt VH, Hunt DF, Kettlesen D, Slingluff CL,
 DR 98-437388/37.
 PT Disease specific immunogen - comprises disease specific cytotoxic T lymphocyte epitope used to elicit melanoma specific CTL response
 PS Disclosure; Page 27; 93pp; English.

The peptide epitope W7119-W7138 were created for human tumour-specific cytotoxic T lymphocyte response. These peptides are are cysteine-depleted mutants of a native disease-specific CTL epitope. The cysteine-depleted CTL epitopes elicit a stronger or more specific CTL response than the native epitope. The epitopes can be used in a disease-specific immunogen to protect a mammal against disease in particular melanomas. The peptides may also be used to screen a sample for the presence of an antigen with the same epitope, or with a different cross-reactive epitope.
 SQ Sequence 9 AA;

| | | | |
|------------------------------|---------------------|---------------|-----------|
| Query Match | Score 61; | DB 1; | Length 9; |
| Best Local Similarity 100.0% | Pred. No. 2.32e-01; | Indels 0; | Gaps 0; |
| Matches 9; | Conservative 0; | Mismatches 0; | Gaps 0; |

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 13
 ID W75734 standard; peptide; 9 AA.
 AC W75734;
 DT 19-NOV-1998 (first entry)

PS Peptidase-resistant peptide 2.
 PA Tumour antigen M22-E; T-cell; immunotherapy; cytolytic T-cell; CTL, therapeutic agent; peptidase; M22-E antigen peptide analogue; HLA; human leucocyte antigen; MHC; lysis; vaccine.

OS Synthetic. Location/Qualifiers
 FH Key
 FT Misc_difference 2 /note= "D-form residue"
 FT Misc_difference 8 /note= "D-form residue"
 FT WO9833511-A1.
 PD 06 AUG-1998.
 PF 19 NOV-1997; U21295.
 PR 05 FEB-1997; US-75733.
 PA (CNRS) CENT NAT RECH SCI.
 PA (LUDW-) LUDWIG INST CANCER RES.
 PI Ayoub N, Gairin JE, Mazarguil H, Monsarrat B, Van Den Eynde B;
 DR WPI; 98-437166/37.
 PT Peptidase-resistant peptide(s) that bind to HLA molecules and related antibodies - particularly for treatment of cancer by inducing proliferation of cytotoxic T cells
 PS Claim 20; Page 20; 32pp; English.
 CC Sequences W75733-W75736 are peptidase-resistant peptides which are analogues of the tumour antigen M22-E. This antigen is a potential target for T-cell based immunotherapy and can also be used to stimulate the antigen-specific CTL, however its use as a therapeutic agent is limited due to its degradation by peptidase. The M22-E antigen peptide analogues were modified at both peptidase sensitive portions, and were all shown to exhibit a longer half-life relative to peptidase degradation as well as the ability to bind a human leucocyte antigen (HLA). The specific peptides W75733 and W75735 were established to have a comparable affinity for the MHC as the tumour antigen, and W75735 was found to be the ideal peptide analog to use due to it also being able to sensitize the target cells to lysis by effector molecules at similar concentrations to those of the antigen M22-E. These peptide analogues can be used in vaccines to induce an immune response for treating conditions in which abnormal HLA-peptide complexes are present on the surface of cells.
 SQ Sequence 9 AA;

| | | | |
|------------------------------|---------------------|-----------|-----------|
| Query Match | Score 61; | DB 1; | Length 9; |
| Best Local Similarity 100.0% | Pred. No. 2.32e-01; | Indels 0; | Gaps 0; |
| Matches 9; | Mismatches 0; | Indels 0; | Gaps 0; |

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

RESULT 14
 ID W00897 standard; Peptide; 9 AA.
 AC W00897;
 DT 23-MAY-1997 (first entry)
 PA Human melanoma MAGE1 tumour associated antigen p161-169.
 PI Adeno-associated virus vector; liposome; transfection;
 DR dendritic cell; melanoma; MAGE1; adoptive immunotherapy;
 KW tumour associated antigen.
 OS Homo sapiens.
 PN W009703703-A1.
 PD 06 FEB-1997.
 PR 19-JUL-1996; U12012.
 PR 21-JUL-1995; US-001312.
 PR 01-NOV-1995; US-007184.
 PR 01-DEC-1995; US-566286.
 PA (RION) RHOE POULENC RORER PHARM INC.
 DR Lebkowski JS; Philip R;
 PT Adeno-associated virus:liposome complexes for transfecting dendritic cells - for inducing immune response, useful for treating e.g. neoplasia or infections
 PS Example 5; Page 58; 134pp; English.
 CC Tumour associated antigens (W13660-61, W00878-903) can be loaded into dendritic cells and used to induce antitumour immunity.
 CC Alternatively, the dendritic cells are transfected with adeno
 CC associated virus plasmid DNA (which includes DNA encoding the tumour associated antigen), complexed with cationic liposomes. The CC antigen loaded or transfected dendritic cells can be used to generate tumour antigen-specific cytotoxic T lymphocytes for use in

CC adoptive immunotherapy in a patient having the corresponding tumour. A suitable antigen comprises amino acids 161-169 (W008997)
 CC of human melanoma MAGE1.
 SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy |||||||
 1 EADPTGHSY 9

RESULT 15

ID W75736 standard; peptide; 9 AA.

AC W75736;
 DT 19-NOV-1998 (first entry)
 DE Peptidase-resistant peptide 4.
 DE Tumour antigen M22-E; T-cell; immunotherapy; cytolytic T-cell; CTL;
 KW therapeutic agent; Peptidase; M22-E antigen peptide analogue; HLA; lysis; vaccine.
 KW human leucocyte antigen; MHC; lysis; vaccine.
 OS Synthetic.

FH

Key Location/Qualifiers

FT Modified_site 2 /note= "N-Methyl-Alanine"

FT Modified_site 8 /note= "N-Methyl-Serine"

FT PN W0983511-A1.

PD 06-AUG-1998.

PR 05-FEB-1997; US-795733.

PA (CNRS) CENT NAT RECH SCI.

(LUDW-) LUDWIG INST CANCER RES.

PI Ayoub, M., Gairin, JE., Mazarquil, H., Monsarrat, B., Van Den Eynde, B;

WP, 98-43716/6-37.

Peptidase-resistant peptide(s) that bind to HLA molecules and related antibodies - particularly for treatment of cancer by inducing proliferation of cytotoxic T cells

Claim 20; Page 20; 32pp; English.

Sequences W75733-W75736 are peptidase-resistant peptides which are analogues of the tumour antigen M22-E. This antigen is a potential target for T-cell based immunotherapy and can also be used to stimulate the antigen specific CTL, however its use as a therapeutic agent is limited due to its degradation by peptidase. The M22-E antigen peptide analogues were modified at both peptidase sensitive portions, and were all shown to exhibit a longer half-life relative to peptidase degradation as well as the ability to bind a human leucocyte antigen (HLA). The specific peptides W75733 and W75735 were established to have a comparable affinity for the MHC as the tumour antigen, and W75735 was found to be the ideal peptide analog to use due to it also being able to sensitise the target cells to lysis by effector molecules at similar concentrations to those of the antigen M22-E. These peptide analogues can be used in CC to induce an immune response for treating conditions in which abnormal HLA/peptide complexes are present on the surface of cells.
 Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

SQ

1 EADPTGHSY 9

Qy |||||||

1 EADPTGHSY 9

CC adoptive immunotherapy in a patient having the corresponding tumour. A suitable antigen comprises amino acids 161-169 (W008997)
 CC of human melanoma MAGE1.
 SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy |||||||

1 EADPTGHSY 9

WO9523874-A1.

PN 08-SEP-1995; U02203.
 PD 23-FEB-1995; US-209172.
 PF 01-MAR-1994; US-204727.
 PR 10-MAR-1994; US-209172.
 PR 01-SEP-1994; US-239849.
 PR 30-NOV-1994; US-346774.
 PA (LUDW-) LUDWIG INST CANCER RES.

PI Bon-Falleur, T., Brassier, F., Chomez, P., De Plaein, E.;
 PI De Smet, C., Gauguer, B., Lethe, B., Marchand, M., Patard, J.;
 PI Szklora, J., Van Den Eynde, B., Van Derbruggen, P., Weynants, P.;
 DR WPI; 95-320586/41.
 PT Determn. of cancerous condition(s) - using a nucleic acid as a PT primer to determine expression of a MAGE tumour rejection antigen PT precursor.

PT Example 13; Page 22; 121pp; English.
 PS Using the sequence of the P815 antigen precursor gene PIA
 CC (TU01176), an antigenic Peptide (R82988) which was A+B+ (i.e. characteristic of cells which express both A and B antigens) was produced. The peptide lysed PO-HTR cells in the presence of cytolytic T lymphocyte cell lines, and may be useful as a vaccine component.

CC Sequence 9 AA;
 SQ

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 17

ID R90632 standard; peptide; 9 AA.

AC R90632; (first entry)
 DT 31-JUL-1996 Human leukocyte antigen (HLA-A1) presented Peptide M22-E.
 DE Human leukocyte antigen; HLA-A1; MAGE-1 derived;
 KW blood mononuclear cell; BMC; CD8-beta+ cell; cytolytic T cell;
 KW CTL cell; treatment; tumour cell; diagnosis; assay;
 KW presented peptide.

OS Synthetic.
 PN W0955500-A1.

PT 28-DEC-1995. PR 14-JUN-1995; U07559.
 PA (LUDW-) LUDWIG INST CANCER RES.

PI Bon-Falleur, T., Coulier, P., Van Der Bruggen, P.;
 DR WPI; 96-058510/06. PT Prod'n. of specific cytolytic T cell sub-populations - by contacting CC blood mononuclear cells with specific peptide(s) and a population of CC CD8-beta+ cells
 PT Claim 5; Page 19; 25pp; English.
 CC The present peptide is the human leucocyte antigen (HLA-A1), MAGE-1 CC derived presented Peptide, M22-E. By contacting a sample of blood CC mononuclear cells (BMC) with the peptide (which binds directly to CC HLA-A1 mols. on the surface of the BMC) and CD8-beta+ cells (which CC stimulate peptide/HLA-A1 complex specific cytolytic T (CTL) cell CC subpopulation can be obt'd. The CTL cells obt'd. can be administered CC to a patient to treat tumour cell related conditions, CC and can be used in diagnostic methods, e.g. in assays for the CC peptide/HLA-A1 complex.

PS Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 16

ID RB298 standard; Peptide; 9 AA.
 AC RB2988; (first entry)
 DT 26-FEB-1996

DE PB15 antigenic Peptide.

KW PB15 antigen; PIA antigen; cancer; vaccine.
 OS Synthetic.

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9

Qy 1 EADPTGHSY 9

RESULT 18
 ID W56729; standard peptide; 9 AA.
 AC W56729;
 DT 31-JUN-1998 (first entry)
 DE MAGE-1 antigenic partial Peptide sequence (residues 161-169).
 KW MAGE; replication defective; adenovirus; tumour; antigen; cancer;
 KW immunotherapy; tumour rejection antigen; HLA; cytotoxic T lymphocyte.
 OS Synthetic.
 PN W09815638-A2.
 PD 16-APR-1998.
 PF 06-OCT-1997; U11948.
 PA (LUDW.) LUDWIG INST CANCER RES.
 PI Cerrotti J, Jongeneel CV, Reed DS, Rimoldi D,
 PI Romero P;
 DR WPI; 98-240824/21.
 PT New replication defective adenoviruses - comprise insert encoding
 PT tumour rejection antigen Precursor(s), useful for, e.g. cancer
 PT immuno-therapy
 Examples: Page 42; 56PP; English.
 This is a partial sequence of the MAGE-1 antigenic peptide used in the
 methods of the invention. The specification provides a new nucleic acid
 molecule comprising a replication defective adenovirus genome containing
 an insert encoding a tumour rejection antigen precursor (TRAP). The
 replication defective adenovirus genome is useful as a vector for
 introducing a TRAP molecule into mammalian (especially human) cells. The
 recombinant adenovirus is preferentially targeted to tumour cells, e.g. by
 binding a ligand to the virus coat. The TRA peptides which are generated
 from the expressed TRAP are presented by human leukocyte antigen (HLA)
 molecules and as a result cytolytic T lymphocyte (CTL) production is
 increased (claimed). The CTL's then kill the TRAP-expressing tumour
 cells. Also, cells transfected by the recombinant adenovirus can be used
 for assessing the processing of TRAs, including post-translational
 modifications. The adenovirus (genome) can be administered by injection,
 topical application or intracavicularly in 106-1010 pfu doses. The range
 of TRA peptides produced by replication defective adenovirus means that
 patients with a range of HLA phenotypes can be treated. Also, host cell
 immune response to TRA's is enhanced, e.g. by induction of tumour-
 specific cytolytic T lymphocytes.
 Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 BADPTGHSY 9
 |||||||
 Qy 1 BADPTGHSY 9

RESULT 19
 ID R75942; standard peptide; 9 AA.
 AC R75942;
 DT 06-MAR-1996 (first entry)
 DE Melanoma antigen (MAGE-1) epitope.
 KW MAGE-1; melanoma antigen; vaccine; immune response; immunogenic peptide;
 KW cytotoxic T lymphocyte response; CTL; melanoma; breast cancer; antibody.
 OS Homo sapiens.
 PN W09511783-A1.
 PD 25-JAN-1995; U01000.
 PR 25-JAN-1994; US-186266.
 PA (CYTE) CYTEL CORP.
 PI Celis E, Grey HM, Kubo RT, Sette A;
 DR WPI; 95-269270/35.
 PT Immunogenic peptide(s) that induce immune response to cancer cells
 - that express a MAGE-3 protein peptide epitope used in vaccines or
 PT adoptive immuno-therapy to induce cytotoxic T lymphocytes
 Examples: Page 33; 44PP; English.
 R75942, is derived from MAGE-1 protein. It was used to show the

CC specificity of CTL response to MAGE-3 peptides shown in R75942-53.
 CC R75942 is derived from the sequence of the melanoma antigen (MAGE-3).
 CC Protein and can be used to elicit a primary cytotoxic T lymphocyte
 response against cells expressing MAGE-3. Synthetic Peptides R75945-5
 CC can be used therapeutically to elicit CTL responses to melanoma, breast
 CC colon, prostate, or other cells which express proteins with this epitope.
 CC The peptides have specific HLA-A1 binding capacity.
 SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 BADPTGHSY 9
 |||||||
 Qy 1 BADPTGHSY 9

RESULT 20
 ID R99443 standard; protein; 9 AA.
 AC R99443;
 DT 22-APR-1997 (first entry)
 DE MAGE-1 nonapeptide.
 KW HLA binding Peptide; cell lysis; cytolytic T cell; MAGE family; human
 KW tumour rejection antigen Precursor; TRA; MAGE-1; tumour; cancer cell;
 KW antibody; melanoma; universal effector cell; vaccine; breast cancer; CTL;
 KW therapy.
 OS Homo sapiens.
 PN W0922621-A1.
 PD 29-AUG-1996;
 PF 01-FEB-1996; U01489.
 PR 23-FEB-1995; US-333273.
 PA (LUDW.) LUDWIG INST CANCER RES.
 PI Bon-Falleur T, De Plaein E, Gaugler B, Lurquin C;
 PI Romao P, Traversari C, Van Den Eynde B, Van Der Bruggen P;
 DR WPI; 96-402317/40.
 DR N-PDB; T35408.

PT New nonapeptide(s) that bind to HLA molecule(s) and induce lysis
 PT by specific cytolytic T cells, for diagnosis and treatment of
 PT tumours and to expand T cells in vitro.
 Example 4; Fig 4; 11PP; English.
 PS R99433-R99350 represent MAGE nonapeptides, based on the tumour reject on
 CC antigen region of the full length MAGE sequences. These peptides were
 CC used to design the nonapeptides of the invention (see R99337-R99342),
 CC which bind to a HLA molecule on a cell, and provoke lysis by cytolytic T
 CC cells (CTLs) specific for a complex of the HLA molecule and nonapeptide.
 CC The nonapeptides can be used diagnostically to identify tumours. Tum
 CC cells can also be used therapeutically, or to identify cancer cells. T
 CC peptides can also be used therapeutically, to induce a CTL response to
 CC tumours (where the peptides are optionally coupled to tumour-specific
 CC antibodies), or to induce a response by CTLs that are otherwise inactive.
 CC The peptide sequences may also be used to expand specific CTLs in vitro.
 CC for later return to the patient, such as for treating melanoma. Tumo
 CC cells can be identified by using DNA encoding the nonapeptides as probes.
 CC Non-human cells transformed with the HLA-A1 gene and a DNA sequence
 CC encoding one of the peptides, can be used to generate CTLs, or to deb ct
 CC the presence of CTLs in human samples. The non-human transformed cel
 CC when polytransfected, are universal effector cells, and can be used 1
 CC vaccines, or for treating melanoma or breast cancer.
 SQ Sequence 9 AA;

Query Match Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 BADPTGHSY 9
 |||||||
 Qy 1 BADPTGHSY 9

RESULT 21
 ID W79838 standard; peptide; 9 AA.
 AC W79838;

DT 17-NOV-1998 (first entry)
DE MAGE-1 protein fragment 161-169.
KW Microparticle; delivery; Polymeric matrix; autoantigen; tumour antigen;
KW class II associated peptide; Pathogen; gene therapy; genetic disease;
KW infection; downregulation; immune response.
OS Homo sapiens.
OS Synthetic.
PN WO983198-A1.
PD 23-JUL-1998; U01499.
PF 22-JAN-1998; US-003253.
PR 22-JAN-1997; US-787547.
PA (PANG-) PANGAEA PHARM INC.
Curley JM, Hedley ML, Langer RS, Lumsford LB;
WPI; 98-427556/36.
DR New preparations of microparticiles - comprising a synthetic polymer
PT matrix and nucleic acid comprising an expression vector for use in
PT gene therapy.
PS Disclosure: Page 10: 101pp; English.
CC A microparticle preparation (MP) has been developed, consisting of
CC microparticles having a diameter of less than 100 μm. The MP comprises:
CC (a) a polymeric matrix (PM) consisting of one or more synthetic polymers
CC having a solubility in water of less than 1 mg/ml; and (b) an expression
CC vector selected from RNA molecules (at least 50% of which are closed
CC circles) or circular plasmid DNA (at least 20 microns in diameter) comprising: (a)
CC also described is a MP of at most 20 microns in diameter comprising: (a)
CC a PM; and (b) a NAM comprising an expression control sequence operatively
CC linked to a coding sequence, where the coding sequence encodes at least 7 amino
CC acids in length, having a sequence identical to the sequence of: (i) a
CC fragment of a naturally-occurring mammalian protein; or (ii) a fragment
CC of a naturally-occurring protein from an infectious agent which infects
CC a mammal; (2) a peptide having a length and sequence which permits it to
CC bind to an MHC class I or II molecule; and (3) the polypeptide or the
CC peptide linked to a trafficking sequence, W6963 to W6965, and W7873
CC to W7887 are peptide fragments for use in the present invention. The
CC MPs are highly effective vehicles for the delivery of polynucleotides
CC into phagocytic cells. They can be used for gene therapy, e.g. for
CC treating genetic diseases, infections or tumours or for downregulating
CC an immune response.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Gaps 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 22
ID R65112 standard; peptide; 9 AA.
R65112-1995.
DT 06-OCT-1995 (first entry)
PA MAGE 1 immunogenic peptide 161-169.
KW MAGE 1; immunogenic peptide 161-169; cytotoxic C cells;
KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
KW fungal infections; tuberculosis; hepatitis.
OS Homo sapiens.
PN WO950481-A.
PD 16-FEB-1995.
PF 01-AUG-1994; U08672.
PR 06-AUG-1993; US-103401.

PA (CYTE-) CYTEL CORP.
Cellis E, Kubo R, Serra H, Tsai V, Wentworth P;
WPI; 95-090895/12.
DR In vitro activation of cytotoxic T cells for selected killing of
PT target cells - for treating e.g. cancer, AIDS, hepatitis etc. by
PT incubating them with antigen presenting cells loaded with
PT appropriate immunogenic peptide
PS Example 3; Page 35; 59PP; English.
CC R65109-R65145 are immunogenic peptides, they are used in a new

method for the in vitro activation of cytotoxic T cells (CTC).
CC This is achieved by incubating the CTCs with antigen presenting
CC cells loaded with an appropriate immunogenic peptide (e.g. one
CC of the above peptides). By selecting the peptides used the
CC following diseases and infections can be treated; cancer, AIDS,
CC hepatitis, other viral and bacterial infections, malaria and
CC tuberculosis.
CC Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Gaps 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 23
ID R63675 standard; Protein; 9 AA.
AC R63675;
DT 22-JUN-1995 (first entry)
DE Synthetic peptide derived from exon 3.1 of MAGE 1.
KW Melanoma antigen-1; MAGE-1; cytolytic T cells; antigen E; exon 3.1.
OS Synthetic.
PN WO923031-A.
PD 13-OCT-1994.
PF 17-MAR-1994; U02877.
PR 26-MAR-1993; US-037230.
PA (LUDWIG INST CANCER RES.
PI Boon falleur E, Gaugier B, Van DER BRUGGEN P;
DR WPI; 94-3319241.
PT New tumour refection antigen precursor MAGB3 - useful in
PT treatment and diagnosis of cancer.
PS Example 34; Page 36; 105PP; English.
CC R63675 is a synthetic peptide derived from exon 3.1 of melanoma
CC antigen-1 (MAGE-1), it was used to transfer antigen E cytolytic T
CC lymphocyte sensitivity to normally non-sensitive cells.
SQ Sequence 9 AA;

Query Match 100.0%; Score 61; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 2.32e-01;
Matches 9; Conservative 0; Gaps 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
Qy 1 EADPTGHSY 9

RESULT 24
ID R78024 standard; peptide; 9 AA.
AC R78024;
DT 26-MAR-1996 (first entry)
DE MAGE 1 cytotoxic T lymphocyte epitope.
KW MAGE 1; cytotoxic T; CTL; epitope; helper T; HIV; lymphocyte;
KW cell; viruses; parasites; tumours; antigens; disease prevention;
KW treatment.
OS Homo sapiens.
PN WO9522317-A1.
PD 24-AUG-1995.
PF 16-FEB-1995; U02121.
PR 16-FEB-1994; US-191484.
PA (CYTE-) CYTEL CORP.
PI Cellis E, Chestnut RW, Grey H, Sette AD, Vitiello MA;
DR WPI; 95-302545/39.
PT Compon. inducing cytotoxic T lymphocyte response to pref. viral,
PT bacterial, parasitic or tumour antigens - useful in the treatment
PT and prevention of diseases associated with the antigen e.g.
PT hepatitis B.
PS Disclosure: Page 17; 109PP; English.
CC A compsn. which induces a cytotoxic T lymphocyte (CTL) response to
CC an antigen (Ag) in a mammal comprises, a CTL Ag response inducing
CC peptide (i.e. R78824-R78853) and a lipid conjugated helper T cell

CC inducing peptide. The compsn. induces a CTL response to bacterial,
 CC viral or tumor Ags and is therefore useful in the treatment and
 CC prevention of diseases associated with the Ag.
 Sequence 9 AA;

Query Match 25 Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
 KW fungal infections; tuberculosis; hepatitis; hepatitis.
 OS Homo sapiens.
 PN WO950817-A.

RESULT 25 ID R65135; standard; peptide; 9 AA.
 AC R65135;
 DT 09-OCT-1995 (first entry)
 DE MAGE 1 immunogenic Peptide A01.
 PR MAGE 1; Immunogenic peptide A01; cytotoxic C cells;
 KW in vitro activation; cancer; AIDS; bacterial infections; malaria;
 KW hepatitis; hepatitis; tuberculosis; hepatitis; hepatitis.
 PT In vitro activation of cytotoxic T cells for selected killing of
 target cells - for treating e.g. cancer, AIDS, hepatitis etc. by
 PT incubating them with antigen presenting cells loaded with
 PT appropriate immunogenic peptide.
 PS Example 3: Page 38, 53PP; English.
 CC R65109-R65145 are immunogenic peptides, they are used in a new
 method for the in vitro activation of cytotoxic T cells (CTC).
 CC This is achieved by incubating the CTCs with antigen presenting
 cells loaded with an appropriate immunogenic peptide (e.g. one
 of the above peptides). By selecting the peptides used the
 CC following diseases and infections can be treated: cancer, AIDS,
 CC hepatitis, other viral and bacterial infections, malaria and
 CC tuberculosis. Sequence 9 AA;

Query Match 100.0% Score 61; DB 1; Length 9;
 Best Local Similarity 100.0%; Pred. No. 2.32e-01;
 Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Db 1 EADPTGHSY 9
 Qy 1 EADPTGHSY 9

PT infection or cancer; or for diagnosis
 PS Example 16; Page 116; 150PP; English.
 CC The sequences Given in R47304-53 and R49201-44 are immunogenic
 CC peptides which have a HLA-A3.2; HLA-A1 or a HLA-A11 binding motif.
 CC These peptides may be used in the composition of the invention.
 CC These peptides are capable of binding selected MHC molecules and
 CC inducing an immune response. They can be used to treat and/or
 prevent viral infection and cancer, eg. prostate cancer, lymphoma,
 hepatitis or AIDS. They can also be used to produce antibodies for
 use as diagnostic or therapeutic agents. The peptides can also be
 used as diagnostic agents.

Sequence 9 AA;

Query Match 26 ID R49224; standard; Protein; 9 AA.
 AC R49224;
 DT 31-AUG-1994 (first entry)
 DE HLA-A1 MAGE 1 antigen peptide fragment 958.01.
 PR Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
 KW immune response; viral infection; cancer; prostate cancer; lymphoma;
 KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
 OS Synthetic.
 PN WO9403205-A.
 PD 17-FEB-1994.
 PR 06-AUG-1993; U07421.
 PR 07-AUG-1992; US-926666.
 PR 05-MAR-1993; US-027746.
 PA (CYTE-) CYTEL CORP.
 PI Cells E, Grey HM, Kubo RT, Sette A;
 DR WPI 94-065403/08.
 PT Peptide which specifically binds selected MHC allele - used to
 PT induce an immune response for treatment or prevention of viral
 PT infection or cancer, or for diagnosis
 PS Example 8; Page 52; 150PP; English.
 PS The sequences given in R47304-53 and R49201-44 are immunogenic
 CC peptides which have a HLA-A3.2; HLA-A1 or a HLA-A11 binding motif.
 CC These peptides may be used in the composition of the invention.
 CC These peptides are capable of binding selected MHC molecules and
 CC inducing an immune response. They can be used to treat and/or
 prevent viral infection and cancer, eg. prostate cancer, lymphoma,
 hepatitis or AIDS. They can also be used to produce antibodies for
 use as diagnostic or therapeutic agents. The peptides can also be
 used as diagnostic agents.

Sequence 9 AA;

Query completed: Wed Sep 13 06:33:38 2000
 Job time : 40 secs.

PT infection or cancer; or for diagnosis
 PS Example 16; Page 116; 150PP; English.
 CC The sequences Given in R47304-53 and R49201-44 are immunogenic
 CC peptides which have a HLA-A3.2; HLA-A1 or a HLA-A11 binding motif.
 CC These peptides may be used in the composition of the invention.
 CC These peptides are capable of binding selected MHC molecules and
 CC inducing an immune response. They can be used to treat and/or
 prevent viral infection and cancer, eg. prostate cancer, lymphoma,
 hepatitis or AIDS. They can also be used to produce antibodies for
 use as diagnostic or therapeutic agents. The peptides can also be
 used as diagnostic agents.

Sequence 9 AA;

Query Match 27 ID R47330 standard; Protein; 9 AA.
 AC R47330;
 DT 31-AUG-1994 (first entry)
 DE HLA-A1 MAGE 1 antigen peptide fragment 161-169.
 PR Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;
 KW immune response; viral infection; cancer; prostate cancer; lymphoma;
 KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.
 OS Synthetic.
 PN WO9403205-A.

RESULT 27 ID R47330 standard; Protein; 9 AA.

AC R47330;

DT 31-AUG-1994 (first entry)

DE HLA-A1 MAGE 1 antigen peptide fragment 161-169.

PR Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;

KW immune response; viral infection; cancer; prostate cancer; lymphoma;

KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.

OS Synthetic.

PN WO9403205-A.

PD 17-FEB-1994.

PR 06-AUG-1993; U07421.

PR 07-AUG-1992; US-926666.

PR 05-MAR-1993; US-027746.

PA (CYTE-) CYTEL CORP.

PI Cells E, Grey HM, Kubo RT, Sette A;

DR WPI 94-065403/08.

PT Peptide which specifically binds selected MHC allele - used to

PT induce an immune response for treatment or prevention of viral

PT infection or cancer, or for diagnosis

PS Example 8; Page 52; 150PP; English.

PS The sequences given in R47304-53 and R49201-44 are immunogenic

CC peptides which have a HLA-A3.2; HLA-A1 or a HLA-A11 binding motif.

CC These peptides may be used in the composition of the invention.

CC These peptides are capable of binding selected MHC molecules and

CC inducing an immune response. They can be used to treat and/or

prevent viral infection and cancer, eg. prostate cancer, lymphoma,

KW hepatitis or AIDS. They can also be used to produce antibodies for

use as diagnostic or therapeutic agents. The peptides can also be

used as diagnostic agents.

Sequence 9 AA;

Query Match 28 ID R49224 standard; Protein; 9 AA.
 AC R49224;

DT 31-AUG-1994 (first entry)

DE HLA-A1 MAGE 1 antigen peptide fragment 958.01.

PR Immunogenic; HLA-A3.2; HLA-A1; binding motif; MHC molecule;

KW immune response; viral infection; cancer; prostate cancer; lymphoma;

KW hepatitis; AIDS; antibody; diagnosis; melanoma antigen.

OS Synthetic.

PN WO9403205-A.

PD 17-FEB-1994.

PR 06-AUG-1993; U07421.

PR 07-AUG-1992; US-926666.

PR 05-MAR-1993; US-027746.

PA (CYTE-) CYTEL CORP.

PI Cells E, Grey HM, Kubo RT, Sette A;

DR WPI 94-065403/08.

PT Peptide which specifically binds selected MHC allele - used to

induce an immune response for treatment or prevention of viral